U.S. patent application number 11/186731 was filed with the patent office on 2005-11-17 for 59079 and 12599, protein kinase family members and uses therefor.
This patent application is currently assigned to Millennium Pharmaceuticals, Inc.. Invention is credited to Acton, Susan L., Kapeller-Libermann, Rosana.
Application Number | 20050255521 11/186731 |
Document ID | / |
Family ID | 26758917 |
Filed Date | 2005-11-17 |
United States Patent
Application |
20050255521 |
Kind Code |
A1 |
Kapeller-Libermann, Rosana ;
et al. |
November 17, 2005 |
59079 and 12599, protein kinase family members and uses
therefor
Abstract
The invention provides isolated nucleic acids molecules,
designated 59079 and 12599 nucleic acid molecules, which encode
novel protein kinase family members. The invention also provides
antisense nucleic acid molecules, recombinant expression vectors
containing 59079 or 12599 nucleic acid molecules, host cells into
which the expression vectors have been introduced, and nonhuman
transgenic animals in which a 59079 or 12599 gene has been
introduced or disrupted. The invention still further provides
isolated 59079 and 12599 proteins, fusion proteins, antigenic
peptides and anti-59079 and anti-12599 antibodies. Diagnostic and
therapeutic methods utilizing compositions of the invention are
also provided.
Inventors: |
Kapeller-Libermann, Rosana;
(Chestnut Hill, MA) ; Acton, Susan L.; (Lexington,
MA) |
Correspondence
Address: |
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
CAMBRIDGE
MA
02139
US
|
Assignee: |
Millennium Pharmaceuticals,
Inc.
|
Family ID: |
26758917 |
Appl. No.: |
11/186731 |
Filed: |
July 21, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11186731 |
Jul 21, 2005 |
|
|
|
10077130 |
Feb 15, 2002 |
|
|
|
60269201 |
Feb 15, 2001 |
|
|
|
Current U.S.
Class: |
435/6.18 ;
435/320.1; 435/325; 435/69.1; 530/350; 536/23.5 |
Current CPC
Class: |
A01K 2217/05 20130101;
C07K 2319/00 20130101; C12N 9/1205 20130101; A61K 38/00
20130101 |
Class at
Publication: |
435/006 ;
435/069.1; 435/320.1; 435/325; 536/023.5; 530/350 |
International
Class: |
C12Q 001/68; C07H
021/04; C12N 009/12; C12N 015/09; C07K 014/705 |
Claims
What is claimed is:
1. An isolated nucleic acid molecule selected from the group
consisting of: a. a nucleic acid molecule comprising a nucleotide
sequence which is at least 85% identical to the nucleotide sequence
of SEQ ID NOs:1, 3, 4, or 6; b. a nucleic acid molecule comprising
a fragment of at least 300 nucleotides of the nucleotide sequence
of SEQ ID NOs:1, 3, 4, or 6; c. a nucleic acid molecule which
encodes a polypeptide comprising the amino acid sequence of SEQ ID
NO:2 or 5; d. a nucleic acid molecule which encodes a fragment of a
polypeptide comprising the amino acid sequence of SEQ ID NO:2 or 5,
wherein the fragment comprises at least 15 contiguous amino acids
of SEQ ID NO: 2 or 5; and e. a nucleic acid molecule which encodes
a naturally occurring allelic variant of a polypeptide comprising
the amino acid sequence of SEQ ID NO:2 or 5, wherein the nucleic
acid molecule hybridizes to a nucleic acid molecule comprising SEQ
ID NO:1, 3, 4, or 6, or a complement thereof, under stringent
conditions.
2. The isolated nucleic acid molecule of claim 1, which is selected
from the group consisting of: a. a nucleic acid comprising the
nucleotide sequence of SEQ ID NO:1, 3, 4, or 6; and b. a nucleic
acid molecule which encodes a polypeptide comprising the amino acid
sequence of SEQ ID NO:2 or 5.
3. The nucleic acid molecule of claim 1 further comprising vector
nucleic acid sequences.
4. The nucleic acid molecule of claim 1 further comprising nucleic
acid sequences encoding a heterologous polypeptide.
5. A host cell which contains the nucleic acid molecule of claim
1.
6. The host cell of claim 5 which is a mammalian host cell.
7. A non-human mammalian host cell containing the nucleic acid
molecule of claim 1.
8. An isolated polypeptide selected from the group consisting of:
a. a polypeptide which is encoded by a nucleic acid molecule
comprising a nucleotide sequence which is at least 85% identical to
a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1,
3, 4, or 6, or a complement thereof; b. a naturally occurring
allelic variant of a polypeptide comprising the amino acid sequence
of SEQ ID NO:2 or 5, wherein the polypeptide is encoded by a
nucleic acid molecule which hybridizes to a nucleic acid molecule
comprising SEQ ID NO:1, 3, 4, or 6; and c. a fragment of a
polypeptide comprising the amino acid sequence of SEQ ID NO:2 or 5,
wherein the fragment comprises at least 15 contiguous amino acids
of SEQ ID NO:2 or 5.
9. The isolated polypeptide of claim 8 comprising the amino acid
sequence of SEQ ID NO:2 or 5.
10. The polypeptide of claim 8 further comprising heterologous
amino acid sequences.
11. An antibody which selectively binds to a polypeptide of claim
8.
12. A method for producing a polypeptide selected from the group
consisting of: a. a polypeptide comprising the amino acid sequence
of SEQ ID NO:2 or 5; b. a polypeptide comprising a fragment of the
amino acid sequence of SEQ ID NO:2 or 5, wherein the fragment
comprises at least 15 contiguous amino acids of SEQ ID NO:2 or 5;
and c. a naturally occurring allelic variant of a polypeptide
comprising the amino acid sequence of SEQ ID NO:2 or 5, wherein the
polypeptide is encoded by a nucleic acid molecule which hybridizes
to a nucleic acid molecule comprising SEQ ID NO:1, 3, 4, or 5, or a
complement thereof under stringent conditions; comprising culturing
the host cell of claim 5 under conditions in which the nucleic acid
molecule is expressed.
13. A method for detecting the presence of a polypeptide of claim 8
in a sample, comprising: contacting the sample with a compound
which selectively binds to a polypeptide of claim 8; and
determining whether the compound binds to the polypeptide in the
sample.
14. The method of claim 13, wherein the compound which binds to the
polypeptide is an antibody.
15. A kit comprising a compound which selectively binds to a
polypeptide of claim 8 and instructions for use.
16. A method for detecting the presence of a nucleic acid molecule
of claim 1 in a sample, comprising the steps of: contacting the
sample with a nucleic acid probe or primer which selectively
hybridizes to the nucleic acid molecule; and determining whether
the nucleic acid probe or primer binds to a nucleic acid molecule
in the sample.
17. The method of claim 16, wherein the sample comprises mRNA
molecules and is contacted with a nucleic acid probe.
18. A kit comprising a compound which selectively hybridizes to a
nucleic acid molecule of claim 1 and instructions for use.
19. A method for identifying a compound which binds to a
polypeptide of claim 8 comprising the steps of: contacting a
polypeptide, or a cell expressing a polypeptide of claim 8 with a
test compound; and determining whether the polypeptide binds to the
test compound.
20. The method of claim 19, wherein the binding of the test
compound to the polypeptide is detected by a method selected from
the group consisting of: a. detection of binding by direct
detecting of test compound/polypeptide binding; b. detection of
binding using a competition binding assay; and c. detection of
binding using an assay for 59079- or 12599-mediated signal
transduction.
21. A method for modulating the activity of a polypeptide of claim
8 comprising contacting a polypeptide or a cell expressing a
polypeptide of claim 8 with a compound which binds to the
polypeptide in a sufficient concentration to modulate the activity
of the polypeptide.
22. A method for identifying a compound which modulates the
activity of a polypeptide of claim 8, comprising: contacting a
polypeptide of claim 8 with a test compound; and determining the
effect of the test compound on the activity of the polypeptide to
thereby identify a compound which modulates the activity of the
polypeptide.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional of U.S. patent application
Ser. No. 10/077,130, filed Feb. 15, 2002, which claims priority to
U.S. Provisional Application No. 60/269,201, filed Feb. 15, 2001,
now abandoned. Each of these applications is hereby incorporated in
its entirety by reference herein.
BACKGROUND OF THE INVENTION
[0002] Phosphate tightly associated with a molecule, e.g., a
protein, has been known since the late nineteenth century. Since
then, a variety of covalent linkages of phosphate to proteins have
been found. The most common involve esterification of phosphate to
serine, threonine, and tyrosine with smaller amounts being linked
to lysine, arginine, histidine, aspartic acid, glutamic acid, and
cysteine. The occurrence of phosphorylated molecules, e.g.,
proteins, implies the existence of one or more kinases, e.g.,
protein kinases, capable of phosphorylating various molecules,
e.g., amino acid residues on proteins, and also of phosphatases,
e.g., protein phosphatases, capable of hydrolyzing various
phosphorylated molecules, e.g., phosphorylated amino acid residues
on proteins.
[0003] Protein kinases play critical roles in the regulation of
biochemical and morphological changes associated with cellular
growth and division (D'Urso et al. (1990) Science 250:786-791;
Birchmeier et al. (1993) Bioessays 15:185-189). For example, these
kinases have been shown to participate in the transmission of
signals from growth-factor receptors (Sturgill et al. (1988) Nature
344:715-718; Gomez et al. (1991) Nature 353:170-173), control of
entry of cells into mitosis (Nurse (1990) Nature 344:503-508;
Maller (1991) Curr. Opin. Cell Biol. 3:269-275), and regulation of
actin bundling (Husain-Chishti et al. (1988) Nature 334:718-721).
Protein kinases serve as growth factor receptors and signal
transducers and have been implicated in cellular transformation and
malignancy (Hunter et al. (1992) Cell 70:375-387; Posada et al.
(1992) Mol. Biol. Cell 3:583-592; Hunter et al. (1994) Cell
79:573-582). Alterations in kinase genes and their products can
lead to deregulated cell proliferation, a hallmark of cancer.
Modulation of these genes and their regulatory activities may
permit the control of tumor cell proliferation and invasion.
[0004] Protein kinases can be divided into different groups based
on either amino acid sequence similarity or specificity for either
serine/threonine or tyrosine residues. A small number of
dual-specificity kinases have also been described. Within the broad
classification, kinases can be further subdivided into families
whose members share a higher degree of catalytic domain amino acid
sequence identity and also have similar biochemical properties.
Most protein kinase family members also share structural features
outside the kinase catalytic domain that reflect their particular
cellular roles. These include regulatory domains that control
kinase activity or interaction with other proteins (Hanks et al.
(1988) Science 241:42-52).
[0005] Extracellular signal-regulated kinases/mitogen-activated
protein kinases (ERKs.backslash.MAPKs) and cyclin-directed kinases
(Cdks) represent two large families of serine-threonine kinases
(see Songyang et al. (1996) Mol. Cell. Biol. 16: 6486-6493). Both
types of kinases function in cell growth, cell division, and cell
differentiation in response to extracellular stimuli. The
ERK.backslash.MAPK family members are critical participants in
intracellular signaling pathways. Upstream activators as well as
the ERK.backslash.MAPK components are phosphorylated following
contact of cells with growth factors or hormones or in response to
cellular stressors, for example, heat, ultraviolet light, and
inflammatory cytokines. These kinases transport messages that have
been relayed from the plasma membrane to the cytoplasm by upstream
kinases into the nucleus where they phosphorylate transcription
factors and effect gene transcription modulation (Karin et al.
(1995) Curr. Biol. 5: 747-757). Substrates of the
ERK.backslash.MAPK family include c-fos, c-jun, APF2, and ETS
family members Elk1, Sap1a, and c-Ets-1 (cited in Brott et al.
(1998) Proc. Natl. Acad. Sci. USA 95: 963-968).
[0006] Signal-transduction pathways that employ members of the
ERK/MAPK family of serine/threonine kinases are widely conserved
among eukaryotes. The multiplicity of these pathways allows the
cell to respond to divergent extracellular stimuli by initiating a
broad array of responses ranging from cell growth to apoptosis.
ERK/MAPK pathways are comprised of a three-tiered core-signaling
module wherein ERK/MAPKs are regulated by MAPK/ERK kinases (MEKs),
and MEKs, in turn, are regulated by MAPK kinase kinases (MAPKKKs).
Mammalian stress-activated ERK/MAPK pathways have been implicated
in numerous important physiological functions, including cell
growth and proliferation, inflammatory responses, and apoptosis.
For example, activation of the ERK1,2 signaling pathway by a
mitogenic growth factor, a tumor promoter, or by transformation
suppresses decorin gene expression in fibroblasts, which in turn
may promote proliferation and migration of normal and malignant
cells (Laine et al. (2000) Biochem. J. 349: 19-25).
[0007] Cdks regulate transitions between successive stages of the
cell cycle. The activity of these molecules is controlled by
phosphorylation events and by association with cyclin. Cdk activity
is negatively regulated by the association of small inhibitory
molecules (Dynlacht (1997) Nature 389:148-152). Cdk targets include
various transcriptional activators such as p110Rb, p107, and
transcription factors, such as p53, E2F, and RNA polymerase II, as
well as various cytoskeletal proteins and cytoplasmic signaling
proteins (cited in Brott et al. (1998) Proc. Natl. Acad. Sci. USA
95: 963-968).
[0008] Protein kinases play critical roles in cellular growth,
particularly in the transduction of signals for cell proliferation,
differentiation, and apoptosis. Therefore, novel protein kinase
polynucleotides and proteins are useful for modulating cellular
growth, differentiation, and/or development.
SUMMARY OF THE INVENTION
[0009] The present invention is based, in part, on the discovery of
novel human protein kinase family members, referred to herein as
"59079" and "12599". The nucleotide sequence of a cDNA encoding
59079 is shown in SEQ ID NO:1, and the amino acid sequence of a
59079 polypeptide is shown in SEQ ID NO:2. In addition, the
nucleotide sequence of the coding region is depicted in SEQ ID
NO:3. The nucleotide sequence of a cDNA encoding 12599 is shown in
SEQ ID NO:4, and the amino acid sequence of a 12599 polypeptide is
shown in SEQ ID NO:5. In addition, the nucleotide sequence of the
coding region is depicted in SEQ ID NO:6.
[0010] Accordingly, in one aspect, the invention features nucleic
acid molecules which encode a 59079 protein or polypeptide or a
12599 protein or polypeptide, e.g., a biologically active portion
of the 59079 or 12599 protein. In a preferred embodiment the
isolated nucleic acid molecule encodes a polypeptide having the
amino acid sequence of SEQ ID NO:2 or 5. In other embodiments, the
invention provides isolated 59079 and 12599 nucleic acid molecules
having the nucleotide sequence shown in SEQ ID NOs:1, 3, 4, or 6.
In still other embodiments, the invention provides nucleic acid
molecules that are substantially identical (e.g., naturally
occurring allelic variants) to the nucleotide sequence shown in SEQ
ID NOs:1, 3, 4, or 6. In other embodiments, the invention provides
a nucleic acid molecule which hybridizes under stringent
hybridization conditions to a nucleic acid molecule comprising the
nucleotide sequence of SEQ ID NO:1, 3, 4, or 6, wherein the nucleic
acid encodes a full length 59079 or 12599 protein, or a
biologically active fragment thereof.
[0011] In a related aspect, the invention further provides nucleic
acid constructs which include a 59079 or 12599 nucleic acid
molecule described herein. In certain embodiments, the nucleic acid
molecules of the invention are operatively linked to native or
heterologous regulatory sequences. Also included are vectors and
host cells containing the 59079 or 12599 nucleic acid molecules of
the invention, e.g., vectors and host cells suitable for producing
59079 or 12599 polypeptides.
[0012] In another related aspect, the invention provides nucleic
acid fragments suitable as primers or hybridization probes for the
detection of 59079- or 12599-encoding nucleic acids.
[0013] In still another related aspect, isolated nucleic acid
molecules that are antisense to a 59079- or 12599-encoding nucleic
acid molecule are provided.
[0014] In another aspect, the invention features 59079 and 12599
polypeptides, and biologically active or antigenic fragments
thereof, that are useful, e.g., as reagents or targets in assays
applicable to treatment and diagnosis of 59079- or 12599-mediated
or -related disorders. In another embodiment, the invention
provides 59079 polypeptides having a 59079 activity and 12599
polypeptides having a 12599 activity. Preferred polypeptides are
59079 and 12599 proteins including at least one protein kinase
catalytic domain, and, preferably, having a 59079 or 12599
activity, e.g., a 59079 or 12599 activity as described herein.
[0015] In other embodiments, the invention provides 59079 and 12599
polypeptides, e.g., a 59079 or 12599 polypeptide having the amino
acid sequence shown in SEQ ID NO:2 or 5; an amino acid sequence
that is substantially identical to the amino acid sequence shown in
SEQ ID NO:2 or 5; or an amino acid sequence encoded by a nucleic
acid molecule having a nucleotide sequence which hybridizes under
stringent hybridization conditions to a nucleic acid molecule
comprising the nucleotide sequence of SEQ ID NOs:1, 3, 4, or 6,
wherein the nucleic acid encodes a full length 59079 or 12599
protein, or a biologically active fragment thereof.
[0016] In a related aspect, the invention further provides nucleic
acid constructs which include a 59079 or 12599 nucleic acid
molecule described herein.
[0017] In a related aspect, the invention provides 59079 and 12599
polypeptides, or fragments thereof, operatively linked to non-59079
or non-12599 polypeptides to form fusion proteins.
[0018] In another aspect, the invention features antibodies, and
antigen-binding fragments thereof, that react with, or more
preferably, specifically or selectively bind 59079 or 12599
polypeptides.
[0019] In another aspect, the invention provides methods of
screening for compounds that modulate the expression or activity of
the 59079 polypeptides or nucleic acids or the 12599 polypeptides
or nucleic acids.
[0020] In still another aspect, the invention provides a process
for modulating 59079 polypeptide or nucleic acid expression or
activity, e.g., using the compounds identified in the screens. In
certain embodiments, the methods involve treatment of conditions or
disorders related to aberrant activity or expression of the 59079
or 12599 polypeptides or nucleic acids, such as conditions
involving aberrant or deficient 59079 or 12599 protein or nucleic
acid expression or activity. In a preferred embodiment, the
disorder characterized by aberrant 59079 or 12599 protein activity
or nucleic acid expression is a nervous system disorder, a
cardiovascular disorder, a sugar or fatty acid metabolism disorder,
an inflammatory or immune disorder, a musculoskeletal disorder, or
a disorder involving aberrant cellular proliferation,
differentiation, or migration.
[0021] The invention also provides assays for determining the
activity of or the presence or absence of 59079 or 12599
polypeptides or nucleic acid molecules in a biological sample,
including for disease diagnosis.
[0022] In a further aspect, the invention provides assays for
determining the presence or absence of a genetic alteration in a
59079 or 12599 polypeptide or nucleic acid molecule, including for
disease diagnosis.
[0023] Other features and advantages of the invention will be
apparent from the following detailed description and from the
claims.
DETAILED DESCRIPTION OF THE INVENTION
[0024] The human 59079 nucleic acid sequence (SEQ ID NO:1), which
is approximately 8106 nucleotides long including untranslated
regions, contains a predicted methionine-initiated coding sequence
of about 7893 nucleotides, including the termination codon (shown
as the nucleotides of SEQ ID NO:1 indicated as coding, and the
sequence shown in SEQ ID NO:3). The coding sequence encodes a 2631
amino acid protein (SEQ ID NO:2).
[0025] The human 12599 nucleic acid sequence (SEQ ID NO:4), which
is approximately 24,120 nucleotides long including untranslated
regions, contains a predicted methionine-initiated coding sequence
of about 23,907 nucleotides, including the termination codon (shown
as the nucleotides of SEQ ID NO:4 indicated as coding, and the
sequence shown in SEQ ID NO:6). The coding sequence encodes a 7968
amino acid protein (SEQ ID NO:5).
[0026] To determine whether a polypeptide or protein of interest
has a conserved sequence or domain common to members of a protein
family, the amino acid sequence of the protein can be searched
against a database of profile hidden Markov models (profile HMMs),
which uses statistical descriptions of a sequence family's
consensus (e.g., HMMER, version 2.1.1) and PFAM, a collection of
multiple sequence alignments and hidden Markov models covering many
common protein domains (e.g., PFAM, version 5.5) using the default
parameters (http://www.sanger.ac.uk/Software/Pfam_- HMM search).
For example, the hmmsf program, which is available as part of the
HMMER package of search programs, is a family specific default
program for MILPAT0063 and a score of 15 is the default threshold
score for determining a hit. Alternatively, the threshold score for
determining a hit can be lowered (e.g., to 8 bits). A description
of the PFAM database can be found in Sonhammer et al., (1997)
Proteins 28(3):405-420 and a detailed description of HMMs can be
found, for example, in Gribskov et al., (1990) Meth. Enzymol.
183:146-159; Gribskov et al., (1987) Proc. Natl. Acad. Sci. USA
84:4355-4358; Krogh et al., (1994) J. Mol. Biol. 235:1501-1531; and
Stultz et al., (1993) Protein Sci. 2:305-314, the contents of which
are incorporated herein by reference. See also, for example,
http://hmmer.wustl.edu/. For general information regarding PFAM
identifiers, PS prefix and PF prefix domain identification numbers,
refer to Sonnhammer et al. (1997) Protein 28:405-420 and
http://pfam.wustl.edu/. See also, for example,
http://www.expasy.ch/prosi- te and
http://smart.embl-heidelberg.de/.
[0027] Using such search tools, the 59079 and 12599 protein
sequences were found to contain significant structural
characteristics in common with members of the protein kinase family
of molecules. Some of these structural characteristics include, for
example, a protein kinase catalytic domain (e.g., PFAM Accession
No. PF00069), a pleckstrin homology domain consensus sequence
(e.g., PFAM Accession No. PF00169), a fibronectin type III domain
(e.g., PFAM Accession No. PF00041), a RhoGEF domain (e.g., PFAM
Accession No. PF00621), and a IQ calmodulin-binding motif (e.g.,
PFAM Accession No. PF00612).
[0028] As used herein, the term "protein kinase" includes a protein
or polypeptide which is capable of modulating its own
phosphorylation state or the phosphorylation state of another
molecule, e.g., protein or polypeptide. Protein kinases can have a
specificity for (i.e., a specificity to phosphorylate)
serine/threonine residues, tyrosine residues, or both
serine/threonine and tyrosine residues, e.g., the dual specificity
kinases.
[0029] The term "family" when referring to the protein and nucleic
acid molecules of the invention is intended to mean two or more
proteins or nucleic acid molecules having a common structural
domain or signature sequence and having sufficient amino acid or
nucleotide sequence homology as defined herein. Such family members
can be naturally or non-naturally occurring and can be from either
the same or different species. For example, a family can contain a
first protein of human origin, as well as other distinct proteins
of human origin, or alternatively, can contain homologues of
non-human origin, e.g., rat or mouse proteins. Members of a family
can also have common functional characteristics.
[0030] With regard to common structural characteristics described
above, the protein kinases of the present invention include a
protein kinase catalytic core or domain and can include at least
one of the following signature sequences or motifs within the
catalytic core: a protein kinase ATP-binding region signature
sequence, a serine/threonine protein kinase active site signature
sequence, and a tyrosine kinase active site signature sequence (see
Hanks et al. (1988) Science 241:42-52).
[0031] As used herein, a "protein kinase catalytic core or domain"
includes a consensus sequence, e.g., PFAM Accession No. PF00069,
that includes the catalytic domain of the enzyme. The catalytic
domain can be characterized by the presence of an ATP binding
signature sequence (e.g., Prosite Accession No. PS00107) and/or a
serine/threonine or tyrosine kinase active-site signature sequence
(e.g., Prosite Accession No. PS00108 or Prosite Accession No.
PS00109). The protein kinase catalytic domain of the present
invention preferably includes a catalytic domain of about 150-400
amino acid residues in length, preferably about 200-300 amino acid
residues in length, or more preferably about 225-300 amino acid
residues in length, which includes at least one of the signature
sequences or motifs described herein.
[0032] Accordingly, protein kinase polypeptides having at least
50-60% homology, preferably about 60-70%, more preferably about
70-80%, or about 80-90% homology with a protein kinase catalytic
domain of 59079 or 12599 are within the scope of the invention.
[0033] The protein kinase ATP-binding region signature sequence is
located in the N-terminal extremity of the catalytic domain and
typically includes a glycine-rich stretch of residues in the
vicinity of a lysine residue. A consensus sequence (Prosite
Accession No. PS00107; SEQ ID NO:7) for this region is
[LIV]-G-{P}-G-{P}-[FYWMGSTNH]-[SGA]-{PW}-[LIVCAT-
]-{PD}-x-[GSTACLIVMFY]-x(5,18)-[LIVMFYWCSTAR]-[AIVP]-[LIV
MFAGCKR]-K. In the above consensus sequence pattern, lysine (K)
binds ATP.
[0034] In this and the following consensus sequence patterns, each
element in the pattern is separated by a dash (-); square brackets,
[ ], indicate the particular residues that are accepted at that
position; ornate brackets, { }, indicate the residues that are not
accepted at that position; x indicates any residue is accepted at
that position; repetition of a particular element is indicated by
following the element with a numerical value or a numerical range
enclosed in parentheses (i.e., above, x(5,18) indicates anywhere
from 5 to 18 residues are present in the element, and any amino
acid residue is accepted at each of these 5 to 18 residue
positions); and the standard IUPAC one-letter code for the amino
acids is used.
[0035] Analysis of the 59079 polypeptide for sequence patterns in
the Prosite database showed a match to a protein kinase ATP binding
region signature pattern of Prosite Accession No. PS00107 at about
amino acids 1136 to 1159 and at about amino acid residues 2340 to
2363 of SEQ ID NO:2. The lysine residue at position 1145, 1150,
1153, 1159, 2354, and/or 2363 of SEQ ID NO:2 can be involved in ATP
binding. Each of these protein kinase ATP-binding region signature
sequences lies within a protein kinase catalytic domain identified
in a PFAM search against the HMM database (HMMER2.1.1); the first,
in the protein kinase catalytic domain spanning amino acid residues
1130 to 1383; the second, in the protein kinase catalytic domain
from amino acid residues 2334 to 2586 of SEQ ID NO:2.
[0036] Analysis of the 12599 polypeptide for sequence patterns in
the Prosite database showed a match to a protein kinase ATP binding
region signature pattern of Prosite Accession No. PS00107 at about
amino acids 6474 to 6497 of SEQ ID NO:5. The lysine residue at
position 6483, 6488, 6491, and/or 6497 of SEQ ID NO:5 can be
involved in ATP binding. This protein kinase ATP binding region
signature pattern lies within a protein kinase catalytic domain
identified in a PFAM search against the HMM database (HMMER2.1.1)
and located from amino acid residues 6468 to 6721 of SEQ ID
NO:5.
[0037] Another region, located in the central part of the catalytic
core or domain, contains a conserved aspartic acid residue, which
is important for the catalytic activity of the enzyme (Knighton et
al. (1991) Science 253:407-414). Two active-site signature
sequences have been described for this region: one specific for
serine/threonine kinases and one for tyrosine kinases. In both
signature sequences aspartic acid (D) is conserved and is an active
site residue. A consensus sequence for the serine/threonine kinases
(Prosite Accession No. PS00108; SEQ ID NO:8) is
[LIVMFYC]-x-[HY]-x-D-[LIVMFY]-K-x(2)-N-[LIVMFYCT](3). A consensus
sequence for the tyrosine kinases (Prosite Accession No. PS00109;
SEQ ID NO:9) is
[LIVMFYC]-x-[HY]-x-D-[LIVMFY]-[RSTAC]-x(2)-N-[LIVMFYC](3).
[0038] Analysis of the 59079 polypeptide for sequence patterns in
the Prosite database showed a match of amino acid residues 1245 to
1257 of SEQ ID NO:2 to the serine/threonine kinase active-site
signature sequence of Prosite Accession No. PS00108. The aspartic
acid residue (D) at position 1249 of SEQ ID NO:2 is an active site
residue. This serine/threonine kinase active-site signature
sequence lies within the protein kinase catalytic domain spanning
amino acid residues 1130 to 1383 of SEQ ID NO:2.
[0039] Analysis of the 12599 polypeptide for sequence patterns in
the Prosite database showed a match of amino acid residues 6583 to
6595 of SEQ ID NO:5 to the serine/threonine kinase active-site
signature sequence of Prosite Accession No. PS00108. The aspartic
acid residue (D) at position 6587 of SEQ ID NO:5 is an active site
residue. This serine/threonine kinase active-site signature
sequence lies within the protein kinase catalytic domain spanning
amino acid residues 6468 to 6721 of SEQ ID NO:2.
[0040] Analysis of the 59079 polypeptide for other sequence
patterns in the Prosite database showed a match of amino acid
residues 2449 to 2461 of SEQ ID NO:2 to the tyrosine protein kinase
active site signature sequence of Prosite Accession No. PS00109.
The aspartic acid residue (D) at position 2453 of SEQ ID NO:2 is an
active site residue. This tyrosine protein kinase active site
signature sequence lies within the protein kinase catalytic domain
spanning amino acid residues 2334 to 2586 of SEQ ID NO:2.
[0041] Analysis of the 12599 polypeptide for other sequence
patterns in the Prosite database showed a match of amino acid
residues 7787 to 7799 of SEQ ID NO:5 to the tyrosine protein kinase
active site signature sequence of Prosite Accession No. PS00109.
The aspartic acid residue (D) at position 7791 of SEQ ID NO:5 is an
active site residue. This tyrosine protein kinase active site
signature sequence lies within the protein kinase catalytic domain
spanning amino acid residues 7672 to 7924 of SEQ ID NO:5.
[0042] As used herein, a "pleckstrin homology domain" is a domain
that is characterized by the matrix profile described by PFAM
Accession No. PF00169 or Prosite Accession No. PS50003. The
pleckstrin homology domain is a domain of about 100 amino acid
residues that can occur in protein kinases, e.g., serine/threonine
protein kinases belonging to the Akt/Rac family, the
beta-adrenergic receptor kinase family, the trypanosomal NrkA
family, and the mu isoform of protein kinase C, and tyrosine
protein kinases, e.g., belonging to the Btk/Itk/Tec subfmaily. This
domain is likely involved in binding phosphorylated
serine/threonine residues. The presence of a pleckstrin homology
domain was identified in 59079 at about amino acid residues 558 to
666 of SEQ ID NO:2 and in 12599 at about amino acid residues 5896
to 6004 of SEQ ID NO:5.
[0043] The sequence analyses of the 59079 and 12599 proteins
demonstrate that the 59079 and 12599 proteins can act as
serine/threonine or tyrosine protein kinases, and can also include
a pleckstrin homology domain. Based on the above-described sequence
similarities, the 59079 and 12599 molecules of the present
invention have similar biological or functional activities as
protein kinase family members.
[0044] As used interchangeably herein, he terms, a "59079- and/or
12599-mediated activity", "biological activity of 59079 and/or
12599" or "functional activity of 59079 and/or 12599", refer to an
activity exerted by a 59079 or 12599 protein, polypeptide or
nucleic acid molecule on, e.g., a 59079- or 12599-responsive cell
or tissue, or on a 59079 or 12599 substrate, ligand, or target
molecule, e.g., a protein substrate or target molecule, as
determined in vivo, in vitro, or in situ according to standard
techniques.
[0045] In one embodiment, a 59079 or 12599 activity is a direct
activity, such as an association with a 59079 or 12599 ligand,
binding partner, or target molecule. As used interchangeably
herein, a "ligand", "binding partner", or "target molecule" is a
molecule with which a 59079 or 12599 protein binds or interacts in
nature, such that a 59079- or 12599-mediated function is achieved.
A 59079 or 12599 target molecule can be a 59079 or a 12599 protein
or polypeptide of the present invention or a non-59079 or non-12599
protein molecule. In one embodiment, a 59079 or 12599 target
molecule can be a non-59079 or a non-12599 protein molecule. In an
exemplary embodiment, a 59079 or 12599 target molecule is a 59079
ligand, e.g., a protein kinase ligand, e.g., serine, threonine, or
tyrosine containing polypeptide.
[0046] Protein kinases play a role in signalling pathways
associated with cellular growth. For example, protein kinases are
involved in the regulation of signal transmission from cellular
receptors, e.g., growth-factor receptors; entry of cells into
mitosis; and the regulation of cytoskeleton function, e.g., actin
bundling. Thus, the 59079 and 12599 molecules of the present
invention can be involved in: 1) the regulation of transmission of
signals from cellular receptors, e.g., cell growth factor
receptors; 2) the modulation of the entry of cells, e.g., precursor
cells, into mitosis; 3) the modulation of cellular differentiation;
4) the modulation of cell death; and 5) the regulation of
cytoskeleton function, e.g., actin bundling. These kinases can
function in these biological activities because of their ability to
phosphorylate themselves or other substrate molecules.
[0047] Substrates of tyrosine protein kinases are generally
characterized by a lysine or an arginine seven residues to the
N-terminal side of the phosphorylated tyrosine. An acidic residue
(aspartic acid or glutatmic acid) is often found at either three or
four residues to the N-terminal side of the tyrosine (see
Patschinsky et al. (1982) Proc. Natl. Acad. Sci. U.S.A. 79:973-977;
Hunter T. (1982) J. Biol. Chem. 257:4843-4848; Cooper et al. (1984)
J. Biol. Chem. 259:7835-7841).
[0048] A 59079 or 12599 activity can also be an indirect activity,
such as an activity mediated by interaction of the 59079 or 12599
protein with a 59079 or 12599 target molecule such that the target
molecule modulates a downstream cellular activity, e.g., a cellular
signaling activity modulated indirectly by an interaction of the
59079 or 12599 protein with a 59079 or 12599 target molecule.
[0049] The 59079 and 12599 molecules of the invention can modulate
the activities of cells in tissues where they are expressed. For
example, 59079 and 12599 mRNA are expressed in normal heart and
upregulated in diseased heart. Accordingly, the 59079 and 12599
molecules of the invention can act as therapeutic or diagnostic
agents for cardiovascular disorders.
[0050] Cardiovascular disorders include, but are not limited to,
heart failure, including but not limited to, cardiac hypertrophy,
left-sided heart failure, and right-sided heart failure; ischemic
heart disease, including but not limited to angina pectoris,
myocardial infarction, chronic ischemic heart disease, and sudden
cardiac death; hypertensive heart disease, including but not
limited to, systemic (left-sided) hypertensive heart disease and
pulmonary (right-sided) hypertensive heart disease; valvular heart
disease, including but not limited to, valvular degeneration caused
by calcification, such as calcification of a congenitally bicuspid
aortic valve, and mitral annular calcification, and myxomatous
degeneration of the mitral valve (mitral valve prolapse), rheumatic
fever and rheumatic heart disease, infective endocarditis, and
noninfected vegetations, such as nonbacterial thrombotic
endocarditis and endocarditis of systemic lupus erythematosus
(Libman-Sacks disease), carcinoid heart disease, and complications
of artificial valves; myocardial disease, including but not limited
to dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive
cardiomyopathy, and myocarditis; pericardial disease, including but
not limited to, pericardial effusion and hemopericardium and
pericarditis, including acute pericarditis and healed pericarditis,
and rheumatoid heart disease; neoplastic heart disease, including
but not limited to, primary cardiac tumors, such as myxoma, lipoma,
papillary fibroelastoma, rhabdomyoma, and sarcoma, and cardiac
effects of noncardiac neoplasms; congenital heart disease,
including but not limited to, left-to-right shunts--late cyanosis,
such as atrial septal defect, ventricular septal defect, patent
ductus arteriosus, and atrioventricular septal defect,
right-to-left shunts-early cyanosis, such as tetralogy of fallot,
transposition of great arteries, truncus arteriosus, tricuspid
atresia, and total anomalous pulmonary venous connection,
obstructive congenital anomalies, such as coarctation of aorta,
pulmonary stenosis and atresia, and aortic stenosis and atresia,
disorders involving cardiac transplantation, and congestive heart
failure.
[0051] Disorders involving blood vessels include, but are not
limited to, responses of vascular cell walls to injury, such as
endothelial dysfunction and endothelial activation and intimal
thickening; vascular diseases including, but not limited to,
congenital anomalies, such as arteriovenous fistula,
atherosclerosis, and hypertensive vascular disease, such as
hypertension; inflammatory disease--the vasculitides, such as giant
cell (temporal) arteritis, Takayasu arteritis, polyarteritis nodosa
(classic), Kawasaki syndrome (mucocutaneous lymph node syndrome),
microscopic polyanglitis (microscopic polyarteritis,
hypersensitivity or leukocytoclastic anglitis), Wegener
granulomatosis, thromboanglitis obliterans (Buerger disease),
vasculitis associated with other disorders, and infectious
arteritis; Raynaud disease; aneurysms and dissection, such as
abdominal aortic aneurysms, syphilitic (luetic) aneurysms, and
aortic dissection (dissecting hematoma); disorders of veins and
lymphatics, such as varicose veins, thrombophlebitis and
phlebothrombosis, obstruction of superior vena cava (superior vena
cava syndrome), obstruction of inferior vena cava (inferior vena
cava syndrome), and lymphangitis and lymphedema; tumors, including
benign tumors and tumor-like conditions, such as hemangioma,
lymphangioma, glomus tumor (glomangioma), vascular ectasias, and
bacillary angiomatosis, and intermediate-grade (borderline
low-grade malignant) tumors, such as Kaposi's sarcoma and
hemangloendothelioma, and malignant tumors, such as angiosarcoma
and hemangiopericytoma; and pathology of therapeutic interventions
in vascular disease, such as balloon angioplasty and related
techniques and vascular replacement, such as coronary artery bypass
graft surgery.
[0052] Blood platelet disorders include, but are not limited to,
thrombocytopenia due to a reduced number of megakaryocytes in the
bone marrow, for example, as a result of chemotherapy; invasive
disorders, such as leukemia, idiopathic or drug- or toxin-induced
aplasia of the marrow, or rare hereditary amegakaryocytic
thrombocytopenias; ineffective thrombopoiesis, for example, as a
result of megaloblastic anemia, alcohol toxicity, vitamin B12 or
folate deficiency, myelodysplastic disorders, or rare hereditary
disorders (e.g., Wiskott-Aldrich syndrome and May-hegglin anomaly);
a reduction in platelet distribution, for example, as a result of
cirrhosis, a splenic invasive disease (e.g., Gaucher's disease), or
myelofibrosis with extramedullary myeloid metaplasia; increased
platelet destruction, for example, as a result of removal of
IgG-coated platelets by the mononuclear phagocytic system (e.g.,
idiopathic thrombocytopenic purpura (ITP), secondary immune
thrombocytopenia (e.g., systemic lupus erythematosus, lymphoma, or
chronic lymphocytic leukemia), drug-related immune
thrombocytopenias (e.g., as with quinidine, aspirin, and heparin),
post-transfusion purpura, and neonatal thrombocytopenia as a result
of maternal platelet autoantibodies or maternal platelet
alloantibodies). Also included are thrombocytopenia secondary to
intravascular clotting and thrombin induced damage to platelets as
a result of, for example, obstetric complications, metastatic
tumors, severe gram-negative bacteremia, thrombotic
thrombocytopenic purpura, or severe illness. Also included is
dilutional thrombocytopenia, for example, due to massive
hemorrhage. Blood platelet disorders also include, but are not
limited to, essential thrombocytosis and thrombocytosis associated
with, for example, splenectomy, acute or chronic inflammatory
diseases, hemolytic anemia, carcinoma, Hodgkin's disease,
lymphoproliferative disorders, and malignant lymphomas.
[0053] As the 59079 and 12599 molecules of the present invention
share structural features with protein kinases and can modulate
protein kinase-mediated activities, the 59079 and 12599
compositions of the invention (e.g., nucleic acids, polypeptides,
proteins, antibodies, and modulators of 59079 or 12599 gene
expression or biological activity) are useful for developing novel
diagnostic and therapeutic agents for protein kinase associated
disorders. As used herein, a "protein kinase associated disorder"
includes a disorder, disease, or condition which is caused by,
characterized by, or associated with a misregulation (e.g., an
aberrant downregulation or upregulation) of a protein kinase
mediated activity. Protein kinase associated disorders can result
in, e.g., upregulated or downregulated, cell growth and/or
proliferation.
[0054] Protein kinase associated disorders can detrimentally affect
cellular functions such as cellular proliferation, growth,
differentiation, and cellular regulation of homeostasis, e.g.,
glucose homeostasis; inter- or intra-cellular communication; tissue
function, such as cardiac function or musculoskeletal function;
systemic responses in an organism, such as nervous system
responses, hormonal responses (e.g., insulin response), or immune
responses; and protection of cells from toxic compounds (e.g.,
carcinogens, toxins, mutagens, and toxic byproducts of metabolic
activity, e.g., reactive oxygen species). Accordingly, the 59079
molecules of the invention, as protein kinases, can mediate various
protein kinase associated disorders, including cellular
proliferative and/or differentiative disorders, hormonal disorders,
immune and inflammatory disorders, neurological disorders,
cardiovascular disorders, blood vessel disorders, and platelet
disorders.
[0055] Examples of cellular proliferative and/or differentiative
disorders include cancer, e.g., carcinoma, sarcoma, metastatic
disorders or hematopoietic neoplastic disorders, e.g., leukemias. A
metastatic tumor can arise from a multitude of primary tumor types,
including but not limited to those of prostate, colon, lung, breast
and liver origin.
[0056] As used herein, the term "cancer" (also used interchangeably
with the terms, "hyperproliferative" and "neoplastic") refers to
cells having the capacity for autonomous growth, i.e., an abnormal
state or condition characterized by rapidly proliferating cell
growth. Cancerous disease states may be categorized as pathologic,
i.e., characterizing or constituting a disease state, e.g.,
malignant tumor growth, or may be categorized as non-pathologic,
i.e., a deviation from normal but not associated with a disease
state, e.g., cell proliferation associated with wound repair. The
term is meant to include all types of cancerous growths or
oncogenic processes, metastatic tissues or malignantly transformed
cells, tissues, or organs, irrespective of histopathologic type or
stage of invasiveness. The term "cancer" includes malignancies of
the various organ systems, such as those affecting lung, breast,
thyroid, lymphoid, gastrointestinal, and genito-urinary tract, as
well as adenocarcinomas which include malignancies such as most
colon cancers, renal-cell carcinoma, prostate cancer and/or
testicular tumors, non-small cell carcinoma of the lung, cancer of
the small intestine and cancer of the esophagus. The term
"carcinoma" is art recognized and refers to malignancies of
epithelial or endocrine tissues including respiratory system
carcinomas, gastrointestinal system carcinomas, genitourinary
system carcinomas, testicular carcinomas, breast carcinomas,
prostatic carcinomas, endocrine system carcinomas, and melanomas.
Exemplary carcinomas include those forming from tissue of the
cervix, lung, prostate, breast, head and neck, colon and ovary. The
term "carcinoma" also includes carcinosarcomas, e.g., which include
malignant tumors composed of carcinomatous and sarcomatous tissues.
An "adenocarcinoma" refers to a carcinoma derived from glandular
tissue or in which the tumor cells form recognizable glandular
structures. The term "sarcoma" is art recognized and refers to
malignant tumors of mesenchymal derivation.
[0057] The 59079 molecules of the invention can be used to monitor,
treat and/or diagnose a variety of proliferative disorders. Such
disorders include hematopoietic neoplastic disorders. As used
herein, the term "hematopoietic neoplastic disorders" includes
diseases involving hyperplastic/neoplastic cells of hematopoietic
origin, e.g., arising from myeloid, lymphoid or erythroid lineages,
or precursor cells thereof. Typically, the diseases arise from
poorly differentiated acute leukemias, e.g., erythroblastic
leukemia and acute megakaryoblastic leukemia. Additional exemplary
myeloid disorders include, but are not limited to, acute promyeloid
leukemia (APML), acute myelogenous leukemia (AML) and chronic
myelogenous leukemia (CML) (reviewed in Vaickus, L., (1991) Crit.
Rev. in Oncol./Hemotol. 11:267-97); lymphoid malignancies include,
but are not limited to acute lymphoblastic leukemia (ALL) which
includes B-lineage ALL and T-lineage ALL, chronic lymphocytic
leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia
(HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of
malignant lymphomas include, but are not limited to non-Hodgkin
lymphoma and variants thereof, peripheral T cell lymphomas, adult T
cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL),
large granular lymphocytic leukemia (LGF), Hodgkin's disease and
Reed-Sternberg disease.
[0058] Protein kinase associated disorders can include hormonal
disorders, such as conditions or diseases in which the production
and/or regulation of hormones in an organism is aberrant. Examples
of such disorders and diseases include type I and type II diabetes
mellitus, pituitary disorders (e.g., growth disorders), thyroid
disorders (e.g., hypothyroidism or hyperthyroidism), and
reproductive or fertility disorders (e.g., disorders which affect
the organs of the reproductive system, e.g., the prostate gland,
the uterus, or the vagina; disorders which involve an imbalance in
the levels of a reproductive hormone in a subject; disorders
affecting the ability of a subject to reproduce; and disorders
affecting secondary sex characteristic development, e.g., adrenal
hyperplasia).
[0059] Protein kinase associated disorders also include immune and
inflammatory disorders, such as autoimmune disorders or immune
deficiency disorders, e.g., congenital X-linked infantile
hypogammaglobulinemia, transient hypogammaglobulinemia, common
variable immunodeficiency, selective IgA deficiency, chronic
mucocutaneous candidiasis, or severe combined immunodeficiency.
Other examples of disorders include autoimmune diseases (including,
for example, diabetes mellitus, arthritis (including rheumatoid
arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic
arthritis), multiple sclerosis, encephalomyelitis, myasthenia
gravis, systemic lupus erythematosis, autoimmune thyroiditis,
dermatitis (including atopic dermatitis and eczematous dermatitis),
psoriasis, Sjogren's Syndrome, inflammatory bowel disease (e.g.,
Crohn's disease and ulcerative colitis), aphthous ulcer, iritis,
conjunctivitis, keratoconjunctivitis, respiratory inflammation
(e.g., asthma, allergic asthma, and chronic obstructive pulmonary
disease), cutaneous lupus erythematosus, scleroderma, vaginitis,
proctitis, drug eruptions, leprosy reversal reactions, erythema
nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis,
acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral
progressive sensorineural hearing loss, aplastic anemia, pure red
cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's
granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome,
idiopathic sprue, lichen planus, Graves' disease, sarcoidosis,
primary biliary cirrhosis, uveitis posterior, and interstitial lung
fibrosis), graft-versus-host disease, cases of transplantation, and
allergy such as, atopic allergy.
[0060] Additional protein kinase associated disorders are
neurological disorders. Such neurological disorders include, for
example, disorders involving neurons, and disorders involving glia,
such as astrocytes, oligodendrocytes, ependymal cells, and
microglia; cerebral edema, raised intracranial pressure and
herniation, and hydrocephalus; malformations and developmental
diseases, such as neural tube defects, forebrain anomalies,
posterior fossa anomalies, and syringomyelia and hydromyelia;
perinatal brain injury; cerebrovascular diseases, such as those
related to hypoxia, ischemia, and infarction, including
hypotension, hypoperfusion, and low-flow states--global cerebral
ischemia and focal cerebral ischemia--infarction from obstruction
of local blood supply, intracranial hemorrhage, including
intracerebral (intraparenchymal) hemorrhage, subarachnoid
hemorrhage and ruptured berry aneurysms, and vascular
malformations, hypertensive cerebrovascular disease, including
lacunar infarcts, slit hemorrhages, and hypertensive
encephalopathy; infections, such as acute meningitis, including
acute pyogenic (bacterial) meningitis and acute aseptic (viral)
meningitis, acute focal suppurative infections, including brain
abscess, subdural empyema, and extradural abscess, chronic
bacterial meningoencephalitis, including tuberculosis and
mycobacterioses, neurosyphilis, and neuroborreliosis (Lyme
disease), viral meningoencephalitis, including arthropod-borne
(Arbo) viral encephalitis, Herpes simplex virus Type 1, Herpes
simplex virus Type 2, Varicella-zoster virus (Herpes zoster),
cytomegalovirus, poliomyelitis, rabies, and human immunodeficiency
virus 1, including HIV-1 meningoencephalitis (subacute
encephalitis), vacuolar myelopathy, AIDS-associated myopathy,
peripheral neuropathy, and AIDS in children, progressive multifocal
leukoencephalopathy, subacute sclerosing panencephalitis, fungal
meningoencephalitis, other infectious diseases of the nervous
system; transmissible spongiform encephalopathies (prion diseases);
demyelinating diseases, including multiple sclerosis, multiple
sclerosis variants, acute disseminated encephalomyelitis and acute
necrotizing hemorrhagic encephalomyelitis, and other diseases with
demyelination; degenerative diseases, such as degenerative diseases
affecting the cerebral cortex, including Alzheimer's disease and
Pick's disease, degenerative diseases of basal ganglia and brain
stem, including Parkinsonism, idiopathic Parkinson's disease
(paralysis agitans), progressive supranuclear palsy, corticobasal
degenration, multiple system atrophy, including striatonigral
degenration, Shy-Drager syndrome, and olivopontocerebellar atrophy,
and Huntington's disease; spinocerebellar degenerations, including
spinocerebellar ataxias, including Friedreich ataxia, and
ataxia-telanglectasia, degenerative diseases affecting motor
neurons, including amyotrophic lateral sclerosis (motor neuron
disease), bulbospinal atrophy (Kennedy syndrome), and spinal
muscular atrophy; inborn errors of metabolism, such as
leukodystrophies, including Krabbe disease, metachromatic
leukodystrophy, adrenoleukodystrophy, Pelizaeus-Merzbacher disease,
and Canavan disease, mitochondrial encephalomyopathies, including
Leigh disease and other mitochondrial encephalomyopathies; toxic
and acquired metabolic diseases, including vitamin deficiencies
such as thiamine (vitamin B.sub.1) deficiency and vitamin B.sub.12
deficiency, neurologic sequelae of metabolic disturbances,
including hypoglycemia, hyperglycemia, and hepatic encephatopathy,
toxic disorders, including carbon monoxide, methanol, ethanol, and
radiation, including combined methotrexate and radiation-induced
injury; tumors, such as gliomas, including astrocytoma, including
fibrillary (diffuse) astrocytoma and glioblastoma multiforme,
pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and brain
stem glioma, oligodendroglioma, and ependymoma and related
paraventricular mass lesions, neuronal tumors, poorly
differentiated neoplasms, including medulloblastoma, other
parenchymal tumors, including primary brain lymphoma, germ cell
tumors, and pineal parenchymal tumors, meningiomas, metastatic
tumors, paraneoplastic syndromes, peripheral nerve sheath tumors,
including schwannoma, neurofibroma, and malignant peripheral nerve
sheath tumor (malignant schwannoma), and neurocutaneous syndromes
(phakomatoses), including neurofibromotosis, including Type 1
neurofibromatosis (NF1) and TYPE 2 neurofibromatosis (NF2),
tuberous sclerosis, and Von Hippel-Lindau disease.
[0061] The 59079 and 12599 proteins, fragments thereof, and
derivatives and other variants of the sequences in SEQ ID NO:2 and
SEQ ID NO:5 are collectively referred to as "polypeptides or
proteins of the invention" or "59079 and/or 12599 polypeptides or
proteins". Nucleic acid molecules encoding such polypeptides or
proteins are collectively referred to as "nucleic acids of the
invention" or "59079 and/or 12599 nucleic acids."
[0062] As used herein, the term "nucleic acid molecule" includes
DNA molecules (e.g., a cDNA or genomic DNA) and RNA molecules
(e.g., an mRNA) and analogs of the DNA or RNA generated, e.g., by
the use of nucleotide analogs. The nucleic acid molecule can be
single-stranded or double-stranded, but preferably is
double-stranded DNA.
[0063] The term "isolated or purified nucleic acid molecule"
includes nucleic acid molecules which are separated from other
nucleic acid molecules which are present in the natural source of
the nucleic acid. For example, with regards to genomic DNA, the
term "isolated" includes nucleic acid molecules which are separated
from the chromosome with which the genomic DNA is naturally
associated. Preferably, an "isolated" nucleic acid is free of
sequences which naturally flank the nucleic acid (i.e., sequences
located at the 5' and/or 3' ends of the nucleic acid) in the
genomic DNA of the organism from which the nucleic acid is derived.
For example, in various embodiments, the isolated nucleic acid
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb,
0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which
naturally flank the nucleic acid molecule in genomic DNA of the
cell from which the nucleic acid is derived. Moreover, an
"isolated" nucleic acid molecule, such as a cDNA molecule, can be
substantially free of other cellular material, or culture medium
when produced by recombinant techniques, or substantially free of
chemical precursors or other chemicals when chemically
synthesized.
[0064] As used herein, the term "hybridizes under stringent
conditions" describes conditions for hybridization and washing.
Stringent conditions are known to those skilled in the art and can
be found in Current Protocols in Molecular Biology, John Wiley
& Sons, N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous
methods are described in that reference and either can be used. A
preferred, example of stringent hybridization conditions are
hybridization in 6.times. sodium chloride/sodium citrate (SSC) at
about 45.degree. C., followed by one or more washes in
0.2.times.SSC, 0.1% SDS at 50.degree. C. Another example of
stringent hybridization conditions are hybridization in 6.times.SSC
at about 45.degree. C., followed by one or more washes in
0.2.times.SSC, 0.1% SDS at 55.degree. C. A further example of
stringent hybridization conditions are hybridization in 6.times.SSC
at about 45.degree. C., followed by one or more washes in
0.2.times.SSC, 0.1% SDS at 60.degree. C. Preferably, stringent
hybridization conditions are hybridization in 6.times.SSC at about
45.degree. C., followed by one or more washes in 0.2.times.SSC,
0.1% SDS at 65.degree. C. Particularly preferred stringency
conditions (and the conditions that should be used if the
practitioner is uncertain about what conditions should be applied
to determine if a molecule is within a hybridization limitation of
the invention) are 0.5M sodium phosphate, 7% SDS at 65.degree. C.,
followed by one or more washes at 0.2.times.SSC, 1% SDS at
65.degree. C. Preferably, an isolated nucleic acid molecule of the
invention that hybridizes under stringent conditions to the
sequence of SEQ ID NOs:1, 3, 4, or 6, corresponds to a
naturally-occurring nucleic acid molecule.
[0065] As used herein, a "naturally-occurring" nucleic acid
molecule refers to an RNA or DNA molecule having a nucleotide
sequence that occurs in nature (e.g., encodes a natural
protein).
[0066] As used herein, the terms "gene" and "recombinant gene"
refer to nucleic acid molecules which include an open reading frame
encoding a 59079 or 12599 protein, preferably a mammalian 59079 or
12599 protein, and can further include non-coding regulatory
sequences, and introns.
[0067] An "isolated" or "purified" polypeptide or protein is
substantially free of cellular material or other contaminating
proteins from the cell or tissue source from which the protein is
derived, or substantially free from chemical precursors or other
chemicals when chemically synthesized. In one embodiment, the
language "substantially free" means a preparation of 59079 or 12599
protein having less than about 30%, 20%, 10% and more preferably 5%
(by dry weight), of non-59079 or non-12599 protein (also referred
to herein as a "contaminating protein"), or of chemical precursors
or non-59079 or non-12599 chemicals. When the 59079 or 12599
protein, or biologically active portion thereof, is recombinantly
produced, it is also preferably substantially free of culture
medium, i.e., culture medium represents less than about 20%, more
preferably less than about 10%, and most preferably less than about
5% of the volume of the protein preparation. The invention includes
isolated or purified preparations of at least 0.01, 0.1, 1.0, and
10 milligrams in dry weight.
[0068] A "non-essential" amino acid residue is a residue that can
be altered from the wild-type sequence of 59079 (e.g., the sequence
of SEQ ID NO:1 or 3) or 12599 (e.g., the sequence of SEQ ID NO:4 or
6) without abolishing or more preferably, without substantially
altering a biological activity, whereas an "essential" amino acid
residue results in such a change. For example, amino acid residues
that are conserved among the polypeptides of the present invention,
e.g., those present in the protein kinasedomain, are predicted to
be particularly unamenable to alteration.
[0069] A "conservative amino acid substitution" is one in which the
amino acid residue is replaced with an amino acid residue having a
similar side chain. Families of amino acid residues having similar
side chains have been defined in the art. These families include
amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g., glycine, asparagine,
glutamine, serine, threonine, tyrosine, cysteine), nonpolar side
chains (e.g., alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan), beta-branched side chains
(e.g., threonine, valine, isoleucine) and aromatic side chains
(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a
predicted nonessential amino acid residue in a 59079 or 12599
protein is preferably replaced with another amino acid residue from
the same side chain family. Alternatively, in another embodiment,
mutations can be introduced randomly along all or part of a 59079
or 12599 coding sequence, such as by saturation mutagenesis, and
the resultant mutants can be screened for 59079 or 12599 biological
activity to identify mutants that retain activity. Following
mutagenesis of SEQ ID NOs:1, 3, 4, or 6, the encoded protein can be
expressed recombinantly and the activity of the protein can be
determined.
[0070] As used herein, a "biologically active portion" of a 59079
or 12599 protein includes a fragment of a 59079 or 12599 protein
which participates in an interaction between a 59079 molecule and a
non-59079 molecule or in an interaction between a 12599 molecule
and a non-12599 molecule. Biologically active portions of a 59079
or 12599 protein include peptides comprising amino acid sequences
sufficiently identical to or derived from the amino acid sequence
of the 59079 protein, e.g., the amino acid sequence shown in SEQ ID
NO:2, or the amino acid sequence of the 12599 protein, e.g., the
amino acid sequence shown in SEQ ID NO:5 which include less amino
acids than the full length 59079 or 12599 proteins, and exhibit at
least one activity of a 59079 or 12599 protein. Typically,
biologically active portions comprise a domain or motif with at
least one activity of the 59079 or 12599 protein, including, e.g.,
the ability to as a protein kinase or activate a protein kinase
activity.
[0071] A biologically active portion of a 59079 or 12599 protein
can be a polypeptide which is, for example, 10, 25, 50, 100, 200,
or more, amino acids in length. Biologically active portions of a
59079 or 12599 protein can be used as targets for developing agents
which modulate a 59079- or 12599-mediated activity as described
herein.
[0072] Calculations of homology or sequence identity (the terms are
used interchangeably herein) between sequences are performed as
follows:
[0073] To determine the percent identity of two amino acid
sequences, or of two nucleic acid sequences, the sequences are
aligned for optimal comparison purposes (e.g., gaps can be
introduced in one or both of a first and a second amino acid or
nucleic acid sequence for optimal alignment and non-homologous
sequences can be disregarded for comparison purposes). In a
preferred embodiment, the length of a reference sequence aligned
for comparison purposes is at least 30%, preferably at least 40%,
more preferably at least 50%, even more preferably at least 60%,
and even more preferably at least 70%, 80%, 90%, 100% of the length
of the reference sequence (e.g., when aligning a second sequence to
the 59079 amino acid sequence of SEQ ID NO:2, at least 789,
preferably at least 1052, more preferably at least 1315, even more
preferably at least 1578, and even more preferably at least 1841,
2104, 2367, or 2630 amino acid residues of the two sequences are
aligned; and when aligning a second sequence to the 12599 amino
acid sequence of SEQ ID NO:5, at least 2391, preferably at least
3187, more preferably at least 3984, even more preferably at least
4781, and even more preferably at least 5578, 6374, 7171, or 7968
amino acid residues of the two sequences are aligned). The amino
acid residues or nucleotides at corresponding amino acid positions
or nucleotide positions are then compared. When a position in the
first sequence is occupied by the same amino acid residue or
nucleotide as the corresponding position in the second sequence,
then the molecules are identical at that position (as used herein
amino acid or nucleic acid "identity" is equivalent to amino acid
or nucleic acid "homology"). The percent identity between the two
sequences is a function of the number of identical positions shared
by the sequences, taking into account the number of gaps, and the
length of each gap, which need to be introduced for optimal
alignment of the two sequences.
[0074] The comparison of sequences and determination of percent
identity between two sequences can be accomplished using a
mathematical algorithm. In a preferred embodiment, the percent
identity between two amino acid sequences is determined using the
Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm
which has been incorporated into the GAP program in the GCG
software package (available at http://www.gcg.com), using either a
Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14,
12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In
yet another preferred embodiment, the percent identity between two
nucleotide sequences is determined using the GAP program in the GCG
software package (available at http://www.gcg.com), using a
NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and
a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred
set of parameters (and the one that should be used if the
practitioner is uncertain about what parameters should be applied
to determine if a molecule is within a sequence identity or
homology limitation of the invention) are a Blossum 62 scoring
matrix with a gap penalty of 12, a gap extend penalty of 4, and a
frameshift gap penalty of 5.
[0075] The percent identity between two amino acid or nucleotide
sequences can be determined using the algorithm of E. Meyers and W.
Miller ((1989) CABIOS, 4:11-17) which has been incorporated into
the ALIGN program (version 2.0), using a PAM 120 weight residue
table, a gap length penalty of 12 and a gap penalty of 4.
[0076] The nucleic acid and protein sequences described herein can
be used as a "query sequence" to perform a search against public
databases to, for example, identify other family members or related
sequences. Such searches can be performed using the NBLAST and
XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol.
Biol. 215:403-10. BLAST nucleotide searches can be performed with
the NBLAST program, score=100, wordlength=12 to obtain nucleotide
sequences homologous to 59079 nucleic acid molecules of the
invention. BLAST protein searches can be performed with the XBLAST
program, score=50, wordlength=3 to obtain amino acid sequences
homologous to 59079 protein molecules of the invention. To obtain
gapped alignments for comparison purposes, Gapped BLAST can be
utilized as described in Altschul et al., (1997) Nucleic Acids Res.
25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the
default parameters of the respective programs (e.g., XBLAST and
NBLAST) can be used. See http://www.ncbi.nlm.nih.gov.
[0077] Particular 59079 and 12599 polypeptides of the present
invention have an amino acid sequence sufficiently identical or
substantially identical to the amino acid sequence of SEQ ID NO:2
or SEQ ID NO:5. The term "sufficiently identical" or "substantially
identical" is used herein to refer to a first amino acid or
nucleotide sequence that contains a sufficient or minimum number of
identical or equivalent (e.g., with a similar side chain) amino
acid residues or nucleotides to a second amino acid or nucleotide
sequence such that the first and second amino acid or nucleotide
sequences have a common structural domain or common functional
activity. For example, amino acid or nucleotide sequences that
contain a common structural domain having at least about 60%, or
65% identity, likely 75% identity, more likely 85%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98% or 99% identity are defined herein as
sufficiently or substantially identical.
[0078] "Misexpression or aberrant expression", as used herein,
refers to a non-wild type pattern of gene expression, at the RNA or
protein level. It includes: expression at non-wild type levels,
i.e., over- or under-expression; a pattern of expression that
differs from wild type in terms of the time or stage at which the
gene is expressed, e.g., increased or decreased expression (as
compared with wild type) at a predetermined developmental period or
stage; a pattern of expression that differs from wild type in terms
of decreased expression (as compared with wild type) in a
predetermined cell type or tissue type; a pattern of expression
that differs from wild type in terms of the splicing size, amino
acid sequence, post-transitional modification, or biological
activity of the expressed polypeptide; a pattern of expression that
differs from wild type in terms of the effect of an environmental
stimulus or extracellular stimulus on expression of the gene, e.g.,
a pattern of increased or decreased expression (as compared with
wild type) in the presence of an increase or decrease in the
strength of the stimulus.
[0079] "Subject", as used herein, can refer to a mammal, e.g., a
human, or to an experimental or animal or disease model. The
subject can also be a non-human animal, e.g., a horse, cow, goat,
or other domestic animal.
[0080] A "purified preparation of cells", as used herein, refers
to, in the case of plant or animal cells, an in vitro preparation
of cells and not an entire intact plant or animal. In the case of
cultured cells or microbial cells, it consists of a preparation of
at least 10% and more preferably 50% of the subject cells.
[0081] Various aspects of the invention are described in further
detail below.
[0082] Isolated Nucleic Acid Molecules
[0083] In one aspect, the invention provides, an isolated or
purified, nucleic acid molecule that encodes a 59079 or 12599
polypeptide described herein, e.g., a full length 59079 or 12599
protein or a fragment thereof, e.g., a biologically active portion
of a 59079 or 12599 protein. Also included is a nucleic acid
fragment suitable for use as a hybridization probe, which can be
used, e.g., to identify a nucleic acid molecule encoding a
polypeptide of the invention, 59079 or 12599 mRNA, and fragments
suitable for use as primers, e.g., PCR primers for the
amplification or mutation of nucleic acid molecules.
[0084] In one embodiment, an isolated nucleic acid molecule of the
invention includes the nucleotide sequence shown in SEQ ID NO:1, or
a portion or fragment thereof. In one embodiment, the nucleic acid
molecule includes sequences encoding the human 59079 protein (i.e.,
"the coding region", from nucleotides 72 to 7964 of SEQ ID NO:1,
including the termination codon, shown as in SEQ ID NO:3), as well
as untranslated (e.g., noncoding) sequences, e.g., 5' untranslated
sequence (i.e., nucleotides 1 to 71 of SEQ ID NO:1) and/or 3'
untranslated sequence (i.e., nucleotides 7965 to 8106 of SEQ ID
NO:1). Alternatively, the nucleic acid molecule can include only
the coding region of SEQ ID NO:1 (e.g., nucleotides 1 to 7893 of
SEQ ID NO:3) and, e.g., no flanking sequences which normally
accompany the subject sequence. In another embodiment, the nucleic
acid molecule encodes a sequence corresponding to the mature
protein of SEQ ID NO:2. In yet another embodiment, the nucleic acid
molecule encodes a sequence corresponding to a fragment of the
protein from about amino acids 1130 to 1383 or from about amino
acids 2334 to 2586 of SEQ ID NO:2.
[0085] In another embodiment, an isolated nucleic acid molecule of
the invention includes the nucleotide sequence shown in SEQ ID
NO:4, or a portion or fragment thereof. In one embodiment, the
nucleic acid molecule includes sequences encoding the human 59079
protein (i.e., "the coding region", from nucleotides 72 to 23,978
of SEQ ID NO:4, including the termination codon, shown as in SEQ ID
NO:3), as well as untranslated (e.g., noncoding) sequences, e.g.,
5' untranslated sequence (i.e., nucleotides 1 to 71 of SEQ ID NO:4)
and/or 3' untranslated sequence (i.e., nucleotides 23,979 to 24,120
of SEQ ID NO:4). Alternatively, the nucleic acid molecule can
include only the coding region of SEQ ID NO:4 (e.g., nucleotides 1
to 23,907 of SEQ ID NO:6) and, e.g., no flanking sequences which
normally accompany the subject sequence. In another embodiment, the
nucleic acid molecule encodes a sequence corresponding to the
mature protein of SEQ ID NO:5. In yet another embodiment, the
nucleic acid molecule encodes a sequence corresponding to a
fragment of the protein from about amino acids 6468 to 6721 or from
about amino acids 7672 to 7924 of SEQ ID NO:5.
[0086] In another embodiment, an isolated nucleic acid molecule of
the invention includes a nucleic acid molecule which is a
complement of the nucleotide sequence shown in SEQ ID NOs:1, 3, 4,
or 6, or a portion or fragment thereof. In other embodiments, the
nucleic acid molecule of the invention is sufficiently
complementary to the nucleotide sequence shown in SEQ ID NOs:1, 3,
4, or 6 such that it can hybridize to the nucleotide sequence shown
in SEQ ID NO:1 or 3, thereby forming a stable duplex.
[0087] In one embodiment, an isolated nucleic acid molecule of the
present invention includes a nucleotide sequence which is at least
about: 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, 99%, or more, homologous to the entire length of the
nucleotide sequence shown in SEQ ID NOs:1, 3, 4, or 6, or a portion
or fragment thereof, preferably of the same length, of any of these
nucleotide sequences.
[0088] 59079 Nucleic Acid Fragments
[0089] A nucleic acid molecule of the invention can include only a
portion or fragment of the nucleic acid sequence of SEQ ID NO:1, 3,
4, or 6. For example, such a nucleic acid molecule can include a
fragment which can be used as a probe or primer or a fragment
encoding a portion of a 59079 or 12599 protein, e.g., an
immunogenic or biologically active portion of a 59079 or 12599
protein. A fragment or portion can comprise those nucleotides of
SEQ ID NO:1 or 4 which encode a protein kinase catalytic domain of
human 59079 or 12599. The nucleotide sequences determined from the
cloning of the 59079 gene allows for the generation of probes and
primers designed for use in identifying and/or cloning other 59079
family members, e.g., 12599, or fragments thereof, as well as 59079
homologues, or fragments thereof, from other species.
[0090] In another embodiment, a nucleic acid includes a nucleotide
sequence that includes part, or all, of the coding region and
extends into either (or both) the 5' or 3' noncoding or
untranslated region. Other embodiments include a fragment which
includes a nucleotide sequence encoding an amino acid fragment
described herein. Nucleic acid fragments can encode a specific
domain or site described herein or fragments thereof, particularly
fragments thereof which are at least 75 amino acids in length.
Fragments also include nucleic acid sequences corresponding to
specific amino acid sequences described above or fragments thereof.
Nucleic acid fragments should not to be construed as encompassing
those fragments that may have been disclosed prior to the
invention.
[0091] A nucleic acid fragment can include a sequence corresponding
to a domain, region, or functional site described herein. A nucleic
acid fragment can also include one or more domain, region, or
functional site described herein. Thus, for example, a 59079
nucleic acid fragment can include a sequence corresponding to a
protein kinase catalytic domain.
[0092] 59079 and 12599 probes and primers are provided. Typically a
probe/primer is an isolated or purified oligonucleotide. The
oligonucleotide typically includes a region of nucleotide sequence
that hybridizes under stringent conditions to at least about 7, 12
or 15, preferably about 20 or 25, more preferably about 30, 35, 40,
45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense or
antisense sequence of SEQ ID NOs:1, 3, 4, or 6, or of a naturally
occurring allelic variant or mutant of SEQ ID NOs:1, 3, 4, or
6.
[0093] In a preferred embodiment the nucleic acid is a probe which
is at least 5 or 10, and less than 200, more preferably less than
100, or less than 50, base pairs in length. It should be identical,
or differ by 1, or less than in 5 or 10 bases, from a sequence
disclosed herein. If alignment is needed for this comparison the
sequences should be aligned for maximum homology. "Looped" out
sequences from deletions or insertions, or mismatches, are
considered differences.
[0094] A probe or primer can be derived from the sense or
anti-sense strand of a nucleic acid which encodes a protein kinase
catalytic domain (e.g., the nucleotides encoding amino acid
residues 1130 to 1383 or 2334 to 2586 of SEQ ID NO:2, and the
nucleotides encoding amino acid residues 6468 to 6721 or 7672 to
7924 of SEQ ID NO:5) or a pleckstrin homology domain (e.g., the
nucleotides encoding amino acid residues 558 to 666 of SEQ ID NO:2,
or the nucleotides encoding amino acid residues 5896 to 6004 of SE
ID NO:5), or a fragment thereof.
[0095] In another embodiment, a set of primers is provided, e.g.,
primers suitable for use in a PCR, which can be used to amplify a
selected region of a 59079 orm12599 sequence, e.g., a domain,
region, site or other sequence described herein. The primers should
be at least 5, 10, or 50 base pairs in length and less than 100, or
less than 200, base pairs in length. The primers should be
identical, or differs by one base from a sequence disclosed herein
or from a naturally occurring variant. For example, primers
suitable for amplifying all or a portion of any of the following
regions are provided: protein kinase catalytic domain from about
amino acids 1130 to 1383 or 2334 to 2586 of SEQ ID NO:2, or from
about amino acids 6468 to 6721 or 7672 to 7924 of SEQ ID NO:5, and
a pleckstrin homology domain from about amino acids 558 to 666 of
SEQ ID NO:2, or from about amino acids 5896 to 6004 of SEQ ID
NO:5.
[0096] A nucleic acid fragment can encode an epitope bearing region
of a polypeptide described herein.
[0097] A nucleic acid fragment encoding a "biologically active
portion of a 59079 or a 12599 polypeptide" can be prepared by
isolating a portion of the nucleotide sequence of SEQ ID NO:1, 3,
4, or 6 which encodes a polypeptide having a 59079 or 12599
biological activity (e.g., any of the biological activities of the
59079 and 12599 proteins described herein), expressing the encoded
portion of the 59079 or 12599 protein (e.g., by recombinant
expression in vitro) and assessing the activity of the encoded
portion of the 59079 or 12599 protein. For example, a nucleic acid
fragment encoding a biologically active portion of 59079 or 12599
includes a protein kinase catalytic domain, e.g., amino acid
residues from about 1130 to 1383 or 2334 to 2586 of SEQ ID NO:2, or
amino acid residues from about 6468 to 6721 or 7672 to 7924 of SEQ
ID NO:5. A nucleic acid fragment encoding a biologically active
portion of a 59079 or 12599 polypeptide, may comprise a nucleotide
sequence which is greater than 700 or more nucleotides in
length.
[0098] In preferred embodiments, a nucleic acid includes a
nucleotide sequence which is about 300, 400, 500, 600, 700, 800,
900, 1000, 1100, 1200, 1300, 2000, 3000, 4000, 5000, 5500, 6000,
6500, 7000, 12,000, 15,000, 18,000, 20,000, 21,000, 22,000, 23,000,
24,000, or more, nucleotides in length and hybridizes under
stringent hybridization conditions to a nucleic acid molecule of
SEQ ID NO:1, 3, 4, or 6, or a complement thereof.
[0099] 59079 and 12599 Nucleic Acid Variants
[0100] The invention further encompasses nucleic acid molecules
that differ from the nucleotide sequence shown in SEQ ID NOs:1, 3,
4, or 6. Such differences can be due to degeneracy of the genetic
code and result in a nucleic acid which encodes the same 59079
proteins as those encoded by the nucleotide sequence disclosed
herein. In another embodiment, an isolated nucleic acid molecule of
the invention has a nucleotide sequence encoding a protein having
an amino acid sequence which differs, by at least 1, but less than
10, 50, 75, 100, 200, 400, or 500 amino acid residues shown in SEQ
ID NO:2, or by at least 1, but less than 100, 200, 300, 400, 500,
700, 1000, 1200, or 1500 amino acid residues shown in SEQ ID NO:5.
If alignment is needed for this comparison, the sequences should be
aligned for maximum homology. "Looped" out sequences from deletions
or insertions, or mismatches, are considered differences.
[0101] Nucleic acids of the inventor can be chosen for having
codons which are preferred or non-preferred for a particular
expression system. For example, the nucleic acid can be one in
which at least one codon, preferably at least 10% or 20% of the
codons, has been altered such that the sequence is optimized for
expression in bacterial (e.g., E. coli), yeast, human, insect, or
nonhuman mammalian (e.g., CHO) cells.
[0102] Nucleic acid variants can be naturally occurring, such as
allelic variants (same locus), homologs (different locus), and
orthologs (different organism) or can be non-naturally occurring.
Non-naturally occurring variants can be made by mutagenesis
techniques, including those applied to polynucleotides, cells, or
organisms. The variants can contain nucleotide substitutions,
deletions, inversions and insertions. Variation can occur in either
or both the coding and non-coding regions. The variations can
produce both conservative and non-conservative amino acid
substitutions (as compared in the encoded product).
[0103] In a preferred embodiment, the nucleic acid differs from
that of SEQ ID NO:1, 3, 4, or 6, e.g., as follows: by at least one
but less than 10, 20, 30, or 40 nucleotides; at least one, but less
than 1%, 5%, 10% or 20%, of the nucleotides in the subject nucleic
acid. If necessary for this analysis the sequences should be
aligned for maximum homology. "Looped" out sequences from deletions
or insertions, or mismatches, are considered differences.
[0104] Orthologs, homologs, and allelic variants can be identified
using methods known in the art. These variants comprise a
nucleotide sequence encoding a polypeptide that is 50%, at least
about 55%, typically at least about 70-75%, more typically at least
about 80-85%, and most typically at least about 90-95% or more,
identical to the nucleotide sequence shown in SEQ ID NO:2, or a
fragment of this sequence. Such nucleic acid molecules can readily
be identified as being able to hybridize under stringent conditions
to the nucleotide sequence shown in SEQ ID NO:2 or 5, or a fragment
of the sequence. Nucleic acid molecules corresponding to orthologs,
homologs, and allelic variants of the 59079 and 12599 cDNAs of the
invention can further be isolated by mapping to the same chromosome
or locus as the 59079 or 12599 genes.
[0105] Preferred variants include those that are correlated with at
least one of the following 59079 and 12599 biological activities:
(1) the ability to act as a protein kinase; (2) the ability to
activate a protein kinase activity; (3) the ability to regulate
transmission of signals from cellular receptors, e.g., cell growth
factor receptors; (4) the ability to modulate the entry of cells,
e.g., precursor cells, into mitosis; (5) the ability to modulate
cellular differentiation; (6) the ability to modulate cell death;
and (7) the ability to regulate cytoskeleton function, e.g., actin
bundling.
[0106] Allelic variants of 59079 and 12599, e.g., human 59079 and
human 12599, include both functional and non-functional proteins.
Functional allelic variants are naturally occurring amino acid
sequence variants of the 59079 or 12599 proteins within a
population that maintain at least one of the 59079 or 12599
biological activities described herein.
[0107] Functional allelic variants will typically contain only
conservative substitution of one or more amino acids of SEQ ID NO:2
or 5, or substitution, deletion or insertion of non-critical
residues in non-critical regions of the protein. Non-functional
allelic variants are naturally occurring amino acid sequence
variants of the 59079 or 12599, e.g., human 59079, protein within a
population that do not have any of the 59079 biological activities
described herein. Non-functional allelic variants can typically
contain a non-conservative substitution, a deletion, or insertion,
or premature truncation of the amino acid sequence of SEQ ID NO:2
or 5, or a substitution, insertion, or deletion in critical
residues or critical regions of the protein.
[0108] Moreover, nucleic acid molecules encoding other 59079 and
12599 family members, and, thus, which have a nucleotide sequence
which differs from the 59079 sequences of SEQ ID NOs:1, 3, 4, or 6
are intended to be within the scope of the invention.
[0109] Antisense Nucleic Acid Molecules, Ribozymes and Modified
59079 Nucleic Acid Molecules
[0110] In another aspect, the invention features, an isolated
nucleic acid molecule which is antisense to 59079 or 12599. An
"antisense" nucleic acid can include a nucleotide sequence which is
complementary to a "sense" nucleic acid encoding a protein, e.g.,
complementary to the coding strand of a double-stranded cDNA
molecule or complementary to an mRNA sequence. The antisense
nucleic acid can be complementary to an entire 59079 or 12599
coding strand, or to only a portion thereof (e.g., the coding
region of human 59079 corresponding to SEQ ID NO:3, or the coding
region of human 12599 corresponding to SEQ ID NO:5). In another
embodiment, the antisense nucleic acid molecule is antisense to a
"noncoding region" of the coding strand of a nucleotide sequence
encoding 59079 or 12599 (e.g., the 5' and 3' untranslated
regions).
[0111] An antisense nucleic acid can be designed such that it is
complementary to the entire coding region of 59079 or 12599 mRNA,
but more preferably is an oligonucleotide which is antisense to
only a portion of the coding or noncoding region of 59079 or 12599
mRNA. For example, the antisense oligonucleotide can be
complementary to the region surrounding the translation start site
of 59079 or 12599 mRNA, e.g., between the -10 and +10 regions of
the target gene nucleotide sequence of interest. An antisense
oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30,
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in
length.
[0112] An antisense nucleic acid of the invention can be
constructed using chemical synthesis and enzymatic ligation
reactions using procedures known in the art. For example, an
antisense nucleic acid (e.g., an antisense oligonucleotide) can be
chemically synthesized using naturally occurring nucleotides or
variously modified nucleotides designed to increase the biological
stability of the molecules or to increase the physical stability of
the duplex formed between the antisense and sense nucleic acids,
e.g., phosphorothioate derivatives and acridine substituted
nucleotides can be used. The antisense nucleic acid also can be
produced biologically using an expression vector into which a
nucleic acid has been subcloned in an antisense orientation (i.e.,
RNA transcribed from the inserted nucleic acid will be of an
antisense orientation to a target nucleic acid of interest,
described further in the following subsection).
[0113] The antisense nucleic acid molecules of the invention are
typically administered to a subject (e.g., by direct injection at a
tissue site), or generated in situ such that they hybridize with or
bind to cellular mRNA and/or genomic DNA encoding a 59079 or 12599
protein to thereby inhibit expression of the protein, e.g., by
inhibiting transcription and/or translation. Alternatively,
antisense nucleic acid molecules can be modified to target selected
cells and then administered systemically. For systemic
administration, antisense molecules can be modified such that they
specifically bind to receptors or antigens expressed on a selected
cell surface, e.g., by linking the antisense nucleic acid molecules
to peptides or antibodies which bind to cell surface receptors or
antigens. The antisense nucleic acid molecules can also be
delivered to cells using the vectors described herein. To achieve
sufficient intracellular concentrations of the antisense molecules,
vector constructs in which the antisense nucleic acid molecule is
placed under the control of a strong pol II or pol III promoter are
preferred.
[0114] In yet another embodiment, the antisense nucleic acid
molecule of the invention is an .alpha.-anomeric nucleic acid
molecule. An .alpha.-anomeric nucleic acid molecule forms specific
double-stranded hybrids with complementary RNA in which, contrary
to the usual .beta.-units, the strands run parallel to each other
(Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641). The
antisense nucleic acid molecule can also comprise a
2'-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res.
15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987)
FEBS Lett. 215:327-330).
[0115] In still another embodiment, an antisense nucleic acid of
the invention is a ribozyme. A ribozyme having specificity for a
59079- or 12599-encoding nucleic acid can include one or more
sequences complementary to the nucleotide sequence of a 59079 or
12599 cDNA disclosed herein (i.e., SEQ ID NOs:1, 3, 4, or 6), and a
sequence having known catalytic sequence responsible for mRNA
cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and Gerlach
(1988) Nature 334:585-591). For example, a derivative of a
Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide
sequence of the active site is complementary to the nucleotide
sequence to be cleaved in a 59079-encoding mRNA. See, e.g., Cech et
al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No.
5,116,742. Alternatively, 59079 mRNA can be used to select a
catalytic RNA having a specific ribonuclease activity from a pool
of RNA molecules. See, e.g., Bartel, D. and Szostak, J. W. (1993)
Science 261:1411-1418.
[0116] 59079 and 12599 gene expression can be inhibited by
targeting nucleotide sequences complementary to the regulatory
region of 59079 or 12599 (e.g., the 59079 or 12599 promoter and/or
enhancers) to form triple helical structures that prevent
transcription of the 59079 gene in target cells. See generally,
Helene, C. (1991) Anticancer Drug Des. 6:569-84; Helene, C. i
(1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher, L. J. (1992)
Bioassays 14:807-15. The potential sequences that can be targeted
for triple helix formation can be increased by creating a so called
"switchback" nucleic acid molecule. Switchback molecules are
synthesized in an alternating 5'-3',3'-5' manner, such that they
base pair with first one strand of a duplex and then the other,
eliminating the necessity for a sizeable stretch of either purines
or pyrimidines to be present on one strand of a duplex.
[0117] The invention also provides detectably labeled
oligonucleotide primer and probe molecules. Typically, such labels
are chemiluminescent, fluorescent, radioactive, or
colorimetric.
[0118] A 59079 or 12599 nucleic acid molecule can be modified at
the base moiety, sugar moiety or phosphate backbone to improve,
e.g., the stability, hybridization, or solubility of the molecule.
For example, the deoxyribose phosphate backbone of the nucleic acid
molecules can be modified to generate peptide nucleic acids (see
Hyrup B. et al. (1996) Bioorganic & Medicinal Chemistry 4:
5-23). As used herein, the terms "peptide nucleic acid" or "PNA"
refers to a nucleic acid mimic, e.g., a DNA mimic, in which the
deoxyribose phosphate backbone is replaced by a pseudopeptide
backbone and only the four natural nucleobases are retained. The
neutral backbone of a PNA can allow for specific hybridization to
DNA and RNA under conditions of low ionic strength. The synthesis
of PNA oligomers can be performed using standard solid phase
peptide synthesis protocols as described in Hyrup B. et al. (1996)
supra; Perry-O'Keefe et al. Proc. Natl. Acad. Sci. 93:
14670-675.
[0119] PNAs of 59079 and 12599 nucleic acid molecules can be used
in therapeutic and diagnostic applications. For example, PNAs can
be used as antisense or antigene agents for sequence-specific
modulation of gene expression by, for example, inducing
transcription or translation arrest or inhibiting replication. PNAs
of 59079 and 12599 nucleic acid molecules can also be used in the
analysis of single base pair mutations in a gene, (e.g., by
PNA-directed PCR clamping); as `artificial restriction enzymes`
when used in combination with other enzymes, (e.g., S1 nucleases
(Hyrup B. et al. (1996) supra)); or as probes or primers for DNA
sequencing or hybridization (Hyrup B. et al. (1996) supra;
Perry-O'Keefe supra).
[0120] In other embodiments, the oligonucleotide may include other
appended groups such as peptides (e.g., for targeting host cell
receptors in vivo), or agents facilitating transport across the
cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad.
Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad.
Sci. USA 84:648-652; PCT Publication No. WO88/09810) or the
blood-brain barrier (see, e.g., PCT Publication No. WO89/10134). In
addition, oligonucleotides can be modified with
hybridization-triggered cleavage agents (see, e.g., Krol et al.
(1988) Bio-Techniques 6:958-976) or intercalating agents. (see,
e.g., Zon (1988) Pharm. Res. 5:539-549). To this end, the
oligonucleotide may be conjugated to another molecule, (e.g., a
peptide, hybridization triggered cross-linking agent, transport
agent, or hybridization-triggered cleavage agent).
[0121] The invention also includes molecular beacon oligonucleotide
primer and probe molecules having at least one region which is
complementary to a 59079 or 12599 nucleic acid of the invention,
two complementary regions one having a fluorophore and one a
quencher such that the molecular beacon is useful for quantitating
the presence of the 59079 or 12599 nucleic acid of the invention in
a sample. Molecular beacon nucleic acids are described, for
example, in Lizardi et al., U.S. Pat. No. 5,854,033; Nazarenko et
al., U.S. Pat. No. 5,866,336, and Livak et al., U.S. Pat. No.
5,876,930.
[0122] Isolated 59079 Polypeptides
[0123] In another aspect, the invention features, isolated 59079
and 12599 proteins, or a fragment, e.g., a biologically active
portion, for use as immunogens or antigens to raise or test (or
more generally to bind) anti-59079 and anti-12599 antibodies. 59079
and 12599 proteins can be isolated from cells or tissue sources
using standard protein purification techniques. 59079 and 12599
proteins, or fragments thereof, can be produced by recombinant DNA
techniques or synthesized chemically.
[0124] Polypeptides of the invention include those which arise as a
result of the existence of multiple genes, alternative
transcription events, alternative RNA splicing events, and
alternative translational and post-translational events. The
polypeptide can be expressed in systems, e.g., cultured cells,
which result in substantially the same post-translational
modifications present when expressed the polypeptide is expressed
in a native cell, or in systems which result in the alteration or
omission of post-translational modifications, e.g., glycosylation
or cleavage, present when expressed in a native cell.
[0125] In a preferred embodiment, a 59079 and a 12599 polypeptide
each has one or more of the following characteristics:
[0126] the ability to act as a protein kinase, activate a protein
kinase activity, act as a substrate for a protein kinase or perform
any of the 59079 or 12599 biological activities described
herein;
[0127] a molecular weight, e.g., a deduced molecular weight, amino
acid composition or other physical characteristic of the
polypeptide of SEQ ID NO:2 or 5;
[0128] an overall sequence similarity of at least 50%, preferably
at least 60%, more preferably at least 70, 80, 90, 95%, 96%, 97%,
or 98%, with a polypeptide of SEQ ID NO:2 or 5; and
[0129] a protein kinase catalytic domain which preferably has an
overall sequence similarity of about 70%, 80%, 90% or 95% with
amino acid residues 1130 to 1383 or 2334 to 2586 of SEQ ID NO:2 or
amino acid residues 6468 to 6721 or 7672 to 7924 of SEQ ID NO:5;
and
[0130] In a preferred embodiment, the 59079 and 12599 proteins, or
a fragment thereof, differs from the corresponding sequence in SEQ
ID NO:2 or 5. In one embodiment it differs by at least one, but by
less than 15, 10 or 5, amino acid residues. In another it differs
from the corresponding sequence in SEQ ID NO:2 or 5 by at least one
residue, but less than 20%, 15%, 10% or 5%, of the residues in it
differ from the corresponding sequence in SEQ ID NO:2 or 5. (If
this comparison requires alignment the sequences should be aligned
for maximum homology. "Looped" out sequences from deletions or
insertions, or mismatches, are considered differences.) The
differences are, preferably, differences or changes at a
nonessential residue or a conservative substitution. In a preferred
embodiment the differences are not in the protein kinase catalytic
domain. In another preferred embodiment one or more differences are
in the protein kinase catalytic domain.
[0131] Other embodiments include a protein that contain one or more
changes in amino acid sequence, e.g., a change in an amino acid
residue which is not essential for activity. Such 59079 and 12599
proteins differ in amino acid sequence from SEQ ID NO:2 and 5, yet
retain biological activity.
[0132] In one embodiment, the protein includes an amino acid
sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 98%, or more, homologous to SEQ ID NO:2 or 5.
[0133] A 59079 protein or fragment is provided which varies from
the sequences of SEQ ID NO.2 in regions defined by amino acids from
about 1 to 1129, 1384 to 2333, or 2587 to 2630 by at least one, but
by less than 50, 15, 10 or 5, amino acid residues in the protein or
fragment, but which does not differ from SEQ ID NO.2 in a region
defined by amino acids about 1130 to 1383 or 2334 to 2586. A 12599
protein or fragment is provided which varies from the sequence of
SEQ ID NO:5 in regions defined by amino acids from about 1 to 6467,
6722 to 7671, or 7925 to 7968 by least one, but by less than 50,
15, 10, or 5, amino acid residues in the protein or fragment, but
which does not differ from SEQ ID NO:5 in a region defind by amino
acids at about 6468 to 6721 or 7672 to 7924 of SEQ ID NO:5. (If
this comparison requires alignment the sequences should be aligned
for maximum homology. "Looped" out sequences from deletions or
insertions, or mismatches, are considered differences.) In some
embodiments the difference is at a non essential residue or is a
conservative substitution, while in others the difference is at an
essential residue or is a non conservative substitution.
[0134] In one embodiment, a biologically active portion of a 59079
or 12599 protein includes a protein kinase catalytic domain.
Moreover, other biologically active portions, in which other
regions of the protein are deleted, can be prepared by recombinant
techniques and evaluated for one or more of the functional
activities of a native 59079 or 12599 protein.
[0135] In a preferred embodiment, the 59079 protein has an amino
acid sequence shown in SEQ ID NO:2. In other embodiments, the 59079
protein is substantially identical to SEQ ID NO:2. In yet another
embodiment, the 59079 protein is substantially identical to SEQ ID
NO:2 and retains the functional activity of the protein of SEQ ID
NO:2, as described herein.
[0136] In a preferred embodiment, the 12599 protein has an amino
acid sequence shown in SEQ ID NO:5. In other embodiments, the 12599
protein is substantially identical to SEQ ID NO:5. In yet another
embodiment, the 12599 protein is substantially identical to SEQ ID
NO:5 and retains the functional activity of the protein of SEQ ID
NO:5, as described herein.
[0137] 59079 and 12599 Chimeric or Fusion Proteins
[0138] In another aspect, the invention provides 59079 and 12599
chimeric or fusion proteins. As used herein, a 59079 or 12599
"chimeric protein" or "fusion protein" includes a 59079 or 12599
polypeptide linked to a non-59079 or non-12599 polypeptide. A
"non-59079 polypeptide" or a "non-12599 polypeptide" refers to a
polypeptide having an amino acid sequence corresponding to a
protein which is not substantially homologous to the 59079 or 12599
protein, e.g., a protein which is different from the 59079 or 12599
protein and which is derived from the same or a different organism.
The 59079 or 12599 polypeptide of the fusion protein can correspond
to all or a portion, e.g., a fragment, described herein of a 59079
or 12599 amino acid sequence. In a preferred embodiment, a 59079
fusion protein includes at least one (or two) biologically active
portion of a 59079 protein. In another preferred embodiment, a
12599 fusion protein includes at least one (or two) biologically
active portion of a 12599 protein. The non-59079 and non-12599
polypeptides can be fused to the N-terminus or C-terminus of the
59079 or 12599 polypeptide.
[0139] The fusion protein can include a moiety which has a high
affinity for a ligand. For example, the fusion protein can be a
GST-59079 or -12599 fusion protein in which the 59079 or 12599
sequences are fused to the C-terminus of the GST sequences. Such
fusion proteins can facilitate the purification of recombinant
59079 or 12599. Alternatively, the fusion protein can be a 59079 or
12599 protein containing a heterologous signal sequence at its
N-terminus. In certain host cells (e.g., mammalian host cells),
expression and/or secretion of 59079 or 12599 can be increased
through use of a heterologous signal sequence.
[0140] Fusion proteins can include all or a part of a serum
protein, e.g., a portion of an immunoglobulin (e.g., IgG, IgA, or
IgE), e.g., an Fc region and/or the hinge C1 and C2 sequences of an
immunoglobulin or human serum albumin.
[0141] The 59079 and 12599 fusion proteins of the invention can be
incorporated into pharmaceutical compositions and administered to a
subject in vivo. The 59079 or 12599 fusion proteins can be used to
affect the bioavailability of a 59079 or 12599 substrate. 59079 and
12599 fusion proteins can be used therapeutically for the treatment
of disorders caused by, for example, (i) aberrant modification or
mutation of a gene encoding a 59079 or 12599 protein; (ii)
mis-regulation of the 59079 or 12599 gene; and (iii) aberrant
post-translational modification of a 59079 or 12599 protein.
[0142] Moreover, the 59079 and 12599 fusion proteins of the
invention can be used as immunogens to produce anti-59079 or
anti-12599 antibodies in a subject, to purify 59079 or 12599
ligands and in screening assays to identify molecules which inhibit
the interaction of 59079 with a 59079 substrate or the interaction
of 12599 with a 12599 substrate.
[0143] Expression vectors are commercially available that already
encode a fusion moiety (e.g., a GST polypeptide). A 59079-encoding
nucleic acid can be cloned into such an expression vector such that
the fusion moiety is linked in-frame to the 59079 protein.
[0144] Variants of 59079 and 12599 Proteins
[0145] In another aspect, the invention also features a variant of
a 59079 and 12599 polypeptide, e.g., which functions as an agonist
(mimetics) or as an antagonist. Variants of the 59079 and 12599
proteins can be generated by mutagenesis, e.g., discrete point
mutation, the insertion or deletion of sequences or the truncation
of a 59079 or 12599 protein. An agonist of the 59079 or 12599
proteins can retain substantially the same, or a subset, of the
biological activities of the naturally occurring form of a 59079 or
12599 protein. An antagonist of a 59079 or 12599 protein can
inhibit one or more of the activities of the naturally occurring
form of the 59079 or 12599 protein by, for example, competitively
modulating a 59079- or 12599-mediated activity of a 59079 or 12599
protein. Thus, specific biological effects can be elicited by
treatment with a variant of limited function. Preferably, treatment
of a subject with a variant having a subset of the biological
activities of the naturally occurring form of the protein has fewer
side effects in a subject relative to treatment with the naturally
occurring form of the 59079 or 12599 protein.
[0146] Variants of a 59079 or 12599 protein can be identified by
screening combinatorial libraries of mutants, e.g., truncation
mutants, of a 59079 or 12599 protein for agonist or antagonist
activity.
[0147] Libraries of fragments, e.g., N terminal, C terminal, or
internal fragments, of a 59079 protein coding sequence can be used
to generate a variegated population of fragments for screening and
subsequent selection of variants of a 59079 or 12599 protein.
[0148] Variants in which a cysteine residues is added or deleted or
in which a residue which is glycosylated is added or deleted are
particularly preferred.
[0149] Methods for screening gene products of combinatorial
libraries made by point mutations or truncation, and for screening
cDNA libraries for gene products having a selected property.
Recursive ensemble mutagenesis (REM), a new technique which
enhances the frequency of functional mutants in the libraries, can
be used in combination with the screening assays to identify 59079
and 12599 variants (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci.
USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering
6:327-331).
[0150] Cell based assays can be exploited to analyze a variegated
59079 library. For example, a library of expression vectors can be
transfected into a cell line, e.g., an endothelial cell line, which
ordinarily responds to 59079 or 12599 in a particular 59079 or
12599 substrate-dependent manner. The transfected cells are then
contacted with 59079 or 12599 and the effect of expression of the
mutant on signaling by the 59079 or 12599 substrate can be
detected, e.g., by monitoring intracellular calcium, IP3, or
diacylglycerol concentration, phosphorylation profile of
intracellular proteins, or the activity of an 59079- or
12599-regulated transcription factor. Plasmid DNA can then be
recovered from the cells which score for inhibition, or
alternatively, potentiation of signaling by the HST-1 substrate,
and the individual clones further characterized.
[0151] In another aspect, the invention features a method of making
a 59079 or 12599 polypeptide, e.g., a peptide having a non-wild
type activity, e.g., an antagonist, agonist, or super agonist of a
naturally occurring 59079 or 12599 polypeptide, e.g., a naturally
occurring 59079 or 12599 polypeptide. The method includes: altering
the sequence of a 59079 polypeptide, e.g., altering the sequence,
e.g., by substitution or deletion of one or more residues of a
non-conserved region, a domain or residue disclosed herein, and
testing the altered polypeptide for the desired activity.
[0152] In another aspect, the invention features a method of making
a fragment or analog of a 59079 or 12599 polypeptide a biological
activity of a naturally occurring 59079 or 12599 polypeptide. The
method includes: altering the sequence, e.g., by substitution or
deletion of one or more residues, of a 59079 or 12599 polypeptide,
e.g., altering the sequence of a non-conserved region, or a domain
or residue described herein, and testing the altered polypeptide
for the desired activity.
[0153] Anti-59079 and Andti-12599 Antibodies
[0154] In another aspect, the invention provides an anti-59079 and
anti-12599 antibodies. The term "antibody" as used herein refers to
an immunoglobulin molecule and immunologically active portions of
immunoglobulin molecules, i.e., molecules that contain an antigen
binding site which specifically binds (immunoreacts with) an
antigen, such as a 59079 or 12599 molecule. Examples of
immunologically active portions of immunoglobulin molecules include
scFV and dcFV fragments, Fab and F(ab').sub.2 fragments which can
be generated by treating the antibody with an enzyme such as papain
or pepsin, respectively.
[0155] The antibody can be a polyclonal, monoclonal, recombinant,
e.g., a chimeric, humanized, fully human, non-human (e.g., murine,
rat, rabbit, or goat), or single chain antibody. In a preferred
embodiment it has effector function and can fix complement. The
antibody can be coupled to a toxin or imaging agent.
[0156] The term "monoclonal antibody" or "monoclonal antibody
composition", as used herein, refers to a population of antibody
molecules that contain only one species of an antigen binding site
capable of immunoreacting with a particular epitope of 59079 or
12599. A monoclonal antibody composition thus typically displays a
single binding affinity for a particular 59079 or 12599 protein
with which it immunoreacts.
[0157] Polyclonal anti-59079 and anti-12599 antibodies can be
prepared as described above by immunizing a suitable subject with a
59079 or 12599 immunogen. The specific antibody titer in the
immunized subject can be monitored over time by standard
techniques, such as with an enzyme linked immunosorbent assay
(ELISA) using immobilized 59079 or 12599. If desired, the antibody
molecules directed against 59079 or 12599 can be isolated from the
mammal (e.g., from the blood) and further purified by well known
techniques, such as protein A chromatography to obtain the IgG
fraction. At an appropriate time after immunization, e.g., when the
anti-59079 or anti-12599 antibody titers are highest,
antibody-producing cells can be obtained from the subject and used
to prepare monoclonal antibodies by standard techniques, such as
the hybridoma technique originally described by Kohler and Milstein
(1975) Nature 256:495-497) (see also, Brown et al. (1981) J.
Immunol. 127:539-46; Brown et al. (1980) J. Biol. Chem 255:4980-83;
Yeh et al. (1976) Proc. Natl. Acad. Sci. USA 76:2927-31; and Yeh et
al. (1982) Int. J. Cancer 29:269-75), the more recent human B cell
hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), the
EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies
and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma
techniques. The technology for producing monoclonal antibody
hybridomas is well known (see generally R. H. Kenneth, in
Monoclonal Antibodies: A New Dimension In Biological Analyses,
Plenum Publishing Corp., New York, N.Y. (1980); E. A. Lerner (1981)
Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic
Cell Genet. 3:231-36). Briefly, an immortal cell line (typically a
myeloma) is fused to lymphocytes (typically splenocytes) from a
mammal immunized with a 59079 immunogen as described above, and the
culture supernatants of the resulting hybridoma cells are screened
to identify a hybridoma producing a monoclonal antibody that binds
59079.
[0158] Any of the many well known protocols used for fusing
lymphocytes and immortalized cell lines can be applied for the
purpose of generating an anti-59079 monoclonal antibody (see, e.g.,
G. Galfre et al. (1977) Nature 266:55052; Gefter et al. Somatic
Cell Genet., cited supra; Lerner, Yale J. Biol. Med., cited supra;
Kenneth, Monoclonal Antibodies, cited supra). Moreover, the
ordinarily skilled worker will appreciate that there are many
variations of such methods which also would be useful. Typically,
the immortal cell line (e.g., a myeloma cell line) is derived from
the same mammalian species as the lymphocytes. For example, murine
hybridomas can be made by fusing lymphocytes from a mouse immunized
with an immunogenic preparation of the present invention with an
immortalized mouse cell line. Preferred immortal cell lines are
mouse myeloma cell lines that are sensitive to culture medium
containing hypoxanthine, aminopterin and thymidine ("HAT medium").
Any of a number of myeloma cell lines can be used as a fusion
partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1,
P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are
available from ATCC. Typically, HAT-sensitive mouse myeloma cells
are fused to mouse splenocytes using polyethylene glycol ("PEG").
Hybridoma cells resulting from the fusion are then selected using
HAT medium, which kills unfused and unproductively fused myeloma
cells (unfused splenocytes die after several days because they are
not transformed). Hybridoma cells producing a monoclonal antibody
of the invention are detected by screening the hybridoma culture
supernatants for antibodies that bind 59079, e.g., using a standard
ELISA assay.
[0159] Alternative to preparing monoclonal antibody-secreting
hybridomas, a monoclonal anti-59079 or anti-12599 antibody can be
identified and isolated by screening a recombinant combinatorial
immunoglobulin library (e.g., an antibody phage display library)
with 59079 or 12599 to thereby isolate immunoglobulin library
members that bind 59079 or 12599. Kits for generating and screening
phage display libraries are commercially available (e.g., the
Pharmacia Recombinant Phage Antibody System, Catalog No.
27-9400-01; and the Stratagene SurfZAP.TM. Phage Display Kit,
Catalog No. 240612). Additionally, examples of methods and reagents
particularly amenable for use in generating and screening antibody
display library can be found in, for example, Ladner et al. U.S.
Pat. No. 5,223,409; Kang et al. PCT International Publication No.
WO 92/18619; Dower et al. PCT International Publication No. WO
91/17271; Winter et al. PCT International Publication WO 92/20791;
Markland et al. PCT International Publication No. WO 92/15679;
Breitling et al. PCT International Publication WO 93/01288;
McCafferty et al. PCT International Publication No. WO 92/01047;
Garrard et al. PCT International Publication No. WO 92/09690;
Ladner et al. PCT International Publication No. WO 90/02809; Fuchs
et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum.
Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science
246:1275-1281; Griffiths et al. (1993) EMBO J. 12:725-734; Hawkins
et al. (1992) J. Mol. Biol. 226:889-896; Clarkson et al. (1991)
Nature 352:624-628; Gram et al. (1992) Proc. Natl. Acad. Sci. USA
89:3576-3580; Garrad et al. (1991) Bio/Technology 9:1373-1377;
Hoogenboom et al. (1991) Nuc. Acid Res. 19:4133-4137; Barbas et al.
(1991) Proc. Natl. Acad. Sci. USA 88:7978-7982; and McCafferty et
al. Nature (1990) 348:552-554.
[0160] Additionally, chimeric, humanized, and completely human
antibodies are also within the scope of the invention. Chimeric,
humanized, but most preferably, completely human antibodies are
desirable for applications which include repeated administration,
e.g., therapeutic treatment of human patients, and some diagnostic
applications.
[0161] Chimeric and humanized monoclonal antibodies, comprising
both human and non-human portions, can be made using standard
recombinant DNA techniques. Such chimeric and humanized monoclonal
antibodies can be produced by recombinant DNA techniques known in
the art, for example using methods described in Robinson et al.
International Application No. PCT/US86/02269; Akira, et al.
European Patent Application 184,187; Taniguchi, M., European Patent
Application 171,496; Morrison et al. European Patent Application
173,494; Neuberger et al. PCT International Publication No. WO
86/01533; Cabilly et al. U.S. Pat. No. 4,816,567; Cabilly et al.
European Patent Application 125,023; Better et al. (1988) Science
240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA
84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et
al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al.
(1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature
314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst.
80:1553-1559); Morrison, S. L. (1985) Science 229:1202-1207; Oi et
al. (1986) BioTechniques 4:214; Winter U.S. Pat. No. 5,225,539;
Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988)
Science 239:1534; and Beidler et al. (1988) J. Immunol.
141:4053-4060.
[0162] Completely human antibodies are particularly desirable for
therapeutic treatment of human patients. Such antibodies can be
produced using transgenic mice that are incapable of expressing
endogenous immunoglobulin heavy and light chains genes, but which
can express human heavy and light chain genes. See, for example,
Lonberg and Huszar (1995) Int. Rev. Immunol. 13:65-93); and U.S.
Pat. Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and
5,545,806. In addition, companies such as Abgenix, Inc. (Fremont,
Calif.) and Medarex, Inc. (Princeton, N.J.), can be engaged to
provide human antibodies directed against a selected antigen using
technology similar to that described above.
[0163] Completely human antibodies that recognize a selected
epitope can be generated using a technique referred to as "guided
selection." In this approach a selected non-human monoclonal
antibody, e.g., a murine antibody, is used to guide the selection
of a completely human antibody recognizing the same epitope. This
technology is described by Jespers et al. (1994) Bio/Technology
12:899-903).
[0164] A full-length 59079 or 12599 protein, or an antigenic
peptide fragment of 59079 or 12599, can be used as an immunogen or
can be used to identify anti-59079 or anti-12599 antibodies made
with other immunogens, e.g., cells, membrane preparations, and the
like. The antigenic peptides of 59079 should include at least 8
amino acid residues of the amino acid sequence shown in SEQ ID NO:2
and encompass an epitope of 59079, respectively. The antigenic
peptides of 12599 should include at least 8 amino acid residues of
the amino acid sequence shown in SEQ ID NO:5 and encompass an
epitope of 12599, respectively. Preferably, the antigenic peptide
includes at least 10 amino acid residues, more preferably at least
15 amino acid residues, even more preferably at least 20 amino acid
residues, and most preferably at least 30 amino acid residues.
[0165] Fragments of 59079 which include, e.g., residues 1130 to
1383 or 2334 to 2586 of SEQ ID NO:2, can be used as immunogens to
make an antibody against the protein kinase catalytic domain of the
59079 protein.
[0166] Fragments of 12599 which include, e.g., residues 6468 to
6721 or 7672 to 7924 of SEQ ID NO:5, can be used as immunogens to
make an antibody against the protein kinase catalytic domain of the
12599 protein.
[0167] Antibodies reactive with, or specific or selective for, any
of these regions, or other regions or domains described herein are
provided.
[0168] In an alternative embodiment, the antibody fails to bind to
an Fc receptor, e.g., it is a type which does not support Fc
receptor binding or has been modified, e.g., by deletion or other
mutation, such that is does not have a functional Fc receptor
binding region.
[0169] Preferred epitopes encompassed by the antigenic peptide are
regions of 59079 and 12599 which are located on the surface of the
protein, e.g., hydrophilic regions, as well as regions with high
antigenicity. For example, an Emini surface probability analysis of
the human 59079 and 12599 protein sequences can be used to identify
the regions that have a particularly high probability of being
localized to the surface of the 59079 or 12599 protein, and are
thus likely to constitute surface residues useful for targeting
antibody production.
[0170] In a preferred embodiment the antibody binds an epitope on
any domain or region on 59079 proteins described herein.
[0171] In another preferred embodiment, the antibody binds an
epitope on any domain or region on 12599 proteins described
herein.
[0172] The anti-59079 or anti-12599 antibody can be a single chain
antibody. A single-chain antibody (scFV) may be engineered as
described, for example, in Colcher, D. et al., (1999) Ann. NY Acad.
Sci. 880: 263-80; and Reiter, Y., Clin. Cancer Res. 1996 February;
2(2):245-52. The single chain antibody can be dimerized or
multimerized to generate multivalent antibodies having
specificities for different epitopes of the same target 59079
protein.
[0173] Anti-59079 and anti-12599 antibodies (e.g., monoclonal
antibodies) can be used to isolate 59079 or 12599, respectively, by
standard techniques, such as affinity chromatography or
immunoprecipitation. Moreover, an anti-59079 or anti-12599 antibody
can be used to detect 59079 or 12599 protein, respectively, (e.g.,
in a cellular lysate or cell supernatant) in order to evaluate the
abundance and pattern of expression of the protein. Anti-59079 and
anti-12599 antibodies can be used diagnostically to monitor protein
levels in tissue as part of a clinical testing procedure, e.g., to,
for example, determine the efficacy of a given treatment regimen.
Detection can be facilitated by coupling (i.e., physically linking)
the antibody to a detectable substance (i.e., antibody labeling).
Examples of detectable substances include various enzymes,
prosthetic groups, fluorescent materials, luminescent materials,
bioluminescent materials, and radioactive materials. Examples of
suitable enzymes include horseradish peroxidase, alkaline
phosphatase, .beta.-galactosidase, or acetylcholinesterase;
examples of suitable prosthetic group complexes include
streptavidin/biotin and avidin/biotin; examples of suitable
fluorescent materials include umbelliferone, fluorescein,
fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine
fluorescein, dansyl chloride or phycoerythrin; an example of a
luminescent material includes luminol; examples of bioluminescent
materials include luciferase, luciferin, and aequorin, and examples
of suitable radioactive material include .sup.125I, .sup.131I,
.sup.35S or .sup.3H.
[0174] Recombinant Expression Vectors, Host Cells and Genetically
Engineered Cells
[0175] In another aspect, the invention includes, vectors,
preferably expression vectors, containing a nucleic acid encoding a
polypeptide described herein. As used herein, the term "vector"
refers to a nucleic acid molecule capable of transporting another
nucleic acid to which it has been linked and can include a plasmid,
cosmid or viral vector. The vector can be capable of autonomous
replication or it can integrate into a host DNA. Viral vectors
include, e.g., replication defective retroviruses, adenoviruses and
adeno-associated viruses.
[0176] A vector can include a 59079 or 12599 nucleic acid in a form
suitable for expression of the nucleic acid in a host cell.
Preferably the recombinant expression vector includes one or more
regulatory sequences operatively linked to the nucleic acid
sequence to be expressed. The term "regulatory sequence" includes
promoters, enhancers and other expression control elements (e.g.,
polyadenylation signals). Regulatory sequences include those which
direct constitutive expression of a nucleotide sequence, as well as
tissue-specific regulatory and/or inducible sequences. The design
of the expression vector can depend on such factors as the choice
of the host cell to be transformed, the level of expression of
protein desired, and the like. The expression vectors of the
invention can be introduced into host cells to thereby produce
proteins or polypeptides, including fusion proteins or
polypeptides, encoded by nucleic acids as described herein (e.g.,
59079 and 12599 proteins, mutant forms of 59079 and 12599 proteins,
fusion proteins, and the like).
[0177] The recombinant expression vectors of the invention can be
designed for expression of 59079 or 12599 proteins in prokaryotic
or eukaryotic cells. For example, polypeptides of the invention can
be expressed in E. coli, insect cells (e.g., using baculovirus
expression vectors), yeast cells or mammalian cells. Suitable host
cells are discussed further in Goeddel, (1990) Gene Expression
Technology: Methods in Enzymology 185, Academic Press, San Diego,
Calif. Alternatively, the recombinant expression vector can be
transcribed and translated in vitro, for example using T7 promoter
regulatory sequences and T7 polymerase.
[0178] Expression of proteins in prokaryotes is most often carried
out in E. coli with vectors containing constitutive or inducible
promoters directing the expression of either fusion or non-fusion
proteins. Fusion vectors add a number of amino acids to a protein
encoded therein, usually to the amino terminus of the recombinant
protein. Such fusion vectors typically serve three purposes: 1) to
increase expression of recombinant protein; 2) to increase the
solubility of the recombinant protein; and 3) to aid in the
purification of the recombinant protein by acting as a ligand in
affinity purification. Often, a proteolytic cleavage site is
introduced at the junction of the fusion moiety and the recombinant
protein to enable separation of the recombinant protein from the
fusion moiety subsequent to purification of the fusion protein.
Such enzymes, and their cognate recognition sequences, include
Factor Xa, thrombin, and enterokinase. Typical fusion expression
vectors include pGEX (Pharmacia Biotech, Inc; Smith, D. B. and
Johnson, K. S. (1988) Gene 67:31-40), pMAL (New England Biolabs,
Beverly Mass.) and pRIT5 (Pharmacia, Piscataway N.J.) which fuse
glutathione S-transferase (GST), maltose E binding protein, or
protein A, respectively, to the target recombinant protein.
[0179] Purified fusion proteins can be used in 59079 or 12599
activity assays, (e.g., direct assays or competitive assays
described in detail below), or to generate antibodies specific for
59079 or 12599 proteins. In a preferred embodiment, a fusion
protein expressed in a retroviral expression vector of the present
invention can be used to infect bone marrow cells which are
subsequently transplanted into irradiated recipients. The pathology
of the subject recipient is then examined after sufficient time has
passed (e.g., six weeks).
[0180] To maximize recombinant protein expression in E. coli is to
express the protein in a host bacteria with an impaired capacity to
proteolytically cleave the recombinant protein (Gottesman, S.,
(1990) Gene Expression Technology: Methods in Enzymology 185,
Academic Press, San Diego, Calif. 119-128). Another strategy is to
alter the nucleic acid sequence of the nucleic acid to be inserted
into an expression vector so that the individual codons for each
amino acid are those preferentially utilized in E. coli (Wada et
al., (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of
nucleic acid sequences of the invention can be carried out by
standard DNA synthesis techniques.
[0181] The 59079 and 12599 expression vector can be a yeast
expression vector, a vector for expression in insect cells, e.g., a
baculovirus expression vector or a vector suitable for expression
in mammalian cells.
[0182] When used in mammalian cells, the expression vector's
control functions are often provided by viral regulatory elements.
For example, commonly used promoters are derived from polyoma,
Adenovirus 2, cytomegalovirus and Simian Virus 40.
[0183] In another embodiment, the recombinant mammalian expression
vector is capable of directing expression of the nucleic acid
preferentially in a particular cell type (e.g., tissue-specific
regulatory elements are used to express the nucleic acid).
Non-limiting examples of suitable tissue-specific promoters include
the albumin promoter (liver-specific; Pinkert et al. (1987) Genes
Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton
(1988) Adv. Immunol. 43:235-275), in particular promoters of T cell
receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and
immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and
Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g.,
the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl.
Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund
et al. (1985) Science 230:912-916), and mammary gland-specific
promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and
European Application Publication No. 264,166).
Developmentally-regulated promoters are also encompassed, for
example, the murine hox promoters (Kessel and Gruss (1990) Science
249:374-379) and the .alpha.-fetoprotein promoter (Campes and
Tilghman (1989) Genes Dev. 3:537-546).
[0184] The invention further provides a recombinant expression
vector comprising a DNA molecule of the invention cloned into the
expression vector in an antisense orientation. Regulatory sequences
(e.g., viral promoters and/or enhancers) operatively linked to a
nucleic acid cloned in the antisense orientation can be chosen
which direct the constitutive, tissue specific or cell type
specific expression of antisense RNA in a variety of cell types.
The antisense expression vector can be in the form of a recombinant
plasmid, phagemid or attenuated virus. For a discussion of the
regulation of gene expression using antisense genes see Weintraub,
H. et al., (1986) Antisense RNA as a molecular tool for genetic
analysis, Reviews--Trends in Genetics 1:1.
[0185] Another aspect the invention provides a host cell which
includes a nucleic acid molecule described herein, e.g., a 59079 or
12599 nucleic acid molecule within a recombinant expression vector
or a 59079 or 12599 nucleic acid molecule containing sequences
which allow it to homologously recombine into a specific site of
the host cell's genome. The terms "host cell" and "recombinant host
cell" are used interchangeably herein. Such terms refer not only to
the particular subject cell but to the progeny or potential progeny
of such a cell. Because certain modifications may occur in
succeeding generations due to either mutation or environmental
influences, such progeny may not, in fact, be identical to the
parent cell, but are still included within the scope of the term as
used herein.
[0186] A host cell can be any prokaryotic or eukaryotic cell. For
example, a 59079 or 12599 protein can be expressed in bacterial
cells such as E. coli, insect cells, yeast or mammalian cells (such
as Chinese hamster ovary cells (CHO) or COS cells). Other suitable
host cells are known to those skilled in the art.
[0187] Vector DNA can be introduced into host cells via
conventional transformation or transfection techniques. As used
herein, the terms "transformation" and "transfection" are intended
to refer to a variety of art-recognized techniques for introducing
foreign nucleic acid (e.g., DNA) into a host cell, including
calcium phosphate or calcium chloride co-precipitation,
DEAE-dextran-mediated transfection, lipofection, or
electroporation.
[0188] A host cell of the invention can be used to produce (i.e.,
express) a 59079 or 12599 protein. Accordingly, the invention
further provides methods for producing a 59079 or 12599 protein
using the host cells of the invention. In one embodiment, the
method includes culturing the host cell of the invention (into
which a recombinant expression vector encoding a 59079 or 12599
protein has been introduced) in a suitable medium such that a 59079
or 12599 protein is produced. In another embodiment, the method
further includes isolating a 59079 or 12599 protein from the medium
or the host cell.
[0189] In another aspect, the invention features a cell or a
purified preparation of cells which includes a 59079 or 12599
transgene, or which otherwise misexpresses 59079 or 12599. The cell
preparation can consist of human or nonhuman cells, e.g., rodent
cells, e.g., mouse or rat cells, rabbit cells, or pig cells. In
preferred embodiments, the cell, or cells, include a 59079 or 12599
transgene, e.g., a heterologous form of 59079 or 12599, e.g., a
gene derived from humans (in the case of a non-human cell). The
59079 or 12599 transgene can be misexpressed, e.g., overexpressed
or underexpressed. In other preferred embodiments, the cell, or
cells, includes a gene which misexpresses an endogenous 59079 or
12599, e.g., a gene, the expression of which is disrupted, e.g., a
knockout. Such cells can serve as a model for studying disorders
which are related to mutated or mis-expressed 59079 or 12599
alleles or for use in drug screening.
[0190] In another aspect, the invention features, a human cell,
e.g., a hematopoietic stem cell, transformed with nucleic acid
which encodes a subject 59079 or 12599 polypeptide.
[0191] Also provided are cells, preferably human cells, e.g., human
hematopoietic or fibroblast cells, in which an endogenous 59079 or
12599 gene is under the control of a regulatory sequence that does
not normally control the expression of the endogenous 59079 or
12599 gene. The expression characteristics of an endogenous gene
within a cell, e.g., a cell line or microorganism, can be modified
by inserting a heterologous DNA regulatory element into the genome
of the cell such that the inserted regulatory element is operably
linked to the endogenous 59079 or 12599 gene. For example, an
endogenous 59079 or 12599 gene which is "transcriptionally silent,"
e.g., not normally expressed, or expressed only at very low levels,
may be activated by inserting a regulatory element which is capable
of promoting the expression of a normally expressed gene product in
that cell. Techniques such as targeted homologous recombinations,
can be used to insert the heterologous DNA as described in, e.g.,
Chappel, U.S. Pat. No. 5,272,071; WO 91/06667, published in May 16,
1991.
[0192] Transgenic Animals
[0193] The invention provides non-human transgenic animals. Such
animals are useful for studying the function and/or activity of a
59079 or a 12599 protein and for identifying and/or evaluating
modulators of 59079 or 12599 activity. As used herein, a
"transgenic animal" is a non-human animal, preferably a mammal,
more preferably a rodent such as a rat or mouse, in which one or
more of the cells of the animal includes a transgene. Other
examples of transgenic animals include non-human primates, sheep,
dogs, cows, goats, chickens, amphibians, and the like. A transgene
is exogenous DNA or a rearrangement, e.g., a deletion of endogenous
chromosomal DNA, which preferably is integrated into or occurs in
the genome of the cells of a transgenic animal. A transgene can
direct the expression of an encoded gene product in one or more
cell types or tissues of the transgenic animal, other transgenes,
e.g., a knockout, reduce expression. Thus, a transgenic animal can
be one in which an endogenous 59079 or 12599 gene has been altered
by, e.g., by homologous recombination between the endogenous gene
and an exogenous DNA molecule introduced into a cell of the animal,
e.g., an embryonic cell of the animal, prior to development of the
animal.
[0194] Intronic sequences and polyadenylation signals can also be
included in the transgene to increase the efficiency of expression
of the transgene. A tissue-specific regulatory sequence(s) can be
operably linked to a transgene of the invention to direct
expression of a 59079 or 12599 protein to particular cells. A
transgenic founder animal can be identified based upon the presence
of a 59079 or 12599 transgene in its genome and/or expression of
59079 or 12599 mRNA in tissues or cells of the animals. A
transgenic founder animal can then be used to breed additional
animals carrying the transgene. Moreover, transgenic animals
carrying a transgene encoding a 59079 or 12599 protein can further
be bred to other transgenic animals carrying other transgenes.
[0195] 59079 and 12599 proteins or polypeptides can be expressed in
transgenic animals or plants, e.g., a nucleic acid encoding the
protein or polypeptide can be introduced into the genome of an
animal. In preferred embodiments the nucleic acid is placed under
the control of a tissue specific promoter, e.g., a milk or egg
specific promoter, and recovered from the milk or eggs produced by
the animal. Suitable animals are mice, pigs, cows, goats, and
sheep.
[0196] The invention also includes a population of cells from a
transgenic animal, as discussed, e.g., below.
[0197] Uses
[0198] The nucleic acid molecules, proteins, protein homologues,
and antibodies described herein can be used in one or more of the
following methods: a) screening assays; b) predictive medicine
(e.g., diagnostic assays, prognostic assays, monitoring clinical
trials, and pharmacogenetics); and c) methods of treatment (e.g.,
therapeutic and prophylactic).
[0199] The isolated nucleic acid molecules of the invention can be
used, for example, to express a 59079 or 12599 protein (e.g., via a
recombinant expression vector in a host cell in gene therapy
applications), to detect a 59079 or 12599 mRNA (e.g., in a
biological sample) or a genetic alteration in a 59079 or 12599
gene, and to modulate 59079 or 12599 activity, as described further
below. The 59079 and 12599 proteins can be used to treat disorders
characterized by insufficient or excessive production of a 59079 or
12599 substrate or production of 59079 or 12599 inhibitors. In
addition, the 59079 and 12599 proteins can be used to screen for
naturally occurring 59079 or 12599 substrates, to screen for drugs
or compounds which modulate 59079 or 12599 activity, as well as to
treat disorders characterized by insufficient or excessive
production of 59079 or 12599 protein or production of 59079 or
12599 protein forms which have decreased, aberrant or unwanted
activity compared to 59079 or 12599 wild type protein. Moreover,
the anti-59079 and anti-12599 antibodies of the invention can be
used to detect and isolate 59079 or 12599 proteins, regulate the
bioavailability of 59079 or 12599 proteins, and modulate 59079 or
12599 activity.
[0200] A method of evaluating a compound for the ability to
interact with, e.g., bind, a subject 59079 or 12599 polypeptide is
provided. The method includes: contacting the compound with the
subject 59079 or 12599 polypeptide; and evaluating ability of the
compound to interact with, e.g., to bind or form a complex with the
subject 59079 or 12599 polypeptide. This method can be performed in
vitro, e.g., in a cell free system, or in vivo, e.g., in a
two-hybrid interaction trap assay. This method can be used to
identify naturally occurring molecules which interact with subject
59079 or 12599 polypeptide. It can also be used to find natural or
synthetic inhibitors of subject 59079 or 12599 polypeptide.
Screening methods are discussed in more detail below.
[0201] Screening Assays:
[0202] The invention provides methods (also referred to herein as
"screening assays") for identifying modulators, i.e., candidate or
test compounds or agents (e.g., proteins, peptides,
peptidomimetics, peptoids, small molecules or other drugs) which
bind to 59079 or 12599 proteins, have a stimulatory or inhibitory
effect on, for example, 59079 or 12599 expression or 59079 or 12599
activity, or have a stimulatory or inhibitory effect on, for
example, the expression or activity of a 59079 or 12599 substrate.
Compounds thus identified can be used to modulate the activity of
target gene products (e.g., 59079 and 12599 genes) in a therapeutic
protocol, to elaborate the biological function of the target gene
product, or to identify compounds that disrupt normal target gene
interactions.
[0203] In one embodiment, the invention provides assays for
screening candidate or test compounds which are substrates of a
59079 or 12599 protein or polypeptide or a biologically active
portion thereof. In another embodiment, the invention provides
assays for screening candidate or test compounds which bind to or
modulate the activity of a 59079 or 12599 protein or polypeptide or
a biologically active portion thereof.
[0204] The test compounds of the present invention can be obtained
using any of the numerous approaches in combinatorial library
methods known in the art, including: biological libraries; peptoid
libraries (libraries of molecules having the functionalities of
peptides, but with a novel, non-peptide backbone which are
resistant to enzymatic degradation but which nevertheless remain
bioactive; see, e.g., Zuckermann, R. N. et al. (1994) J. Med. Chem.
37:2678-85); spatially addressable parallel solid phase or solution
phase libraries; synthetic library methods requiring deconvolution;
the `one-bead one-compound` library method; and synthetic library
methods using affinity chromatography selection. The biological
library and peptoid library approaches are limited to peptide
libraries, while the other four approaches are applicable to
peptide, non-peptide oligomer or small molecule libraries of
compounds (Lam, K. S. (1997) Anticancer Drug Des. 12:145).
[0205] Examples of methods for the synthesis of molecular libraries
can be found in the art, for example in: DeWitt et al. (1993) Proc.
Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl.
Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem.
37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994)
Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew.
Chem. Int. Ed. Engl. 33:2061; and in Gallop et al. (1994) J. Med.
Chem. 37: 1233. Libraries of compounds may be presented in solution
(e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam
(1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556),
bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner U.S.
Pat. No. '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA
89:1865-1869) or on phage (Scott and Smith (1990) Science
249:386-390; Devlin (1990) Science 249:404-406; Cwirla et al.
(1990) Proc. Natl. Acad. Sci. 87:6378-6382; Felici (1991) J. Mol.
Biol. 222:301-310; Ladner supra.).
[0206] In another embodiment, an assay is a cell-based assay
comprising contacting a cell expressing a 59079 or 12599 target
molecule (e.g., a 59079 or 12599 phosphorylation substrate) with a
test compound and determining the ability of the test compound to
modulate (e.g., stimulate or inhibit) the activity of the 59079 or
12599 target molecule. Determining the ability of the test compound
to modulate the activity of a 59079 or 12599 target molecule can be
accomplished, for example, by determining the ability of the 59079
or 12599 protein to bind to or interact with the 59079 or 12599
target molelcule, or by determining the ability of the 59079 or
12599 protein to phosphorylate the 59079 or 12599 target
molecule.
[0207] The ability of the 59079 or 12599 protein to phosphorylate a
substrate or target molecule can be determined by, for example, an
in vitro kinase assay. Briefly, a substrate or target molecule,
e.g., an immunoprecipitated substrate or target molecule from a
cell line expressing such a molecule, can be incubated with the
59079 or 12599 protein and radioactive ATP, e.g.,
[.gamma.-.sup.32P] ATP, in a buffer containing MgCl.sub.2 and
MnCl.sub.2, e.g., 10 mM MgCl.sub.2 and 5 mM MnCl.sub.2. Following
the incubation, the immunoprecipitated substrate/target molecule
can be separated by SDS-polyacrylamide gel electrophoresis under
reducing conditions, transferred to a membrane, e.g., a PVDF
membrane, and autoradiographed. The appearance of detectable bands
on the autoradiograph indicates that the 59079 or 12599 substrate
or target molecule has been phosphorylated. Phosphoamino acid
analysis of the phosphorylated substrate or target molecule can
also be performed in order to determine which residues on the 59079
or 12599 substrate or target molecule are phosphorylated and
isolated by SDS polyacrylamidge gel electrophoresis. Briefly, the
radiophosphorylated protein band can be excised from the SDS gel
and subjected to partial acid hydrolysis. The products can then be
separated by one-dimensional electrophoresis and analyzed on, for
example, a phosphoimager and compared to ninhydrin-stained
phosphoaminoacid standards.
[0208] The ability of the test compound to modulate 59079 or 12599
binding to a compound, e.g., a 59079 or 12599 substrate, or to bind
to 59079 or 12599 can also be evaluated. This can be accomplished,
for example, by coupling the compound, e.g., the substrate, with a
radioisotope or enzymatic label such that binding of the compound,
e.g., the substrate, to 59079 or 12599 can be determined by
detecting the labeled compound, e.g., substrate, in a complex.
Alternatively, 59079 or 12599 could be coupled with a radioisotope
or enzymatic label to monitor the ability of a test compound to
modulate 59079 or 12599 binding to a 59079 or 12599 substrate in a
complex. For example, compounds (e.g., 59079 or 12599 substrates)
can be labeled with .sup.125I, .sup.35S, .sup.14C, or .sup.3H,
either directly or indirectly, and the radioisotope detected by
direct counting of radioemmission or by scintillation counting.
Alternatively, compounds can be enzymatically labeled with, for
example, horseradish peroxidase, alkaline phosphatase, or
luciferase, and the enzymatic label detected by determination of
conversion of an appropriate substrate to product.
[0209] The ability of a compound (e.g., a 59079 or 12599 substrate)
to interact with 59079, with or without the labeling of any of the
interactants, can be evaluated. For example, a microphysiometer can
be used to detect the interaction of a compound with 59079 or 12599
without the labeling of either the compound or the 59079 or 12599.
McConnell, H. M. et al. (1992) Science 257:1906-1912. As used
herein, a "microphysiometer" (e.g., Cytosensor) is an analytical
instrument that measures the rate at which a cell acidifies its
environment using a light-addressable potentiometric sensor (LAPS).
Changes in this acidification rate can be used as an indicator of
the interaction between a compound and 59079 or between a compound
and 12599.
[0210] In yet another embodiment, a cell-free assay is provided in
which a 59079 or a 12599 protein, or biologically active portion
thereof, is contacted with a test compound and the ability of the
test compound to bind to the 59079 or 12599 protein, or
biologically active portion thereof, is evaluated. Preferred
biologically active portions of the 59079 and 12599 proteins to be
used in assays of the present invention include fragments which
participate in interactions with non-59079 or non-12599 molecules,
e.g., fragments with high surface probability scores.
[0211] Soluble and/or membrane-bound forms of isolated proteins
(e.g., 59079 and 12599 proteins, or biologically active portions
thereof) can be used in the cell-free assays of the invention. When
membrane-bound forms of the protein are used, it may be desirable
to utilize a solubilizing agent. Examples of such solubilizing
agents include non-ionic detergents such as n-octylglucoside,
n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide,
decanoyl-N-methylglucamide, Triton.RTM. X-100, Triton.RTM. X-114,
Thesit.RTM., Isotridecypoly(ethylene glycol ether).sub.n,
3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS),
3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane
sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane
sulfonate.
[0212] Cell-free assays involve preparing a reaction mixture of the
target gene protein and the test compound under conditions and for
a time sufficient to allow the two components to interact and bind,
thus forming a complex that can be removed and/or detected.
[0213] The interaction between two molecules can also be detected,
e.g., using fluorescence energy transfer (FET) (see, for example,
Lakowicz et al., U.S. Pat. No. 5,631,169; Stavrianopoulos, et al.,
U.S. Pat. No. 4,868,103). A fluorophore label on the first, `donor`
molecule is selected such that its emitted fluorescent energy will
be absorbed by a fluorescent label on a second, `acceptor`
molecule, which in turn is able to fluoresce due to the absorbed
energy. Alternately, the `donor` protein molecule may simply
utilize the natural fluorescent energy of tryptophan residues.
Labels are chosen that emit different wavelengths of light, such
that the `acceptor` molecule label may be differentiated from that
of the `donor`. Since the efficiency of energy transfer between the
labels is related to the distance separating the molecules, the
spatial relationship between the molecules can be assessed. In a
situation in which binding occurs between the molecules, the
fluorescent emission of the `acceptor` molecule label in the assay
should be maximal. An FET binding event can be conveniently
measured through standard fluorometric detection means well known
in the art (e.g., using a fluorimeter).
[0214] In another embodiment, determining the ability of the 59079
and 12599 protein to bind to a target molecule can be accomplished
using real-time Biomolecular Interaction Analysis (BIA) (see, e.g.,
Sjolander, S. and Urbaniczky, C. (1991) Anal. Chem. 63:2338-2345
and Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699-705).
"Surface plasmon resonance" or "BIA" detects biospecific
interactions in real time, without labeling any of the interactants
(e.g., BIAcore). Changes in the mass at the binding surface
(indicative of a binding event) result in alterations of the
refractive index of light near the surface (the optical phenomenon
of surface plasmon resonance (SPR)), resulting in a detectable
signal which can be used as an indication of real-time reactions
between biological molecules.
[0215] In one embodiment, the target gene product or the test
substance is anchored onto a solid phase. The target gene
product/test compound complexes anchored on the solid phase can be
detected at the end of the reaction. Preferably, the target gene
product can be anchored onto a solid surface, and the test
compound, (which is not anchored), can be labeled, either directly
or indirectly, with detectable labels discussed herein.
[0216] It may be desirable to immobilize 59079 or 12599, an
anti-59079 or anti-12599 antibody, or a 59079 or 12599 target
molecule to facilitate separation of complexed from uncomplexed
forms of one or both of the proteins, as well as to accommodate
automation of the assay. Binding of a test compound to a 59079 or
12599 protein, or interaction of a 59079 or 12599 protein with a
target molecule in the presence and absence of a candidate
compound, can be accomplished in any vessel suitable for containing
the reactants. Examples of such vessels include microtiter plates,
test tubes, and micro-centrifuge tubes. In one embodiment, a fusion
protein can be provided which adds a domain that allows one or both
of the proteins to be bound to a matrix. For example,
glutathione-S-transferase/59079 fusion proteins or
glutathione-S-transferase/12599 fusion proteins or
glutathione-S-transferase/target fusion proteins can be adsorbed
onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.)
or glutathione derivatized microtiter plates, which are then
combined with the test compound or the test compound and either the
non-adsorbed target protein or 59079 or 12599 protein, and the
mixture incubated under conditions conducive to complex formation
(e.g., at physiological conditions for salt and pH). Following
incubation, the beads or microtiter plate wells are washed to
remove any unbound components, the matrix immobilized in the case
of beads, complex determined either directly or indirectly, for
example, as described above. Alternatively, the complexes can be
dissociated from the matrix, and the level of 59079 or 12599
binding or activity determined using standard techniques.
[0217] Other techniques for immobilizing either a 59079 or 12599
protein or a target molecule on matrices include using conjugation
of biotin and streptavidin. Biotinylated 59079 or 12599 protein or
target molecules can be prepared from
biotin-NHS(N-hydroxysuccinimide) using techniques known in the art
(e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and
immobilized in the wells of streptavidin-coated 96 well plates
(Pierce Chemical).
[0218] In order to conduct the assay, the non-immobilized component
is added to the coated surface containing the anchored component.
After the reaction is complete, unreacted components are removed
(e.g., by washing) under conditions such that any complexes formed
will remain immobilized on the solid surface. The detection of
complexes anchored on the solid surface can be accomplished in a
number of ways. Where the previously non-immobilized component is
pre-labeled, the detection of label immobilized on the surface
indicates that complexes were formed. Where the previously
non-immobilized component is not pre-labeled, an indirect label can
be used to detect complexes anchored on the surface; e.g., using a
labeled antibody specific for the immobilized component (the
antibody, in turn, can be directly labeled or indirectly labeled
with, e.g., a labeled anti-Ig antibody).
[0219] In one embodiment, this assay is performed utilizing
antibodies reactive with 59079 or 12599 protein or target molecules
but which do not interfere with binding of the 59079 or 12599
protein to its target molecule. Such antibodies can be derivatized
to the wells of the plate, and unbound target or 59079 or 12599
protein trapped in the wells by antibody conjugation. Methods for
detecting such complexes, in addition to those described above for
the GST-immobilized complexes, include immunodetection of complexes
using antibodies reactive with the 59079 or 12599 protein or target
molecule, as well as enzyme-linked assays which rely on detecting
an enzymatic activity associated with the 59079 or 12599 protein or
target molecule.
[0220] Alternatively, cell-free assays can be conducted in a liquid
phase. In such an assay, the reaction products are separated from
unreacted components, by any of a number of standard techniques,
including but not limited to: differential centrifugation (see, for
example, Rivas, G., and Minton, A. P., (1993) Trends Biochem Sci
18:284-7); chromatography (gel filtration chromatography,
ion-exchange chromatography); electrophoresis (see, e.g., Ausubel,
F. et al., eds. Current Protocols in Molecular Biology 1999, J.
Wiley: New York); and immunoprecipitation (see, for example,
Ausubel, F. et al., eds. (1999) Current Protocols in Molecular
Biology, J. Wiley: New York). Such resins and chromatographic
techniques are known to one skilled in the art (see, e.g.,
Heegaard, N. H., (1998) J Mol Recognit 11: 141-8; Hage, D. S., and
Tweed, S. A. (1997) J Chromatogr B Biomed Sci Appl. 699:499-525).
Further, fluorescence energy transfer may also be conveniently
utilized, as described herein, to detect binding without further
purification of the complex from solution.
[0221] In a preferred embodiment, the assay includes contacting the
59079 or 12599 protein, or biologically active portion thereof,
with a known compound which binds 59079 or 12599 to form an assay
mixture, contacting the assay mixture with a test compound, and
determining the ability of the test compound to interact with a
59079 or 12599 protein, wherein determining the ability of the test
compound to interact with a 59079 protein includes determining the
ability of the test compound to preferentially bind to 59079 or
12599, or biologically active portion thereof, or to modulate the
activity of a target molecule, as compared to the known
compound.
[0222] The target gene products of the invention can, in vivo,
interact with one or more cellular or extracellular macromolecules,
such as proteins. For the purposes of this discussion, such
cellular and extracellular macromolecules are referred to herein as
"binding partners." Compounds that disrupt such interactions can be
useful in regulating the activity of the target gene product. Such
compounds can include, but are not limited to, molecules such as
antibodies, peptides, and small molecules. The preferred target
genes/products for use in this embodiment are the 59079 and 12599
genes herein identified. In an alternative embodiment, the
invention provides methods for determining the ability of the test
compound to modulate the activity of a 59079 or 12599 protein
through modulation of the activity of a downstream effector of a
59079 or 12599 target molecule. For example, the activity of the
effector molecule on an appropriate target can be determined, or
the binding of the effector to an appropriate target can be
determined, as previously described.
[0223] To identify compounds that interfere with the interaction
between the target gene product and its cellular or extracellular
binding partner(s), a reaction mixture containing the target gene
product and the binding partner is prepared, under conditions and
for a time sufficient, to allow the two products to form complex.
In order to test an inhibitory agent, the reaction mixture is
provided in the presence and absence of the test compound. The test
compound can be initially included in the reaction mixture, or can
be added at a time subsequent to the addition of the target gene
and its cellular or extracellular binding partner. Control reaction
mixtures are incubated without the test compound or with a placebo.
The formation of any complexes between the target gene product and
the cellular or extracellular binding partner is then detected. The
formation of a complex in the control reaction, but not in the
reaction mixture containing the test compound, indicates that the
compound interferes with the interaction of the target gene product
and the interactive binding partner. Additionally, complex
formation within reaction mixtures containing the test compound and
normal target gene product can also be compared to complex
formation within reaction mixtures containing the test compound and
mutant target gene product. This comparison can be important in
those cases wherein it is desirable to identify compounds that
disrupt interactions of mutant but not normal target gene
products.
[0224] These assays can be conducted in a heterogeneous or
homogeneous format. Heterogeneous assays involve anchoring either
the target gene product or the binding partner onto a solid phase,
and detecting complexes anchored on the solid phase at the end of
the reaction. In homogeneous assays, the entire reaction is carried
out in a liquid phase. In either approach, the order of addition of
reactants can be varied to obtain different information about the
compounds being tested. For example, test compounds that interfere
with the interaction between the target gene products and the
binding partners, e.g., by competition, can be identified by
conducting the reaction in the presence of the test substance.
Alternatively, test compounds that disrupt preformed complexes,
e.g., compounds with higher binding constants that displace one of
the components from the complex, can be tested by adding the test
compound to the reaction mixture after complexes have been formed.
The various formats are briefly described below.
[0225] In a heterogeneous assay system, either the target gene
product or the interactive cellular or extracellular binding
partner, is anchored onto a solid surface (e.g., a microtiter
plate), while the non-anchored species is labeled, either directly
or indirectly. The anchored species can be immobilized by
non-covalent or covalent attachments. Alternatively, an immobilized
antibody specific for the species to be anchored can be used to
anchor the species to the solid surface.
[0226] In order to conduct the assay, the partner of the
immobilized species is exposed to the coated surface with or
without the test compound. After the reaction is complete,
unreacted components are removed (e.g., by washing) and any
complexes formed will remain immobilized on the solid surface.
Where the non-immobilized species is pre-labeled, the detection of
label immobilized on the surface indicates that complexes were
formed. Where the non-immobilized species is not pre-labeled, an
indirect label can be used to detect complexes anchored on the
surface; e.g., using a labeled antibody specific for the initially
non-immobilized species (the antibody, in turn, can be directly
labeled or indirectly labeled with, e.g., a labeled anti-Ig
antibody). Depending upon the order of addition of reaction
components, test compounds that inhibit complex formation or that
disrupt preformed complexes can be detected.
[0227] Alternatively, the reaction can be conducted in a liquid
phase in the presence or absence of the test compound, the reaction
products separated from unreacted components, and complexes
detected; e.g., using an immobilized antibody specific for one of
the binding components to anchor any complexes formed in solution,
and a labeled antibody specific for the other partner to detect
anchored complexes. Again, depending upon the order of addition of
reactants to the liquid phase, test compounds that inhibit complex
or that disrupt preformed complexes can be identified.
[0228] In an alternate embodiment of the invention, a homogeneous
assay can be used. For example, a preformed complex of the target
gene product and the interactive cellular or extracellular binding
partner product is prepared in that either the target gene products
or their binding partners are labeled, but the signal generated by
the label is quenched due to complex formation (see, e.g., U.S.
Pat. No. 4,109,496 that utilizes this approach for immunoassays).
The addition of a test substance that competes with and displaces
one of the species from the preformed complex will result in the
generation of a signal above background. In this way, test
substances that disrupt target gene product-binding partner
interaction can be identified.
[0229] In yet another aspect, the 59079 proteins can be used as
"bait proteins" in a two-hybrid assay or three-hybrid assay (see,
e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell
72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054;
Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al.
(1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify
other proteins, which bind to or interact with 59079 or 12599
("59079-binding proteins" or "59079-bps", "12599-binding proteins"
or "12599-bps") and are involved in 59079 or 12599 activity. Such
59079-bps and 12599-bps can be activators or inhibitors of signals
by the 59079 or 12599 proteins or 59079 or 12599 targets as, for
example, downstream elements of a 59079- or 12599-mediated
signaling pathway.
[0230] The two-hybrid system is based on the modular nature of most
transcription factors, which consist of separable DNA-binding and
activation domains. Briefly, the assay utilizes two different DNA
constructs. In one construct, the gene that codes for a 59079 or
12599 protein is fused to a gene encoding the DNA binding domain of
a known transcription factor (e.g., GAL-4). In the other construct,
a DNA sequence, from a library of DNA sequences, that encodes an
unidentified protein ("prey" or "sample") is fused to a gene that
codes for the activation domain of the known transcription factor.
(Alternatively the: 59079 or 12599 protein can be the fused to the
activator domain.) If the "bait" and the "prey" proteins are able
to interact, in vivo, forming a 59079-dependent complex, the
DNA-binding and activation domains of the transcription factor are
brought into close proximity. This proximity allows transcription
of a reporter gene (e.g., lacZ) which is operably linked to a
transcriptional regulatory site responsive to the transcription
factor. Expression of the reporter gene can be detected and cell
colonies containing the functional transcription factor can be
isolated and used to obtain the cloned gene which encodes the
protein which interacts with the 59079 protein.
[0231] In another embodiment, modulators of 59079 or 12599
expression are identified. For example, a cell or cell free mixture
is contacted with a candidate compound and the expression of 59079
or 12599 mRNA or protein evaluated relative to the level of
expression of 59079 or 12599 mRNA or protein in the absence of the
candidate compound. When expression of 59079 or 12599 mRNA or
protein is greater in the presence of the candidate compound than
in its absence, the candidate compound is identified as a
stimulator of 59079 or 12599 mRNA or protein expression.
Alternatively, when expression of 59079 or 12599 mRNA or protein is
less (statistically significantly less) in the presence of the
candidate compound than in its absence, the candidate compound is
identified as an inhibitor of 59079 or 12599 mRNA or protein
expression. The level of 59079 or 12599 mRNA or protein expression
can be determined by methods described herein for detecting 59079
or 12599 mRNA or protein.
[0232] In another aspect, the invention pertains to a combination
of two or more of the assays described herein. For example, a
modulating agent can be identified using a cell-based or a cell
free assay, and the ability of the agent to modulate the activity
of a 59079 or 12599 protein can be confirmed in vivo in an animal
model.
[0233] This invention further pertains to novel agents identified
by the above-described screening assays. Accordingly, it is within
the scope of this invention to further use an agent identified as
described herein (e.g., a 59079 or 12599 modulating agent, an
anti-sense 59079 or 12599 nucleic acid molecule, a 59079- or
12599-specific antibody, or a 59079- or 12599-binding partner) in
an appropriate animal model to determine the efficacy, toxicity,
side effects, or mechanism of action, of treatment with such an
agent. Furthermore, novel agents identified by the above-described
screening assays can be used for treatments as described
herein.
[0234] Detection Assays
[0235] Portions or fragments of the nucleic acid sequences
identified herein can be used as polynucleotide reagents. For
example, these sequences can be used to: (i) map their respective
genes on a chromosome e.g., to locate gene regions associated with
genetic disease or to associate 59079 and 12599 with a disease;
(ii) identify an individual from a minute biological sample (tissue
typing); and (iii) aid in forensic identification of a biological
sample. These applications are described in the subsections
below.
[0236] Chromosome Mapping
[0237] The 59079 and 12599 nucleotide sequences or portions thereof
can be used to map the location of the 59079 and 12599 genes on a
chromosome. This process is called chromosome mapping. Chromosome
mapping is useful in correlating the 59079 amd 12599 sequences with
genes associated with disease.
[0238] Briefly, 59079 and 12599 genes can be mapped to chromosomes
by preparing PCR primers (preferably 15-25 bp in length) from the
59079 or 12599 nucleotide sequences. These primers can then be used
for PCR screening of somatic cell hybrids containing individual
human chromosomes. Only those hybrids containing the human gene
corresponding to the 59079 or 12599 sequences will yield an
amplified fragment.
[0239] A panel of somatic cell hybrids in which each cell line
contains either a single human chromosome or a small number of
human chromosomes, and a full set of mouse chromosomes, can allow
easy mapping of individual genes to specific human chromosomes.
(D'Eustachio P. et al. (1983) Science 220:919-924).
[0240] Other mapping strategies e.g., in situ hybridization
(described in Fan, Y. et al. (1990) Proc. Natl. Acad. Sci. USA,
87:6223-27), pre-screening with labeled flow-sorted chromosomes,
and pre-selection by hybridization to chromosome specific cDNA
libraries can be used to map 59079 or 12599 to a chromosomal
location.
[0241] Fluorescence in situ hybridization (FISH) of a DNA sequence
to a metaphase chromosomal spread can further be used to provide a
precise chromosomal location in one step. The FISH technique can be
used with a DNA sequence as short as 500 or 600 bases. However,
clones larger than 1,000 bases have a higher likelihood of binding
to a unique chromosomal location with sufficient signal intensity
for simple detection. Preferably 1,000 bases, and more preferably
2,000 bases will suffice to get good results at a reasonable amount
of time. For a review of this technique, see Verma et al., Human
Chromosomes: A Manual of Basic Techniques ((1988) Pergamon Press,
New York).
[0242] Reagents for chromosome mapping can be used individually to
mark a single chromosome or a single site on that chromosome, or
panels of reagents can be used for marking multiple sites and/or
multiple chromosomes. Reagents corresponding to noncoding regions
of the genes actually are preferred for mapping purposes. Coding
sequences are more likely to be conserved within gene families,
thus increasing the chance of cross hybridizations during
chromosomal mapping.
[0243] Once a sequence has been mapped to a precise chromosomal
location, the physical position of the sequence on the chromosome
can be correlated with genetic map data. (Such data are found, for
example, in V. McKusick, Mendelian Inheritance in Man, available
on-line through Johns Hopkins University Welch Medical Library).
The relationship between a gene and a disease, mapped to the same
chromosomal region, can then be identified through linkage analysis
(co-inheritance of physically adjacent genes), described in, for
example, Egeland, J. et al. (1987) Nature, 325:783-787.
[0244] Moreover, differences in the DNA sequences between
individuals affected and unaffected with a disease associated with
the 59079 or 12599 gene, can be determined. If a mutation is
observed in some or all of the affected individuals but not in any
unaffected individuals, then the mutation is likely to be the
causative agent of the particular disease. Comparison of affected
and unaffected individuals generally involves first looking for
structural alterations in the chromosomes, such as deletions or
translocations that are visible from chromosome spreads or
detectable using PCR based on that DNA sequence. Ultimately,
complete sequencing of genes from several individuals can be
performed to confirm the presence of a mutation and to distinguish
mutations from polymorphisms.
[0245] Tissue Typing
[0246] 59079 and 12599 sequences can be used to identify
individuals from biological samples using, e.g., restriction
fragment length polymorphism (RFLP). In this technique, an
individual's genomic DNA is digested with one or more restriction
enzymes, the fragments separated, e.g., in a Southern blot, and
probed to yield bands for identification. The sequences of the
present invention are useful as additional DNA markers for RFLP
(described in U.S. Pat. No. 5,272,057).
[0247] Furthermore, the sequences of the present invention can also
be used to determine the actual base-by-base DNA sequence of
selected portions of an individual's genome. Thus, the 59079 and
12599 nucleotide sequences described herein can be used to prepare
two PCR primers from the 5' and 3' ends of the sequences. These
primers can then be used to amplify an individual's DNA and
subsequently sequence it. Panels of corresponding DNA sequences
from individuals, prepared in this manner, can provide unique
individual identifications, as each individual will have a unique
set of such DNA sequences due to allelic differences.
[0248] Allelic variation occurs to some degree in the coding
regions of these sequences, and to a greater degree in the
noncoding regions. Each of the sequences described herein can, to
some degree, be used as a standard against which DNA from an
individual can be compared for identification purposes. Because
greater numbers of polymorphisms occur in the noncoding regions,
fewer sequences are necessary to differentiate individuals. The
noncoding sequences of SEQ ID NO:1 and SEQ ID NO:4 can provide
positive individual identification with a panel of perhaps 10 to
1,000 primers which each yield a noncoding amplified sequence of
100 bases. If predicted coding sequences, such as those in SEQ ID
NO:3 and 5 are used, a more appropriate number of primers for
positive individual identification would be 500-2,000.
[0249] If a panel of reagents from 59079 or 12599 nucleotide
sequences described herein is used to generate a unique
identification database for an individual, those same reagents can
later be used to identify tissue from that individual. Using the
unique identification database, positive identification of the
individual, living or dead, can be made from extremely small tissue
samples.
[0250] Use of Partial 59079 and 12599 Sequences in Forensic
Biology
[0251] DNA-based identification techniques can also be used in
forensic biology. To make such an identification, PCR technology
can be used to amplify DNA sequences taken from very small
biological samples such as tissues, e.g., hair or skin, or body
fluids, e.g., blood, saliva, or semen found at a crime scene. The
amplified sequence can then be compared to a standard, thereby
allowing identification of the origin of the biological sample.
[0252] The sequences of the present invention can be used to
provide polynucleotide reagents, e.g., PCR primers, targeted to
specific loci in the human genome, which can enhance the
reliability of DNA-based forensic identifications by, for example,
providing another "identification marker" (i.e. another DNA
sequence that is unique to a particular individual). As mentioned
above, actual base sequence information can be used for
identification as an accurate alternative to patterns formed by
restriction enzyme generated fragments. Sequences targeted to
noncoding regions of SEQ ID NO:1 or 4 (e.g., fragments derived from
the noncoding regions of SEQ ID NO:1 or 4 having a length of at
least 20 bases, preferably at least 30 bases) are particularly
appropriate for this use.
[0253] The 59079 and 12599 nucleotide sequences described herein
can further be used to provide polynucleotide reagents, e.g.,
labeled or labelable probes which can be used in, for example, an
in situ hybridization technique, to identify a specific tissue.
This can be very useful in cases where a forensic pathologist is
presented with a tissue of unknown origin. Panels of such 59079 or
12599 probes can be used to identify tissue by species and/or by
organ type.
[0254] In a similar fashion, these reagents, e.g., 59079 and 12599
primers or probes can be used to screen tissue culture for
contamination (i.e. screen for the presence of a mixture of
different types of cells in a culture).
[0255] Predictive Medicine
[0256] The present invention also pertains to the field of
predictive medicine in which diagnostic assays, prognostic assays,
and monitoring clinical trials are used for prognostic (predictive)
purposes to thereby treat an individual.
[0257] Generally, the invention provides, a method of determining
if a subject is at risk for a disorder related to a lesion in or
the misexpression of a gene which encodes 59079.
[0258] Such disorders include, e.g., a disorder associated with the
misexpression of 59079 or 12599 gene.
[0259] The method includes one or more of the following:
[0260] detecting, in a tissue of the subject, the presence or
absence of a mutation which affects the expression of the 59079 or
12599 gene, or detecting the presence or absence of a mutation in a
region which controls the expression of the gene, e.g., a mutation
in the 5' control region;
[0261] detecting, in a tissue of the subject, the presence or
absence of a mutation which alters the structure of the 59079 or
12599 gene;
[0262] detecting, in a tissue of the subject, the misexpression of
the 59079 or 12599 gene, at the mRNA level, e.g., detecting a
non-wild type level of a mRNA; or
[0263] detecting, in a tissue of the subject, the misexpression of
the gene, at the protein level, e.g., detecting a non-wild type
level of a 59079 or 12599 polypeptide.
[0264] In preferred embodiments the method includes: ascertaining
the existence of at least one of: a deletion of one or more
nucleotides from the 59079 or 12599 gene; an insertion of one or
more nucleotides into the gene, a point mutation, e.g., a
substitution of one or more nucleotides of the gene, a gross
chromosomal rearrangement of the gene, e.g., a translocation,
inversion, or deletion.
[0265] For example, detecting the genetic lesion can include: (i)
providing a probe/primer including an oligonucleotide containing a
region of nucleotide sequence which hybridizes to a sense or
antisense sequence from SEQ ID NO:1 or 4, or naturally occurring
mutants thereof or 5' or 3' flanking sequences naturally associated
with the 59079 or 12599 gene; (ii) exposing the probe/primer to
nucleic acid of the tissue; and detecting, by hybridization, e.g.,
in situ hybridization, of the probe/primer to the nucleic acid, the
presence or absence of the genetic lesion.
[0266] In preferred embodiments detecting the misexpression
includes ascertaining the existence of at least one of: an
alteration in the level of a messenger RNA transcript of the 59079
or 12599 gene; the presence of a non-wild type splicing pattern of
a messenger RNA transcript of the gene; or a non-wild type level of
59079 or 12599.
[0267] Methods of the invention can be used prenatally or to
determine if a subject's offspring will be at risk for a
disorder.
[0268] In preferred embodiments the method includes determining the
structure of a 59079 gene, an abnormal structure being indicative
of risk for the disorder.
[0269] In preferred embodiments the method includes contacting a
sample from the subject with an antibody to the 59079 protein or a
nucleic acid, which hybridizes specifically with the gene. There
and other embodiments are discussed below.
[0270] Diagnostic and Prognostic Assays
[0271] The presence, level, or absence of 59079 or 12599 protein or
nucleic acid in a biological sample can be evaluated by obtaining a
biological sample from a test subject and contacting the biological
sample with a compound or an agent capable of detecting 59079 or
12599 protein or nucleic acid (e.g., mRNA, genomic DNA) that
encodes 59079 or 12599 protein such that the presence of 59079 or
12599 protein or nucleic acid is detected in the biological sample.
The term "biological sample" includes tissues, cells and biological
fluids isolated from a subject, as well as tissues, cells and
fluids present within a subject. A preferred biological sample is
serum. The level of expression of the 59079 or 12599 gene can be
measured in a number of ways, including, but not limited to:
measuring the mRNA encoded by the 59079 or 12599 genes; measuring
the amount of protein encoded by the 59079 or 12599 genes; or
measuring the activity of the protein encoded by the 59079 or 12599
genes.
[0272] The level of mRNA corresponding to the 59079 or 12599 gene
in a cell can be determined both by in situ and by in vitro
formats.
[0273] The isolated mRNA can be used in hybridization or
amplification assays that include, but are not limited to, Southern
or Northern analyses, polymerase chain reaction analyses and probe
arrays. One preferred diagnostic method for the detection of mRNA
levels involves contacting the isolated mRNA with a nucleic acid
molecule (probe) that can hybridize to the mRNA encoded by the gene
being detected. The nucleic acid probe can be, for example, a
full-length 59079 or 12599 nucleic acid, such as the nucleic acid
of SEQ ID NO:1 or 4, or a portion thereof, such as an
oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500
nucleotides in length and sufficient to specifically hybridize
under stringent conditions to 59079 or 12599 mRNA or genomic DNA.
Other suitable probes for use in the diagnostic assays are
described herein.
[0274] In one format, mRNA (or cDNA) is immobilized on a surface
and contacted with the probes, for example by running the isolated
mRNA on an agarose gel and transferring the mRNA from the gel to a
membrane, such as nitrocellulose. In an alternative format, the
probes are immobilized on a surface and the mRNA (or cDNA) is
contacted with the probes, for example, in a two-dimensional gene
chip array. A skilled artisan can adapt known mRNA detection
methods for use in detecting the level of mRNA encoded by the 59079
or 12599 genes.
[0275] The level of mRNA in a sample that is encoded by 59079 or
12599 can be evaluated with nucleic acid amplification, e.g., by
rtPCR (Mullis (1987) U.S. Pat. No. 4,683,202), ligase chain
reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193),
self sustained sequence replication (Guatelli et al., (1990) Proc.
Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification
system (Kwoh et al., (1989), Proc. Natl. Acad. Sci. USA
86:1173-1177), Q-Beta Replicase (Lizardi et al., (1988)
Bio/Technology 6:1197), rolling circle replication (Lizardi et al.,
U.S. Pat. No. 5,854,033) or any other nucleic acid amplification
method, followed by the detection of the amplified molecules using
techniques known in the art. As used herein, amplification primers
are defined as being a pair of nucleic acid molecules that can
anneal to 5' or 3' regions of a gene (plus and minus strands,
respectively, or vice-versa) and contain a short region in between.
In general, amplification primers are from about 10 to 30
nucleotides in length and flank a region from about 50 to 200
nucleotides in length. Under appropriate conditions and with
appropriate reagents, such primers permit the amplification of a
nucleic acid molecule comprising the nucleotide sequence flanked by
the primers.
[0276] For in situ methods, a cell or tissue sample can be
prepared/processed and immobilized on a support, typically a glass
slide, and then contacted with a probe that can hybridize to mRNA
that encodes the 59079 or 12599 gene being analyzed.
[0277] In another embodiment, the methods further contacting a
control sample with a compound or agent capable of detecting 59079
or 12599 mRNA, or genomic DNA, and comparing the presence of 59079
or 12599 mRNA or genomic DNA in the control sample with the
presence of 59079 or 12599 mRNA or genomic DNA in the test
sample.
[0278] A variety of methods can be used to determine the level of
protein encoded by 59079 or 12599. In general, these methods
include contacting an agent that selectively binds to the protein,
such as an antibody with a sample, to evaluate the level of protein
in the sample. In a preferred embodiment, the antibody bears a
detectable label. Antibodies can be polyclonal, or more preferably,
monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or
F(ab').sub.2) can be used. The term "labeled", with regard to the
probe or antibody, is intended to encompass direct labeling of the
probe or antibody by coupling (i.e., physically linking) a
detectable substance to the probe or antibody, as well as indirect
labeling of the probe or antibody by reactivity with a detectable
substance. Examples of detectable substances are provided
herein.
[0279] The detection methods can be used to detect 59079 or 12599
protein in a biological sample in vitro, as well as in vivo. In
vitro techniques for detection of 59079 or 12599 protein include
enzyme linked immunosorbent assays (ELISAs), immunoprecipitations,
immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay
(RIA), and Western blot analysis. In vivo techniques for detection
of 59079 or 12599 protein include introducing into a subject a
labeled anti-59079 or anti-12599 antibody. For example, the
antibody can be labeled with a radioactive marker whose presence
and location in a subject can be detected by standard imaging
techniques.
[0280] In another embodiment, the methods further include
contacting the control sample with a compound or agent capable of
detecting 59079 or 12599 protein, and comparing the presence of
59079 or 12599 protein in the control sample with the presence of
59079 or 12599 protein in the test sample.
[0281] The invention also includes kits for detecting the presence
of 59079 or 12599 in a biological sample. For example, the kit can
include a compound or agent capable of detecting 59079 or 12599
protein or mRNA in a biological sample; and a standard. The
compound or agent can be packaged in a suitable container. The kit
can further comprise instructions for using the kit to detect 59079
or 12599 protein or nucleic acid.
[0282] For antibody-based kits, the kit can include: (1) a first
antibody (e.g., attached to a solid support) which binds to a
polypeptide corresponding to a marker of the invention; and,
optionally, (2) a second, different antibody which binds to either
the polypeptide or the first antibody and is conjugated to a
detectable agent.
[0283] For oligonucleotide-based kits, the kit can include: (1) an
oligonucleotide, e.g., a detectably labeled oligonucleotide, which
hybridizes to a nucleic acid sequence encoding a polypeptide
corresponding to a marker of the invention, or (2) a pair of
primers useful for amplifying a nucleic acid molecule corresponding
to a marker of the invention. The kit can also includes a buffering
agent, a preservative, or a protein stabilizing agent. The kit can
also includes components necessary for detecting the detectable
agent (e.g., an enzyme or a substrate). The kit can also contain a
control sample or a series of control samples which can be assayed
and compared to the test sample contained. Each component of the
kit can be enclosed within an individual container and all of the
various containers can be within a single package, along with
instructions for interpreting the results of the assays performed
using the kit.
[0284] The diagnostic methods described herein can identify
subjects having, or at risk of developing, a disease or disorder
associated with misexpressed or aberrant or unwanted 59079 or 12599
expression or activity. As used interchangeably herein, the terms
"unwanted" and "undesirable" include an unwanted phenomenon
involved in a biological response such as pain or deregulated cell
proliferation.
[0285] In one embodiment, a disease or disorder associated with
aberrant or unwanted 59079 or 12599 expression or activity is
identified. A test sample is obtained from a subject and 59079 or
12599 protein or nucleic acid (e.g., mRNA or genomic DNA) is
evaluated, wherein the level, e.g., the presence or absence, of
59079 or 12599 protein or nucleic acid is diagnostic for a subject
having or at risk of developing a disease or disorder associated
with aberrant or unwanted 59079 or 12599 expression or activity. As
used herein, a "test sample" refers to a biological sample obtained
from a subject of interest, including a biological fluid (e.g.,
serum), cell sample, or tissue.
[0286] The prognostic assays described herein can be used to
determine whether a subject can be administered an agent (e.g., an
agonist, antagonist, peptidomimetic, protein, peptide, nucleic
acid, small molecule, or other drug candidate) to treat a disease
or disorder associated with aberrant or unwanted 59079 or 12599
expression or activity. For example, such methods can be used to
determine whether a subject can be effectively treated with an
agent for a cellular proliferative and/or differentiative disorder,
a hormonal disorder, an immune or inflammatory disorder, a
neurological disorder, a cardiovascular disorder, a blood vessel
disorder, or a platelet disorder.
[0287] The methods of the invention can also be used to detect
genetic alterations in a 59079 or 12599 gene, thereby determining
if a subject with the altered gene is at risk for a disorder
characterized by misregulation in 59079 or 12599 protein activity
or nucleic acid expression, such as a cellular proliferative and/or
differentiative disorder, a hormonal disorder, an immune or
inflammatory disorder, a neurological disorder, a cardiovascular
disorder, a blood vessel disorder, or a platelet disorder. In
preferred embodiments, the methods include detecting, in a sample
from the subject, the presence or absence of a genetic alteration
characterized by at least one of an alteration affecting the
integrity of a gene encoding a 59079 or 12599 protein, or the
mis-expression of the 59079 or 12599 gene. For example, such
genetic alterations can be detected by ascertaining the existence
of at least one of: (1) a deletion of one or more nucleotides from
a 59079 or 12599 gene; (2) an addition of one or more nucleotides
to a 59079 or 12599 gene; (3) a substitution of one or more
nucleotides of a 59079 or 12599 gene, (4) a chromosomal
rearrangement of a 59079 or 12599 gene; (5) an alteration in the
level of a messenger RNA transcript of a 59079 or 12599 gene; (6)
aberrant modification of a 59079 or 12599 gene, such as of the
methylation pattern of the genomic DNA; (7) the presence of a
non-wild type splicing pattern of a messenger RNA transcript of a
59079 or 12599 gene; (8) a non-wild type level of a 59079 or 12599
protein; (9) allelic loss of a 59079 or 12599 gene; and (10)
inappropriate post-translational modification of a 59079 or 12599
protein.
[0288] An alteration can be detected without a probe/primer in a
polymerase chain reaction, such as anchor PCR or RACE PCR, or,
alternatively, in a ligation chain reaction (LCR), the latter of
which can be particularly useful for detecting point mutations in
the 59079 or 12599 gene. This method can include the steps of
collecting a sample of cells from a subject, isolating nucleic acid
(e.g., genomic, mRNA or both) from the sample, contacting the
nucleic acid sample with one or more primers which specifically
hybridize to a 59079 or 12599 gene under conditions such that
hybridization and amplification of the 59079 or 12599 gene (if
present) occurs, and detecting the presence or absence of an
amplification product, or detecting the size of the amplification
product and comparing the length to a control sample. It is
anticipated that PCR and/or LCR may be desirable to use as a
preliminary amplification step in conjunction with any of the
techniques used for detecting mutations described herein.
Alternatively, other amplification methods described herein or
known in the art can be used.
[0289] In another embodiment, mutations in a 59079 or 12599 gene
from a sample cell can be identified by detecting alterations in
restriction enzyme cleavage patterns. For example, sample and
control DNA is isolated, amplified (optionally), digested with one
or more restriction endonucleases, and fragment length sizes are
determined, e.g., by gel electrophoresis and compared. Differences
in fragment length sizes between sample and control DNA indicates
mutations in the sample DNA. Moreover, the use of sequence specific
ribozymes (see, for example, U.S. Pat. No. 5,498,531) can be used
to score for the presence of specific mutations by development or
loss of a ribozyme cleavage site.
[0290] In other embodiments, genetic mutations in 59079 and 12599
can be identified by hybridizing a sample and control nucleic
acids, e.g., DNA or RNA, two dimensional arrays, e.g., chip based
arrays. Such arrays include a plurality of addresses, each of which
is positionally distinguishable from the other. A different probe
is located at each address of the plurality. The arrays can have a
high density of addresses, e.g., can contain hundreds or thousands
of oligonucleotides probes (Cronin, M. T. et al. (1996) Human
Mutation 7: 244-255; Kozal, M. J. et al. (1996) Nature Medicine 2:
753-759). For example, genetic mutations in 59079 or 12599 can be
identified in two dimensional arrays containing light-generated DNA
probes as described in Cronin, M. T. et al. supra. Briefly, a first
hybridization array of probes can be used to scan through long
stretches of DNA in a sample and control to identify base changes
between the sequences by making linear arrays of sequential
overlapping probes. This step allows the identification of point
mutations. This step is followed by a second hybridization array
that allows the characterization of specific mutations by using
smaller, specialized probe arrays complementary to all variants or
mutations detected. Each mutation array is composed of parallel
probe sets, one complementary to the wild-type gene and the other
complementary to the mutant gene.
[0291] In yet another embodiment, any of a variety of sequencing
reactions known in the art can be used to directly sequence the
59079 and 12599 genes and detect mutations by comparing the
sequence of the sample 59079 or 12599 with the corresponding
wild-type (control) sequence. Automated sequencing procedures can
be utilized when performing the diagnostic assays ((1995)
Biotechniques 19:448), including sequencing by mass
spectrometry.
[0292] Other methods for detecting mutations in the 59079 or 12599
gene include methods in which protection from cleavage agents is
used to detect mismatched bases in RNA/RNA or RNA/DNA
heteroduplexes (Myers et al. (1985) Science 230:1242; Cotton et al.
(1988) Proc. Natl. Acad Sci USA 85:4397; Saleeba et al. (1992)
Methods Enzymol. 217:286-295).
[0293] In still another embodiment, the mismatch cleavage reaction
employs one or more proteins that recognize mismatched base pairs
in double-stranded DNA (so called "DNA mismatch repair" enzymes) in
defined systems for detecting and mapping point mutations in 59079
or 12599 cDNAs obtained from samples of cells. For example, the
mutY enzyme of E. coli cleaves A at G/A mismatches and the
thymidine DNA glycosylase from HeLa cells cleaves T at G/T
mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662; U.S.
Pat. No. 5,459,039).
[0294] In other embodiments, alterations in electrophoretic
mobility will be used to identify mutations in 59079 and 12599
genes. For example, single strand conformation polymorphism (SSCP)
may be used to detect differences in electrophoretic mobility
between mutant and wild type nucleic acids (Orita et al. (1989)
Proc Natl. Acad. Sci USA: 86:2766, see also Cotton (1993) Mutat.
Res. 285:125-144; and Hayashi (1992) Genet. Anal. Tech. Appl.
9:73-79). Single-stranded DNA fragments of sample and control 59079
and 12599 nucleic acids will be denatured and allowed to renature.
The secondary structure of single-stranded nucleic acids varies
according to sequence, the resulting alteration in electrophoretic
mobility enables the detection of even a single base change. The
DNA fragments may be labeled or detected with labeled probes. The
sensitivity of the assay may be enhanced by using RNA (rather than
DNA), in which the secondary structure is more sensitive to a
change in sequence. In a preferred embodiment, the subject method
utilizes heteroduplex analysis to separate double stranded
heteroduplex molecules on the basis of changes in electrophoretic
mobility (Keen et al. (1991) Trends Genet 7:5).
[0295] In yet another embodiment, the movement of mutant or
wild-type fragments in polyacrylamide gels containing a gradient of
denaturant is assayed using denaturing gradient gel electrophoresis
(DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as
the method of analysis, DNA will be modified to insure that it does
not completely denature, for example by adding a GC clamp of
approximately 40 bp of high-melting GC-rich DNA by PCR. In a
further embodiment, a temperature gradient is used in place of a
denaturing gradient to identify differences in the mobility of
control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem
265:12753).
[0296] Examples of other techniques for detecting point mutations
include, but are not limited to, selective oligonucleotide
hybridization, selective amplification, or selective primer
extension (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989)
Proc. Natl. Acad. Sci USA 86:6230).
[0297] Alternatively, allele specific amplification technology
which depends on selective PCR amplification may be used in
conjunction with the instant invention. Oligonucleotides used as
primers for specific amplification may carry the mutation of
interest in the center of the molecule (so that amplification
depends on differential hybridization) (Gibbs et al. (1989) Nucleic
Acids Res. 17:2437-2448) or at the extreme 3' end of one primer
where, under appropriate conditions, mismatch can prevent, or
reduce polymerase extension (Prossner (1993) Tibtech 11:238). In
addition it may be desirable to introduce a novel restriction site
in the region of the mutation to create cleavage-based detection
(Gasparini et al. (1992) Mol. Cell Probes 6: 1). It is anticipated
that in certain embodiments amplification may also be performed
using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad.
Sci USA 88:189). In such cases, ligation will occur only if there
is a perfect match at the 3' end of the 5' sequence making it
possible to detect the presence of a known mutation at a specific
site by looking for the presence or absence of amplification.
[0298] The methods described herein may be performed, for example,
by utilizing prepackaged diagnostic kits comprising at least one
probe nucleic acid or antibody reagent described herein, which may
be conveniently used, e.g., in clinical settings to diagnose
patients exhibiting symptoms or family history of a disease or
illness involving a 59079 gene.
[0299] Use of 59079 Molecules as Surrogate Markers
[0300] The 59079 and 12599 molecules of the invention are also
useful as markers of disorders or disease states, as markers for
precursors of disease states, as markers for predisposition of
disease states, as markers of drug activity, or as markers of the
pharmacogenomic profile of a subject. Using the methods described
herein, the presence, absence and/or quantity of the 59079 or 12599
molecules of the invention may be detected, and may be correlated
with one or more biological states in vivo. For example, the 59079
and 12599 molecules of the invention may serve as surrogate markers
for one or more disorders or disease states or for conditions
leading up to disease states. As used herein, a "surrogate marker"
is an objective biochemical marker which correlates with the
absence or presence of a disease or disorder, or with the
progression of a disease or disorder (e.g., with the presence or
absence of a tumor). The presence or quantity of such markers is
independent of the disease. Therefore, these markers may serve to
indicate whether a particular course of treatment is effective in
lessening a disease state or disorder. Surrogate markers are of
particular use when the presence or extent of a disease state or
disorder is difficult to assess through standard methodologies
(e.g., early stage tumors), or when an assessment of disease
progression is desired before a potentially dangerous clinical
endpoint is reached (e.g., an assessment of cardiovascular disease
may be made using cholesterol levels as a surrogate marker, and an
analysis of HIV infection may be made using HIV RNA levels as a
surrogate marker, well in advance of the undesirable clinical
outcomes of myocardial infarction or fully-developed AIDS).
Examples of the use of surrogate markers in the art include: Koomen
et al. (2000) J. Mass. Spectrom. 35: 258-264; and James (1994) AIDS
Treatment News Archive 209.
[0301] The 59079 and 12599 molecules of the invention are also
useful as pharmacodynamic markers. As used herein, a
"pharmacodynamic marker" is an objective biochemical marker which
correlates specifically with drug effects. The presence or quantity
of a pharmacodynamic marker is not related to the disease state or
disorder for which the drug is being administered; therefore, the
presence or quantity of the marker is indicative of the presence or
activity of the drug in a subject. For example, a pharmacodynamic
marker may be indicative of the concentration of the drug in a
biological tissue, in that the marker is either expressed or
transcribed or not expressed or transcribed in that tissue in
relationship to the level of the drug. In this fashion, the
distribution or uptake of the drug may be monitored by the
pharmacodynamic marker. Similarly, the presence or quantity of the
pharmacodynamic marker may be related to the presence or quantity
of the metabolic product of a drug, such that the presence or
quantity of the marker is indicative of the relative breakdown rate
of the drug in vivo. Pharmacodynamic markers are of particular use
in increasing the sensitivity of detection of drug effects,
particularly when the drug is administered in low doses. Since even
a small amount of a drug may be sufficient to activate multiple
rounds of marker (e.g., a 59079 marker) transcription or
expression, the amplified marker may be in a quantity which is more
readily detectable than the drug itself. Also, the marker may be
more easily detected due to the nature of the marker itself; for
example, using the methods described herein, anti-59079 and
anti-12599 antibodies may be employed in an immune-based detection
system for a 59079 or 12599 protein marker, or 59079- or
12599-specific radiolabeled probes may be used to detect a 59079 or
12599 mRNA marker. Furthermore, the use of a pharmacodynamic marker
may offer mechanism-based prediction of risk due to drug treatment
beyond the range of possible direct observations. Examples of the
use of pharmacodynamic markers in the art include: Matsuda et al.
U.S. Pat. No. 6,033,862; Hattis et al. (1991) Env. Health Perspect.
90: 229-238; Schentag (1999) Am. J. Health-Syst. Pharm. 56 Suppl.
3: S21-S24; and Nicolau (1999) Am. J. Health-Syst. Pharm. 56 Suppl.
3: S16-S20.
[0302] The 59079 and 12599 molecules of the invention are also
useful as pharmacogenomic markers. As used herein, a
"pharmacogenomic marker" is an objective biochemical marker which
correlates with a specific clinical drug response or susceptibility
in a subject (see, e.g., McLeod et al. (1999) Eur. J. Cancer
35:1650-1652). The presence or quantity of the pharmacogenomic
marker is related to the predicted response of the subject to a
specific drug or class of drugs prior to administration of the
drug. By assessing the presence or quantity of one or more
pharmacogenomic markers in a subject, a drug therapy which is most
appropriate for the subject, or which is predicted to have a
greater degree of success, may be selected. For example, based on
the presence or quantity of RNA, or protein (e.g., 59079 and 12599
protein or RNA) for specific tumor markers in a subject, a drug or
course of treatment may be selected that is optimized for the
treatment of the specific tumor likely to be present in the
subject. Similarly, the presence or absence of a specific sequence
mutation in 59079 or 12599 DNA may correlate 59079 or 12599 drug
response. The use of pharmacogenomic markers therefore permits the
application of the most appropriate treatment for each subject
without having to administer the therapy.
[0303] Pharmaceutical Compositions
[0304] The nucleic acid and polypeptides, fragments thereof, as
well as anti-59079 and anti-12599 antibodies and small molecule
modulators of 59079 and 12599 molecules (also referred to herein as
"active compounds") of the invention can be incorporated into
pharmaceutical compositions. Such compositions typically include
the nucleic acid molecule, protein, or antibody and a
pharmaceutically acceptable carrier. As used herein, a
"pharmaceutically acceptable carrier" includes solvents, dispersion
media, coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents, and the like, compatible with
pharmaceutical administration. Supplementary active compounds can
also be incorporated into the compositions.
[0305] A pharmaceutical composition is formulated to be compatible
with its intended route of administration. Examples of routes of
administration include parenteral, e.g., intravenous, intradermal,
subcutaneous, oral (e.g., inhalation), transdermal (topical),
transmucosal, and rectal administration. Solutions or suspensions
used for parenteral, intradermal, or subcutaneous application can
include the following components: a sterile diluent such as water
for injection, saline solution, fixed oils, polyethylene glycols,
glycerine, propylene glycol or other synthetic solvents;
antibacterial agents such as benzyl alcohol or methyl parabens;
antioxidants such as ascorbic acid or sodium bisulfite; chelating
agents such as ethylenediaminetetraacetic acid; buffers such as
acetates, citrates or phosphates and agents for the adjustment of
tonicity such as sodium chloride or dextrose. pH can be adjusted
with acids or bases, such as hydrochloric acid or sodium hydroxide.
The parenteral preparation can be enclosed in ampoules, disposable
syringes or multiple dose vials made of glass or plastic.
[0306] Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous preparation
of sterile injectable solutions or dispersion. For intravenous
administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor EL.TM. (BASF, Parsippany N.J.) or
phosphate buffered saline (PBS). In all cases, the composition must
be sterile and should be fluid to the extent that easy
syringability exists. It should be stable under the conditions of
manufacture and storage and must be preserved against the
contaminating action of microorganisms such as bacteria and fungi.
The carrier can be a solvent or dispersion medium containing, for
example, water, ethanol, polyol (for example, glycerol, propylene
glycol, and liquid polyetheylene glycol, and the like), and
suitable mixtures thereof. The proper fluidity can be maintained,
for example, by the use of a coating such as lecithin, by the
maintenance of the required particle size in the case of dispersion
and by the use of surfactants. Prevention of the action of
microorganisms can be achieved by various antibacterial and
antifungal agents, for example, parabens, chlorobutanol, phenol,
ascorbic acid, thimerosal, and the like. In many cases, it will be
preferable to include isotonic agents, for example, sugars,
polyalcohols such as manitol, sorbitol, sodium chloride in the
composition. Prolonged absorption of the injectable compositions
can be brought about by including in the composition an agent which
delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the
active compound in the required amount in an appropriate solvent
with one or a combination of ingredients enumerated above, as
required, followed by filtered sterilization. Generally,
dispersions are prepared by incorporating the active compound into
a sterile vehicle which contains a basic dispersion medium and the
required other ingredients from those enumerated above. In the case
of sterile powders for the preparation of sterile injectable
solutions, the preferred methods of preparation are vacuum drying
and freeze-drying which yields a powder of the active ingredient
plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
[0307] Oral compositions generally include an inert diluent or an
edible carrier. For the purpose of oral therapeutic administration,
the active compound can be incorporated with excipients and used in
the form of tablets, troches, or capsules, e.g., gelatin capsules.
Oral compositions can also be prepared using a fluid carrier for
use as a mouthwash. Pharmaceutically compatible binding agents,
and/or adjuvant materials can be included as part of the
composition. The tablets, pills, capsules, troches and the like can
contain any of the following ingredients, or compounds of a similar
nature: a binder such as microcrystalline cellulose, gum tragacanth
or gelatin; an excipient such as starch or lactose, a
disintegrating agent such as alginic acid, Primogel, or corn
starch; a lubricant such as magnesium stearate or Sterotes; a
glidant such as colloidal silicon dioxide; a sweetening agent such
as sucrose or saccharin; or a flavoring agent such as peppermint,
methyl salicylate, or orange flavoring.
[0308] For administration by inhalation, the compounds are
delivered in the form of an aerosol spray from pressured container
or dispenser which contains a suitable propellant, e.g., a gas such
as carbon dioxide, or a nebulizer.
[0309] Systemic administration can also be by transmucosal or
transdermal means. For transmucosal or transdermal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the art,
and include, for example, for transmucosal administration,
detergents, bile salts, and fusidic acid derivatives. Transmucosal
administration can be accomplished through the use of nasal sprays
or suppositories. For transdermal administration, the active
compounds are formulated into ointments, salves, gels, or creams as
generally known in the art.
[0310] The compounds can also be prepared in the form of
suppositories (e.g., with conventional suppository bases such as
cocoa butter and other glycerides) or retention enemas for rectal
delivery.
[0311] In one embodiment, the active compounds are prepared with
carriers that will protect the compound against rapid elimination
from the body, such as a controlled release formulation, including
implants and microencapsulated delivery systems. Biodegradable,
biocompatible polymers can be used, such as ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and
polylactic acid. Methods for preparation of such formulations will
be apparent to those skilled in the art. The materials can also be
obtained commercially from Alza Corporation (Palo Alto Calif.) and
Nova Pharmaceuticals, Inc. Liposomal suspensions (including
liposomes targeted to infected cells with monoclonal antibodies to
viral antigens) can also be used as pharmaceutically acceptable
carriers. These can be prepared according to methods known to those
skilled in the art, for example, as described in U.S. Pat. No.
4,522,811.
[0312] It is advantageous to formulate oral or parenteral
compositions in dosage unit form for ease of administration and
uniformity of dosage. Dosage unit form as used herein refers to
physically discrete units suited as unitary dosages for the subject
to be treated; each unit containing a predetermined quantity of
active compound calculated to produce the desired therapeutic
effect in association with the required pharmaceutical carrier.
[0313] Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the LD.sub.50 (the
dose lethal to 50% of the population) and the ED.sub.50 (the dose
therapeutically effective in 50% of the population). The dose ratio
between toxic and therapeutic effects is the therapeutic index and
it can be expressed as the ratio LD.sub.50/ED.sub.50. Compounds
which exhibit high therapeutic indices are preferred. While
compounds that exhibit toxic side effects may be used, care should
be taken to design a delivery system that targets such compounds to
the site of affected tissue in order to minimize potential damage
to uninfected cells and, thereby, reduce side effects.
[0314] The data obtained from the cell culture assays and animal
studies can be used in formulating a range of dosage for use in
humans. The dosage of such compounds lies preferably within a range
of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage may vary within this range
depending upon the dosage form employed and the route of
administration utilized. For any compound used in the method of the
invention, the therapeutically effective dose can be estimated
initially from cell culture assays. A dose may be formulated in
animal models to achieve a circulating plasma concentration range
that includes the IC.sub.50 (i.e., the concentration of the test
compound which achieves a half-maximal inhibition of symptoms) as
determined in cell culture. Such information can be used to more
accurately determine useful doses in humans. Levels in plasma may
be measured, for example, by high performance liquid
chromatography.
[0315] As defined herein, a therapeutically effective amount of
protein or polypeptide (i.e., an effective dosage) ranges from
about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25
mg/kg body weight, more preferably about 0.1 to 20 mg/kg body
weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg,
3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The
protein or polypeptide can be administered one time per week for
between about 1 to 10 weeks, preferably between 2 to 8 weeks, more
preferably between about 3 to 7 weeks, and even more preferably for
about 4, 5, or 6 weeks. The skilled artisan will appreciate that
certain factors may influence the dosage and timing required to
effectively treat a subject, including but not limited to the
severity of the disease or disorder, previous treatments, the
general health and/or age of the subject, and other diseases
present. Moreover, treatment of a subject with a therapeutically
effective amount of a protein, polypeptide, or antibody can include
a single treatment or, preferably, can include a series of
treatments.
[0316] For antibodies, the preferred dosage is 0.1 mg/kg of body
weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act
in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually
appropriate. Generally, partially human antibodies and fully human
antibodies have a longer half-life within the human body than other
antibodies. Accordingly, lower dosages and less frequent
administration is often possible. Modifications such as lipidation
can be used to stabilize antibodies and to enhance uptake and
tissue penetration (e.g., into the brain). A method for lipidation
of antibodies is described by Cruikshank et al. ((1997) J. Acquired
Immune Deficiency Syndromes and Human Retrovirology 14:193).
[0317] The present invention encompasses agents which modulate
expression or activity. An agent may, for example, be a small
molecule. For example, such small molecules include, but are not
limited to, peptides, peptidomimetics (e.g., peptoids), amino
acids, amino acid analogs, polynucleotides, polynucleotide analogs,
nucleotides, nucleotide analogs, organic or inorganic compounds
(i.e., including heteroorganic and organometallic compounds) having
a molecular weight less than about 10,000 grams per mole, organic
or inorganic compounds having a molecular weight less than about
5,000 grams per mole, organic or inorganic compounds having a
molecular weight less than about 1,000 grams per mole, organic or
inorganic compounds having a molecular weight less than about 500
grams per mole, and salts, esters, and other pharmaceutically
acceptable forms of such compounds.
[0318] Exemplary doses include milligram or microgram amounts of
the small molecule per kilogram of subject or sample weight (e.g.,
about 1 microgram per kilogram to about 500 milligrams per
kilogram, about 100 micrograms per kilogram to about 5 milligrams
per kilogram, or about 1 microgram per kilogram to about 50
micrograms per kilogram. It is furthermore understood that
appropriate doses of a small molecule depend upon the potency of
the small molecule with respect to the expression or activity to be
modulated. When one or more of these small molecules is to be
administered to an animal (e.g., a human) in order to modulate
expression or activity of a polypeptide or nucleic acid of the
invention, a physician, veterinarian, or researcher may, for
example, prescribe a relatively low dose at first, subsequently
increasing the dose until an appropriate response is obtained. In
addition, it is understood that the specific dose level for any
particular animal subject will depend upon a variety of factors
including the activity of the specific compound employed, the age,
body weight, general health, gender, and diet of the subject, the
time of administration, the route of administration, the rate of
excretion, any drug combination, and the degree of expression or
activity to be modulated.
[0319] An antibody (or fragment thereof) may be conjugated to a
therapeutic moiety such as a cytotoxin, a therapeutic agent or a
radioactive metal ion. A cytotoxin or cytotoxic agent includes any
agent that is detrimental to cells. Examples include taxol,
cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,
etoposide, tenoposide, vincristine, vinblastine, colchicin,
doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone,
mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids,
procaine, tetracaine, lidocaine, propranolol, and puromycin and
analogs or homologs thereof. Therapeutic agents include, but are
not limited to, antimetabolites (e.g., methotrexate,
6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil
decarbazine), alkylating agents (e.g., mechlorethamine, thioepa
chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU),
cyclothosphamide, busulfan, dibromomannitol, streptozotocin,
mitomycin C, and cis-dichlorodiamine platinum (II) (DDP)
cisplatin), anthracyclines (e.g., daunorubicin (formerly
daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin
(formerly actinomycin), bleomycin, mithramycin, and anthramycin
(AMC)), and anti-mitotic agents (e.g., vincristine and
vinblastine).
[0320] The conjugates of the invention can be used for modifying a
given biological response, the drug moiety is not to be construed
as limited to classical chemical therapeutic agents. For example,
the drug moiety may be a protein or polypeptide possessing a
desired biological activity. Such proteins may include, for
example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or
diphtheria toxin; a protein such as tumor necrosis factor,
.alpha.-interferon, .beta.-interferon, nerve growth factor,
platelet derived growth factor, tissue plasminogen activator; or,
biological response modifiers such as, for example, lymphokines,
interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6
("IL-6"), granulocyte macrophase colony stimulating factor
("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or
other growth factors.
[0321] Alternatively, an antibody can be conjugated to a second
antibody to form an antibody heteroconjugate as described by Segal
in U.S. Pat. No. 4,676,980.
[0322] The nucleic acid molecules of the invention can be inserted
into vectors and used as gene therapy vectors. Gene therapy vectors
can be delivered to a subject by, for example, intravenous
injection, local administration (see U.S. Pat. No. 5,328,470) or by
stereotactic injection (see e.g., Chen et al. (1994) Proc. Natl.
Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the
gene therapy vector can include the gene therapy vector in an
acceptable diluent, or can comprise a slow release matrix in which
the gene delivery vehicle is imbedded. Alternatively, where the
complete gene delivery vector can be produced intact from
recombinant cells, e.g., retroviral vectors, the pharmaceutical
preparation can include one or more cells which produce the gene
delivery system.
[0323] The pharmaceutical compositions can be included in a
container, pack, or dispenser together with instructions for
administration.
[0324] Methods of Treatment
[0325] The present invention provides for both prophylactic and
therapeutic methods of treating a subject at risk of (or
susceptible to) a disorder or having a disorder associated with
aberrant or undesirable 59079 or 12599 expression or activity. With
regard to both prophylactic and therapeutic methods of treatment,
such treatments may be specifically tailored or modified, based on
knowledge obtained from the field of pharmacogenomics.
"Pharmacogenomics", as used herein, refers to the application of
genomics technologies such as gene sequencing, statistical
genetics, and gene expression analysis to drugs in clinical
development and commercially available. More specifically, the term
refers the study of how a patient's genes determine his or her
response to a drug (e.g., a patient's "drug response phenotype", or
"drug response genotype".) Thus, another aspect of the invention
provides methods for tailoring an individual's prophylactic or
therapeutic treatment with either the 59079 or 12599 molecules of
the present invention or 59079 or 12599 modulators according to
that individual's drug response genotype. Pharmacogenomics allows a
clinician or physician to target prophylactic or therapeutic
treatments to patients who will most benefit from the treatment and
to identify patients who will experience toxic drug-related side
effects.
[0326] "Treatment", as used herein, is defined as the application
or administration of a therapeutic agent to a patient, or
application or administration of a therapeutic agent to an isolated
tissue or cell line from a patient, who has a disease, a symptom of
disease or a predisposition toward a disease, with the purpose to
cure, heal, alleviate, relieve, alter, remedy, ameliorate,
palliate, improve or affect the disease, the symptoms of disease or
the predisposition toward disease. A therapeutic agent includes,
but is not limited to, small molecules, peptides, antibodies,
ribozymes and antisense oligonucleotides.
[0327] In one aspect, the invention provides a method for
preventing in a subject, a disease or condition associated with an
aberrant or undesirable 59079 or 12599 expression or activity, by
administering to the subject a 59079 or 12599 molecule or an agent
which modulates 59079 or 12599 expression or at least one 59079 or
12599 activity. Subjects at risk for a disease which is caused or
contributed to by aberrant or undesirable 59079 or 12599 expression
or activity can be identified by, for example, any or a combination
of diagnostic or prognostic assays as described herein.
Administration of a prophylactic agent can occur prior to the
manifestation of symptoms characteristic of the 59079 or 12599
aberrance, such that a disease or disorder is prevented or,
alternatively, delayed in its progression. Depending on the type of
59079 or 12599 aberrance, for example, a 59079 or 12599 molecule
(e.g., a 59079 or 12599 nucleic acid molecule or a 59079 or 12599
protein or polypeptide, or a fragment thereof, as described
herein), or 59079 or 12599 agonist or 59079 or 12599 antagonist
agent can be used for treating the subject. The appropriate agent
can be determined based on screening assays described herein.
[0328] It is possible that some 59079 and 12599 disorders can be
caused, at least in part, by an abnormal level of gene product, or
by the presence of a gene product exhibiting abnormal activity. As
such, the reduction in the level and/or activity of such gene
products would bring about the amelioration of disorder
symptoms.
[0329] As discussed, successful treatment of 59079 and 12599
disorders can be brought about by techniques that serve to inhibit
the expression or activity of 59079 or 12599 target gene products.
For example, compounds, e.g., an agent identified using an assays
described above, that proves to exhibit negative modulatory
activity, can be used in accordance with the invention to prevent
and/or ameliorate symptoms of 59079 or 12599 disorders. Such
molecules can include, but are not limited to peptides,
phosphopeptides, small organic or inorganic molecules, or
antibodies (including, for example, polyclonal, monoclonal,
humanized, anti-idiotypic, chimeric or single chain antibodies, and
Fab, F(ab').sub.2 and Fab expression library fragments, scFV
molecules, and epitope-binding fragments thereof).
[0330] Further, antisense and ribozyme molecules that inhibit
expression of the target gene can also be used in accordance with
the invention to reduce the level of target gene expression, thus
effectively reducing the level of target gene activity. Still
further, triple helix molecules can be utilized in reducing the
level of target gene activity. Antisense, ribozyme and triple helix
molecules are discussed above.
[0331] It is possible that the use of antisense, ribozyme, and/or
triple helix molecules to reduce or inhibit mutant gene expression
can also reduce or inhibit the transcription (triple helix) and/or
translation (antisense, ribozyme) of mRNA produced by normal target
gene alleles, such that the concentration of normal target gene
product present can be lower than is necessary for a normal
phenotype. In such cases, nucleic acid molecules that encode and
express target gene polypeptides exhibiting normal target gene
activity can be introduced into cells via gene therapy method.
Alternatively, in instances in that the target gene encodes an
extracellular protein, it can be preferable to co-administer normal
target gene protein into the cell or tissue in order to maintain
the requisite level of cellular or tissue target gene activity.
[0332] Another method by which nucleic acid molecules may be
utilized in treating or preventing a disease characterized by
undesirable 59079 or 12599 expression is through the use of aptamer
molecules specific for 59079 or 12599 protein. Aptamers are nucleic
acid molecules having a tertiary structure which permits them to
specifically bind to protein ligands (see, e.g., Osborne, et al.,
Curr. Opin. Chem. Biol. 1997, 1:5-9; and Patel, D. J., Curr. Opin.
Chem. Biol. 1997 June; 1:32-46). Since nucleic acid molecules may
in many cases be more conveniently introduced into target cells
than therapeutic protein molecules may be, aptamers offer a method
by which 59079 protein activity may be specifically decreased
without the introduction of drugs or other molecules which may have
pluripotent effects.
[0333] Antibodies can be generated that are both specific for
target gene product and that reduce target gene product activity.
Such antibodies may, therefore, by administered in instances
whereby negative modulatory techniques are appropriate for the
treatment of 59079 or 12599 disorders. For a description of
antibodies, see the Antibody section above.
[0334] In circumstances wherein injection of an animal or a human
subject with a 59079 or 12599 protein or epitope for stimulating
antibody production is harmful to the subject, it is possible to
generate an immune response against 59079 or 12599 through the use
of anti-idiotypic antibodies (see, for example, Herlyn, D., Ann.
Med. 1999; 31:66-78; and Bhattacharya-Chatterjee, M., and Foon, K.
A. (1998) Cancer Treat. Res. 94:51-68). If an anti-idiotypic
antibody is introduced into a mammal or human subject, it should
stimulate the production of anti-anti-idiotypic antibodies, which
should be specific to the 59079 or 12599 protein. Vaccines directed
to a disease characterized by 59079 or 12599 expression may also be
generated in this fashion.
[0335] In instances where the target antigen is intracellular and
whole antibodies are used, internalizing antibodies may be
preferred. Lipofectin or liposomes can be used to deliver the
antibody or a fragment of the Fab region that binds to the target
antigen into cells. Where fragments of the antibody are used, the
smallest inhibitory fragment that binds to the target antigen is
preferred. For example, peptides having an amino acid sequence
corresponding to the Fv region of the antibody can be used.
Alternatively, single chain neutralizing antibodies that bind to
intracellular target antigens can also be administered. Such single
chain antibodies can be administered, for example, by expressing
nucleotide sequences encoding single-chain antibodies within the
target cell population (see e.g., Marasco et al., (1993, Proc.
Natl. Acad. Sci. USA 90:7889-7893).
[0336] The identified compounds that inhibit target gene
expression, synthesis and/or activity can be administered to a
patient at therapeutically effective doses to prevent, treat or
ameliorate 59079 and 12599 disorders. A therapeutically effective
dose refers to that amount of the compound sufficient to result in
amelioration of symptoms of the disorders.
[0337] Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the LD.sub.50 (the
dose lethal to 50% of the population) and the ED.sub.50 (the dose
therapeutically effective in 50% of the population). The dose ratio
between toxic and therapeutic effects is the therapeutic index and
it can be expressed as the ratio LD.sub.50/ED.sub.50. Compounds
that exhibit large therapeutic indices are preferred. While
compounds that exhibit toxic side effects can be used, care should
be taken to design a delivery system that targets such compounds to
the site of affected tissue in order to minimize potential damage
to uninfected cells and, thereby, reduce side effects.
[0338] The data obtained from the cell culture assays and animal
studies can be used in formulating a range of dosage for use in
humans. The dosage of such compounds lies preferably within a range
of circulating concentrations that include the ED.sub.50 with
little or no toxicity. The dosage can vary within this range
depending upon the dosage form employed and the route of
administration utilized. For any compound used in the method of the
invention, the therapeutically effective dose can be estimated
initially from cell culture assays. A dose can be formulated in
animal models to achieve a circulating plasma concentration range
that includes the IC.sub.50 (i.e., the concentration of the test
compound that achieves a half-maximal inhibition of symptoms) as
determined in cell culture. Such information can be used to more
accurately determine useful doses in humans. Levels in plasma can
be measured, for example, by high performance liquid
chromatography.
[0339] Another measurement which can be used to determine the
effective dose for an individual is to directly assay levels of
"free" and "bound" compound in the serum of the test subject. Such
assays may utilize antibody mimics and/or "biosensors" that have
been created through molecular imprinting techniques. The compound
which is able to modulate 59079 activity is used as a template, or
"imprinting molecule", to spatially organize polymerizable monomers
prior to their polymerization with catalytic reagents. The
subsequent removal of the imprinted molecule leaves a polymer
matrix which contains a repeated "negative image" of the compound
and is able to selectively rebind the molecule under biological
assay conditions. A detailed review of this technique is found in
Ansell, R. J. et al., (1996) Current Opinion in Biotechnology
7:89-94 and in Shea, K. J., (1994) Trends in Polymer Science
2:166-173. Such "imprinted" affinity matrixes are amenable to
ligand-binding assays, whereby the immobilized monoclonal antibody
component is replaced by an appropriately imprinted matrix. An
example of the use of such matrices in this way can be seen in
Vlatakis, G. et al., (1993) Nature 361:645-647. Through the use of
isotope-labeling, the "free" concentration of compound which
modulates the expression or activity of 59079 can be readily
monitored and used in calculations of IC.sub.50.
[0340] Such "imprinted" affinity matrices can also be designed to
include fluorescent groups whose photon-emitting properties
measurably change upon local and selective binding of target
compound. These changes can be readily assayed in real time using
appropriate fiberoptic devices, in turn allowing the dose in a test
subject to be quickly optimized based on its individual IC.sub.50.
A rudimentary example of such a "biosensor" is discussed in Kriz,
D. et al., (1995) Analytical Chemistry 67:2142-2144.
[0341] Another aspect of the invention pertains to methods of
modulating 59079 expression or activity for therapeutic purposes.
Accordingly, in an exemplary embodiment, the modulatory method of
the invention involves contacting a cell with a 59079 molecule
(e.g., a 59079 or 12599 nucleic acid molecule or 59079 or 12599
protein or polypeptide, or a fragment thereof, as described herein)
or an agent that modulates one or more of the activities of the
59079 or 12599 protein activity associated with the cell. An agent
that modulates 59079 or 12599 protein activity can be an agent as
described herein, such as a nucleic acid or a protein, a
naturally-occurring target molecule of a 59079 or 12599 protein
(e.g., a 59079 or 12599 substrate, ligand, or receptor), an
anti-59079 or anti-12599 antibody, a 59079 or 12599 agonist or
antagonist, a peptidomimetic of a 59079 or 12599 agonist or
antagonist, or other small molecule.
[0342] In one embodiment, the agent stimulates one or more 59079 or
12599 activities. Examples of such stimulatory agents include
active 59079 and 12599 proteins and nucleic acid molecules encoding
a 59079 or 12599 protein or polypeptide, or a fragment thereof. In
another embodiment, the agent inhibits one or more 59079 or 12599
activities. Examples of such inhibitory agents include antisense
59079 and 12599 nucleic acid molecules, anti-59079 and anti-12599
antibodies, and 59079 and 12599 inhibitors. These modulatory
methods can be performed in vitro (e.g., by culturing the cell with
the agent) or, alternatively, in vivo (e.g., by administering the
agent to a subject), or in situ. As such, the present invention
provides methods of treating an individual afflicted with a disease
or disorder characterized by aberrant or unwanted expression or
activity of a 59079 or 12599 protein or nucleic acid molecule. In
one embodiment, the method involves administering an agent (e.g.,
an agent identified by a screening assay described herein), or
combination of agents that modulates (e.g., upregulates or
downregulates) 59079 or 12599 expression or activity. In another
embodiment, the method involves administering a 59079 or 12599
protein or nucleic acid molecule as therapy to compensate for
reduced, aberrant, or undesirable 59079 or 12599 expression or
activity.
[0343] Stimulation of 59079 or 12599 expression or activity is
desirable in situations in which 59079 or 12599 expression or
activity is abnormally downregulated and/or in which increased
59079 or 12599 expression or activity is likely to have a
beneficial effect. Likewise, inhibition of 59079 or 12599
expression or activity is desirable in situations in which 59079 or
12599 expression or activity is abnormally upregulated and/or in
which decreased 59079 or 12599 expression or activity is likely to
have a beneficial effect.
[0344] The 59079 and 12599 molecules can act as novel diagnostic
targets and therapeutic agents for controlling one or more of
cellular proliferative and/or differentiative disorders, hormonal
disorders, immune and inflammatory disorders, neurological
disorders, cardiovascular disorders, blood vessel disorders, and
platelet disorders, as described above, as well as disorders
associated with bone metabolism, hepatic disorders, viral diseases,
and pain and metabolic or pain disorders.
[0345] Aberrant expression and/or activity of 59079 or 12599
molecules may mediate disorders associated with bone metabolism.
"Bone metabolism" refers to direct or indirect effects in the
formation or degeneration of bone structures, e.g., bone formation,
bone resorption, etc., which may ultimately affect the
concentrations in serum of calcium and phosphate. This term also
includes activities mediated by 59079 or 12599 molecules effects in
bone cells, e.g. osteoclasts and osteoblasts, that may in turn
result in bone formation and degeneration. For example, 59079 or
12599 molecules may support different activities of bone resorbing
osteoclasts such as the stimulation of differentiation of monocytes
and mononuclear phagocytes into osteoclasts. Accordingly, 59079 and
12599 molecules that modulate the production of bone cells can
influence bone formation and degeneration, and thus may be used to
treat bone disorders. Examples of such disorders include, but are
not limited to, osteoporosis, osteodystrophy, osteomalacia,
rickets, osteitis fibrosa cystica, renal osteodystrophy,
osteosclerosis, anti-convulsant treatment, osteopenia,
fibrogenesis-imperfecta ossium, secondary hyperparathyrodism,
hypoparathyroidism, hyperparathyroidism, cirrhosis, obstructive
jaundice, drug induced metabolism, medullary carcinoma, chronic
renal disease, rickets, sarcoidosis, glucocorticoid antagonism,
malabsorption syndrome, steatorrhea, tropical sprue, idiopathic
hypercalcemia and milk fever.
[0346] Hepatic disorders which can be treated or diagnosed by
methods described herein include, but are not limited to, disorders
associated with an accumulation in the liver of fibrous tissue,
such as that resulting from an imbalance between production and
degradation of the extracellular matrix accompanied by the collapse
and condensation of preexisting fibers. The methods described
herein can be used to diagnose or treat hepatocellular necrosis or
injury induced by a wide variety of agents including processes
which disturb homeostasis, such as an inflammatory process, tissue
damage resulting from toxic injury or altered hepatic blood flow,
and infections (e.g., bacterial, viral and parasitic). For example,
the methods can be used for the early detection of hepatic injury,
such as portal hypertension or hepatic fibrosis. In addition, the
methods can be employed to detect liver fibrosis attributed to
inborn errors of metabolsim, for example, fibrosis resulting from a
storage disorder such as Gaucher's disease (lipid abnormalities) or
a glycogen storage disease, A1-antitrypsin deficiency; a disorder
mediating the accumulation (e.g., storage) of an exogenous
substance, for example, hemochromatosis (iron-overload syndrome)
and copper storage diseases (Wilson's disease), disorders resulting
in the accumulation of a toxic metabolite (e.g., tyrosinemia,
fructosemia and galactosemia) and peroxisomal disorders (e.g.,
Zellweger syndrome). Additionally, the methods described herein may
be useful for the early detection and treatment of liver injury
associated with the administration of various chemicals or drugs,
such as for example, methotrexate, isonizaid, oxyphenisatin,
methyldopa, chlorpromazine, tolbutamide or alcohol, or which
represents a hepatic manifestation of a vascular disorder such as
obstruction of either the intrahepatic or extrahepatic bile flow or
an alteration in hepatic circulation resulting, for example, from
chronic heart failure, veno-occlusive disease, portal vein
thrombosis or Budd-Chiari syndrome.
[0347] Additionally, 59079 and 12599 molecules may play an
important role in the etiology of certain viral diseases, including
but not limited to, Hepatitis B, Hepatitis C and Herpes Simplex
Virus (HSV). Modulators of 59079 activity can be used to control
viral diseases. The modulators can be used in the treatment and/or
diagnosis of viral infected tissue or virus-associated tissue
fibrosis, especially liver and liver fibrosis. Also, 59079
modulators can be used in the treatment and/or diagnosis of
virus-associated carcinomas, especially hepatocellular cancers.
[0348] Additionally, 59079 and 12599 may play an important role in
the regulation of metabolism or pain disorders. Diseases of
metabolic imbalance include, but are not limited to, obesity,
anorexia nervosa, bullemia, cachexia, lipid disorders, and
diabetes. Examples of pain disorders include, but are not limited
to, pain response elicited during various forms of tissue injury,
e.g., inflammation, infection, and ischemia, usually referred to as
hyperalgesia (described in, for example, Fields, H. L., (1987)
Pain, New York: McGraw-Hill); pain associated with muscoloskeletal
disorders, e.g., joint pain; tooth pain; headaches; pain associated
with surgery; pain related to irritable bowel syndrome; and chest
pain.
[0349] Pharmacogenomics
[0350] The 59079 and 12599 molecules of the present invention, as
well as agents, and modulators which have a stimulatory or
inhibitory effect on a 59079 or 12599 activity (e.g., 59079 or
12599 gene expression) as identified by a screening assay described
herein can be administered to individuals to treat
(prophylactically or therapeutically) 59079 and 12599 associated
disorders (e.g., cellular proliferative and/or differentiative
disorders, hormonal disorders, immune and inflammatory disorders,
neurological disorders, cardiovascular disorders, blood vessel
disorders, and platelet disorders) associated with aberrant or
undesirable 59079 or 12599 activity. In conjunction with such
treatment, pharmacogenomics (i.e., the study of the relationship
between an individual's genotype and that individual's response to
a foreign compound or drug) may be considered. Differences in
metabolism of therapeutics can lead to severe toxicity or
therapeutic failure by altering the relation between dose and blood
concentration of the pharmacologically active drug. Thus, a
physician or clinician may consider applying knowledge obtained in
relevant pharmacogenomics studies in determining whether to
administer a 59079 or 12599 molecule or 59079 or 12599 modulator as
well as tailoring the dosage and/or therapeutic regimen of
treatment with a 59079 or 12599 molecule or 59079 or 12599
modulator.
[0351] Pharmacogenomics deals with clinically significant
hereditary variations in the response to drugs due to altered drug
disposition and abnormal action in affected persons. See, for
example, Eichelbaum, M. et al. (1996) Clin. Exp. Pharmacol.
Physiol. 23:983-985 and Linder, M. W. et al. (1997) Clin. Chem.
43:254-266. In general, two types of pharmacogenetic conditions can
be differentiated. Genetic conditions transmitted as a single
factor altering the way drugs act on the body (altered drug action)
or genetic conditions transmitted as single factors altering the
way the body acts on drugs (altered drug metabolism). These
pharmacogenetic conditions can occur either as rare genetic defects
or as naturally-occurring polymorphisms. For example,
glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common
inherited enzymopathy in which the main clinical complication is
haemolysis after ingestion of oxidant drugs (anti-malarials,
sulfonamides, analgesics, nitrofurans) and consumption of fava
beans.
[0352] One pharmacogenomics approach to identifying genes that
predict drug response, known as "a genome-wide association", relies
primarily on a high-resolution map of the human genome consisting
of already known gene-related markers (e.g., a "bi-allelic" gene
marker map which consists of 60,000-100,000 polymorphic or variable
sites on the human genome, each of which has two variants.) Such a
high-resolution genetic map can be compared to a map of the genome
of each of a statistically significant number of patients taking
part in a Phase II/III drug trial to identify markers associated
with a particular observed drug response or side effect.
Alternatively, such a high resolution map can be generated from a
combination of some ten-million known single nucleotide
polymorphisms (SNPs) in the human genome. As used herein, a "SNP"
is a common alteration that occurs in a single nucleotide base in a
stretch of DNA. For example, a SNP may occur once per every 1000
bases of DNA. A SNP may be involved in a disease process, however,
the vast majority may not be disease-associated. Given a genetic
map based on the occurrence of such SNPs, individuals can be
grouped into genetic categories depending on a particular pattern
of SNPs in their individual genome. In such a manner, treatment
regimens can be tailored to groups of genetically similar
individuals, taking into account traits that may be common among
such genetically similar individuals.
[0353] Alternatively, a method termed the "candidate gene
approach", can be utilized to identify genes that predict drug
response. According to this method, if a gene that encodes a drug's
target is known (e.g., a 59079 or 12599 protein of the present
invention), all common variants of that gene can be fairly easily
identified in the population and it can be determined if having one
version of the gene versus another is associated with a particular
drug response.
[0354] Alternatively, a method termed the "gene expression
profiling", can be utilized to identify genes that predict drug
response. For example, the gene expression of an animal dosed with
a drug (e.g., a 59079 or 12599 molecule or 59079 or 12599 modulator
of the present invention) can give an indication whether gene
pathways related to toxicity have been turned on.
[0355] Information generated from more than one of the above
pharmacogenomics approaches can be used to determine appropriate
dosage and treatment regimens for prophylactic or therapeutic
treatment of an individual. This knowledge, when applied to dosing
or drug selection, can avoid adverse reactions or therapeutic
failure and thus enhance therapeutic or prophylactic efficiency
when treating a subject with a 59079 or 12599 molecule or 59079 or
12599 modulator, such as a modulator identified by one of the
exemplary screening assays described herein.
[0356] The present invention further provides methods for
identifying new agents, or combinations, that are based on
identifying agents that modulate the activity of one or more of the
gene products encoded by one or more of the 59079 and 12599 genes
of the present invention, wherein these products may be associated
with resistance of the cells to a therapeutic agent. Specifically,
the activity of the proteins encoded by the 59079 and 12599 genes
of the present invention can be used as a basis for identifying
agents for overcoming agent resistance. By blocking the activity of
one or more of the resistance proteins, target cells, e.g., human
cells, will become sensitive to treatment with an agent that the
unmodified target cells were resistant to.
[0357] Monitoring the influence of agents (e.g., drugs) on the
expression or activity of a 59079 or 12599 protein can be applied
in clinical trials. For example, the effectiveness of an agent
determined by a screening assay as described herein to increase
59079 or 12599 gene expression or protein levels, or upregulate
59079 or 12599 activity, can be monitored in clinical trials of
subjects exhibiting decreased 59079 or 12599 gene expression or
protein levels, or downregulated 59079 or 12599 activity.
Alternatively, the effectiveness of an agent determined by a
screening assay to decrease 59079 or 12599 gene expression or
protein levels, or downregulate 59079 or 12599 activity, can be
monitored in clinical trials of subjects exhibiting increased 59079
or 12599 gene expression or protein levels, or upregulated 59079 or
12599 activity. In such clinical trials, the expression or activity
of a 59079 or 12599 gene, and preferably, other genes that have
been implicated in, for example, a protein kinase associated
disorder can be used as a "read out" or markers of the phenotype of
a particular cell.
Other Embodiments
[0358] In another aspect, the invention features a method of
analyzing a plurality of capture probes. The method is useful,
e.g., to analyze gene expression. The method includes: providing a
two dimensional array having a plurality of addresses, each address
of the plurality being positionally distinguishable from each other
address of the plurality, and each address of the plurality having
a unique capture probe, e.g., a nucleic acid or peptide sequence,
wherein the capture probes are from a cell or subject which
expresses 59079 or 12599 or from a cell or subject in which a
59079- or 12599-mediated response has been elicited; contacting the
array with a 59079 nucleic acid (preferably purified), a 59079 or
12599 polypeptide (preferably purified), or an anti-59079 or
anti-12599 antibody, and thereby evaluating the plurality of
capture probes. Binding, e.g., in the case of a nucleic acid,
hybridization with a capture probe at an address of the plurality,
is detected, e.g., by a signal generated from a label attached to
the 59079 or 12599 nucleic acid, polypeptide, or antibody.
[0359] The capture probes can be a set of nucleic acids from a
selected sample, e.g., a sample of nucleic acids derived from a
control or non-stimulated tissue or cell.
[0360] The method can include contacting the 59079 or 12599 nucleic
acid, polypeptide, or antibody with a first array having a
plurality of capture probes and a second array having a different
plurality of capture probes. The results of each hybridization can
be compared, e.g., to analyze differences in expression between a
first and second sample. The first plurality of capture probes can
be from a control sample, e.g., a wild type, normal, or
non-diseased, non-stimulated, sample, e.g., a biological fluid,
tissue, or cell sample. The second plurality of capture probes can
be from an experimental sample, e.g., a mutant type, at risk,
disease-state or disorder-state, or stimulated, sample, e.g., a
biological fluid, tissue, or cell sample.
[0361] The plurality of capture probes can be a plurality of
nucleic acid probes each of which specifically hybridizes, with an
allele of 59079 or 12599. Such methods can be used to diagnose a
subject, e.g., to evaluate risk for a disease or disorder, to
evaluate suitability of a selected treatment for a subject, to
evaluate whether a subject has a disease or disorder.
[0362] The method can be used to detect SNPs, as described
above.
[0363] In another aspect, the invention features, a method of
analyzing 59079 or 12599, e.g., analyzing structure, function, or
relatedness to other nucleic acid or amino acid sequences. The
method includes: providing a 59079 or 12599 nucleic acid or amino
acid sequence; comparing the 59079 or 12599 sequence with one or
more preferably a plurality of sequences from a collection of
sequences, e.g., a nucleic acid or protein sequence database; to
thereby analyze 59079 or 12599.
[0364] The method can include evaluating the sequence identity
between a 59079 or 12599 sequence and a database sequence. The
method can be performed by accessing the database at a second site,
e.g., over the internet. Preferred databases include GenBank.TM.
and SwissProt.
[0365] In another aspect, the invention features, a set of
oligonucleotides, useful, e.g., for identifying SNP's, or
identifying specific alleles of 59079 or 12599. The set includes a
plurality of oligonucleotides, each of which has a different
nucleotide at an interrogation position, e.g., an SNP or the site
of a mutation. In a preferred embodiment, the oligonucleotides of
the plurality identical in sequence with one another (except for
differences in length). The oligonucleotides can be provided with
differential labels, such that an oligonucleotides which hybridizes
to one allele provides a signal that is distinguishable from an
oligonucleotides which hybridizes to a second allele.
[0366] The sequence of a 59079 or 12599 molecule is provided in a
variety of mediums to facilitate use thereof. A sequence can be
provided as a manufacture, other than an isolated nucleic acid or
amino acid molecule, which contains a 59079 or 12599 molecule. Such
a manufacture can provide a nucleotide or amino acid sequence,
e.g., an open reading frame, in a form which allows examination of
the manufacture using means not directly applicable to examining
the nucleotide or amino acid sequences, or a subset thereof, as
they exists in nature or in purified form.
[0367] A 59079 or 12599 nucleotide or amino acid sequence can be
recorded on computer readable media. As used herein, "computer
readable media" refers to any medium that can be read and accessed
directly by a computer. Such media include, but are not limited to:
magnetic storage media, such as floppy discs, hard disc storage
medium, and magnetic tape; optical storage media such as compact
disc and CD-ROM; electrical storage media such as RAM, ROM, EPROM,
EEPROM, and the like; and general hard disks and hybrids of these
categories such as magnetic/optical storage media. The medium is
adapted or configured for having thereon 59079 sequence information
of the present invention.
[0368] As used herein, the term "electronic apparatus" is intended
to include any suitable computing or processing apparatus of other
device configured or adapted for storing data or information.
Examples of electronic apparatus suitable for use with the present
invention include stand-alone computing apparatus; networks,
including a local area network (LAN), a wide area network (WAN)
Internet, Intranet, and Extranet; electronic appliances such as
personal digital assistants (PDAs), cellular phones, pagers, and
the like; and local and distributed processing systems.
[0369] As used herein, "recorded" refers to a process for storing
or encoding information on the electronic apparatus readable
medium. Those skilled in the art can readily adopt any of the
presently known methods for recording information on known media to
generate manufactures comprising the 59079 or 12599 sequence
information.
[0370] A variety of data storage structures are available to a
skilled artisan for creating a computer readable medium having
recorded thereon a nucleotide or amino acid sequence of the present
invention. The choice of the data storage structure will generally
be based on the means chosen to access the stored information. In
addition, a variety of data processor programs and formats can be
used to store the nucleotide sequence information of the present
invention on computer readable medium. The sequence information can
be represented in a word processing text file, formatted in
commercially-available software such as WordPerfect and Microsoft
Word, or represented in the form of an ASCII file, stored in a
database application, such as DB2, Sybase, Oracle, or the like. The
skilled artisan can readily adapt any number of data processor
structuring formats (e.g., text file or database) in order to
obtain computer readable medium having recorded thereon the
nucleotide sequence information of the present invention.
[0371] By providing the nucleotide or amino acid sequences of the
invention in computer readable form, the skilled artisan can
routinely access the sequence information for a variety of
purposes. For example, one skilled in the art can use the
nucleotide or amino acid sequences of the invention in computer
readable form to compare a target sequence or target structural
motif with the sequence information stored within the data storage
means. A search is used to identify fragments or regions of the
sequences of the invention which match a particular target sequence
or target motif.
[0372] The present invention therefore provides a medium for
holding instructions for performing a method for determining
whether a subject has a protein kinase associated disease or
disorder or a pre-disposition to a protein kinase associated
disease or disorder, wherein the method comprises the steps of
determining 59079 or 12599 sequence information associated with the
subject and based on the 59079 or 12599 sequence information,
determining whether the subject has a protein kinase associated
disease or disorder and/or recommending a particular treatment for
the disease, disorder, or pre-disease condition.
[0373] The present invention further provides in an electronic
system and/or in a network, a method for determining whether a
subject has a protein kinase associated disease or disorder or a
pre-disposition to a disease associated with 59079 or 12599,
wherein the method comprises the steps of determining 59079 or
12599 sequence information associated with the subject, and based
on the 59079 or 12599 sequence information, determining whether the
subject has a protein kinase associated disease or disorder or a
pre-disposition to a protein kinase associated disease or disorder,
and/or recommending a particular treatment for the disease,
disorder, or pre-disease condition. The method may further comprise
the step of receiving phenotypic information associated with the
subject and/or acquiring from a network phenotypic information
associated with the subject.
[0374] The present invention also provides in a network, a method
for determining whether a subject has a protein kinase associated
disease or disorder or a pre-disposition to a protein kinase
associated disease or disorder, said method comprising the steps of
receiving 59079 or 12599 sequence information from the subject
and/or information related thereto, receiving phenotypic
information associated with the subject, acquiring information from
the network corresponding to 59079 or 12599 and/or corresponding to
a protein kinase associated disease or disorder, and based on one
or more of the phenotypic information, the 59079 or 12599
information (e.g., sequence information and/or information related
thereto), and the acquired information, determining whether the
subject has a protein kinase associated disease or disorder or a
pre-disposition to a protein kinase associated disease or disorder.
The method may further comprise the step of recommending a
particular treatment for the disease, disorder, or pre-disease
condition.
[0375] The present invention also provides a business method for
determining whether a subject has a protein kinase associated
disease or disorder or a pre-disposition to a protein kinase
associated disease or disorder, said method comprising the steps of
receiving information related to 59079 (e.g., sequence information
and/or information related thereto), receiving phenotypic
information associated with the subject, acquiring information from
the network related to 59079 or 12599 and/or related to a protein
kinase associated disease or disorder, and based on one or more of
the phenotypic information, the 59079 or 12599 information, and the
acquired information, determining whether the subject has a protein
kinase associated disease or disorder or a pre-disposition to a
protein kinase associated disease or disorder. The method may
further comprise the step of recommending a particular treatment
for the disease, disorder, or pre-disease condition.
[0376] The invention also includes an array comprising a 59079 or
12599 sequence of the present invention. The array can be used to
assay expression of one or more genes in the array. In one
embodiment, the array can be used to assay gene expression in a
tissue to ascertain tissue specificity of genes in the array. In
this manner, up to about 7600 genes can be simultaneously assayed
for expression, which can include 59079 and/or 12599. This allows a
profile to be developed showing a battery of genes specifically
expressed in one or more tissues.
[0377] In addition to such qualitative information, the invention
allows the quantitation of gene expression. Thus, not only tissue
specificity, but also the level of expression of a battery of genes
in the tissue if ascertainable. Thus, genes can be grouped on the
basis of their tissue expression per se and level of expression in
that tissue. This is useful, for example, in ascertaining the
relationship of gene expression in that tissue. Thus, one tissue
can be perturbed and the effect on gene expression in a second
tissue can be determined. In this context, the effect of one cell
type on another cell type in response to a biological stimulus can
be determined. In this context, the effect of one cell type on
another cell type in response to a biological stimulus can be
determined. Such a determination is useful, for example, to know
the effect of cell-cell interaction at the level of gene
expression. If an agent is administered therapeutically to treat
one cell type but has an undesirable effect on another cell type,
the invention provides an assay to determine the molecular basis of
the undesirable effect and thus provides the opportunity to
co-administer a counteracting agent or otherwise treat the
undesired effect. Similarly, even within a single cell type,
undesirable biological effects can be determined at the molecular
level. Thus, the effects of an agent on expression of other than
the target gene can be ascertained and counteracted.
[0378] In another embodiment, the array can be used to monitor the
time course of expression of one or more genes in the array. This
can occur in various biological contexts, as disclosed herein, for
example development of a protein kinase associated disease or
disorder, progression of protein kinase associated disease or
disorder, and processes, such a cellular transformation associated
with the protein kinase associated disease or disorder.
[0379] The array is also useful for ascertaining the effect of the
expression of a gene on the expression of other genes in the same
cell or in different cells (e.g., ascertaining the effect of 59079
or 12599 expression on the expression of other genes). This
provides, for example, for a selection of alternate molecular
targets for therapeutic intervention if the ultimate or downstream
target cannot be regulated.
[0380] The array is also useful for ascertaining differential
expression patterns of one or more genes in normal and abnormal
cells. This provides a battery of genes (e.g., including 59079)
that could serve as a molecular target for diagnosis or therapeutic
intervention.
[0381] As used herein, a "target sequence" can be any DNA or amino
acid sequence of six or more nucleotides or two or more amino
acids. A skilled artisan can readily recognize that the longer a
target sequence is, the less likely a target sequence will be
present as a random occurrence in the database. Typical sequence
lengths of a target sequence are from about 10 to 100 amino acids
or from about 30 to 300 nucleotide residues. However, it is well
recognized that commercially important fragments, such as sequence
fragments involved in gene expression and protein processing, may
be of shorter length.
[0382] Computer software is publicly available which allows a
skilled artisan to access sequence information provided in a
computer readable medium for analysis and comparison to other
sequences. A variety of known algorithms are disclosed publicly and
a variety of commercially available software for conducting search
means are and can be used in the computer-based systems of the
present invention. Examples of such software include, but are not
limited to, MacPattern (EMBL), BLASTN and BLASTX (NCBI).
[0383] Thus, the invention features a method of making a computer
readable record of a sequence of a 59079 or 12599 sequence which
includes recording the sequence on a computer readable matrix. In a
preferred embodiment the record includes one or more of the
following: identification of an ORF; identification of a domain,
region, or site; identification of the start of transcription;
identification of the transcription terminator; the full length
amino acid sequence of the protein, or a mature form thereof; the
5' end of the translated region.
[0384] In another aspect, the invention features, a method of
analyzing a sequence. The method includes: providing a 59079 or
12599 sequence, or record, in computer readable form; comparing a
second sequence to the 59079 or 12599 sequence; thereby analyzing a
sequence. Comparison can include comparing to sequences for
sequence identity or determining if one sequence is included within
the other, e.g., determining if the 59079 or 12599 sequence
includes a sequence being compared. In a preferred embodiment the
59079 or second sequence is stored on a first computer, e.g., at a
first site and the comparison is performed, read, or recorded on a
second computer, e.g., at a second site. For example, the 59079 or
12599 or second sequence can be stored in a public or proprietary
database in one computer, and the results of the comparison
performed, read, or recorded on a second computer. In a preferred
embodiment the record includes one or more of the following:
identification of an ORF; identification of a domain, region, or
site; identification of the start of transcription; identification
of the transcription terminator; the full length amino acid
sequence of the protein, or a mature form thereof; the 5' end of
the translated region.
[0385] This invention is further illustrated by the following
exemplification, which should not be construed as limiting.
Exemplification
[0386] 59079 Gene Expression Analysis
[0387] Total RNA was prepared from various human tissues by a
single step extraction method using RNA STAT-60 according to the
manufacturer's instructions (TelTest, Inc). Each RNA preparation
was treated with DNase I (Ambion) at 37.degree. C. for 1 hour.
DNAse I treatment was determined to be complete if the sample
required at least 38 PCR amplification cycles to reach a threshold
level of fluorescence using .beta.-2 microglobulin as an internal
amplicon reference. The integrity of the RNA samples following
DNase I treatment was confirmed by agarose gel electrophoresis and
ethidium bromide staining. After phenol extraction cDNA was
prepared from the sample using the SUPERSCRIPT.TM. Choice System
following the manufacturer's instructions (GibcoBRL). A negative
control of RNA without reverse transcriptase was mock reverse
transcribed for each RNA sample.
[0388] Human 59079 expression was measured by TaqMan.RTM.
quantitative PCR (Perkin Elmer Applied Biosystems) in cDNA prepared
from a variety of normal and diseased (e.g., cancerous) human
tissues or cell lines.
[0389] Probes were designed by PrimerExpress software (PE
Biosystems) based on the sequence of the human 59079 gene. Each
human 59079 gene probe was labeled using FAM
(6-carboxyfluorescein), and the .beta.2-microglobulin reference
probe was labeled with a different fluorescent dye, VIC. The
differential labeling of the target gene and internal reference
gene thus enabled measurement in same well. Forward and reverse
primers and the probes for both .beta.2-microglobulin and target
gene were added to the TaqMan.RTM. Universal PCR Master Mix (PE
Applied Biosystems). Although the final concentration of primer and
probe could vary, each was internally consistent within a given
experiment. A typical experiment contained 200 nM of forward and
reverse primers plus 100 nM probe for .beta.-2 microglobulin and
600 nM forward and reverse primers plus 200 nM probe for the target
gene. TaqMan matrix experiments were carried out on an ABI PRISM
7700 Sequence Detection System (PE Applied Biosystems). The thermal
cycler conditions were as follows: hold for 2 min at 50.degree. C.
and 10 min at 95.degree. C., followed by two-step PCR for 40 cycles
of 95.degree. C. for 15 sec followed by 60.degree. C. for 1
min.
[0390] The following method was used to quantitatively calculate
human 59079 gene expression in the various tissues relative to
.alpha.-2 microglobulin expression in the same tissue. The
threshold cycle (Ct) value is defined as the cycle at which a
statistically significant increase in fluorescence is detected. A
lower Ct value is indicative of a higher mRNA concentration. The Ct
value of the human 59079 gene is normalized by subtracting the Ct
value of the .alpha.-2 microglobulin gene to obtain a
.sub..DELTA.Ct value using the following formula:
.sub..DELTA.Ct=Ct.sub.human 59914 and 59921-Ct.sub..beta.-2
microglobulin. Expression is then calibrated against a cDNA sample
showing a comparatively low level of expression of the human 59079
gene. The .sub..DELTA.Ct value for the calibrator sample is then
subtracted from .sub..DELTA.Ct for each tissue sample according to
the following formula:
.sub..DELTA..DELTA.Ct=.sub..DELTA.Ct-.sub.sample-.sub..DELTA.Ct--
.sub.calibrator. Relative expression is then calculated using the
arithmetic formula given by 2.sup.-.DELTA..DELTA.Ct. Expression of
the target human 59079 gene in each of the tissues tested is then
graphically represented as discussed in more detail below.
[0391] The results indicate significant 59079 expression in normal
heart and upregulated expression in diseased heart. Significant
expression was also seen in skeletal muscle.
[0392] The contents of all references, patents and published patent
applications cited throughout this application are incorporated
herein by reference.
[0393] Equivalents
[0394] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein.
Sequence CWU 1
1
9 1 8106 DNA Homo sapiens 5'UTR (1)...(71) CDS (72)...(7964) 3'UTR
(7965)...(8106) 1 tgcacaccct ggagatcatc tccgtcaccc gggaggactc
tggccagtat gcagcctata 60 tcagcaatgc c atg ggt gct gcc tac tcg tct
gcc cgg ctg ctg gtt cga 110 Met Gly Ala Ala Tyr Ser Ser Ala Arg Leu
Leu Val Arg 1 5 10 ggc cct gat gag cca gaa gag aag cct gca tca gat
gtg cat gag cag 158 Gly Pro Asp Glu Pro Glu Glu Lys Pro Ala Ser Asp
Val His Glu Gln 15 20 25 ctg gtg ccg ccc cga atg ctg gag agg ttc
acc ccc aag aaa gtg aag 206 Leu Val Pro Pro Arg Met Leu Glu Arg Phe
Thr Pro Lys Lys Val Lys 30 35 40 45 aaa ggc tcc agc atc acc ttc tct
gtg aag gta gaa gga cgc ccg gtg 254 Lys Gly Ser Ser Ile Thr Phe Ser
Val Lys Val Glu Gly Arg Pro Val 50 55 60 ccc acc gtg cac tgg ctc
agg gag gag gct gag aga ggc gtg ctg tgg 302 Pro Thr Val His Trp Leu
Arg Glu Glu Ala Glu Arg Gly Val Leu Trp 65 70 75 att ggc cct gac
aca ccg ggc tac acc gtg gcc agc tct gcg cag cag 350 Ile Gly Pro Asp
Thr Pro Gly Tyr Thr Val Ala Ser Ser Ala Gln Gln 80 85 90 cac agc
ctg gtc ctg ctg gac gtg ggc cgg cag cac cag ggc acc tac 398 His Ser
Leu Val Leu Leu Asp Val Gly Arg Gln His Gln Gly Thr Tyr 95 100 105
aca tgc att gcc agc aac gct gcc ggc cag gcc ctc tgc tcc gcc agc 446
Thr Cys Ile Ala Ser Asn Ala Ala Gly Gln Ala Leu Cys Ser Ala Ser 110
115 120 125 ctg cac gtc tcg ggc ctg cct aag gtg gag gag cag gag aaa
gtg aag 494 Leu His Val Ser Gly Leu Pro Lys Val Glu Glu Gln Glu Lys
Val Lys 130 135 140 gaa gcg ctg att tcc act ttc ctg cag ggg acc aca
caa gcc atc tca 542 Glu Ala Leu Ile Ser Thr Phe Leu Gln Gly Thr Thr
Gln Ala Ile Ser 145 150 155 gca cag ggg ttg gaa act gcg agt ttt gct
gac ctt ggt ggg cag agg 590 Ala Gln Gly Leu Glu Thr Ala Ser Phe Ala
Asp Leu Gly Gly Gln Arg 160 165 170 aaa gaa gag cct ctg gct gcc aag
gag gcc ctc ggc cac ctg tcc ctc 638 Lys Glu Glu Pro Leu Ala Ala Lys
Glu Ala Leu Gly His Leu Ser Leu 175 180 185 gct gag gtg ggc aca gag
gag ttc ctg cag aaa ctg acc tcc cag atc 686 Ala Glu Val Gly Thr Glu
Glu Phe Leu Gln Lys Leu Thr Ser Gln Ile 190 195 200 205 act gag atg
gta tcg gcc aag atc acg cag gcc aag ctg cag gtg ccc 734 Thr Glu Met
Val Ser Ala Lys Ile Thr Gln Ala Lys Leu Gln Val Pro 210 215 220 gga
ggt gac agt gat gag gac tcc aag aca cca tct gca tcc ccc cgc 782 Gly
Gly Asp Ser Asp Glu Asp Ser Lys Thr Pro Ser Ala Ser Pro Arg 225 230
235 cat ggc cga tca cgg cca tcc tcc agc atc cag gag tct tcc tca gag
830 His Gly Arg Ser Arg Pro Ser Ser Ser Ile Gln Glu Ser Ser Ser Glu
240 245 250 tca gag gac ggc gat gcc cga ggc gag atc ttt gac atc tac
gtg gtc 878 Ser Glu Asp Gly Asp Ala Arg Gly Glu Ile Phe Asp Ile Tyr
Val Val 255 260 265 acc gct gac tac ctg ccc cta ggg gct gag cag gat
gcc atc acg ctg 926 Thr Ala Asp Tyr Leu Pro Leu Gly Ala Glu Gln Asp
Ala Ile Thr Leu 270 275 280 285 cgg gaa ggc cag tat gtg gag gtc ctg
gat gca gcc cac cca ctg cgc 974 Arg Glu Gly Gln Tyr Val Glu Val Leu
Asp Ala Ala His Pro Leu Arg 290 295 300 tgg ctt gtc cgc acc aag ccc
acc aag tcc agc ccc tca cgg cag ggc 1022 Trp Leu Val Arg Thr Lys
Pro Thr Lys Ser Ser Pro Ser Arg Gln Gly 305 310 315 tgg gtg tca cca
gcc tac ctg gac agg agg ctc aag ctg tca cct gag 1070 Trp Val Ser
Pro Ala Tyr Leu Asp Arg Arg Leu Lys Leu Ser Pro Glu 320 325 330 tgg
ggg gcc gct gag gcc cct gag ttc cct ggg gag gct gtg tct gaa 1118
Trp Gly Ala Ala Glu Ala Pro Glu Phe Pro Gly Glu Ala Val Ser Glu 335
340 345 gac gaa tac aag gca agg ctg agc tct gtg atc cag gag ctg ctg
agt 1166 Asp Glu Tyr Lys Ala Arg Leu Ser Ser Val Ile Gln Glu Leu
Leu Ser 350 355 360 365 tct gag cag gcc ttc gtg gag gag ctg cag ttc
ctg cag agc cac cac 1214 Ser Glu Gln Ala Phe Val Glu Glu Leu Gln
Phe Leu Gln Ser His His 370 375 380 ctg cag cac ctg gag cgc tgc ccc
cac gtg ccc ata gcc gtg gcc ggc 1262 Leu Gln His Leu Glu Arg Cys
Pro His Val Pro Ile Ala Val Ala Gly 385 390 395 cag aag gca gtc atc
ttc cgc aat gtg cgg gac atc ggc cgc ttc cac 1310 Gln Lys Ala Val
Ile Phe Arg Asn Val Arg Asp Ile Gly Arg Phe His 400 405 410 agc agc
ttc ctg cag gag ttg cag cag tgc gac acg gac gac gac gtg 1358 Ser
Ser Phe Leu Gln Glu Leu Gln Gln Cys Asp Thr Asp Asp Asp Val 415 420
425 gcc atg tgc ttc atc aag aac cag gcg gcc ttt gag cag tac ctg gag
1406 Ala Met Cys Phe Ile Lys Asn Gln Ala Ala Phe Glu Gln Tyr Leu
Glu 430 435 440 445 ttc ctg gtg ggg cgt gtg cag gct gag tcg gtg gtc
gtc agc acg gcc 1454 Phe Leu Val Gly Arg Val Gln Ala Glu Ser Val
Val Val Ser Thr Ala 450 455 460 atc cag gag ttc tac aag aaa tac gcg
gag gag gcc ctg ttg gca ggg 1502 Ile Gln Glu Phe Tyr Lys Lys Tyr
Ala Glu Glu Ala Leu Leu Ala Gly 465 470 475 gac ccc tct cag ccc ccg
cca cca cct ctg cag cac tac ctg gag cag 1550 Asp Pro Ser Gln Pro
Pro Pro Pro Pro Leu Gln His Tyr Leu Glu Gln 480 485 490 cca gtg gag
cgg gtg cag cgc tac cag gcc ttg ctg aag gag ttg atc 1598 Pro Val
Glu Arg Val Gln Arg Tyr Gln Ala Leu Leu Lys Glu Leu Ile 495 500 505
cgc aac aag gcg cgg aac aga cag aac tgc gcg ctg ctg gag cag gcc
1646 Arg Asn Lys Ala Arg Asn Arg Gln Asn Cys Ala Leu Leu Glu Gln
Ala 510 515 520 525 tat gcc gtg gtg tct gcc ctg cca cag cgc gct gag
aac aag ctg cac 1694 Tyr Ala Val Val Ser Ala Leu Pro Gln Arg Ala
Glu Asn Lys Leu His 530 535 540 gtg tcc ctc atg gag aac tac cca ggc
acc ctg gag gcc ctg ggc gag 1742 Val Ser Leu Met Glu Asn Tyr Pro
Gly Thr Leu Glu Ala Leu Gly Glu 545 550 555 ccc atc cgc cag ggc cac
ttc atc gtg tgg gag ggt gca ccg ggg gcc 1790 Pro Ile Arg Gln Gly
His Phe Ile Val Trp Glu Gly Ala Pro Gly Ala 560 565 570 cgc atg ccc
tgg aag ggc cac aac cgt cac gtg ttc ctc ttc cgc aac 1838 Arg Met
Pro Trp Lys Gly His Asn Arg His Val Phe Leu Phe Arg Asn 575 580 585
cac ctg gta atc tgc aag ccc cgg cga gac tcc cgc acc gat acc gtc
1886 His Leu Val Ile Cys Lys Pro Arg Arg Asp Ser Arg Thr Asp Thr
Val 590 595 600 605 agc tac gtg ttc cgg aac atg atg aag ctg agc agc
atc gac ctg aac 1934 Ser Tyr Val Phe Arg Asn Met Met Lys Leu Ser
Ser Ile Asp Leu Asn 610 615 620 gac cag gtg gag ggg gat gac cgc gcc
ttc gag gtg tgg cag gag cgg 1982 Asp Gln Val Glu Gly Asp Asp Arg
Ala Phe Glu Val Trp Gln Glu Arg 625 630 635 gag gac tcg gtg cgc aag
tac ctg ctg cag gca cgg aca gcc att atc 2030 Glu Asp Ser Val Arg
Lys Tyr Leu Leu Gln Ala Arg Thr Ala Ile Ile 640 645 650 aag agc tcg
tgg gtg aag gag atc tgt ggc atc cag cag cgt ctg gcc 2078 Lys Ser
Ser Trp Val Lys Glu Ile Cys Gly Ile Gln Gln Arg Leu Ala 655 660 665
ctg cct gtg tgg cgg ccc ccg gac ttt gaa gag gag ctg gcc gac tgc
2126 Leu Pro Val Trp Arg Pro Pro Asp Phe Glu Glu Glu Leu Ala Asp
Cys 670 675 680 685 aca gcc gag ctg ggt gag aca gtc aag ctg gcc tgc
cgc gtg acg ggc 2174 Thr Ala Glu Leu Gly Glu Thr Val Lys Leu Ala
Cys Arg Val Thr Gly 690 695 700 aca ccc aag cct gtc atc agc tgg tac
aaa gat ggg aaa gca gtg cag 2222 Thr Pro Lys Pro Val Ile Ser Trp
Tyr Lys Asp Gly Lys Ala Val Gln 705 710 715 gtg gac ccc cac cac atc
ctc att gaa gac cct gat ggc tcg tgt gca 2270 Val Asp Pro His His
Ile Leu Ile Glu Asp Pro Asp Gly Ser Cys Ala 720 725 730 ctc atc ctg
gac agc ctg acc ggt gtg gac tct ggc cag tac atg tgc 2318 Leu Ile
Leu Asp Ser Leu Thr Gly Val Asp Ser Gly Gln Tyr Met Cys 735 740 745
ttc gcg gcc agc gcc gct ggc aac tgc agt acc ctg ggc aag atc ctg
2366 Phe Ala Ala Ser Ala Ala Gly Asn Cys Ser Thr Leu Gly Lys Ile
Leu 750 755 760 765 gtg caa gtc cca cca cgg ttc gtg aac aag gtc cgg
gcc tca ccc ttt 2414 Val Gln Val Pro Pro Arg Phe Val Asn Lys Val
Arg Ala Ser Pro Phe 770 775 780 gtg gag gga gag gac gcc cag ttc acc
tgc acc atc gaa ggc gcc ccg 2462 Val Glu Gly Glu Asp Ala Gln Phe
Thr Cys Thr Ile Glu Gly Ala Pro 785 790 795 tac ccg cag atc agg tgg
tac aag gac ggg gcc ctg ctg acc act ggc 2510 Tyr Pro Gln Ile Arg
Trp Tyr Lys Asp Gly Ala Leu Leu Thr Thr Gly 800 805 810 aac aag ttc
cag aca ctg agt gag cct cgc agc ggc ctg cta gtg ctg 2558 Asn Lys
Phe Gln Thr Leu Ser Glu Pro Arg Ser Gly Leu Leu Val Leu 815 820 825
gtg atc cgg gcg gcc agc aag gag gac ctg ggg ctc tac gag tgt gag
2606 Val Ile Arg Ala Ala Ser Lys Glu Asp Leu Gly Leu Tyr Glu Cys
Glu 830 835 840 845 ctg gtg aac cgg ctg ggc tcc gcg cgg gct agt gcg
gag ctg cgc att 2654 Leu Val Asn Arg Leu Gly Ser Ala Arg Ala Ser
Ala Glu Leu Arg Ile 850 855 860 cag agc ccc atg ctg cag gcc cag gag
cag tgt cac agg gag cag ctc 2702 Gln Ser Pro Met Leu Gln Ala Gln
Glu Gln Cys His Arg Glu Gln Leu 865 870 875 gtg gct gca gtg gaa gac
acc acc ctg gag cga gcg gac cag gag gtc 2750 Val Ala Ala Val Glu
Asp Thr Thr Leu Glu Arg Ala Asp Gln Glu Val 880 885 890 aca tct gtc
ctg aag aga ctg ctg ggc ccc aag gcg cca ggc ccc tcc 2798 Thr Ser
Val Leu Lys Arg Leu Leu Gly Pro Lys Ala Pro Gly Pro Ser 895 900 905
aca ggg gac ctc act ggc cct ggc ccc tgc ccc agg ggg gca ccc gca
2846 Thr Gly Asp Leu Thr Gly Pro Gly Pro Cys Pro Arg Gly Ala Pro
Ala 910 915 920 925 ctc cag gaa acc ggc tcc cag ccc cca gtc acc gga
act tcg gag gca 2894 Leu Gln Glu Thr Gly Ser Gln Pro Pro Val Thr
Gly Thr Ser Glu Ala 930 935 940 cct gcc gtg ccc ccg agg gtg cca cag
ccc ctc ctc cac gaa ggc cca 2942 Pro Ala Val Pro Pro Arg Val Pro
Gln Pro Leu Leu His Glu Gly Pro 945 950 955 gag cag gag ccg gag gcc
att gcc aga gcc cag gaa tgg act gtg ccc 2990 Glu Gln Glu Pro Glu
Ala Ile Ala Arg Ala Gln Glu Trp Thr Val Pro 960 965 970 att cgg atg
gag ggt gca gcc tgg ccc ggg gca ggc aca ggg gag ctg 3038 Ile Arg
Met Glu Gly Ala Ala Trp Pro Gly Ala Gly Thr Gly Glu Leu 975 980 985
ctc tgg gac gtc cac agc cac gtg gtc aga gag acc aca cag agg acc
3086 Leu Trp Asp Val His Ser His Val Val Arg Glu Thr Thr Gln Arg
Thr 990 995 1000 1005 tac aca tac cag gcc atc gac acg cac acc gca
cgg ccc cca tcc atg 3134 Tyr Thr Tyr Gln Ala Ile Asp Thr His Thr
Ala Arg Pro Pro Ser Met 1010 1015 1020 cag gta acc atc gag gat gtg
cag gca cag aca ggc gga acg gcc caa 3182 Gln Val Thr Ile Glu Asp
Val Gln Ala Gln Thr Gly Gly Thr Ala Gln 1025 1030 1035 ttc gag gct
atc att gag ggc gac cca cag ccc tcg gtg acc tgg tac 3230 Phe Glu
Ala Ile Ile Glu Gly Asp Pro Gln Pro Ser Val Thr Trp Tyr 1040 1045
1050 aag gac agc gtc cag ctg gtg gac agc acc cgg ctt agc cag cag
caa 3278 Lys Asp Ser Val Gln Leu Val Asp Ser Thr Arg Leu Ser Gln
Gln Gln 1055 1060 1065 gaa ggc acc aca tac tcc ctg gtg ctg agg cat
gtg gcc tcg aag gat 3326 Glu Gly Thr Thr Tyr Ser Leu Val Leu Arg
His Val Ala Ser Lys Asp 1070 1075 1080 1085 gcc ggc gtt tac acc tgc
ctg gcc caa aac act ggt ggc cag gtg ctc 3374 Ala Gly Val Tyr Thr
Cys Leu Ala Gln Asn Thr Gly Gly Gln Val Leu 1090 1095 1100 tgc aag
gca gag ctg ctg gtg ctt ggg ggg gac aat gag ccg gac tca 3422 Cys
Lys Ala Glu Leu Leu Val Leu Gly Gly Asp Asn Glu Pro Asp Ser 1105
1110 1115 gag aag caa agc cac cgg agg aag ctg cac tcc ttc tat gag
gtc aag 3470 Glu Lys Gln Ser His Arg Arg Lys Leu His Ser Phe Tyr
Glu Val Lys 1120 1125 1130 gag gag att gga agg ggc gtg ttt ggc ttc
gta aaa aga gtg cag cac 3518 Glu Glu Ile Gly Arg Gly Val Phe Gly
Phe Val Lys Arg Val Gln His 1135 1140 1145 aaa gga aac aag atc ttg
tgc gct gcc aag ttc atc ccc cta cgg agc 3566 Lys Gly Asn Lys Ile
Leu Cys Ala Ala Lys Phe Ile Pro Leu Arg Ser 1150 1155 1160 1165 aga
act cgg gcc cag gca tac agg gag cga gac atc ctg gcc gcg ctg 3614
Arg Thr Arg Ala Gln Ala Tyr Arg Glu Arg Asp Ile Leu Ala Ala Leu
1170 1175 1180 agc cac ccg ctg gtc acg ggg ctg ctg gac cag ttt gag
acc cgc aag 3662 Ser His Pro Leu Val Thr Gly Leu Leu Asp Gln Phe
Glu Thr Arg Lys 1185 1190 1195 acc ctc atc ctc atc ctg gag ctg tgc
tca tcc gag gag ctg ctg gac 3710 Thr Leu Ile Leu Ile Leu Glu Leu
Cys Ser Ser Glu Glu Leu Leu Asp 1200 1205 1210 cgc ctg tac agg aag
ggc gtg gtg acg gag gcc gag gtc aag gtc tac 3758 Arg Leu Tyr Arg
Lys Gly Val Val Thr Glu Ala Glu Val Lys Val Tyr 1215 1220 1225 atc
cag cag ctg gtg gag ggg ctg cac tac ctg cac agc cat ggc gtt 3806
Ile Gln Gln Leu Val Glu Gly Leu His Tyr Leu His Ser His Gly Val
1230 1235 1240 1245 ctc cac ctg gac ata aag ccc tct aac atc ctg atg
gtg cat cct gcc 3854 Leu His Leu Asp Ile Lys Pro Ser Asn Ile Leu
Met Val His Pro Ala 1250 1255 1260 cgg gaa gac att aaa atc tgc gac
ttt ggc ttt gcc cag aac atc acc 3902 Arg Glu Asp Ile Lys Ile Cys
Asp Phe Gly Phe Ala Gln Asn Ile Thr 1265 1270 1275 cca gca gag ctg
cag ttc agc cag tac ggc tcc cct gag ttc gtc tcc 3950 Pro Ala Glu
Leu Gln Phe Ser Gln Tyr Gly Ser Pro Glu Phe Val Ser 1280 1285 1290
ccc gag atc atc cag cag aac cct gtg agc gaa gcc tcc gac att tgg
3998 Pro Glu Ile Ile Gln Gln Asn Pro Val Ser Glu Ala Ser Asp Ile
Trp 1295 1300 1305 gcc atg ggt gtc atc tcc tac ctc agc ctg acc tgc
tca tcc cca ttt 4046 Ala Met Gly Val Ile Ser Tyr Leu Ser Leu Thr
Cys Ser Ser Pro Phe 1310 1315 1320 1325 gcc ggc gag agt gac cgt gcc
acc ctc ctg aac gtc ctg gag ggg cgc 4094 Ala Gly Glu Ser Asp Arg
Ala Thr Leu Leu Asn Val Leu Glu Gly Arg 1330 1335 1340 gtg tca tgg
agc agc ccc atg gct gcc cac ctc agc gaa gac gcc aaa 4142 Val Ser
Trp Ser Ser Pro Met Ala Ala His Leu Ser Glu Asp Ala Lys 1345 1350
1355 gac ttc atc aag gct acg ctg cag aga gcc cct cag gcc cgg cct
agt 4190 Asp Phe Ile Lys Ala Thr Leu Gln Arg Ala Pro Gln Ala Arg
Pro Ser 1360 1365 1370 gcg gcc cag tgc ctc tcc cac ccc tgg ttc ctg
aaa tcc atg cct gcg 4238 Ala Ala Gln Cys Leu Ser His Pro Trp Phe
Leu Lys Ser Met Pro Ala 1375 1380 1385 gag gag gcc cac ttc atc aac
acc aag cag ctc aag ttc ctc ctg gcc 4286 Glu Glu Ala His Phe Ile
Asn Thr Lys Gln Leu Lys Phe Leu Leu Ala 1390 1395 1400 1405 cga agt
cgc tgg cag cgt tcc ctg atg agc tac aag tcc atc ctg gtg 4334 Arg
Ser Arg Trp Gln Arg Ser Leu Met Ser Tyr Lys Ser Ile Leu Val 1410
1415 1420 atg cgc tcc atc cct gag ctg ctg cgg ggc cca ccc gac agc
ccc tcc 4382 Met Arg Ser Ile Pro Glu Leu Leu Arg Gly Pro Pro Asp
Ser Pro Ser 1425 1430 1435 ctc ggc gta gcc cgg cac ctc tgc agg gac
act ggt ggc tcc tcc agt 4430 Leu Gly Val Ala Arg His Leu Cys Arg
Asp Thr Gly Gly Ser Ser Ser 1440 1445 1450 tcc tcc tcc tcc tct gac
aac gag ctc gcc cca ttt gcc cgg gct aag 4478 Ser Ser Ser Ser Ser
Asp Asn Glu Leu Ala Pro Phe Ala Arg Ala Lys 1455 1460 1465 tca ctg
cca ccc tcc ccg gtg aca cac tca cca ctg ctg cac ccc cgg 4526 Ser
Leu Pro Pro Ser Pro Val Thr His Ser Pro Leu Leu His Pro Arg 1470
1475 1480 1485 ggc ttc ctg cgg ccc tcg gcc agc ctg cct gag gaa gcc
gag gcc agt 4574 Gly Phe Leu Arg Pro Ser Ala Ser Leu Pro Glu Glu
Ala Glu Ala Ser 1490 1495
1500 gag cgc tcc acc gag gcc cca gct ccg cct gca tct ccc gag ggt
gcc 4622 Glu Arg Ser Thr Glu Ala Pro Ala Pro Pro Ala Ser Pro Glu
Gly Ala 1505 1510 1515 ggg cca ccg gcc gcc cag ggc tgc gtg ccc cgg
cac agc gtc atc cgc 4670 Gly Pro Pro Ala Ala Gln Gly Cys Val Pro
Arg His Ser Val Ile Arg 1520 1525 1530 agc ctg ttc tac cac cag gcg
ggt gag agc cct gag cac ggg gcc ctg 4718 Ser Leu Phe Tyr His Gln
Ala Gly Glu Ser Pro Glu His Gly Ala Leu 1535 1540 1545 gcc ccg ggg
agc agg cgg cac ccg gcc cgg cgg cgg cac ctg ctg aag 4766 Ala Pro
Gly Ser Arg Arg His Pro Ala Arg Arg Arg His Leu Leu Lys 1550 1555
1560 1565 ggc ggg tac att gcg ggg gcg ctg cca ggc ctg cgc gag cca
ctg atg 4814 Gly Gly Tyr Ile Ala Gly Ala Leu Pro Gly Leu Arg Glu
Pro Leu Met 1570 1575 1580 gag cac cgc gtg ctg gag gag gag gcc gcc
agg gag gag cag gcc acc 4862 Glu His Arg Val Leu Glu Glu Glu Ala
Ala Arg Glu Glu Gln Ala Thr 1585 1590 1595 ctc ctg gcc aaa gcc ccc
tca ttc gag act gcc ctc cgg ctg cct gcc 4910 Leu Leu Ala Lys Ala
Pro Ser Phe Glu Thr Ala Leu Arg Leu Pro Ala 1600 1605 1610 tct ggc
acc cac ttg gcc cct ggc cac agc cac tcc ctg gaa cat gac 4958 Ser
Gly Thr His Leu Ala Pro Gly His Ser His Ser Leu Glu His Asp 1615
1620 1625 tct ccg agc acc ccc cgc ccc tcc tcg gag gcc tgc ggt gag
gca cag 5006 Ser Pro Ser Thr Pro Arg Pro Ser Ser Glu Ala Cys Gly
Glu Ala Gln 1630 1635 1640 1645 cga ctg cct tca gcc ccc tcc ggg ggg
gcc cct atc agg gac atg ggg 5054 Arg Leu Pro Ser Ala Pro Ser Gly
Gly Ala Pro Ile Arg Asp Met Gly 1650 1655 1660 cac cct cag ggc tcc
aag cag ctt cca tcc act ggt ggc cac cca ggc 5102 His Pro Gln Gly
Ser Lys Gln Leu Pro Ser Thr Gly Gly His Pro Gly 1665 1670 1675 act
gct cag cca gag agg cca tcc ccg gac agc cct tgg ggg cag cca 5150
Thr Ala Gln Pro Glu Arg Pro Ser Pro Asp Ser Pro Trp Gly Gln Pro
1680 1685 1690 gcc cct ttc tgc cac ccc aag cag ggt tct gcc ccc cag
gag ggc tgc 5198 Ala Pro Phe Cys His Pro Lys Gln Gly Ser Ala Pro
Gln Glu Gly Cys 1695 1700 1705 agc ccc cac cca gca gtt gcc cca tgc
cct cct ggc tcc ttc cct cca 5246 Ser Pro His Pro Ala Val Ala Pro
Cys Pro Pro Gly Ser Phe Pro Pro 1710 1715 1720 1725 gga tct tgc aaa
gag gcc ccc tta gta ccc tca agc ccc ttc ttg gga 5294 Gly Ser Cys
Lys Glu Ala Pro Leu Val Pro Ser Ser Pro Phe Leu Gly 1730 1735 1740
cag ccc cag gca ccc cct gcc cct gcc aaa gca agc ccc cca ttg gac
5342 Gln Pro Gln Ala Pro Pro Ala Pro Ala Lys Ala Ser Pro Pro Leu
Asp 1745 1750 1755 tct aag atg ggg cct gga gac atc tct ctt cct ggg
agg cca aaa ccc 5390 Ser Lys Met Gly Pro Gly Asp Ile Ser Leu Pro
Gly Arg Pro Lys Pro 1760 1765 1770 ggc ccc tgc agt tcc cca ggg tca
gcc tcc cag gcg agc tct tcc caa 5438 Gly Pro Cys Ser Ser Pro Gly
Ser Ala Ser Gln Ala Ser Ser Ser Gln 1775 1780 1785 gtg agc tcc ctc
agg gtg ggc tcc tcc cag gtg ggc aca gag cct ggc 5486 Val Ser Ser
Leu Arg Val Gly Ser Ser Gln Val Gly Thr Glu Pro Gly 1790 1795 1800
1805 ccc tcc ctg gat gcg gag ggc tgg acc cag gag gct gag gat ctg
tcc 5534 Pro Ser Leu Asp Ala Glu Gly Trp Thr Gln Glu Ala Glu Asp
Leu Ser 1810 1815 1820 gac tcc aca ccc acc ttg cag cgg cct cag gaa
cag gcg acc atg cgc 5582 Asp Ser Thr Pro Thr Leu Gln Arg Pro Gln
Glu Gln Ala Thr Met Arg 1825 1830 1835 aag ttc tcc ctg ggt ggt cgc
ggg ggc tac gca ggc gtg gct ggc tat 5630 Lys Phe Ser Leu Gly Gly
Arg Gly Gly Tyr Ala Gly Val Ala Gly Tyr 1840 1845 1850 ggc acc ttt
gcc ttt ggt gga gat gca ggg ggc atg ctg ggg cag ggg 5678 Gly Thr
Phe Ala Phe Gly Gly Asp Ala Gly Gly Met Leu Gly Gln Gly 1855 1860
1865 ccc atg tgg gcc agg ata gcc tgg gct gtg tcc cag tcg gag gag
gag 5726 Pro Met Trp Ala Arg Ile Ala Trp Ala Val Ser Gln Ser Glu
Glu Glu 1870 1875 1880 1885 gag cag gag gag gcc agg gct gag tcc cag
tcg gag gag cag cag gag 5774 Glu Gln Glu Glu Ala Arg Ala Glu Ser
Gln Ser Glu Glu Gln Gln Glu 1890 1895 1900 gcc agg gct gag agc cca
ctg ccc cag gtc agt gca agg cct gtg cct 5822 Ala Arg Ala Glu Ser
Pro Leu Pro Gln Val Ser Ala Arg Pro Val Pro 1905 1910 1915 gag gtc
ggc agg gct ccc acc agg agc tct cca gag ccc acc cca tgg 5870 Glu
Val Gly Arg Ala Pro Thr Arg Ser Ser Pro Glu Pro Thr Pro Trp 1920
1925 1930 gag gac atc ggg cag gtc tcc ctg gtg cag atc cgg gac ctg
tca ggt 5918 Glu Asp Ile Gly Gln Val Ser Leu Val Gln Ile Arg Asp
Leu Ser Gly 1935 1940 1945 gat gcg gag gcg gcc gac aca ata tcc ctg
gac att tcc gag gtg gac 5966 Asp Ala Glu Ala Ala Asp Thr Ile Ser
Leu Asp Ile Ser Glu Val Asp 1950 1955 1960 1965 ccc gcc tac ctc aac
ctc tca gac ctg tac gat atc aag tac ctc cca 6014 Pro Ala Tyr Leu
Asn Leu Ser Asp Leu Tyr Asp Ile Lys Tyr Leu Pro 1970 1975 1980 ttc
gag ttt atg atc ttc agg aaa gtc ccc aag tcc gct cag cca gag 6062
Phe Glu Phe Met Ile Phe Arg Lys Val Pro Lys Ser Ala Gln Pro Glu
1985 1990 1995 ccg ccc tcc ccc atg gct gag gag gag ctg gcc gag ttc
ccg gag ccc 6110 Pro Pro Ser Pro Met Ala Glu Glu Glu Leu Ala Glu
Phe Pro Glu Pro 2000 2005 2010 acg tgg ccc tgg cca ggt gaa ctg ggc
ccc cac gca ggc ctg gag atc 6158 Thr Trp Pro Trp Pro Gly Glu Leu
Gly Pro His Ala Gly Leu Glu Ile 2015 2020 2025 aca gag gag tca gag
gat gtg gac gcg ctg ctg gca gag gct gcc gtg 6206 Thr Glu Glu Ser
Glu Asp Val Asp Ala Leu Leu Ala Glu Ala Ala Val 2030 2035 2040 2045
ggc agg aag cgc aag tgg tcc tcg ccg tca cgc agc ctc ttc cac ttc
6254 Gly Arg Lys Arg Lys Trp Ser Ser Pro Ser Arg Ser Leu Phe His
Phe 2050 2055 2060 cct ggg agg cac ctg ccg ctg gat gag cct gca gag
ctg ggg ctg cgt 6302 Pro Gly Arg His Leu Pro Leu Asp Glu Pro Ala
Glu Leu Gly Leu Arg 2065 2070 2075 gag aga gtg aag gcc tcc gtg gag
cac atc tcc cgg atc ctg aag ggc 6350 Glu Arg Val Lys Ala Ser Val
Glu His Ile Ser Arg Ile Leu Lys Gly 2080 2085 2090 agg ccg gaa ggt
ctg gag aag gag ggg ccc ccc agg aag aag cca ggc 6398 Arg Pro Glu
Gly Leu Glu Lys Glu Gly Pro Pro Arg Lys Lys Pro Gly 2095 2100 2105
ctt gct tcc ttc cgg ctc tca ggt ctg aag agc tgg gac cga gcg ccg
6446 Leu Ala Ser Phe Arg Leu Ser Gly Leu Lys Ser Trp Asp Arg Ala
Pro 2110 2115 2120 2125 aca ttc cta agg gag ctc tca gat gag act gtg
gtc ctg ggc cag tca 6494 Thr Phe Leu Arg Glu Leu Ser Asp Glu Thr
Val Val Leu Gly Gln Ser 2130 2135 2140 gtg aca ctg gcc tgc cag gtg
tca gcc cag cca gct gcc cag gcc acc 6542 Val Thr Leu Ala Cys Gln
Val Ser Ala Gln Pro Ala Ala Gln Ala Thr 2145 2150 2155 tgg agc aaa
gac gga gcc ccc ctg gag agc agc agc cgt gtc ctc atc 6590 Trp Ser
Lys Asp Gly Ala Pro Leu Glu Ser Ser Ser Arg Val Leu Ile 2160 2165
2170 tct gcc acc ctc aag aac ttc cag ctt ctg acc atc ctg gtg gtg
gtg 6638 Ser Ala Thr Leu Lys Asn Phe Gln Leu Leu Thr Ile Leu Val
Val Val 2175 2180 2185 gct gag gac ctg ggt gtg tac acc tgc agc gtg
agc aat gcg ctg ggg 6686 Ala Glu Asp Leu Gly Val Tyr Thr Cys Ser
Val Ser Asn Ala Leu Gly 2190 2195 2200 2205 aca gtg acc acc acg ggc
gtc ctc cgg aag gca gag cgc ccc tca tct 6734 Thr Val Thr Thr Thr
Gly Val Leu Arg Lys Ala Glu Arg Pro Ser Ser 2210 2215 2220 tcg cca
tgc ccg gat atc ggg gag gtg tac gcg gat ggg gtg ctg ctg 6782 Ser
Pro Cys Pro Asp Ile Gly Glu Val Tyr Ala Asp Gly Val Leu Leu 2225
2230 2235 gtc tgg aag ccc gtg gaa tcc tac ggc cct gtg acc tac att
gtg cag 6830 Val Trp Lys Pro Val Glu Ser Tyr Gly Pro Val Thr Tyr
Ile Val Gln 2240 2245 2250 tgc agc cta gaa ggc ggc agc tgg acc aca
ctg gcc tcc gac atc ttt 6878 Cys Ser Leu Glu Gly Gly Ser Trp Thr
Thr Leu Ala Ser Asp Ile Phe 2255 2260 2265 gac tgc tgc tac ctg acc
agc aag ctc tcc cgg ggt ggc acc tac acc 6926 Asp Cys Cys Tyr Leu
Thr Ser Lys Leu Ser Arg Gly Gly Thr Tyr Thr 2270 2275 2280 2285 ttc
cgc acg gca tgt gtc agc aag gca gga atg ggt ccc tac agc agc 6974
Phe Arg Thr Ala Cys Val Ser Lys Ala Gly Met Gly Pro Tyr Ser Ser
2290 2295 2300 ccc tcg gag caa gtc ctc ctg gga ggg ccc agc cac ctg
gcc tct gag 7022 Pro Ser Glu Gln Val Leu Leu Gly Gly Pro Ser His
Leu Ala Ser Glu 2305 2310 2315 gag gag agc cag ggg cgg tca gcc caa
ccc ctg ccc agc aca aag acc 7070 Glu Glu Ser Gln Gly Arg Ser Ala
Gln Pro Leu Pro Ser Thr Lys Thr 2320 2325 2330 ttc gca ttc cag aca
cag atc cag agg ggc cgc ttc agc gtg gtg cgg 7118 Phe Ala Phe Gln
Thr Gln Ile Gln Arg Gly Arg Phe Ser Val Val Arg 2335 2340 2345 caa
tgc tgg gag aag gcc agc ggg cgg gcg ctg gcc gcc aag atc atc 7166
Gln Cys Trp Glu Lys Ala Ser Gly Arg Ala Leu Ala Ala Lys Ile Ile
2350 2355 2360 2365 ccc tac cac ccc aag gac aag aca gca gtg ctg cgc
gaa tac gag gcc 7214 Pro Tyr His Pro Lys Asp Lys Thr Ala Val Leu
Arg Glu Tyr Glu Ala 2370 2375 2380 ctc aag ggc ctg cgc cac ccg cac
ctg gcc cag ctg cac gca gcc tac 7262 Leu Lys Gly Leu Arg His Pro
His Leu Ala Gln Leu His Ala Ala Tyr 2385 2390 2395 ctc agc ccc cgg
cac ctg gtg ctc atc ttg gag ctg tgc tct ggg ccc 7310 Leu Ser Pro
Arg His Leu Val Leu Ile Leu Glu Leu Cys Ser Gly Pro 2400 2405 2410
gag ctg ctc ccc tgc ctg gcc gag agg gcc tcc tac tca gaa tcc gag
7358 Glu Leu Leu Pro Cys Leu Ala Glu Arg Ala Ser Tyr Ser Glu Ser
Glu 2415 2420 2425 gtg aag gac tac ctg tgg cag atg ttg agt gcc acc
cag tac ctg cac 7406 Val Lys Asp Tyr Leu Trp Gln Met Leu Ser Ala
Thr Gln Tyr Leu His 2430 2435 2440 2445 aac cag cac atc ctg cac ctg
gac ctg agg tcc gag aac atg atc atc 7454 Asn Gln His Ile Leu His
Leu Asp Leu Arg Ser Glu Asn Met Ile Ile 2450 2455 2460 acc gaa tac
aac ctg ctc aag gtc gtg gac ctg ggc aat gca cag agc 7502 Thr Glu
Tyr Asn Leu Leu Lys Val Val Asp Leu Gly Asn Ala Gln Ser 2465 2470
2475 ctc agc cag gag aag gtg ctg ccc tca gac aag ttc aag gac tac
cta 7550 Leu Ser Gln Glu Lys Val Leu Pro Ser Asp Lys Phe Lys Asp
Tyr Leu 2480 2485 2490 gag acc atg gct cca gag ctc ctg gag ggc cag
ggg gct gtt cca cag 7598 Glu Thr Met Ala Pro Glu Leu Leu Glu Gly
Gln Gly Ala Val Pro Gln 2495 2500 2505 aca gac atc tgg gcc atc ggt
gtg aca gcc ttc atc atg ctg agc gcc 7646 Thr Asp Ile Trp Ala Ile
Gly Val Thr Ala Phe Ile Met Leu Ser Ala 2510 2515 2520 2525 gag tac
ccg gtg agc agc gag ggt gca cgc gac ctg cag aga gga ctg 7694 Glu
Tyr Pro Val Ser Ser Glu Gly Ala Arg Asp Leu Gln Arg Gly Leu 2530
2535 2540 cgc aag ggg ctg gtc cgg ctg agc cgc tgc tac gcg ggg ctg
tcc ggg 7742 Arg Lys Gly Leu Val Arg Leu Ser Arg Cys Tyr Ala Gly
Leu Ser Gly 2545 2550 2555 ggc gcc gtg gcc ttc ctg cgc agc act ctg
tgc gcc cag ccc tgg ggc 7790 Gly Ala Val Ala Phe Leu Arg Ser Thr
Leu Cys Ala Gln Pro Trp Gly 2560 2565 2570 cgg ccc tgc gcg tcc agc
tgc ctg cag tgc ccg tgg cta aca gag gag 7838 Arg Pro Cys Ala Ser
Ser Cys Leu Gln Cys Pro Trp Leu Thr Glu Glu 2575 2580 2585 ggc ccg
gcc tgt tcg cgg ccc gcg ccc gtg acc ttc cct acc gcg cgg 7886 Gly
Pro Ala Cys Ser Arg Pro Ala Pro Val Thr Phe Pro Thr Ala Arg 2590
2595 2600 2605 ctg cgc gtc ttc gtg cgc aat cgc gag aag aga cgc gcg
ctg ctg tac 7934 Leu Arg Val Phe Val Arg Asn Arg Glu Lys Arg Arg
Ala Leu Leu Tyr 2610 2615 2620 aag agg cac aac ctg gcc cag gtg cgc
tga gggtcgcccc ggccacaccc 7984 Lys Arg His Asn Leu Ala Gln Val Arg
* 2625 2630 ttggtctccc cgctgggggt cgctgcagac gcgccaataa aaacgcccag
ccgggcgaga 8044 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaag
gcggccgcta aaaaagtcta 8104 ga 8106 2 2630 PRT Homo sapiens 2 Met
Gly Ala Ala Tyr Ser Ser Ala Arg Leu Leu Val Arg Gly Pro Asp 1 5 10
15 Glu Pro Glu Glu Lys Pro Ala Ser Asp Val His Glu Gln Leu Val Pro
20 25 30 Pro Arg Met Leu Glu Arg Phe Thr Pro Lys Lys Val Lys Lys
Gly Ser 35 40 45 Ser Ile Thr Phe Ser Val Lys Val Glu Gly Arg Pro
Val Pro Thr Val 50 55 60 His Trp Leu Arg Glu Glu Ala Glu Arg Gly
Val Leu Trp Ile Gly Pro 65 70 75 80 Asp Thr Pro Gly Tyr Thr Val Ala
Ser Ser Ala Gln Gln His Ser Leu 85 90 95 Val Leu Leu Asp Val Gly
Arg Gln His Gln Gly Thr Tyr Thr Cys Ile 100 105 110 Ala Ser Asn Ala
Ala Gly Gln Ala Leu Cys Ser Ala Ser Leu His Val 115 120 125 Ser Gly
Leu Pro Lys Val Glu Glu Gln Glu Lys Val Lys Glu Ala Leu 130 135 140
Ile Ser Thr Phe Leu Gln Gly Thr Thr Gln Ala Ile Ser Ala Gln Gly 145
150 155 160 Leu Glu Thr Ala Ser Phe Ala Asp Leu Gly Gly Gln Arg Lys
Glu Glu 165 170 175 Pro Leu Ala Ala Lys Glu Ala Leu Gly His Leu Ser
Leu Ala Glu Val 180 185 190 Gly Thr Glu Glu Phe Leu Gln Lys Leu Thr
Ser Gln Ile Thr Glu Met 195 200 205 Val Ser Ala Lys Ile Thr Gln Ala
Lys Leu Gln Val Pro Gly Gly Asp 210 215 220 Ser Asp Glu Asp Ser Lys
Thr Pro Ser Ala Ser Pro Arg His Gly Arg 225 230 235 240 Ser Arg Pro
Ser Ser Ser Ile Gln Glu Ser Ser Ser Glu Ser Glu Asp 245 250 255 Gly
Asp Ala Arg Gly Glu Ile Phe Asp Ile Tyr Val Val Thr Ala Asp 260 265
270 Tyr Leu Pro Leu Gly Ala Glu Gln Asp Ala Ile Thr Leu Arg Glu Gly
275 280 285 Gln Tyr Val Glu Val Leu Asp Ala Ala His Pro Leu Arg Trp
Leu Val 290 295 300 Arg Thr Lys Pro Thr Lys Ser Ser Pro Ser Arg Gln
Gly Trp Val Ser 305 310 315 320 Pro Ala Tyr Leu Asp Arg Arg Leu Lys
Leu Ser Pro Glu Trp Gly Ala 325 330 335 Ala Glu Ala Pro Glu Phe Pro
Gly Glu Ala Val Ser Glu Asp Glu Tyr 340 345 350 Lys Ala Arg Leu Ser
Ser Val Ile Gln Glu Leu Leu Ser Ser Glu Gln 355 360 365 Ala Phe Val
Glu Glu Leu Gln Phe Leu Gln Ser His His Leu Gln His 370 375 380 Leu
Glu Arg Cys Pro His Val Pro Ile Ala Val Ala Gly Gln Lys Ala 385 390
395 400 Val Ile Phe Arg Asn Val Arg Asp Ile Gly Arg Phe His Ser Ser
Phe 405 410 415 Leu Gln Glu Leu Gln Gln Cys Asp Thr Asp Asp Asp Val
Ala Met Cys 420 425 430 Phe Ile Lys Asn Gln Ala Ala Phe Glu Gln Tyr
Leu Glu Phe Leu Val 435 440 445 Gly Arg Val Gln Ala Glu Ser Val Val
Val Ser Thr Ala Ile Gln Glu 450 455 460 Phe Tyr Lys Lys Tyr Ala Glu
Glu Ala Leu Leu Ala Gly Asp Pro Ser 465 470 475 480 Gln Pro Pro Pro
Pro Pro Leu Gln His Tyr Leu Glu Gln Pro Val Glu 485 490 495 Arg Val
Gln Arg Tyr Gln Ala Leu Leu Lys Glu Leu Ile Arg Asn Lys 500 505 510
Ala Arg Asn Arg Gln Asn Cys Ala Leu Leu Glu Gln Ala Tyr Ala Val 515
520 525 Val Ser Ala Leu Pro Gln Arg Ala Glu Asn Lys Leu His Val Ser
Leu 530 535 540 Met Glu Asn Tyr Pro Gly Thr Leu Glu Ala Leu Gly Glu
Pro Ile Arg 545 550 555 560 Gln Gly His Phe Ile Val Trp Glu Gly Ala
Pro Gly Ala Arg Met Pro 565
570 575 Trp Lys Gly His Asn Arg His Val Phe Leu Phe Arg Asn His Leu
Val 580 585 590 Ile Cys Lys Pro Arg Arg Asp Ser Arg Thr Asp Thr Val
Ser Tyr Val 595 600 605 Phe Arg Asn Met Met Lys Leu Ser Ser Ile Asp
Leu Asn Asp Gln Val 610 615 620 Glu Gly Asp Asp Arg Ala Phe Glu Val
Trp Gln Glu Arg Glu Asp Ser 625 630 635 640 Val Arg Lys Tyr Leu Leu
Gln Ala Arg Thr Ala Ile Ile Lys Ser Ser 645 650 655 Trp Val Lys Glu
Ile Cys Gly Ile Gln Gln Arg Leu Ala Leu Pro Val 660 665 670 Trp Arg
Pro Pro Asp Phe Glu Glu Glu Leu Ala Asp Cys Thr Ala Glu 675 680 685
Leu Gly Glu Thr Val Lys Leu Ala Cys Arg Val Thr Gly Thr Pro Lys 690
695 700 Pro Val Ile Ser Trp Tyr Lys Asp Gly Lys Ala Val Gln Val Asp
Pro 705 710 715 720 His His Ile Leu Ile Glu Asp Pro Asp Gly Ser Cys
Ala Leu Ile Leu 725 730 735 Asp Ser Leu Thr Gly Val Asp Ser Gly Gln
Tyr Met Cys Phe Ala Ala 740 745 750 Ser Ala Ala Gly Asn Cys Ser Thr
Leu Gly Lys Ile Leu Val Gln Val 755 760 765 Pro Pro Arg Phe Val Asn
Lys Val Arg Ala Ser Pro Phe Val Glu Gly 770 775 780 Glu Asp Ala Gln
Phe Thr Cys Thr Ile Glu Gly Ala Pro Tyr Pro Gln 785 790 795 800 Ile
Arg Trp Tyr Lys Asp Gly Ala Leu Leu Thr Thr Gly Asn Lys Phe 805 810
815 Gln Thr Leu Ser Glu Pro Arg Ser Gly Leu Leu Val Leu Val Ile Arg
820 825 830 Ala Ala Ser Lys Glu Asp Leu Gly Leu Tyr Glu Cys Glu Leu
Val Asn 835 840 845 Arg Leu Gly Ser Ala Arg Ala Ser Ala Glu Leu Arg
Ile Gln Ser Pro 850 855 860 Met Leu Gln Ala Gln Glu Gln Cys His Arg
Glu Gln Leu Val Ala Ala 865 870 875 880 Val Glu Asp Thr Thr Leu Glu
Arg Ala Asp Gln Glu Val Thr Ser Val 885 890 895 Leu Lys Arg Leu Leu
Gly Pro Lys Ala Pro Gly Pro Ser Thr Gly Asp 900 905 910 Leu Thr Gly
Pro Gly Pro Cys Pro Arg Gly Ala Pro Ala Leu Gln Glu 915 920 925 Thr
Gly Ser Gln Pro Pro Val Thr Gly Thr Ser Glu Ala Pro Ala Val 930 935
940 Pro Pro Arg Val Pro Gln Pro Leu Leu His Glu Gly Pro Glu Gln Glu
945 950 955 960 Pro Glu Ala Ile Ala Arg Ala Gln Glu Trp Thr Val Pro
Ile Arg Met 965 970 975 Glu Gly Ala Ala Trp Pro Gly Ala Gly Thr Gly
Glu Leu Leu Trp Asp 980 985 990 Val His Ser His Val Val Arg Glu Thr
Thr Gln Arg Thr Tyr Thr Tyr 995 1000 1005 Gln Ala Ile Asp Thr His
Thr Ala Arg Pro Pro Ser Met Gln Val Thr 1010 1015 1020 Ile Glu Asp
Val Gln Ala Gln Thr Gly Gly Thr Ala Gln Phe Glu Ala 1025 1030 1035
1040 Ile Ile Glu Gly Asp Pro Gln Pro Ser Val Thr Trp Tyr Lys Asp
Ser 1045 1050 1055 Val Gln Leu Val Asp Ser Thr Arg Leu Ser Gln Gln
Gln Glu Gly Thr 1060 1065 1070 Thr Tyr Ser Leu Val Leu Arg His Val
Ala Ser Lys Asp Ala Gly Val 1075 1080 1085 Tyr Thr Cys Leu Ala Gln
Asn Thr Gly Gly Gln Val Leu Cys Lys Ala 1090 1095 1100 Glu Leu Leu
Val Leu Gly Gly Asp Asn Glu Pro Asp Ser Glu Lys Gln 1105 1110 1115
1120 Ser His Arg Arg Lys Leu His Ser Phe Tyr Glu Val Lys Glu Glu
Ile 1125 1130 1135 Gly Arg Gly Val Phe Gly Phe Val Lys Arg Val Gln
His Lys Gly Asn 1140 1145 1150 Lys Ile Leu Cys Ala Ala Lys Phe Ile
Pro Leu Arg Ser Arg Thr Arg 1155 1160 1165 Ala Gln Ala Tyr Arg Glu
Arg Asp Ile Leu Ala Ala Leu Ser His Pro 1170 1175 1180 Leu Val Thr
Gly Leu Leu Asp Gln Phe Glu Thr Arg Lys Thr Leu Ile 1185 1190 1195
1200 Leu Ile Leu Glu Leu Cys Ser Ser Glu Glu Leu Leu Asp Arg Leu
Tyr 1205 1210 1215 Arg Lys Gly Val Val Thr Glu Ala Glu Val Lys Val
Tyr Ile Gln Gln 1220 1225 1230 Leu Val Glu Gly Leu His Tyr Leu His
Ser His Gly Val Leu His Leu 1235 1240 1245 Asp Ile Lys Pro Ser Asn
Ile Leu Met Val His Pro Ala Arg Glu Asp 1250 1255 1260 Ile Lys Ile
Cys Asp Phe Gly Phe Ala Gln Asn Ile Thr Pro Ala Glu 1265 1270 1275
1280 Leu Gln Phe Ser Gln Tyr Gly Ser Pro Glu Phe Val Ser Pro Glu
Ile 1285 1290 1295 Ile Gln Gln Asn Pro Val Ser Glu Ala Ser Asp Ile
Trp Ala Met Gly 1300 1305 1310 Val Ile Ser Tyr Leu Ser Leu Thr Cys
Ser Ser Pro Phe Ala Gly Glu 1315 1320 1325 Ser Asp Arg Ala Thr Leu
Leu Asn Val Leu Glu Gly Arg Val Ser Trp 1330 1335 1340 Ser Ser Pro
Met Ala Ala His Leu Ser Glu Asp Ala Lys Asp Phe Ile 1345 1350 1355
1360 Lys Ala Thr Leu Gln Arg Ala Pro Gln Ala Arg Pro Ser Ala Ala
Gln 1365 1370 1375 Cys Leu Ser His Pro Trp Phe Leu Lys Ser Met Pro
Ala Glu Glu Ala 1380 1385 1390 His Phe Ile Asn Thr Lys Gln Leu Lys
Phe Leu Leu Ala Arg Ser Arg 1395 1400 1405 Trp Gln Arg Ser Leu Met
Ser Tyr Lys Ser Ile Leu Val Met Arg Ser 1410 1415 1420 Ile Pro Glu
Leu Leu Arg Gly Pro Pro Asp Ser Pro Ser Leu Gly Val 1425 1430 1435
1440 Ala Arg His Leu Cys Arg Asp Thr Gly Gly Ser Ser Ser Ser Ser
Ser 1445 1450 1455 Ser Ser Asp Asn Glu Leu Ala Pro Phe Ala Arg Ala
Lys Ser Leu Pro 1460 1465 1470 Pro Ser Pro Val Thr His Ser Pro Leu
Leu His Pro Arg Gly Phe Leu 1475 1480 1485 Arg Pro Ser Ala Ser Leu
Pro Glu Glu Ala Glu Ala Ser Glu Arg Ser 1490 1495 1500 Thr Glu Ala
Pro Ala Pro Pro Ala Ser Pro Glu Gly Ala Gly Pro Pro 1505 1510 1515
1520 Ala Ala Gln Gly Cys Val Pro Arg His Ser Val Ile Arg Ser Leu
Phe 1525 1530 1535 Tyr His Gln Ala Gly Glu Ser Pro Glu His Gly Ala
Leu Ala Pro Gly 1540 1545 1550 Ser Arg Arg His Pro Ala Arg Arg Arg
His Leu Leu Lys Gly Gly Tyr 1555 1560 1565 Ile Ala Gly Ala Leu Pro
Gly Leu Arg Glu Pro Leu Met Glu His Arg 1570 1575 1580 Val Leu Glu
Glu Glu Ala Ala Arg Glu Glu Gln Ala Thr Leu Leu Ala 1585 1590 1595
1600 Lys Ala Pro Ser Phe Glu Thr Ala Leu Arg Leu Pro Ala Ser Gly
Thr 1605 1610 1615 His Leu Ala Pro Gly His Ser His Ser Leu Glu His
Asp Ser Pro Ser 1620 1625 1630 Thr Pro Arg Pro Ser Ser Glu Ala Cys
Gly Glu Ala Gln Arg Leu Pro 1635 1640 1645 Ser Ala Pro Ser Gly Gly
Ala Pro Ile Arg Asp Met Gly His Pro Gln 1650 1655 1660 Gly Ser Lys
Gln Leu Pro Ser Thr Gly Gly His Pro Gly Thr Ala Gln 1665 1670 1675
1680 Pro Glu Arg Pro Ser Pro Asp Ser Pro Trp Gly Gln Pro Ala Pro
Phe 1685 1690 1695 Cys His Pro Lys Gln Gly Ser Ala Pro Gln Glu Gly
Cys Ser Pro His 1700 1705 1710 Pro Ala Val Ala Pro Cys Pro Pro Gly
Ser Phe Pro Pro Gly Ser Cys 1715 1720 1725 Lys Glu Ala Pro Leu Val
Pro Ser Ser Pro Phe Leu Gly Gln Pro Gln 1730 1735 1740 Ala Pro Pro
Ala Pro Ala Lys Ala Ser Pro Pro Leu Asp Ser Lys Met 1745 1750 1755
1760 Gly Pro Gly Asp Ile Ser Leu Pro Gly Arg Pro Lys Pro Gly Pro
Cys 1765 1770 1775 Ser Ser Pro Gly Ser Ala Ser Gln Ala Ser Ser Ser
Gln Val Ser Ser 1780 1785 1790 Leu Arg Val Gly Ser Ser Gln Val Gly
Thr Glu Pro Gly Pro Ser Leu 1795 1800 1805 Asp Ala Glu Gly Trp Thr
Gln Glu Ala Glu Asp Leu Ser Asp Ser Thr 1810 1815 1820 Pro Thr Leu
Gln Arg Pro Gln Glu Gln Ala Thr Met Arg Lys Phe Ser 1825 1830 1835
1840 Leu Gly Gly Arg Gly Gly Tyr Ala Gly Val Ala Gly Tyr Gly Thr
Phe 1845 1850 1855 Ala Phe Gly Gly Asp Ala Gly Gly Met Leu Gly Gln
Gly Pro Met Trp 1860 1865 1870 Ala Arg Ile Ala Trp Ala Val Ser Gln
Ser Glu Glu Glu Glu Gln Glu 1875 1880 1885 Glu Ala Arg Ala Glu Ser
Gln Ser Glu Glu Gln Gln Glu Ala Arg Ala 1890 1895 1900 Glu Ser Pro
Leu Pro Gln Val Ser Ala Arg Pro Val Pro Glu Val Gly 1905 1910 1915
1920 Arg Ala Pro Thr Arg Ser Ser Pro Glu Pro Thr Pro Trp Glu Asp
Ile 1925 1930 1935 Gly Gln Val Ser Leu Val Gln Ile Arg Asp Leu Ser
Gly Asp Ala Glu 1940 1945 1950 Ala Ala Asp Thr Ile Ser Leu Asp Ile
Ser Glu Val Asp Pro Ala Tyr 1955 1960 1965 Leu Asn Leu Ser Asp Leu
Tyr Asp Ile Lys Tyr Leu Pro Phe Glu Phe 1970 1975 1980 Met Ile Phe
Arg Lys Val Pro Lys Ser Ala Gln Pro Glu Pro Pro Ser 1985 1990 1995
2000 Pro Met Ala Glu Glu Glu Leu Ala Glu Phe Pro Glu Pro Thr Trp
Pro 2005 2010 2015 Trp Pro Gly Glu Leu Gly Pro His Ala Gly Leu Glu
Ile Thr Glu Glu 2020 2025 2030 Ser Glu Asp Val Asp Ala Leu Leu Ala
Glu Ala Ala Val Gly Arg Lys 2035 2040 2045 Arg Lys Trp Ser Ser Pro
Ser Arg Ser Leu Phe His Phe Pro Gly Arg 2050 2055 2060 His Leu Pro
Leu Asp Glu Pro Ala Glu Leu Gly Leu Arg Glu Arg Val 2065 2070 2075
2080 Lys Ala Ser Val Glu His Ile Ser Arg Ile Leu Lys Gly Arg Pro
Glu 2085 2090 2095 Gly Leu Glu Lys Glu Gly Pro Pro Arg Lys Lys Pro
Gly Leu Ala Ser 2100 2105 2110 Phe Arg Leu Ser Gly Leu Lys Ser Trp
Asp Arg Ala Pro Thr Phe Leu 2115 2120 2125 Arg Glu Leu Ser Asp Glu
Thr Val Val Leu Gly Gln Ser Val Thr Leu 2130 2135 2140 Ala Cys Gln
Val Ser Ala Gln Pro Ala Ala Gln Ala Thr Trp Ser Lys 2145 2150 2155
2160 Asp Gly Ala Pro Leu Glu Ser Ser Ser Arg Val Leu Ile Ser Ala
Thr 2165 2170 2175 Leu Lys Asn Phe Gln Leu Leu Thr Ile Leu Val Val
Val Ala Glu Asp 2180 2185 2190 Leu Gly Val Tyr Thr Cys Ser Val Ser
Asn Ala Leu Gly Thr Val Thr 2195 2200 2205 Thr Thr Gly Val Leu Arg
Lys Ala Glu Arg Pro Ser Ser Ser Pro Cys 2210 2215 2220 Pro Asp Ile
Gly Glu Val Tyr Ala Asp Gly Val Leu Leu Val Trp Lys 2225 2230 2235
2240 Pro Val Glu Ser Tyr Gly Pro Val Thr Tyr Ile Val Gln Cys Ser
Leu 2245 2250 2255 Glu Gly Gly Ser Trp Thr Thr Leu Ala Ser Asp Ile
Phe Asp Cys Cys 2260 2265 2270 Tyr Leu Thr Ser Lys Leu Ser Arg Gly
Gly Thr Tyr Thr Phe Arg Thr 2275 2280 2285 Ala Cys Val Ser Lys Ala
Gly Met Gly Pro Tyr Ser Ser Pro Ser Glu 2290 2295 2300 Gln Val Leu
Leu Gly Gly Pro Ser His Leu Ala Ser Glu Glu Glu Ser 2305 2310 2315
2320 Gln Gly Arg Ser Ala Gln Pro Leu Pro Ser Thr Lys Thr Phe Ala
Phe 2325 2330 2335 Gln Thr Gln Ile Gln Arg Gly Arg Phe Ser Val Val
Arg Gln Cys Trp 2340 2345 2350 Glu Lys Ala Ser Gly Arg Ala Leu Ala
Ala Lys Ile Ile Pro Tyr His 2355 2360 2365 Pro Lys Asp Lys Thr Ala
Val Leu Arg Glu Tyr Glu Ala Leu Lys Gly 2370 2375 2380 Leu Arg His
Pro His Leu Ala Gln Leu His Ala Ala Tyr Leu Ser Pro 2385 2390 2395
2400 Arg His Leu Val Leu Ile Leu Glu Leu Cys Ser Gly Pro Glu Leu
Leu 2405 2410 2415 Pro Cys Leu Ala Glu Arg Ala Ser Tyr Ser Glu Ser
Glu Val Lys Asp 2420 2425 2430 Tyr Leu Trp Gln Met Leu Ser Ala Thr
Gln Tyr Leu His Asn Gln His 2435 2440 2445 Ile Leu His Leu Asp Leu
Arg Ser Glu Asn Met Ile Ile Thr Glu Tyr 2450 2455 2460 Asn Leu Leu
Lys Val Val Asp Leu Gly Asn Ala Gln Ser Leu Ser Gln 2465 2470 2475
2480 Glu Lys Val Leu Pro Ser Asp Lys Phe Lys Asp Tyr Leu Glu Thr
Met 2485 2490 2495 Ala Pro Glu Leu Leu Glu Gly Gln Gly Ala Val Pro
Gln Thr Asp Ile 2500 2505 2510 Trp Ala Ile Gly Val Thr Ala Phe Ile
Met Leu Ser Ala Glu Tyr Pro 2515 2520 2525 Val Ser Ser Glu Gly Ala
Arg Asp Leu Gln Arg Gly Leu Arg Lys Gly 2530 2535 2540 Leu Val Arg
Leu Ser Arg Cys Tyr Ala Gly Leu Ser Gly Gly Ala Val 2545 2550 2555
2560 Ala Phe Leu Arg Ser Thr Leu Cys Ala Gln Pro Trp Gly Arg Pro
Cys 2565 2570 2575 Ala Ser Ser Cys Leu Gln Cys Pro Trp Leu Thr Glu
Glu Gly Pro Ala 2580 2585 2590 Cys Ser Arg Pro Ala Pro Val Thr Phe
Pro Thr Ala Arg Leu Arg Val 2595 2600 2605 Phe Val Arg Asn Arg Glu
Lys Arg Arg Ala Leu Leu Tyr Lys Arg His 2610 2615 2620 Asn Leu Ala
Gln Val Arg 2625 2630 3 7893 DNA Homo sapiens 3 atgggtgctg
cctactcgtc tgcccggctg ctggttcgag gccctgatga gccagaagag 60
aagcctgcat cagatgtgca tgagcagctg gtgccgcccc gaatgctgga gaggttcacc
120 cccaagaaag tgaagaaagg ctccagcatc accttctctg tgaaggtaga
aggacgcccg 180 gtgcccaccg tgcactggct cagggaggag gctgagagag
gcgtgctgtg gattggccct 240 gacacaccgg gctacaccgt ggccagctct
gcgcagcagc acagcctggt cctgctggac 300 gtgggccggc agcaccaggg
cacctacaca tgcattgcca gcaacgctgc cggccaggcc 360 ctctgctccg
ccagcctgca cgtctcgggc ctgcctaagg tggaggagca ggagaaagtg 420
aaggaagcgc tgatttccac tttcctgcag gggaccacac aagccatctc agcacagggg
480 ttggaaactg cgagttttgc tgaccttggt gggcagagga aagaagagcc
tctggctgcc 540 aaggaggccc tcggccacct gtccctcgct gaggtgggca
cagaggagtt cctgcagaaa 600 ctgacctccc agatcactga gatggtatcg
gccaagatca cgcaggccaa gctgcaggtg 660 cccggaggtg acagtgatga
ggactccaag acaccatctg catccccccg ccatggccga 720 tcacggccat
cctccagcat ccaggagtct tcctcagagt cagaggacgg cgatgcccga 780
ggcgagatct ttgacatcta cgtggtcacc gctgactacc tgcccctagg ggctgagcag
840 gatgccatca cgctgcggga aggccagtat gtggaggtcc tggatgcagc
ccacccactg 900 cgctggcttg tccgcaccaa gcccaccaag tccagcccct
cacggcaggg ctgggtgtca 960 ccagcctacc tggacaggag gctcaagctg
tcacctgagt ggggggccgc tgaggcccct 1020 gagttccctg gggaggctgt
gtctgaagac gaatacaagg caaggctgag ctctgtgatc 1080 caggagctgc
tgagttctga gcaggccttc gtggaggagc tgcagttcct gcagagccac 1140
cacctgcagc acctggagcg ctgcccccac gtgcccatag ccgtggccgg ccagaaggca
1200 gtcatcttcc gcaatgtgcg ggacatcggc cgcttccaca gcagcttcct
gcaggagttg 1260 cagcagtgcg acacggacga cgacgtggcc atgtgcttca
tcaagaacca ggcggccttt 1320 gagcagtacc tggagttcct ggtggggcgt
gtgcaggctg agtcggtggt cgtcagcacg 1380 gccatccagg agttctacaa
gaaatacgcg gaggaggccc tgttggcagg ggacccctct 1440 cagcccccgc
caccacctct gcagcactac ctggagcagc cagtggagcg ggtgcagcgc 1500
taccaggcct tgctgaagga gttgatccgc aacaaggcgc ggaacagaca gaactgcgcg
1560 ctgctggagc aggcctatgc cgtggtgtct gccctgccac agcgcgctga
gaacaagctg 1620 cacgtgtccc tcatggagaa ctacccaggc accctggagg
ccctgggcga gcccatccgc 1680 cagggccact tcatcgtgtg ggagggtgca
ccgggggccc gcatgccctg gaagggccac 1740 aaccgtcacg tgttcctctt
ccgcaaccac ctggtaatct gcaagccccg gcgagactcc 1800 cgcaccgata
ccgtcagcta cgtgttccgg aacatgatga agctgagcag catcgacctg 1860
aacgaccagg tggaggggga tgaccgcgcc ttcgaggtgt ggcaggagcg ggaggactcg
1920 gtgcgcaagt acctgctgca ggcacggaca gccattatca agagctcgtg
ggtgaaggag 1980 atctgtggca tccagcagcg tctggccctg cctgtgtggc
ggcccccgga ctttgaagag 2040 gagctggccg actgcacagc cgagctgggt
gagacagtca agctggcctg ccgcgtgacg 2100 ggcacaccca agcctgtcat
cagctggtac aaagatggga aagcagtgca ggtggacccc 2160 caccacatcc
tcattgaaga ccctgatggc tcgtgtgcac tcatcctgga cagcctgacc 2220
ggtgtggact ctggccagta catgtgcttc gcggccagcg ccgctggcaa ctgcagtacc
2280 ctgggcaaga tcctggtgca agtcccacca cggttcgtga acaaggtccg
ggcctcaccc 2340 tttgtggagg gagaggacgc ccagttcacc tgcaccatcg
aaggcgcccc gtacccgcag 2400 atcaggtggt acaaggacgg ggccctgctg
accactggca acaagttcca gacactgagt 2460 gagcctcgca gcggcctgct
agtgctggtg atccgggcgg ccagcaagga ggacctgggg 2520 ctctacgagt
gtgagctggt gaaccggctg ggctccgcgc gggctagtgc ggagctgcgc 2580
attcagagcc ccatgctgca ggcccaggag cagtgtcaca gggagcagct cgtggctgca
2640 gtggaagaca ccaccctgga gcgagcggac caggaggtca catctgtcct
gaagagactg 2700 ctgggcccca aggcgccagg cccctccaca ggggacctca
ctggccctgg cccctgcccc 2760 aggggggcac ccgcactcca ggaaaccggc
tcccagcccc cagtcaccgg aacttcggag 2820 gcacctgccg tgcccccgag
ggtgccacag cccctcctcc acgaaggccc agagcaggag 2880 ccggaggcca
ttgccagagc ccaggaatgg actgtgccca ttcggatgga gggtgcagcc 2940
tggcccgggg caggcacagg ggagctgctc tgggacgtcc acagccacgt ggtcagagag
3000 accacacaga ggacctacac ataccaggcc atcgacacgc acaccgcacg
gcccccatcc 3060 atgcaggtaa ccatcgagga tgtgcaggca cagacaggcg
gaacggccca attcgaggct 3120 atcattgagg gcgacccaca gccctcggtg
acctggtaca aggacagcgt ccagctggtg 3180 gacagcaccc ggcttagcca
gcagcaagaa ggcaccacat actccctggt gctgaggcat 3240 gtggcctcga
aggatgccgg cgtttacacc tgcctggccc aaaacactgg tggccaggtg 3300
ctctgcaagg cagagctgct ggtgcttggg ggggacaatg agccggactc agagaagcaa
3360 agccaccgga ggaagctgca ctccttctat gaggtcaagg aggagattgg
aaggggcgtg 3420 tttggcttcg taaaaagagt gcagcacaaa ggaaacaaga
tcttgtgcgc tgccaagttc 3480 atccccctac ggagcagaac tcgggcccag
gcatacaggg agcgagacat cctggccgcg 3540 ctgagccacc cgctggtcac
ggggctgctg gaccagtttg agacccgcaa gaccctcatc 3600 ctcatcctgg
agctgtgctc atccgaggag ctgctggacc gcctgtacag gaagggcgtg 3660
gtgacggagg ccgaggtcaa ggtctacatc cagcagctgg tggaggggct gcactacctg
3720 cacagccatg gcgttctcca cctggacata aagccctcta acatcctgat
ggtgcatcct 3780 gcccgggaag acattaaaat ctgcgacttt ggctttgccc
agaacatcac cccagcagag 3840 ctgcagttca gccagtacgg ctcccctgag
ttcgtctccc ccgagatcat ccagcagaac 3900 cctgtgagcg aagcctccga
catttgggcc atgggtgtca tctcctacct cagcctgacc 3960 tgctcatccc
catttgccgg cgagagtgac cgtgccaccc tcctgaacgt cctggagggg 4020
cgcgtgtcat ggagcagccc catggctgcc cacctcagcg aagacgccaa agacttcatc
4080 aaggctacgc tgcagagagc ccctcaggcc cggcctagtg cggcccagtg
cctctcccac 4140 ccctggttcc tgaaatccat gcctgcggag gaggcccact
tcatcaacac caagcagctc 4200 aagttcctcc tggcccgaag tcgctggcag
cgttccctga tgagctacaa gtccatcctg 4260 gtgatgcgct ccatccctga
gctgctgcgg ggcccacccg acagcccctc cctcggcgta 4320 gcccggcacc
tctgcaggga cactggtggc tcctccagtt cctcctcctc ctctgacaac 4380
gagctcgccc catttgcccg ggctaagtca ctgccaccct ccccggtgac acactcacca
4440 ctgctgcacc cccggggctt cctgcggccc tcggccagcc tgcctgagga
agccgaggcc 4500 agtgagcgct ccaccgaggc cccagctccg cctgcatctc
ccgagggtgc cgggccaccg 4560 gccgcccagg gctgcgtgcc ccggcacagc
gtcatccgca gcctgttcta ccaccaggcg 4620 ggtgagagcc ctgagcacgg
ggccctggcc ccggggagca ggcggcaccc ggcccggcgg 4680 cggcacctgc
tgaagggcgg gtacattgcg ggggcgctgc caggcctgcg cgagccactg 4740
atggagcacc gcgtgctgga ggaggaggcc gccagggagg agcaggccac cctcctggcc
4800 aaagccccct cattcgagac tgccctccgg ctgcctgcct ctggcaccca
cttggcccct 4860 ggccacagcc actccctgga acatgactct ccgagcaccc
cccgcccctc ctcggaggcc 4920 tgcggtgagg cacagcgact gccttcagcc
ccctccgggg gggcccctat cagggacatg 4980 gggcaccctc agggctccaa
gcagcttcca tccactggtg gccacccagg cactgctcag 5040 ccagagaggc
catccccgga cagcccttgg gggcagccag cccctttctg ccaccccaag 5100
cagggttctg ccccccagga gggctgcagc ccccacccag cagttgcccc atgccctcct
5160 ggctccttcc ctccaggatc ttgcaaagag gcccccttag taccctcaag
ccccttcttg 5220 ggacagcccc aggcaccccc tgcccctgcc aaagcaagcc
ccccattgga ctctaagatg 5280 gggcctggag acatctctct tcctgggagg
ccaaaacccg gcccctgcag ttccccaggg 5340 tcagcctccc aggcgagctc
ttcccaagtg agctccctca gggtgggctc ctcccaggtg 5400 ggcacagagc
ctggcccctc cctggatgcg gagggctgga cccaggaggc tgaggatctg 5460
tccgactcca cacccacctt gcagcggcct caggaacagg cgaccatgcg caagttctcc
5520 ctgggtggtc gcgggggcta cgcaggcgtg gctggctatg gcacctttgc
ctttggtgga 5580 gatgcagggg gcatgctggg gcaggggccc atgtgggcca
ggatagcctg ggctgtgtcc 5640 cagtcggagg aggaggagca ggaggaggcc
agggctgagt cccagtcgga ggagcagcag 5700 gaggccaggg ctgagagccc
actgccccag gtcagtgcaa ggcctgtgcc tgaggtcggc 5760 agggctccca
ccaggagctc tccagagccc accccatggg aggacatcgg gcaggtctcc 5820
ctggtgcaga tccgggacct gtcaggtgat gcggaggcgg ccgacacaat atccctggac
5880 atttccgagg tggaccccgc ctacctcaac ctctcagacc tgtacgatat
caagtacctc 5940 ccattcgagt ttatgatctt caggaaagtc cccaagtccg
ctcagccaga gccgccctcc 6000 cccatggctg aggaggagct ggccgagttc
ccggagccca cgtggccctg gccaggtgaa 6060 ctgggccccc acgcaggcct
ggagatcaca gaggagtcag aggatgtgga cgcgctgctg 6120 gcagaggctg
ccgtgggcag gaagcgcaag tggtcctcgc cgtcacgcag cctcttccac 6180
ttccctggga ggcacctgcc gctggatgag cctgcagagc tggggctgcg tgagagagtg
6240 aaggcctccg tggagcacat ctcccggatc ctgaagggca ggccggaagg
tctggagaag 6300 gaggggcccc ccaggaagaa gccaggcctt gcttccttcc
ggctctcagg tctgaagagc 6360 tgggaccgag cgccgacatt cctaagggag
ctctcagatg agactgtggt cctgggccag 6420 tcagtgacac tggcctgcca
ggtgtcagcc cagccagctg cccaggccac ctggagcaaa 6480 gacggagccc
ccctggagag cagcagccgt gtcctcatct ctgccaccct caagaacttc 6540
cagcttctga ccatcctggt ggtggtggct gaggacctgg gtgtgtacac ctgcagcgtg
6600 agcaatgcgc tggggacagt gaccaccacg ggcgtcctcc ggaaggcaga
gcgcccctca 6660 tcttcgccat gcccggatat cggggaggtg tacgcggatg
gggtgctgct ggtctggaag 6720 cccgtggaat cctacggccc tgtgacctac
attgtgcagt gcagcctaga aggcggcagc 6780 tggaccacac tggcctccga
catctttgac tgctgctacc tgaccagcaa gctctcccgg 6840 ggtggcacct
acaccttccg cacggcatgt gtcagcaagg caggaatggg tccctacagc 6900
agcccctcgg agcaagtcct cctgggaggg cccagccacc tggcctctga ggaggagagc
6960 caggggcggt cagcccaacc cctgcccagc acaaagacct tcgcattcca
gacacagatc 7020 cagaggggcc gcttcagcgt ggtgcggcaa tgctgggaga
aggccagcgg gcgggcgctg 7080 gccgccaaga tcatccccta ccaccccaag
gacaagacag cagtgctgcg cgaatacgag 7140 gccctcaagg gcctgcgcca
cccgcacctg gcccagctgc acgcagccta cctcagcccc 7200 cggcacctgg
tgctcatctt ggagctgtgc tctgggcccg agctgctccc ctgcctggcc 7260
gagagggcct cctactcaga atccgaggtg aaggactacc tgtggcagat gttgagtgcc
7320 acccagtacc tgcacaacca gcacatcctg cacctggacc tgaggtccga
gaacatgatc 7380 atcaccgaat acaacctgct caaggtcgtg gacctgggca
atgcacagag cctcagccag 7440 gagaaggtgc tgccctcaga caagttcaag
gactacctag agaccatggc tccagagctc 7500 ctggagggcc agggggctgt
tccacagaca gacatctggg ccatcggtgt gacagccttc 7560 atcatgctga
gcgccgagta cccggtgagc agcgagggtg cacgcgacct gcagagagga 7620
ctgcgcaagg ggctggtccg gctgagccgc tgctacgcgg ggctgtccgg gggcgccgtg
7680 gccttcctgc gcagcactct gtgcgcccag ccctggggcc ggccctgcgc
gtccagctgc 7740 ctgcagtgcc cgtggctaac agaggagggc ccggcctgtt
cgcggcccgc gcccgtgacc 7800 ttccctaccg cgcggctgcg cgtcttcgtg
cgcaatcgcg agaagagacg cgcgctgctg 7860 tacaagaggc acaacctggc
ccaggtgcgc tga 7893 4 24120 DNA Homo sapiens 5'UTR (1)...(71) CDS
(72)...(23978) 3'UTR (23979)...(24120) 4 tgcctaccag cagcccacac
tccggccgct gcccagagcc cccatagaga gaggtccccg 60 ccgccaccgt c atg gat
cag cca cag ttc agc ggg gcg ccc cgc ttt ctc 110 Met Asp Gln Pro Gln
Phe Ser Gly Ala Pro Arg Phe Leu 1 5 10 acc cgg ccc aag gcc ttc gtg
gtg tcg gtg ggc aag gac gcc acc ctc 158 Thr Arg Pro Lys Ala Phe Val
Val Ser Val Gly Lys Asp Ala Thr Leu 15 20 25 agc tgc cag atc gtg
ggt aat ccc acg cca cag gtg agc tgg gag aag 206 Ser Cys Gln Ile Val
Gly Asn Pro Thr Pro Gln Val Ser Trp Glu Lys 30 35 40 45 gac cag cag
ccg gtg acg gcc ggc gcg cgc ttc cgt ctg gcc cag gac 254 Asp Gln Gln
Pro Val Thr Ala Gly Ala Arg Phe Arg Leu Ala Gln Asp 50 55 60 ggc
gac ctc tac cgc ctc act atc ctg gac ctg gcg ctg ggc gac agt 302 Gly
Asp Leu Tyr Arg Leu Thr Ile Leu Asp Leu Ala Leu Gly Asp Ser 65 70
75 ggg caa tac gtg tgc cgc gcg cgc aat gcc ata ggc gag gcc ttc gct
350 Gly Gln Tyr Val Cys Arg Ala Arg Asn Ala Ile Gly Glu Ala Phe Ala
80 85 90 gcc gtg ggc ctg cag gtg gac gcg gag gcc gcg tgc gcc gag
cag gcg 398 Ala Val Gly Leu Gln Val Asp Ala Glu Ala Ala Cys Ala Glu
Gln Ala 95 100 105 ccg cac ttc ctg ctg cgg ccc acg tcc atc cgc gtg
cgc gag ggc tca 446 Pro His Phe Leu Leu Arg Pro Thr Ser Ile Arg Val
Arg Glu Gly Ser 110 115 120 125 gag gcc acc ttc cgc tgc cgc gtg ggt
ggc tcc ccg agg ccg gca gtg 494 Glu Ala Thr Phe Arg Cys Arg Val Gly
Gly Ser Pro Arg Pro Ala Val 130 135 140 agc tgg tcc aag gac ggg cgg
cgc ctg ggt gag ccc gac ggc ccc cgc 542 Ser Trp Ser Lys Asp Gly Arg
Arg Leu Gly Glu Pro Asp Gly Pro Arg 145 150 155 gtg cgc gtg gag gag
ctc ggc gag gca agt gcg ctg cgc att cgg gcg 590 Val Arg Val Glu Glu
Leu Gly Glu Ala Ser Ala Leu Arg Ile Arg Ala 160 165 170 gcg cgg ccg
cgc gac ggc ggc act tac gag gtc cgc gcc gag aac ccg 638 Ala Arg Pro
Arg Asp Gly Gly Thr Tyr Glu Val Arg Ala Glu Asn Pro 175 180 185 ctg
ggc gct gcc agc gcc gcc gcg gcg cta gtg gtg gac tcg gac gcc 686 Leu
Gly Ala Ala Ser Ala Ala Ala Ala Leu Val Val Asp Ser Asp Ala 190 195
200 205 gcg gac acg gcc agc cgg ccc ggg acc tcc acg gcc gcg ctc ctg
gcg 734 Ala Asp Thr Ala Ser Arg Pro Gly Thr Ser Thr Ala Ala Leu Leu
Ala 210 215 220 cac ctg cag cgg cgg cgc gag gct atg cgc gcc gag ggc
gcc ccc gcc 782 His Leu Gln Arg Arg Arg Glu Ala Met Arg Ala Glu Gly
Ala Pro Ala 225 230 235 tca ccg ccc agc acc ggc acg cgc acc tgc acg
gtg act gaa ggc aag 830 Ser Pro Pro Ser Thr Gly Thr Arg Thr Cys Thr
Val Thr Glu Gly Lys 240 245 250 cac gcg cgc ctc agc tgc tac gtg acc
ggc gag ccc aag ccc gag acg 878 His Ala Arg Leu Ser Cys Tyr Val Thr
Gly Glu Pro Lys Pro Glu Thr 255 260 265 gtg tgg aag aag gac ggc cag
ctg gtg acc gag ggc cgg cgc cac gtg 926 Val Trp Lys Lys Asp Gly Gln
Leu Val Thr Glu Gly Arg Arg His Val 270 275 280 285 gtg tac gag gac
gcg cag gag aac ttc gtg ctc aag atc ctc ttc tgc 974 Val Tyr Glu Asp
Ala Gln Glu Asn Phe Val Leu Lys Ile Leu Phe Cys 290 295 300 aag cag
tcg gac cgc ggc ctc tac acc tgc acg gcg tcc aac ctc gtg 1022 Lys
Gln Ser Asp Arg Gly Leu Tyr Thr Cys Thr Ala Ser Asn Leu Val 305 310
315 ggc cag acc tac agc tct gtg ctg gtc gta gtg cgc gag ccc gcg gtt
1070 Gly Gln Thr Tyr Ser Ser Val Leu Val Val Val Arg Glu Pro Ala
Val 320 325 330 ccc ttc aaa aag cgg ctg caa gat ctg gag gtg cgg gag
aag gag tcg 1118 Pro Phe Lys Lys Arg Leu Gln Asp Leu Glu Val Arg
Glu Lys Glu Ser 335 340 345 gct acg ttc cta tgt gag gtg ccc cag ccg
tcc act gag gcc gcg tgg 1166 Ala Thr Phe Leu Cys Glu Val Pro Gln
Pro Ser Thr Glu Ala Ala Trp 350 355 360 365 ttc aag gag gag acg cgg
ttg tgg gcg agc gcc aag tac ggc atc gag 1214 Phe Lys Glu Glu Thr
Arg Leu Trp Ala Ser Ala Lys Tyr Gly Ile Glu 370 375 380 gag gag ggc
acc gag cgc cgc ctg acc gtg cgc aat gtc tcg gcc gac 1262 Glu Glu
Gly Thr Glu Arg Arg Leu Thr Val Arg Asn Val Ser Ala Asp 385 390 395
gac gac gcg gtg tac atc tgc gag acg cca gag ggc agc cgc acg gtg
1310 Asp Asp Ala Val Tyr Ile Cys Glu Thr Pro Glu Gly Ser Arg Thr
Val 400 405 410 gcg gag ctc gca gtc caa gga aac ctc ctc cga aag ctc
cct cgg aag 1358 Ala Glu Leu Ala Val Gln Gly Asn Leu Leu Arg Lys
Leu Pro Arg Lys 415 420 425 acg gcg gtg cgc gtg ggc gac acg gct atg
ttt tgc gtg gag ctg gcg 1406 Thr Ala Val Arg Val Gly Asp Thr Ala
Met Phe Cys Val Glu Leu Ala 430 435 440 445 gtc ccg gtg ggc ccc gtc
cac tgg ctg cgg aac cag gag gaa gtg gtg 1454 Val Pro Val Gly Pro
Val His Trp Leu Arg Asn Gln Glu Glu Val Val 450 455 460 gcg ggg ggc
cgc gtg gcc atc tcc gcg gag ggc acg cgc cac aca ctg 1502 Ala Gly
Gly Arg Val Ala Ile Ser Ala Glu Gly Thr Arg His Thr Leu 465 470 475
acc atc tcc cag tgc tgc ctg gag gat gtg ggc cag gtg gcc ttt atg
1550 Thr Ile Ser Gln Cys Cys Leu Glu Asp Val Gly Gln Val Ala Phe
Met 480 485 490 gct ggc gac tgc cag acg tcc acc cgg ttc tgc gtg tcg
gcc ccc agg 1598 Ala Gly Asp Cys Gln Thr Ser Thr Arg Phe Cys Val
Ser Ala Pro Arg 495 500 505 aag cct ccc ctg caa ccc cct gtg gat cct
gtg gta aag gcc agg atg 1646 Lys Pro Pro Leu Gln Pro Pro Val Asp
Pro Val Val Lys Ala Arg Met 510 515 520 525 gag agt tcc gtg att ctc
agc tgg tcc cca cca ccc cat ggg gaa cgc 1694 Glu Ser Ser Val Ile
Leu Ser Trp Ser Pro Pro Pro His Gly Glu Arg 530 535 540 cct gtc act
atc gac ggc tac ctg gta gag aag aag aag ctt ggc acc 1742 Pro Val
Thr Ile Asp Gly Tyr Leu Val Glu Lys Lys Lys Leu Gly Thr 545 550 555
tac acc tgg atc agg tgc cac gag gct gaa tgg gtg gct aca cct gag
1790 Tyr Thr Trp Ile Arg Cys His Glu Ala Glu Trp Val Ala Thr Pro
Glu 560 565 570 ctg acc gtg gct gat gtg gcg gag gag ggg aac ttc cag
ttc cga gtg 1838 Leu Thr Val Ala Asp Val Ala Glu Glu Gly Asn Phe
Gln Phe Arg Val 575 580 585 tcc gct ctc aac agc ttt ggt cag agt ccc
tac ctc gag ttc ccg ggg 1886 Ser Ala Leu Asn Ser Phe Gly Gln Ser
Pro Tyr Leu Glu Phe Pro Gly 590 595 600 605 act gtc cac ctg gcc ccc
aag ctg gcc gtg agg aca ccg ctg aag gcg 1934 Thr Val His Leu Ala
Pro Lys Leu Ala Val Arg Thr Pro Leu Lys Ala 610 615 620 gtg cag gcg
gta gag ggt ggc gag gtc act ttc tcc gtg gac ctc acg 1982 Val Gln
Ala Val Glu Gly Gly Glu Val Thr Phe Ser Val Asp Leu Thr 625 630 635
gtg gcc tca gcg ggt gag tgg ttc ctg gat ggg cag gcc ctg aag gcc
2030 Val Ala Ser Ala Gly Glu Trp Phe Leu Asp Gly Gln Ala Leu Lys
Ala 640 645 650 agc agt gtg tat gag atc cac tgt gat cgc acc cgg cac
acg ctc acc 2078 Ser Ser Val Tyr Glu Ile His Cys Asp Arg Thr Arg
His Thr Leu Thr 655 660 665 atc cgg gag gtg ccc gcc agc ctg cac ggg
gcg cag ctg aag ttc gtg 2126 Ile Arg Glu Val Pro Ala Ser Leu His
Gly Ala Gln Leu Lys Phe Val 670 675 680 685 gcc aac ggc att gag agc
agc atc cgg atg gag gtc cgg gcg gcc cca 2174 Ala Asn Gly Ile Glu
Ser Ser Ile Arg Met Glu Val Arg Ala Ala Pro 690 695 700 ggg ctg act
gcc aac aag ccg cca gcc gca gct gcc cgg gag gtg ctg 2222 Gly Leu
Thr Ala Asn Lys Pro Pro Ala Ala Ala Ala Arg Glu Val Leu 705 710 715
gct cgg ctg cac gag gag gcg cag ctg ctg gct gag ctg tca gat cag
2270 Ala Arg Leu His Glu Glu Ala Gln Leu Leu Ala Glu Leu Ser Asp
Gln 720 725 730 gct gcg gct gtg acg tgg ctg aag gat ggt cgc aca ctg
tcc cca ggc 2318 Ala Ala Ala Val Thr Trp Leu Lys Asp Gly Arg Thr
Leu Ser Pro Gly 735 740 745 ccc aag tat gag gtg cag gca tcg gcc ggg
cgg cgg gtg ctc ctt gtg 2366 Pro Lys Tyr Glu Val Gln Ala Ser Ala
Gly Arg Arg Val Leu Leu Val 750 755 760 765 cga gat gtg gcc cgg gac
gat gca ggc ctc tac gag tgc gtc agc cgc 2414 Arg Asp Val Ala Arg
Asp Asp Ala Gly Leu Tyr Glu Cys Val Ser Arg 770 775 780 ggg ggc cgc
atc gcc tac cag ctc tcc gtg caa ggc ctc gcg cgc ttt 2462 Gly Gly
Arg Ile Ala Tyr Gln Leu Ser Val Gln Gly Leu Ala Arg Phe 785 790 795
ctg cac aag gac atg gcg ggc agc tgt gtg gat gcc gtg gct ggg ggc
2510 Leu His Lys Asp Met Ala Gly Ser Cys Val Asp Ala Val Ala Gly
Gly 800 805 810 ccg gcg cag ttt gag tgt gag acc tcc gaa gcc cac gtc
cac gtg cac 2558 Pro Ala Gln Phe Glu Cys Glu Thr Ser Glu Ala His
Val His Val His 815 820 825 tgg tac aag gat ggc atg gag ctg ggc cac
tcc ggt gag cgc ttc ttg 2606 Trp Tyr Lys Asp Gly Met Glu Leu Gly
His Ser Gly Glu Arg Phe Leu 830 835 840 845 cag gag gat gtg ggg acg
cgg cac cgg ctg gtg gca gcc aca gtc acc 2654 Gln Glu Asp Val Gly
Thr Arg His Arg Leu Val Ala Ala Thr Val Thr 850 855 860 agg cag gat
gaa ggc acc tac tcc tgc cgc gtg ggc gag gac tct gtg 2702 Arg Gln
Asp Glu Gly Thr Tyr Ser Cys Arg Val Gly Glu Asp Ser Val 865 870 875
gac ttc cgg ctc cgc gtc tct gag ccc aag gtg gtg ttt gct aag gag
2750 Asp Phe Arg Leu Arg Val Ser Glu Pro Lys Val Val Phe Ala Lys
Glu 880 885 890 cag ctg gca cgc agg aag ctg cag gca gag gca gga gcc
agt gcc aca 2798 Gln Leu Ala Arg Arg Lys Leu Gln Ala Glu Ala Gly
Ala Ser Ala Thr 895 900 905 ctg agc tgc gag gtg gcc cag gcc cag acg
gag gtg acg tgg tac aag 2846 Leu Ser Cys Glu Val Ala Gln Ala Gln
Thr Glu Val Thr Trp Tyr Lys 910 915 920 925 gat ggg aag aag ctg agc
tcc agc tcg aaa
gtg tgc atg gag gcc aca 2894 Asp Gly Lys Lys Leu Ser Ser Ser Ser
Lys Val Cys Met Glu Ala Thr 930 935 940 ggc tgc acg cgc agg ctg gtt
gtg cag cag gca ggc cag gcg gat gcc 2942 Gly Cys Thr Arg Arg Leu
Val Val Gln Gln Ala Gly Gln Ala Asp Ala 945 950 955 ggg gag tat agc
tgc gag gct ggg ggc cag cgg ctc tcc ttc cat ctg 2990 Gly Glu Tyr
Ser Cys Glu Ala Gly Gly Gln Arg Leu Ser Phe His Leu 960 965 970 gat
gtc aaa gag ccc aag gtg gtg ttt gcc aag gac cag gtg gca cac 3038
Asp Val Lys Glu Pro Lys Val Val Phe Ala Lys Asp Gln Val Ala His 975
980 985 agt gag gtg cag gct gag gca ggg gcc aat gcc acg ctg agc tgc
gag 3086 Ser Glu Val Gln Ala Glu Ala Gly Ala Asn Ala Thr Leu Ser
Cys Glu 990 995 1000 1005 gtg gcc cag gcc cag gcg gag gtg atg tgg
tac aaa gat ggg aag aag 3134 Val Ala Gln Ala Gln Ala Glu Val Met
Trp Tyr Lys Asp Gly Lys Lys 1010 1015 1020 ctg agc tcc agc ttg aaa
gtg cat gta gag gcc aaa ggc tgc aga cgg 3182 Leu Ser Ser Ser Leu
Lys Val His Val Glu Ala Lys Gly Cys Arg Arg 1025 1030 1035 agg ctg
gtg gtg cag cag gca ggc aag acg gat gcc ggg gac tac agc 3230 Arg
Leu Val Val Gln Gln Ala Gly Lys Thr Asp Ala Gly Asp Tyr Ser 1040
1045 1050 tgc gag gcc agg ggc cag agg gtc tcc ttc cgc ctg cac atc
aca gag 3278 Cys Glu Ala Arg Gly Gln Arg Val Ser Phe Arg Leu His
Ile Thr Glu 1055 1060 1065 ccc aag atg atg ttt gca aag gag cag tca
gtg cat aat gag gtg cag 3326 Pro Lys Met Met Phe Ala Lys Glu Gln
Ser Val His Asn Glu Val Gln 1070 1075 1080 1085 gct gag gcg ggg gcc
agt gcc atg ctg agc tgt gag gtg gcc cag gcc 3374 Ala Glu Ala Gly
Ala Ser Ala Met Leu Ser Cys Glu Val Ala Gln Ala 1090 1095 1100 cag
acg gag gtg acg tgg tac aag gat ggg aag aag ctg agc tcc agc 3422
Gln Thr Glu Val Thr Trp Tyr Lys Asp Gly Lys Lys Leu Ser Ser Ser
1105 1110 1115 tca aaa gtg ggc atg gag gtc aaa ggg tgc aca cgg agg
ctg gtg ctg 3470 Ser Lys Val Gly Met Glu Val Lys Gly Cys Thr Arg
Arg Leu Val Leu 1120 1125 1130 cca cag gcg ggc aaa gca gat gct ggg
gag tac agc tgt gag gct ggg 3518 Pro Gln Ala Gly Lys Ala Asp Ala
Gly Glu Tyr Ser Cys Glu Ala Gly 1135 1140 1145 ggc cag aga gtc tcc
ttc cac ctg cac atc aca gag ccc aag ggg gtg 3566 Gly Gln Arg Val
Ser Phe His Leu His Ile Thr Glu Pro Lys Gly Val 1150 1155 1160 1165
ttt gcg aag gag cag tca gtg cat aat gag gtg cag gct gag gcg ggg
3614 Phe Ala Lys Glu Gln Ser Val His Asn Glu Val Gln Ala Glu Ala
Gly 1170 1175 1180 acc act gcc atg ctg agc tgt gag gtg gcc cag ccc
cag acg gag gtg 3662 Thr Thr Ala Met Leu Ser Cys Glu Val Ala Gln
Pro Gln Thr Glu Val 1185 1190 1195 acg tgg tac aag gac ggg aag aag
ctg agc tcc agc tca aaa gta cgc 3710 Thr Trp Tyr Lys Asp Gly Lys
Lys Leu Ser Ser Ser Ser Lys Val Arg 1200 1205 1210 atg gag gtc aag
ggc tgc aca cga agg ctg gta gtg cag cag gtg ggc 3758 Met Glu Val
Lys Gly Cys Thr Arg Arg Leu Val Val Gln Gln Val Gly 1215 1220 1225
aaa gca gat gct ggg gag tac agc tgc gag gct ggg ggc cag aga gtc
3806 Lys Ala Asp Ala Gly Glu Tyr Ser Cys Glu Ala Gly Gly Gln Arg
Val 1230 1235 1240 1245 tcc ttt caa ctg cac atc aca gag ccc aag gca
gtg ttt gcc aag gag 3854 Ser Phe Gln Leu His Ile Thr Glu Pro Lys
Ala Val Phe Ala Lys Glu 1250 1255 1260 cag ttg gtg cat aat gag gtg
cgg act gag gca ggg gcc agt gcc aca 3902 Gln Leu Val His Asn Glu
Val Arg Thr Glu Ala Gly Ala Ser Ala Thr 1265 1270 1275 ctg agc tgt
gag gtg gcc cag gcc cag aca gag gtg acg tgg tac aag 3950 Leu Ser
Cys Glu Val Ala Gln Ala Gln Thr Glu Val Thr Trp Tyr Lys 1280 1285
1290 gat ggg aag aag ctg agc tcc agt tcg aaa gtg cgc ata gag gct
gcg 3998 Asp Gly Lys Lys Leu Ser Ser Ser Ser Lys Val Arg Ile Glu
Ala Ala 1295 1300 1305 ggc tgc atg cgg cag ctg gtg gtg cag cag gca
ggc cag gca gat gct 4046 Gly Cys Met Arg Gln Leu Val Val Gln Gln
Ala Gly Gln Ala Asp Ala 1310 1315 1320 1325 ggg gag tac acc tgt gag
gct ggg ggc cag cgg ctc tcc ttc cac ctg 4094 Gly Glu Tyr Thr Cys
Glu Ala Gly Gly Gln Arg Leu Ser Phe His Leu 1330 1335 1340 gat gtt
tca gag ccc aag gcg gtg ttt gca aag gag cag ctg gca cac 4142 Asp
Val Ser Glu Pro Lys Ala Val Phe Ala Lys Glu Gln Leu Ala His 1345
1350 1355 agg aag gtg cag gcc gag gcg ggg gcc att gcc acg ctg agc
tgc gag 4190 Arg Lys Val Gln Ala Glu Ala Gly Ala Ile Ala Thr Leu
Ser Cys Glu 1360 1365 1370 gtg gcc cag gcc cag aca gag gtg acg tgg
tac aag gac ggg aag aag 4238 Val Ala Gln Ala Gln Thr Glu Val Thr
Trp Tyr Lys Asp Gly Lys Lys 1375 1380 1385 ctg agc tcc agc tcg aaa
gtt cga atg gag gct gtg ggc tgc aca cgg 4286 Leu Ser Ser Ser Ser
Lys Val Arg Met Glu Ala Val Gly Cys Thr Arg 1390 1395 1400 1405 agg
ctg gtg gtg cag cag gca tgc cag gcg gac acc ggg gag tat agc 4334
Arg Leu Val Val Gln Gln Ala Cys Gln Ala Asp Thr Gly Glu Tyr Ser
1410 1415 1420 tgc gag gcc ggg ggc cag cgg ctc tcc ttc agc ctg gac
gtg gca gag 4382 Cys Glu Ala Gly Gly Gln Arg Leu Ser Phe Ser Leu
Asp Val Ala Glu 1425 1430 1435 ccc aag gtg gtg ttt gcc aag gag cag
cca gtg cac agg gag gtg cag 4430 Pro Lys Val Val Phe Ala Lys Glu
Gln Pro Val His Arg Glu Val Gln 1440 1445 1450 gcc cag gcg ggg gcc
agc acc aca ctc agc tgc gag gtg gct cag gcc 4478 Ala Gln Ala Gly
Ala Ser Thr Thr Leu Ser Cys Glu Val Ala Gln Ala 1455 1460 1465 cag
acg gag gtg atg tgg tac aag gac ggg aag aag ctg agc ttc agc 4526
Gln Thr Glu Val Met Trp Tyr Lys Asp Gly Lys Lys Leu Ser Phe Ser
1470 1475 1480 1485 tcg aaa gtg cgc atg gag gct gtg ggc tgc aca cgg
agg ctg gtg gtg 4574 Ser Lys Val Arg Met Glu Ala Val Gly Cys Thr
Arg Arg Leu Val Val 1490 1495 1500 cag cag gcg ggc cag gcg gac gcc
ggg gag tac agc tgc gag gcg ggg 4622 Gln Gln Ala Gly Gln Ala Asp
Ala Gly Glu Tyr Ser Cys Glu Ala Gly 1505 1510 1515 agc cag cgg ctc
tcc ttc cac ctg cac gtg gca gag ccc aag gcg gtg 4670 Ser Gln Arg
Leu Ser Phe His Leu His Val Ala Glu Pro Lys Ala Val 1520 1525 1530
ttt gcc aag gag cag cca gcg agc agg gag gtg cag gct gag gcg ggg
4718 Phe Ala Lys Glu Gln Pro Ala Ser Arg Glu Val Gln Ala Glu Ala
Gly 1535 1540 1545 acc agt gcc acg ctg agc tgc gag gtg gcc cag gcc
cag aca gag gtg 4766 Thr Ser Ala Thr Leu Ser Cys Glu Val Ala Gln
Ala Gln Thr Glu Val 1550 1555 1560 1565 acg tgg tac aag gac ggg aag
aaa ctg agc tcc agc tcg aaa gtg cga 4814 Thr Trp Tyr Lys Asp Gly
Lys Lys Leu Ser Ser Ser Ser Lys Val Arg 1570 1575 1580 atg gag gcc
gtg ggc tgc aca cgg agg ctg gtg gtg cag gag gca ggc 4862 Met Glu
Ala Val Gly Cys Thr Arg Arg Leu Val Val Gln Glu Ala Gly 1585 1590
1595 cag gcg gac gcc ggg gag tac agc tgc aag gcc ggg gat cag cgg
ctg 4910 Gln Ala Asp Ala Gly Glu Tyr Ser Cys Lys Ala Gly Asp Gln
Arg Leu 1600 1605 1610 tcc ttc cac ctg cac gtg gca gag ccc aag gtg
gtg ttt gcc aag gag 4958 Ser Phe His Leu His Val Ala Glu Pro Lys
Val Val Phe Ala Lys Glu 1615 1620 1625 cag cca gca cac agg gag gtg
cag gct gag gcg ggg gcc agt gcc acg 5006 Gln Pro Ala His Arg Glu
Val Gln Ala Glu Ala Gly Ala Ser Ala Thr 1630 1635 1640 1645 ctg agc
tgc gag gtg gcc cag gcc cag aca gag gtg acg tgg tac aag 5054 Leu
Ser Cys Glu Val Ala Gln Ala Gln Thr Glu Val Thr Trp Tyr Lys 1650
1655 1660 gat ggg aag aag ctg agt tcc agc tcg aaa gtg cgc gtg gag
gcc gtg 5102 Asp Gly Lys Lys Leu Ser Ser Ser Ser Lys Val Arg Val
Glu Ala Val 1665 1670 1675 ggc tgc aca cgg agg ctg gtg gtg cag cag
gcg ggc cag gcg gat gct 5150 Gly Cys Thr Arg Arg Leu Val Val Gln
Gln Ala Gly Gln Ala Asp Ala 1680 1685 1690 ggg gag tac agc tgt gag
gcg ggg ggc caa cgg ctg tcc ttc cgc ctg 5198 Gly Glu Tyr Ser Cys
Glu Ala Gly Gly Gln Arg Leu Ser Phe Arg Leu 1695 1700 1705 cac gtg
gca gag ctg gag ccc caa att tca gag aga ccc tgc cgc agg 5246 His
Val Ala Glu Leu Glu Pro Gln Ile Ser Glu Arg Pro Cys Arg Arg 1710
1715 1720 1725 gag cct ctg gtg gtc aag gag cat gaa gac atc atc ctg
acc gcc aca 5294 Glu Pro Leu Val Val Lys Glu His Glu Asp Ile Ile
Leu Thr Ala Thr 1730 1735 1740 ctg gcc aca ccc tct gcg gcc acg gtg
acc tgg ctc aag gat ggt gtg 5342 Leu Ala Thr Pro Ser Ala Ala Thr
Val Thr Trp Leu Lys Asp Gly Val 1745 1750 1755 gag att cgc cgc agc
aag cgg cat gag aca gcc agc cag ggg gac acc 5390 Glu Ile Arg Arg
Ser Lys Arg His Glu Thr Ala Ser Gln Gly Asp Thr 1760 1765 1770 cac
acc ctg acc gtg cat ggc gcc cag gtt ctg gac agc gcc atc tac 5438
His Thr Leu Thr Val His Gly Ala Gln Val Leu Asp Ser Ala Ile Tyr
1775 1780 1785 agc tgc cgt gtg ggc gca gag ggg cag gac ttc cca gtg
cag gtg gaa 5486 Ser Cys Arg Val Gly Ala Glu Gly Gln Asp Phe Pro
Val Gln Val Glu 1790 1795 1800 1805 gag gtg gcc gcc aag ttc tgc cgg
ctg ctg gag cct gtg tgc ggc gag 5534 Glu Val Ala Ala Lys Phe Cys
Arg Leu Leu Glu Pro Val Cys Gly Glu 1810 1815 1820 ctg ggt ggc acg
gtg aca ctg gcc tgc gag cta agc cca gcg tgt gca 5582 Leu Gly Gly
Thr Val Thr Leu Ala Cys Glu Leu Ser Pro Ala Cys Ala 1825 1830 1835
gag gtg gtg tgg cgc tgc ggc aac acg cag cct cgg gtg ggc aag cgc
5630 Glu Val Val Trp Arg Cys Gly Asn Thr Gln Pro Arg Val Gly Lys
Arg 1840 1845 1850 ttc cag atg gtg gcc gag ggg ccc gtg cgc tca ctc
act gtg ttg ggg 5678 Phe Gln Met Val Ala Glu Gly Pro Val Arg Ser
Leu Thr Val Leu Gly 1855 1860 1865 ctg cgc gca gag gac gca ggg gag
tac gtg tgt gag agc cgt gat gac 5726 Leu Arg Ala Glu Asp Ala Gly
Glu Tyr Val Cys Glu Ser Arg Asp Asp 1870 1875 1880 1885 cac acc agt
gcg cag ctc acc gtc agt gtg ccc cga gtg gtg aag ttt 5774 His Thr
Ser Ala Gln Leu Thr Val Ser Val Pro Arg Val Val Lys Phe 1890 1895
1900 atg tct ggg ctg agc acc gtg gtc gca gag gag ggc ggc gag gcc
acc 5822 Met Ser Gly Leu Ser Thr Val Val Ala Glu Glu Gly Gly Glu
Ala Thr 1905 1910 1915 ttc cag tgc gtg gtg tcc ccc agt gat gtg gca
gtc gtg tgg ttc cgg 5870 Phe Gln Cys Val Val Ser Pro Ser Asp Val
Ala Val Val Trp Phe Arg 1920 1925 1930 gac ggt gcc ctg ctt cag ccc
agc gag aag ttt gcc ata tca cag agt 5918 Asp Gly Ala Leu Leu Gln
Pro Ser Glu Lys Phe Ala Ile Ser Gln Ser 1935 1940 1945 ggc gcc agc
cac agc ctg acc atc tca gac ctg gtg ctg gag gac gcg 5966 Gly Ala
Ser His Ser Leu Thr Ile Ser Asp Leu Val Leu Glu Asp Ala 1950 1955
1960 1965 ggc cag atc acc gtg gag gct gag ggc gcc tca tcc tct gct
gcc ctg 6014 Gly Gln Ile Thr Val Glu Ala Glu Gly Ala Ser Ser Ser
Ala Ala Leu 1970 1975 1980 agg gtc cga gag gcg cct gtg ctg ttc aaa
aag aag ctg gag ccg cag 6062 Arg Val Arg Glu Ala Pro Val Leu Phe
Lys Lys Lys Leu Glu Pro Gln 1985 1990 1995 acg gtg gag gag cgg agc
tcg gtg acc ctg gag gtg gag ctg acg cgg 6110 Thr Val Glu Glu Arg
Ser Ser Val Thr Leu Glu Val Glu Leu Thr Arg 2000 2005 2010 ccg tgg
ccg gag ctg agg tgg aca cgg aac gcg acg gcc ctg gcg ccg 6158 Pro
Trp Pro Glu Leu Arg Trp Thr Arg Asn Ala Thr Ala Leu Ala Pro 2015
2020 2025 gga aag aac gtg gag atc cac gcc gag ggc gcc cgc cac cgc
ctg gtt 6206 Gly Lys Asn Val Glu Ile His Ala Glu Gly Ala Arg His
Arg Leu Val 2030 2035 2040 2045 ctg cac aac gta ggt ttt gcc gac cgt
ggc ttc ttt ggc tgc gag acg 6254 Leu His Asn Val Gly Phe Ala Asp
Arg Gly Phe Phe Gly Cys Glu Thr 2050 2055 2060 ccg gat gac aag aca
cag gcc aaa ctc acc gtg gag atg cgc cag gta 6302 Pro Asp Asp Lys
Thr Gln Ala Lys Leu Thr Val Glu Met Arg Gln Val 2065 2070 2075 cgg
ctc gta cgg ggc ctg cag gca gtg gag gca cgg gag cag ggc acg 6350
Arg Leu Val Arg Gly Leu Gln Ala Val Glu Ala Arg Glu Gln Gly Thr
2080 2085 2090 gct acc atg gag gtg cag ctg tcg cat gcg gac gtg gat
ggc agc tgg 6398 Ala Thr Met Glu Val Gln Leu Ser His Ala Asp Val
Asp Gly Ser Trp 2095 2100 2105 act cgt gac ggt ctg cgg ttc cag cag
ggg ccc acg tgc cac ctg gct 6446 Thr Arg Asp Gly Leu Arg Phe Gln
Gln Gly Pro Thr Cys His Leu Ala 2110 2115 2120 2125 gtg cgg ggc ccc
atg cac acc ctc aca ctc tcg ggg ctg cgg cca gag 6494 Val Arg Gly
Pro Met His Thr Leu Thr Leu Ser Gly Leu Arg Pro Glu 2130 2135 2140
gat agt ggc ctt atg gtc ttc aag gcc gaa gga gtg cac acg tcg gcg
6542 Asp Ser Gly Leu Met Val Phe Lys Ala Glu Gly Val His Thr Ser
Ala 2145 2150 2155 cgg ctc gtg gtc acc gag ctt ccc gtg agc ttc agc
cgc ccg ctg cag 6590 Arg Leu Val Val Thr Glu Leu Pro Val Ser Phe
Ser Arg Pro Leu Gln 2160 2165 2170 gac gtg gtg acc act gag aag gag
aag gtt acc ctg gag tgc gag ctg 6638 Asp Val Val Thr Thr Glu Lys
Glu Lys Val Thr Leu Glu Cys Glu Leu 2175 2180 2185 tcg cgt cct aat
gtg gat gtg cgc tgg ctg aag gac ggt gtg gag ctg 6686 Ser Arg Pro
Asn Val Asp Val Arg Trp Leu Lys Asp Gly Val Glu Leu 2190 2195 2200
2205 cgg gca ggc aag acg atg gcc atc gca gcc cag ggc gcc tgc agg
agc 6734 Arg Ala Gly Lys Thr Met Ala Ile Ala Ala Gln Gly Ala Cys
Arg Ser 2210 2215 2220 ctc acc att tac cgg tgc gag ttc gcg gat cag
gga gtg tat gtg tgt 6782 Leu Thr Ile Tyr Arg Cys Glu Phe Ala Asp
Gln Gly Val Tyr Val Cys 2225 2230 2235 gat gcc cat gat gcc cag agc
tct gcc tcc gtg aag gta caa gga agg 6830 Asp Ala His Asp Ala Gln
Ser Ser Ala Ser Val Lys Val Gln Gly Arg 2240 2245 2250 aca tac act
ctc atc tac cgg aga gtc ctg gcg gaa gat gca gga gag 6878 Thr Tyr
Thr Leu Ile Tyr Arg Arg Val Leu Ala Glu Asp Ala Gly Glu 2255 2260
2265 atc caa ttt gta gcc gaa aat gca gaa tcg cga gcc cag ctc cga
gtg 6926 Ile Gln Phe Val Ala Glu Asn Ala Glu Ser Arg Ala Gln Leu
Arg Val 2270 2275 2280 2285 aag gag ctg cca gtg acc ctc gtg cgc ccg
ctg cgg gac aag att gcc 6974 Lys Glu Leu Pro Val Thr Leu Val Arg
Pro Leu Arg Asp Lys Ile Ala 2290 2295 2300 atg gag aag cac cgc ggt
gtg ctg gag tgt cag gtg tcc cgg gcc agc 7022 Met Glu Lys His Arg
Gly Val Leu Glu Cys Gln Val Ser Arg Ala Ser 2305 2310 2315 gcc cag
gtg cgg tgg ttc aag ggc agt cag gag ctg cag ccc ggg ccc 7070 Ala
Gln Val Arg Trp Phe Lys Gly Ser Gln Glu Leu Gln Pro Gly Pro 2320
2325 2330 aag tac gag ctg gtc agt gat ggc ctc tac cgc aag ctg atc
atc agt 7118 Lys Tyr Glu Leu Val Ser Asp Gly Leu Tyr Arg Lys Leu
Ile Ile Ser 2335 2340 2345 gat gtc cac gca gag gac gag gac acc tac
acc tgt gac gcc ggt gat 7166 Asp Val His Ala Glu Asp Glu Asp Thr
Tyr Thr Cys Asp Ala Gly Asp 2350 2355 2360 2365 gtc aag acc agt gca
cag ttc ttc gtg gaa gag caa tcc atc acc att 7214 Val Lys Thr Ser
Ala Gln Phe Phe Val Glu Glu Gln Ser Ile Thr Ile 2370 2375 2380 gtg
cgg ggt ctg cag gac gtg aca gtg atg gag ccc gct cct gcc tgg 7262
Val Arg Gly Leu Gln Asp Val Thr Val Met Glu Pro Ala Pro Ala Trp
2385 2390 2395 ttt gag tgt gag acc tcc atc ccc tca gtg cgg cca cct
aag tgg ctc 7310 Phe Glu Cys Glu Thr Ser Ile Pro Ser Val Arg Pro
Pro Lys Trp Leu 2400 2405 2410 ctg ggg aag acg gtg ttg cag gct ggg
ggg aac gtg ggc ctg gag cag 7358 Leu Gly Lys Thr Val Leu Gln Ala
Gly Gly Asn Val Gly Leu Glu Gln 2415 2420 2425 gag ggc acg gtg cac
cgg ctg atg ctg cgg cgg acc tgc tcc acc atg 7406 Glu Gly
Thr Val His Arg Leu Met Leu Arg Arg Thr Cys Ser Thr Met 2430 2435
2440 2445 acc ggg ccc gtg cac ttc acc gtt ggc aag tcg cgc tcc tct
gcc cgc 7454 Thr Gly Pro Val His Phe Thr Val Gly Lys Ser Arg Ser
Ser Ala Arg 2450 2455 2460 ctg gtg gtc tca gac atc ccc gta gtc ctc
aca cgg ccg ttg gag ccc 7502 Leu Val Val Ser Asp Ile Pro Val Val
Leu Thr Arg Pro Leu Glu Pro 2465 2470 2475 aag aca ggg cgt gag ctg
cag tca gtg gtc ctg tcc tgc gac ttc cgg 7550 Lys Thr Gly Arg Glu
Leu Gln Ser Val Val Leu Ser Cys Asp Phe Arg 2480 2485 2490 cca gcc
ccc aag gct gtg cag tgg tac aag gat gac acg ccc ctg tct 7598 Pro
Ala Pro Lys Ala Val Gln Trp Tyr Lys Asp Asp Thr Pro Leu Ser 2495
2500 2505 ccc tct gag aag ttt aag atg agc ctg gag ggt cag atg gct
gag ctg 7646 Pro Ser Glu Lys Phe Lys Met Ser Leu Glu Gly Gln Met
Ala Glu Leu 2510 2515 2520 2525 cgc atc ctc cgg ctc atg cct gct gat
gct ggt gtc tac cgg tgc cag 7694 Arg Ile Leu Arg Leu Met Pro Ala
Asp Ala Gly Val Tyr Arg Cys Gln 2530 2535 2540 gcg ggc agt gcc cac
agc agc act gag gtc act gtg gaa gcg cgg gag 7742 Ala Gly Ser Ala
His Ser Ser Thr Glu Val Thr Val Glu Ala Arg Glu 2545 2550 2555 gtg
aca gtg aca ggg ccg cta cag gat gca gag gcc acg gag gag ggc 7790
Val Thr Val Thr Gly Pro Leu Gln Asp Ala Glu Ala Thr Glu Glu Gly
2560 2565 2570 tgg gcc agc ttc tcc tgt gag ctg tcc cac gag gat gag
gag gtc gag 7838 Trp Ala Ser Phe Ser Cys Glu Leu Ser His Glu Asp
Glu Glu Val Glu 2575 2580 2585 tgg tcg ctc aac ggg atg ccc ctg tac
aac gac agc ttc cat gag atc 7886 Trp Ser Leu Asn Gly Met Pro Leu
Tyr Asn Asp Ser Phe His Glu Ile 2590 2595 2600 2605 tca cac aag ggc
cgg cgc cac acg ctg gta ctg aag agc atc cag cgg 7934 Ser His Lys
Gly Arg Arg His Thr Leu Val Leu Lys Ser Ile Gln Arg 2610 2615 2620
gct gat gcg ggc ata gta cgc gcc tcc tcc ctg aag gtg tcg acc tct
7982 Ala Asp Ala Gly Ile Val Arg Ala Ser Ser Leu Lys Val Ser Thr
Ser 2625 2630 2635 gcc cgc ctg gag gtc cga gtg aag ccg gtg gtg ttc
ctg aag gcg ctg 8030 Ala Arg Leu Glu Val Arg Val Lys Pro Val Val
Phe Leu Lys Ala Leu 2640 2645 2650 gat gac ctg tcc gca gag gag cgc
ggc acc ctg gcc ctg cag tgt gaa 8078 Asp Asp Leu Ser Ala Glu Glu
Arg Gly Thr Leu Ala Leu Gln Cys Glu 2655 2660 2665 gtc tct gac ccc
gag gcc cat gtg gtg tgg cgc aaa gat ggc gtg cag 8126 Val Ser Asp
Pro Glu Ala His Val Val Trp Arg Lys Asp Gly Val Gln 2670 2675 2680
2685 ctg ggc ccc agt gac aag tat gac ttc ctg cac acg gcg ggc acg
cgg 8174 Leu Gly Pro Ser Asp Lys Tyr Asp Phe Leu His Thr Ala Gly
Thr Arg 2690 2695 2700 ggg ctc gtg gtg cat gac gtg agc cct gaa gac
gcc ggc ctg tac acc 8222 Gly Leu Val Val His Asp Val Ser Pro Glu
Asp Ala Gly Leu Tyr Thr 2705 2710 2715 tgc cac gtg ggc tcc gag gag
acc cgg gcc cgg gtc cgc gtg cac gat 8270 Cys His Val Gly Ser Glu
Glu Thr Arg Ala Arg Val Arg Val His Asp 2720 2725 2730 ctg cac gtg
ggc atc acc aag agg ctg aag aca atg gag gtg ctg gaa 8318 Leu His
Val Gly Ile Thr Lys Arg Leu Lys Thr Met Glu Val Leu Glu 2735 2740
2745 ggg gaa agc tgc agc ttt gag tgc gtc ctg tcc cac gag agt gcc
agc 8366 Gly Glu Ser Cys Ser Phe Glu Cys Val Leu Ser His Glu Ser
Ala Ser 2750 2755 2760 2765 gac ccg gcc atg tgg aca gtc ggt ggg aag
aca gtg ggc agc tcc agc 8414 Asp Pro Ala Met Trp Thr Val Gly Gly
Lys Thr Val Gly Ser Ser Ser 2770 2775 2780 cgc ttc cag gcc aca cgt
cag ggc cga aaa tac atc ctg gtg gtc cgg 8462 Arg Phe Gln Ala Thr
Arg Gln Gly Arg Lys Tyr Ile Leu Val Val Arg 2785 2790 2795 gag gct
gca cca agt gat gcc ggg gag gtg gtc ttc tct gtg cgg ggc 8510 Glu
Ala Ala Pro Ser Asp Ala Gly Glu Val Val Phe Ser Val Arg Gly 2800
2805 2810 ctc acc tcc aag gcc tca ctc att gtc aga gag agg ccg gcc
gcc atc 8558 Leu Thr Ser Lys Ala Ser Leu Ile Val Arg Glu Arg Pro
Ala Ala Ile 2815 2820 2825 atc aag ccc ctg gaa gac cag tgg gtg gcg
cca ggg gag gac gtg gag 8606 Ile Lys Pro Leu Glu Asp Gln Trp Val
Ala Pro Gly Glu Asp Val Glu 2830 2835 2840 2845 ctg cgc tgt gag ctg
tca cgg gcg gga acg ccc gtg cac tgg ctg aag 8654 Leu Arg Cys Glu
Leu Ser Arg Ala Gly Thr Pro Val His Trp Leu Lys 2850 2855 2860 gac
agg aag gcc atc cgc aag agc cag aag tat gat gtg gtc tgc gag 8702
Asp Arg Lys Ala Ile Arg Lys Ser Gln Lys Tyr Asp Val Val Cys Glu
2865 2870 2875 ggc acg atg gcc atg ctg gtc atc cgc ggg gcc tcg ctc
aag gac gcg 8750 Gly Thr Met Ala Met Leu Val Ile Arg Gly Ala Ser
Leu Lys Asp Ala 2880 2885 2890 ggc gag tac acg tgt gag gtg gag gct
tcc aag agc aca gcc agc ctc 8798 Gly Glu Tyr Thr Cys Glu Val Glu
Ala Ser Lys Ser Thr Ala Ser Leu 2895 2900 2905 cat gtg gaa gaa aaa
gca aac tgc ttc aca gag gag ctg acc aat ctg 8846 His Val Glu Glu
Lys Ala Asn Cys Phe Thr Glu Glu Leu Thr Asn Leu 2910 2915 2920 2925
cag gtg gag gag aaa ggc aca gct gtg ttc acg tgc aag acg gag cac
8894 Gln Val Glu Glu Lys Gly Thr Ala Val Phe Thr Cys Lys Thr Glu
His 2930 2935 2940 ccc gcg gcc aca gtg acc tgg cgc aag ggc ctc ttg
gag cta cgg gcc 8942 Pro Ala Ala Thr Val Thr Trp Arg Lys Gly Leu
Leu Glu Leu Arg Ala 2945 2950 2955 tca ggg aag cac cag ccc agc cag
gag ggc ctg acc ctg cgg ctc acc 8990 Ser Gly Lys His Gln Pro Ser
Gln Glu Gly Leu Thr Leu Arg Leu Thr 2960 2965 2970 atc agt gcc ctg
gag aag gca gac agc gac acc tat acc tgc gac att 9038 Ile Ser Ala
Leu Glu Lys Ala Asp Ser Asp Thr Tyr Thr Cys Asp Ile 2975 2980 2985
ggc cag gcc cag tcc cgg gcc cag ctc cta gtg caa ggc cgg aga gtg
9086 Gly Gln Ala Gln Ser Arg Ala Gln Leu Leu Val Gln Gly Arg Arg
Val 2990 2995 3000 3005 cac atc atc gag gac ctg gag gat gtg gat gtg
cag gag ggc tcc tcg 9134 His Ile Ile Glu Asp Leu Glu Asp Val Asp
Val Gln Glu Gly Ser Ser 3010 3015 3020 gcc acc ttc cgt tgc cgg atc
tcc ccg gcc aac tac gag cct gtg cac 9182 Ala Thr Phe Arg Cys Arg
Ile Ser Pro Ala Asn Tyr Glu Pro Val His 3025 3030 3035 tgg ttc ctg
gac aag aca ccc ctg cat gcc aac gag ctc aat gag atc 9230 Trp Phe
Leu Asp Lys Thr Pro Leu His Ala Asn Glu Leu Asn Glu Ile 3040 3045
3050 gat gcc cag ccc ggg ggc tac cac gtg ctg acc ctg cgg cag ctg
gcg 9278 Asp Ala Gln Pro Gly Gly Tyr His Val Leu Thr Leu Arg Gln
Leu Ala 3055 3060 3065 ctc aag gac tcg ggc acc atc tac ttt gag gcg
ggt gac cag cgg gcc 9326 Leu Lys Asp Ser Gly Thr Ile Tyr Phe Glu
Ala Gly Asp Gln Arg Ala 3070 3075 3080 3085 tcg gcc gcc ctg cgg gtc
act gag aag cca agc gtc ttc tcc cgg gag 9374 Ser Ala Ala Leu Arg
Val Thr Glu Lys Pro Ser Val Phe Ser Arg Glu 3090 3095 3100 ctc aca
gat gcc acc atc aca gag ggt gag gac ttg acc ctg gtg tgc 9422 Leu
Thr Asp Ala Thr Ile Thr Glu Gly Glu Asp Leu Thr Leu Val Cys 3105
3110 3115 gag acc agc acc tgc gac att cct atg tgc tgg acc aag gat
ggg aag 9470 Glu Thr Ser Thr Cys Asp Ile Pro Met Cys Trp Thr Lys
Asp Gly Lys 3120 3125 3130 acc ctg cgg ggg tct gcc cgg tgc cag ctg
agc cat gag ggc cac cgg 9518 Thr Leu Arg Gly Ser Ala Arg Cys Gln
Leu Ser His Glu Gly His Arg 3135 3140 3145 gcc cag ctg ctc atc act
ggg gcc acc ctg cag gac agt gga cgc tac 9566 Ala Gln Leu Leu Ile
Thr Gly Ala Thr Leu Gln Asp Ser Gly Arg Tyr 3150 3155 3160 3165 aag
tgt gag gct ggg ggc gcc tgc agc agc tcc att gtc agg gtg cat 9614
Lys Cys Glu Ala Gly Gly Ala Cys Ser Ser Ser Ile Val Arg Val His
3170 3175 3180 gcg cgg cca gtg cgg ttc cag gag gcc ctg aag gac ctg
gag gtg ctg 9662 Ala Arg Pro Val Arg Phe Gln Glu Ala Leu Lys Asp
Leu Glu Val Leu 3185 3190 3195 gag ggt ggt gct gcc aca ctg cgc tgt
gtg ctg tca tct gtg gct gcg 9710 Glu Gly Gly Ala Ala Thr Leu Arg
Cys Val Leu Ser Ser Val Ala Ala 3200 3205 3210 ccc gtg aag tgg tgc
tat gga aac aac gtc ctg agg cca ggt gac aaa 9758 Pro Val Lys Trp
Cys Tyr Gly Asn Asn Val Leu Arg Pro Gly Asp Lys 3215 3220 3225 tac
agc cta cgc cag gag ggt gcc atg ctg gag ctg gtg gtc cgg aac 9806
Tyr Ser Leu Arg Gln Glu Gly Ala Met Leu Glu Leu Val Val Arg Asn
3230 3235 3240 3245 ctc cgg ccg cag gac agc ggg cgg tac tca tgc tcc
ttc ggg gac cag 9854 Leu Arg Pro Gln Asp Ser Gly Arg Tyr Ser Cys
Ser Phe Gly Asp Gln 3250 3255 3260 act act tct gcc acc ctc aca gtg
act gcc ctg cct gcc cag ttc atc 9902 Thr Thr Ser Ala Thr Leu Thr
Val Thr Ala Leu Pro Ala Gln Phe Ile 3265 3270 3275 ggg aaa ctg aga
aac aag gag gcc aca gaa ggg gcc acg gcc acg ctg 9950 Gly Lys Leu
Arg Asn Lys Glu Ala Thr Glu Gly Ala Thr Ala Thr Leu 3280 3285 3290
cgg tgt gag ctg agc aag aca gcc cct gtg gag tgg aga aag ggg tcc
9998 Arg Cys Glu Leu Ser Lys Thr Ala Pro Val Glu Trp Arg Lys Gly
Ser 3295 3300 3305 gag acc ctc aga gat ggg gac aga tac tgt ctg agg
cag gac ggg gcc 10046 Glu Thr Leu Arg Asp Gly Asp Arg Tyr Cys Leu
Arg Gln Asp Gly Ala 3310 3315 3320 3325 atg tgt gag ctg cag atc cgt
ggc ctg gcc atg gtg gat gcc gcg gag 10094 Met Cys Glu Leu Gln Ile
Arg Gly Leu Ala Met Val Asp Ala Ala Glu 3330 3335 3340 tac tcg tgt
gtg tgt gga gag gag agg acc tca gcc tca ctc acc atc 10142 Tyr Ser
Cys Val Cys Gly Glu Glu Arg Thr Ser Ala Ser Leu Thr Ile 3345 3350
3355 agg ccc atg cct gcc cac ttc ata gga aga ctg aga cac caa gag
agc 10190 Arg Pro Met Pro Ala His Phe Ile Gly Arg Leu Arg His Gln
Glu Ser 3360 3365 3370 ata gaa ggg gcc aca gcc acg ctg cgg tgt gag
ctg agc aag gcg gcc 10238 Ile Glu Gly Ala Thr Ala Thr Leu Arg Cys
Glu Leu Ser Lys Ala Ala 3375 3380 3385 ccc gtg gag tgg agg aag ggg
cgt gag agc ctc aga gat ggg gac aga 10286 Pro Val Glu Trp Arg Lys
Gly Arg Glu Ser Leu Arg Asp Gly Asp Arg 3390 3395 3400 3405 cat agc
ctg agg cag gac ggg gct gtg tgc gag ctg cag atc tgt ggc 10334 His
Ser Leu Arg Gln Asp Gly Ala Val Cys Glu Leu Gln Ile Cys Gly 3410
3415 3420 ctg gct gtg gca gat gct ggg gag tac tcc tgt gtg tgt ggg
gag gag 10382 Leu Ala Val Ala Asp Ala Gly Glu Tyr Ser Cys Val Cys
Gly Glu Glu 3425 3430 3435 agg acc tct gcc act ctc acc gtg aag gcc
ctg cca gcc aag ttc aca 10430 Arg Thr Ser Ala Thr Leu Thr Val Lys
Ala Leu Pro Ala Lys Phe Thr 3440 3445 3450 gag ggt ctg agg aat gaa
gag gcc gtg gaa ggg gcc aca gcc atg ttg 10478 Glu Gly Leu Arg Asn
Glu Glu Ala Val Glu Gly Ala Thr Ala Met Leu 3455 3460 3465 tgg tgt
gaa ctg agc aag gtg gcc cct gtg gag tgg agg aag ggg ccc 10526 Trp
Cys Glu Leu Ser Lys Val Ala Pro Val Glu Trp Arg Lys Gly Pro 3470
3475 3480 3485 gag aac ctc aga gat ggg gac aga tac atc ctg agg cag
gag ggg acc 10574 Glu Asn Leu Arg Asp Gly Asp Arg Tyr Ile Leu Arg
Gln Glu Gly Thr 3490 3495 3500 agg tgt gag ctg cag atc tgt ggc ctg
gcc atg gcg gac gcc ggg gag 10622 Arg Cys Glu Leu Gln Ile Cys Gly
Leu Ala Met Ala Asp Ala Gly Glu 3505 3510 3515 tac ttg tgt gtg tgc
ggg cag gag agg acc tca gcc acg ctc acc atc 10670 Tyr Leu Cys Val
Cys Gly Gln Glu Arg Thr Ser Ala Thr Leu Thr Ile 3520 3525 3530 agg
gct ctg cct gcc agg ttc ata gaa gat gtg aaa aac cag gag gcc 10718
Arg Ala Leu Pro Ala Arg Phe Ile Glu Asp Val Lys Asn Gln Glu Ala
3535 3540 3545 aga gaa ggg gcc acg gct gtg ctg cag tgt gag ctg aac
agt gca gcc 10766 Arg Glu Gly Ala Thr Ala Val Leu Gln Cys Glu Leu
Asn Ser Ala Ala 3550 3555 3560 3565 cct gtg gag tgg aga aag ggg tct
gag acc ctc aga gat ggg gac aga 10814 Pro Val Glu Trp Arg Lys Gly
Ser Glu Thr Leu Arg Asp Gly Asp Arg 3570 3575 3580 tac agc ctg agg
cag gac ggg act aaa tgt gag ctg cag att cgt ggc 10862 Tyr Ser Leu
Arg Gln Asp Gly Thr Lys Cys Glu Leu Gln Ile Arg Gly 3585 3590 3595
ctg gcc atg gca gac act ggg gag tac tcg tgc gtg tgc ggg cag gag
10910 Leu Ala Met Ala Asp Thr Gly Glu Tyr Ser Cys Val Cys Gly Gln
Glu 3600 3605 3610 agg acc tcg gct atg ctc acc gtc agg gct cta ccc
atc aag ttc aca 10958 Arg Thr Ser Ala Met Leu Thr Val Arg Ala Leu
Pro Ile Lys Phe Thr 3615 3620 3625 gag ggt ctg agg aac gaa gag gcc
aca gaa ggg gca aca gcc gtg ctg 11006 Glu Gly Leu Arg Asn Glu Glu
Ala Thr Glu Gly Ala Thr Ala Val Leu 3630 3635 3640 3645 cgg tgt gag
ctg agc aag atg gcc ccc gtg gag tgg tgg aag ggg cat 11054 Arg Cys
Glu Leu Ser Lys Met Ala Pro Val Glu Trp Trp Lys Gly His 3650 3655
3660 gag acc ctc aga gat gga gac aga cac agc ctg agg cag gac ggg
gcc 11102 Glu Thr Leu Arg Asp Gly Asp Arg His Ser Leu Arg Gln Asp
Gly Ala 3665 3670 3675 agg tgt gag ctg cag atc cgc ggc ctc gtg gca
gag gac gct ggg gag 11150 Arg Cys Glu Leu Gln Ile Arg Gly Leu Val
Ala Glu Asp Ala Gly Glu 3680 3685 3690 tac ctg tgc atg tgc ggg aag
gag agg acc tca gcc atg ctc acc gtc 11198 Tyr Leu Cys Met Cys Gly
Lys Glu Arg Thr Ser Ala Met Leu Thr Val 3695 3700 3705 agg gcc atg
cct tcc aag ttc ata gag ggt ctg agg aat gaa gag gcc 11246 Arg Ala
Met Pro Ser Lys Phe Ile Glu Gly Leu Arg Asn Glu Glu Ala 3710 3715
3720 3725 aca gaa ggg gac acg gcc acg ctg tgg tgt gag ctg agc aag
gcg gca 11294 Thr Glu Gly Asp Thr Ala Thr Leu Trp Cys Glu Leu Ser
Lys Ala Ala 3730 3735 3740 ccg gtg gag tgg agg aag ggg cat gag acc
ctc aga gat ggg gac aga 11342 Pro Val Glu Trp Arg Lys Gly His Glu
Thr Leu Arg Asp Gly Asp Arg 3745 3750 3755 cac agc ctg agg cag gac
ggg tcc agg tgt gag ctg cag atc cgt ggc 11390 His Ser Leu Arg Gln
Asp Gly Ser Arg Cys Glu Leu Gln Ile Arg Gly 3760 3765 3770 ctg gct
gtg gtg gat gcc ggg gag tac tcg tgt gtg tgc ggg cag gag 11438 Leu
Ala Val Val Asp Ala Gly Glu Tyr Ser Cys Val Cys Gly Gln Glu 3775
3780 3785 agg acc tca gcc aca ctc act gtc agg gcc ctg cct gcc aga
ttc ata 11486 Arg Thr Ser Ala Thr Leu Thr Val Arg Ala Leu Pro Ala
Arg Phe Ile 3790 3795 3800 3805 gaa gat gtg aaa aac cag gag gcc aga
gaa ggg gcc acg gcc gtg ctg 11534 Glu Asp Val Lys Asn Gln Glu Ala
Arg Glu Gly Ala Thr Ala Val Leu 3810 3815 3820 caa tgt gag ctg agc
aag gcg gcc ccc gtg gag tgg agg aag ggg tct 11582 Gln Cys Glu Leu
Ser Lys Ala Ala Pro Val Glu Trp Arg Lys Gly Ser 3825 3830 3835 gag
acc ctc aga ggt ggg gac aga tac agc ctg agg cag gat ggg acc 11630
Glu Thr Leu Arg Gly Gly Asp Arg Tyr Ser Leu Arg Gln Asp Gly Thr
3840 3845 3850 aga tgt gag ctg cag att cat ggc ctg tct gtg gca gac
act ggg gag 11678 Arg Cys Glu Leu Gln Ile His Gly Leu Ser Val Ala
Asp Thr Gly Glu 3855 3860 3865 tac tcg tgt gtg tgc ggg cag gag agg
acc tcg gcc aca ctc acc gtc 11726 Tyr Ser Cys Val Cys Gly Gln Glu
Arg Thr Ser Ala Thr Leu Thr Val 3870 3875 3880 3885 agg gcc cca cag
cca gtg ttc cgg gag ccg ctg cag agt ctg cag gcg 11774 Arg Ala Pro
Gln Pro Val Phe Arg Glu Pro Leu Gln Ser Leu Gln Ala 3890 3895 3900
gag gag ggc tcc acg gcc acc ctg cag tgt gag ctg tct gag ccc act
11822 Glu Glu Gly Ser Thr Ala Thr Leu Gln Cys Glu Leu Ser Glu Pro
Thr 3905 3910 3915 gct aca gtg gtc tgg agc aag ggt ggc ctg cag ctg
cag gcc aat ggg 11870 Ala Thr Val Val Trp Ser Lys Gly Gly Leu Gln
Leu Gln Ala Asn Gly 3920 3925 3930 cgc cgg gag cca cgg ctt cag ggc
tgc acc gcg gag ctg gtg tta cag 11918 Arg Arg Glu Pro Arg Leu
Gln Gly Cys Thr Ala Glu Leu Val Leu Gln 3935 3940 3945 gac cta caa
cgt gaa gac act ggc gaa tac act tgc acc tgt ggc tcc 11966 Asp Leu
Gln Arg Glu Asp Thr Gly Glu Tyr Thr Cys Thr Cys Gly Ser 3950 3955
3960 3965 cag gcc acc agt gcc acc ctc act gtc aca gct gcg cct gtg
cgg ttc 12014 Gln Ala Thr Ser Ala Thr Leu Thr Val Thr Ala Ala Pro
Val Arg Phe 3970 3975 3980 ctc cga gag ctg cag cac cag gag gtg gat
gag gga ggc acc gca cac 12062 Leu Arg Glu Leu Gln His Gln Glu Val
Asp Glu Gly Gly Thr Ala His 3985 3990 3995 tta tgc tgc gag ctg agc
cgg gcg ggt gcg agc gtg gag tgg cgc aag 12110 Leu Cys Cys Glu Leu
Ser Arg Ala Gly Ala Ser Val Glu Trp Arg Lys 4000 4005 4010 ggc tcc
cta cag ctc ttc cct tgt gcc aag tac cag atg gtg cag gat 12158 Gly
Ser Leu Gln Leu Phe Pro Cys Ala Lys Tyr Gln Met Val Gln Asp 4015
4020 4025 ggt gca gct gca gag ctg ctg gta cgc gga gtg gag cag gag
gat gcg 12206 Gly Ala Ala Ala Glu Leu Leu Val Arg Gly Val Glu Gln
Glu Asp Ala 4030 4035 4040 4045 ggt gac tac acg tgt gac acg ggc cac
acg cag agc atg gcc agc ctc 12254 Gly Asp Tyr Thr Cys Asp Thr Gly
His Thr Gln Ser Met Ala Ser Leu 4050 4055 4060 tct gtc cgt gtc ccc
agg ccc aag ttc aag acc cgg ctt cag agt ctg 12302 Ser Val Arg Val
Pro Arg Pro Lys Phe Lys Thr Arg Leu Gln Ser Leu 4065 4070 4075 gag
cag gag aca ggt gac ata gcc cgg ctg tgc tgt cag ctg agt gat 12350
Glu Gln Glu Thr Gly Asp Ile Ala Arg Leu Cys Cys Gln Leu Ser Asp
4080 4085 4090 gca gag tcg ggg gcc gtg gtg caa tgg ctc aag gag ggc
gtg gag ctg 12398 Ala Glu Ser Gly Ala Val Val Gln Trp Leu Lys Glu
Gly Val Glu Leu 4095 4100 4105 cat gcg ggc ccc aag tac gag atg cgg
agc cag ggg gcc acg cgg gag 12446 His Ala Gly Pro Lys Tyr Glu Met
Arg Ser Gln Gly Ala Thr Arg Glu 4110 4115 4120 4125 ctg ctg atc cac
caa ctg gag gcc aag gac acg ggc gag tat gcc tgt 12494 Leu Leu Ile
His Gln Leu Glu Ala Lys Asp Thr Gly Glu Tyr Ala Cys 4130 4135 4140
gtg aca ggc ggc cag aaa acc gct gcc tcc ctc agg gtc aca gag cct
12542 Val Thr Gly Gly Gln Lys Thr Ala Ala Ser Leu Arg Val Thr Glu
Pro 4145 4150 4155 gag gtg acc att gta cgg ggg ctg gtt gat gcg gag
gtg acg gcc gat 12590 Glu Val Thr Ile Val Arg Gly Leu Val Asp Ala
Glu Val Thr Ala Asp 4160 4165 4170 gag gat gtt gag ttc agc tgt gag
gtg tcc agg gct gga gcc aca ggc 12638 Glu Asp Val Glu Phe Ser Cys
Glu Val Ser Arg Ala Gly Ala Thr Gly 4175 4180 4185 gtg cag tgg tgc
cta cag ggc ctg cca ctg caa agc aat gag gtg aca 12686 Val Gln Trp
Cys Leu Gln Gly Leu Pro Leu Gln Ser Asn Glu Val Thr 4190 4195 4200
4205 gag gtg gct gtg cgg gat ggc cgc atc cac acc ctg cgg ctg aag
ggc 12734 Glu Val Ala Val Arg Asp Gly Arg Ile His Thr Leu Arg Leu
Lys Gly 4210 4215 4220 gtg acg ccc gag gac gct ggc act gtc tcc ttc
cat ttg gga aac cat 12782 Val Thr Pro Glu Asp Ala Gly Thr Val Ser
Phe His Leu Gly Asn His 4225 4230 4235 gct tcc tct gcc cag ctc acc
gtc aga gct cct gag gtg acc atc ctg 12830 Ala Ser Ser Ala Gln Leu
Thr Val Arg Ala Pro Glu Val Thr Ile Leu 4240 4245 4250 gag ccc ctg
cag gac gtg cag ctc agt gag ggc cag gat gcc agc ttc 12878 Glu Pro
Leu Gln Asp Val Gln Leu Ser Glu Gly Gln Asp Ala Ser Phe 4255 4260
4265 cag tgc cgg cta tcc aga gct tca ggc cag gag gcc cgc tgg gct
tta 12926 Gln Cys Arg Leu Ser Arg Ala Ser Gly Gln Glu Ala Arg Trp
Ala Leu 4270 4275 4280 4285 gga ggg gtg ccc ctg cag gcc aac gag atg
aat gac atc act gtg gag 12974 Gly Gly Val Pro Leu Gln Ala Asn Glu
Met Asn Asp Ile Thr Val Glu 4290 4295 4300 cag ggc aca ctc cac ctg
ctc acc ctg cac aag gtg acc ctt gag gat 13022 Gln Gly Thr Leu His
Leu Leu Thr Leu His Lys Val Thr Leu Glu Asp 4305 4310 4315 gct gga
act gtc agt ttc cac gtg ggc acg tgt agc tct gag gcc cag 13070 Ala
Gly Thr Val Ser Phe His Val Gly Thr Cys Ser Ser Glu Ala Gln 4320
4325 4330 ctg aaa gtc aca gcc aag aac acg gtg gtg cgg ggg ctg gag
aat gtg 13118 Leu Lys Val Thr Ala Lys Asn Thr Val Val Arg Gly Leu
Glu Asn Val 4335 4340 4345 gag gcg ctg gag ggc ggc gag gcg ctg ttc
gag tgc cag ctg tcc cag 13166 Glu Ala Leu Glu Gly Gly Glu Ala Leu
Phe Glu Cys Gln Leu Ser Gln 4350 4355 4360 4365 ccc gag gtg gcc gcc
cac acc tgg ctg ctg gac gac gaa ccc gtg cgc 13214 Pro Glu Val Ala
Ala His Thr Trp Leu Leu Asp Asp Glu Pro Val Arg 4370 4375 4380 acc
tcg gag aac gcc gag gtg gtc ttc ttc gag aac ggc ctg cgc cac 13262
Thr Ser Glu Asn Ala Glu Val Val Phe Phe Glu Asn Gly Leu Arg His
4385 4390 4395 ctg ctg ctg ctc aaa aac ttg cgg cca caa gac agc tgc
cgg gtg acc 13310 Leu Leu Leu Leu Lys Asn Leu Arg Pro Gln Asp Ser
Cys Arg Val Thr 4400 4405 4410 ttc ctg gct ggg gat atg gtg acg tcc
gca ttc ctc acg gtc cga ggc 13358 Phe Leu Ala Gly Asp Met Val Thr
Ser Ala Phe Leu Thr Val Arg Gly 4415 4420 4425 tgg cgc ctg gag atc
ctg gag cct ctg aaa aac gcg gcg gtc cgg gcc 13406 Trp Arg Leu Glu
Ile Leu Glu Pro Leu Lys Asn Ala Ala Val Arg Ala 4430 4435 4440 4445
ggc gca cag gca cgc ttc acc tgc acg ctc agc gag gcg gtg ccc gtg
13454 Gly Ala Gln Ala Arg Phe Thr Cys Thr Leu Ser Glu Ala Val Pro
Val 4450 4455 4460 gga gag gcg tcc tgg tac atc aat ggc gcg gca gtg
cag ccg gat gac 13502 Gly Glu Ala Ser Trp Tyr Ile Asn Gly Ala Ala
Val Gln Pro Asp Asp 4465 4470 4475 agc gac tgg act gtc acc gcc gac
ggc agt cac caa gcc cta ctg ctg 13550 Ser Asp Trp Thr Val Thr Ala
Asp Gly Ser His Gln Ala Leu Leu Leu 4480 4485 4490 cgc agc gcc cag
ccc cac cac gcc ggg gag gtc acc ttc gct tgc cgc 13598 Arg Ser Ala
Gln Pro His His Ala Gly Glu Val Thr Phe Ala Cys Arg 4495 4500 4505
gac gcc gtg gcc tct gca cgg ctc acc gtg ctg ggc ctc cct gat ccc
13646 Asp Ala Val Ala Ser Ala Arg Leu Thr Val Leu Gly Leu Pro Asp
Pro 4510 4515 4520 4525 cca gag gat gct gag gtg gtg gct cac agc agc
cac act gtg aca ctg 13694 Pro Glu Asp Ala Glu Val Val Ala His Ser
Ser His Thr Val Thr Leu 4530 4535 4540 tct tgg gca gct ccc atg agt
gat gga ggc ggt ggt ctc tgt ggc tac 13742 Ser Trp Ala Ala Pro Met
Ser Asp Gly Gly Gly Gly Leu Cys Gly Tyr 4545 4550 4555 cgc gtg gag
gtg aag gag ggg gcc aca ggc cag tgg cgg ctg tgc cac 13790 Arg Val
Glu Val Lys Glu Gly Ala Thr Gly Gln Trp Arg Leu Cys His 4560 4565
4570 gag ctg gtg cct gga ccc gag tgt gtg gtg gat ggc ctg gcc ccc
ggg 13838 Glu Leu Val Pro Gly Pro Glu Cys Val Val Asp Gly Leu Ala
Pro Gly 4575 4580 4585 gag acc tac cgc ttc cgt gtg gca gct gtg ggc
cct gtg ggt gct ggg 13886 Glu Thr Tyr Arg Phe Arg Val Ala Ala Val
Gly Pro Val Gly Ala Gly 4590 4595 4600 4605 gaa ccg gtt cac ctg ccc
cag aca gtg cgg ctt gca gag cca ccg aag 13934 Glu Pro Val His Leu
Pro Gln Thr Val Arg Leu Ala Glu Pro Pro Lys 4610 4615 4620 cct gtg
cct ccc cag ccc tca gcc cct gag agc cgg cag gtg gca gct 13982 Pro
Val Pro Pro Gln Pro Ser Ala Pro Glu Ser Arg Gln Val Ala Ala 4625
4630 4635 ggt gaa gat gtc tct ctg gag ctt gag gtg gtg gct gag gct
ggt gag 14030 Gly Glu Asp Val Ser Leu Glu Leu Glu Val Val Ala Glu
Ala Gly Glu 4640 4645 4650 gtc atc tgg cac aag gga atg gag cgc atc
cag ccc ggt ggg cgg ttc 14078 Val Ile Trp His Lys Gly Met Glu Arg
Ile Gln Pro Gly Gly Arg Phe 4655 4660 4665 gag gtg gtc tcc cag ggt
cgg caa cag atg ctg gtg atc aag ggc ttc 14126 Glu Val Val Ser Gln
Gly Arg Gln Gln Met Leu Val Ile Lys Gly Phe 4670 4675 4680 4685 acg
gca gaa gac cag ggc gag tac cac tgt ggc ctg gct cag ggc tcc 14174
Thr Ala Glu Asp Gln Gly Glu Tyr His Cys Gly Leu Ala Gln Gly Ser
4690 4695 4700 atc tgc cct gcg gct gcc acc ttc cag gtg gca ctg agc
cca gcc tct 14222 Ile Cys Pro Ala Ala Ala Thr Phe Gln Val Ala Leu
Ser Pro Ala Ser 4705 4710 4715 gtg gat gag gcc cct cag ccc agc ttg
ccc ccc gag gca gcc cag gag 14270 Val Asp Glu Ala Pro Gln Pro Ser
Leu Pro Pro Glu Ala Ala Gln Glu 4720 4725 4730 ggt gac ctg cac cta
ctg tgg gag gcc ctg gct cgg aaa cgt cgc atg 14318 Gly Asp Leu His
Leu Leu Trp Glu Ala Leu Ala Arg Lys Arg Arg Met 4735 4740 4745 agc
cgt gag ccc acg ctg gac tcc att agc gag ctg cca gag gag gac 14366
Ser Arg Glu Pro Thr Leu Asp Ser Ile Ser Glu Leu Pro Glu Glu Asp
4750 4755 4760 4765 ggc cgc tcg cag cgc ctg cca cag gag gca gag gag
gtg gca cct gat 14414 Gly Arg Ser Gln Arg Leu Pro Gln Glu Ala Glu
Glu Val Ala Pro Asp 4770 4775 4780 ctc tct gaa ggc tac tcc acg gcc
gat gag ctg gcc cgc act gga gat 14462 Leu Ser Glu Gly Tyr Ser Thr
Ala Asp Glu Leu Ala Arg Thr Gly Asp 4785 4790 4795 gct gac ctc tca
cac acc agc tct gat gat gag tcc cgg gca ggc acc 14510 Ala Asp Leu
Ser His Thr Ser Ser Asp Asp Glu Ser Arg Ala Gly Thr 4800 4805 4810
cct tcc ctg gtc acc tac ctc aag aag gct ggg agg cca ggc acc tca
14558 Pro Ser Leu Val Thr Tyr Leu Lys Lys Ala Gly Arg Pro Gly Thr
Ser 4815 4820 4825 cca ctg gcc agc aag gtt ggg gcc cca gca gcc ccc
tct gtg aag cca 14606 Pro Leu Ala Ser Lys Val Gly Ala Pro Ala Ala
Pro Ser Val Lys Pro 4830 4835 4840 4845 cag cag cag cag gag cca ctg
gct gct gtg cgc cca cca ctg gga gac 14654 Gln Gln Gln Gln Glu Pro
Leu Ala Ala Val Arg Pro Pro Leu Gly Asp 4850 4855 4860 ctg agc acc
aaa gac ctg ggt gat ccc tca atg gac aag gca gct gtg 14702 Leu Ser
Thr Lys Asp Leu Gly Asp Pro Ser Met Asp Lys Ala Ala Val 4865 4870
4875 aag atc cag gct gcc ttt aag ggc tac aag gtc cgg aag gag atg
aag 14750 Lys Ile Gln Ala Ala Phe Lys Gly Tyr Lys Val Arg Lys Glu
Met Lys 4880 4885 4890 cag cag gaa ggg ccc atg ttc tcc cac aca ttt
ggg gac acc gag gca 14798 Gln Gln Glu Gly Pro Met Phe Ser His Thr
Phe Gly Asp Thr Glu Ala 4895 4900 4905 cag gtg ggg gat gcc ctg cgg
ctg gag tgt gtc gtg gcc agc aag gca 14846 Gln Val Gly Asp Ala Leu
Arg Leu Glu Cys Val Val Ala Ser Lys Ala 4910 4915 4920 4925 gat gtg
cga gcc cgc tgg ctg aag gat ggt gtg gag ctg acc gat ggg 14894 Asp
Val Arg Ala Arg Trp Leu Lys Asp Gly Val Glu Leu Thr Asp Gly 4930
4935 4940 cgg cac cat cac atc gac cag ctt ggg gat ggc acc tgc tct
ctg ctg 14942 Arg His His His Ile Asp Gln Leu Gly Asp Gly Thr Cys
Ser Leu Leu 4945 4950 4955 atc gct ggc ctg gac cgt gct gat gct ggc
tgc tac acc tgt cag gtg 14990 Ile Ala Gly Leu Asp Arg Ala Asp Ala
Gly Cys Tyr Thr Cys Gln Val 4960 4965 4970 agc aac aag ttt ggc cag
gtg acc cac agt gcc tgt gtg gtg gtc agt 15038 Ser Asn Lys Phe Gly
Gln Val Thr His Ser Ala Cys Val Val Val Ser 4975 4980 4985 ggg tca
gag agt gaa gcc gag agc tcc tct ggg ggt gag ctg gac gat 15086 Gly
Ser Glu Ser Glu Ala Glu Ser Ser Ser Gly Gly Glu Leu Asp Asp 4990
4995 5000 5005 gcc ttc cgc cgg gct gcc cgt cgg ctg cac cgg ctc ttc
cgc acc aaa 15134 Ala Phe Arg Arg Ala Ala Arg Arg Leu His Arg Leu
Phe Arg Thr Lys 5010 5015 5020 agt ccg gct gaa gtt tca gat gag gag
ctc ttc ctg agt gca gac gag 15182 Ser Pro Ala Glu Val Ser Asp Glu
Glu Leu Phe Leu Ser Ala Asp Glu 5025 5030 5035 ggc cct gca gag cca
gag gag ccc gcg gac tgg cag aca tac cgc gaa 15230 Gly Pro Ala Glu
Pro Glu Glu Pro Ala Asp Trp Gln Thr Tyr Arg Glu 5040 5045 5050 gat
gag cat ttc atc tgc atc cgt ttt gag gcg ctc act gag gcc cgc 15278
Asp Glu His Phe Ile Cys Ile Arg Phe Glu Ala Leu Thr Glu Ala Arg
5055 5060 5065 cag gcg gta act cgc ttc cag gag atg ttt gcc aca ctg
ggc att ggg 15326 Gln Ala Val Thr Arg Phe Gln Glu Met Phe Ala Thr
Leu Gly Ile Gly 5070 5075 5080 5085 gtg gag atc aag ctg gtg gaa cag
ggg cct cgg agg gta gag atg tgc 15374 Val Glu Ile Lys Leu Val Glu
Gln Gly Pro Arg Arg Val Glu Met Cys 5090 5095 5100 atc agc aaa gag
act cct gcc cct gtg gtg cct cca gag cca ttg ccc 15422 Ile Ser Lys
Glu Thr Pro Ala Pro Val Val Pro Pro Glu Pro Leu Pro 5105 5110 5115
agc cta ctg act tct gac gct gcc cca gtg ttc ctg act gag ttg cag
15470 Ser Leu Leu Thr Ser Asp Ala Ala Pro Val Phe Leu Thr Glu Leu
Gln 5120 5125 5130 aac caa gaa gtg cag gat ggg tat cct gtg agc ttt
gac tgc gtg gtg 15518 Asn Gln Glu Val Gln Asp Gly Tyr Pro Val Ser
Phe Asp Cys Val Val 5135 5140 5145 aca ggt cag ccc atg ccc agt gtg
cgc tgg ttc aag gat ggg aag ttg 15566 Thr Gly Gln Pro Met Pro Ser
Val Arg Trp Phe Lys Asp Gly Lys Leu 5150 5155 5160 5165 ttg gag gag
gat gat cac tac atg att aat gaa gac caa cag ggt ggc 15614 Leu Glu
Glu Asp Asp His Tyr Met Ile Asn Glu Asp Gln Gln Gly Gly 5170 5175
5180 cat cag ctc atc atc aca gcc gtg gtg cca gca gac atg ggc gtc
tac 15662 His Gln Leu Ile Ile Thr Ala Val Val Pro Ala Asp Met Gly
Val Tyr 5185 5190 5195 cgc tgc ctg gcc gag aac agc atg ggt gtc tcc
tcc acc aag gct gag 15710 Arg Cys Leu Ala Glu Asn Ser Met Gly Val
Ser Ser Thr Lys Ala Glu 5200 5205 5210 ctc cgt gtg gac ttg aca agc
aca gac tat gac act gca gca gat gcc 15758 Leu Arg Val Asp Leu Thr
Ser Thr Asp Tyr Asp Thr Ala Ala Asp Ala 5215 5220 5225 acg gag tcc
tca tcc tac ttc agt gcc caa ggc tac ctg tcc agc cgg 15806 Thr Glu
Ser Ser Ser Tyr Phe Ser Ala Gln Gly Tyr Leu Ser Ser Arg 5230 5235
5240 5245 gag cag gag gga aca gag tcc acc act gat gag ggc cag ctg
ccc cag 15854 Glu Gln Glu Gly Thr Glu Ser Thr Thr Asp Glu Gly Gln
Leu Pro Gln 5250 5255 5260 gtg gtg gag gag ctg aga gac ctc cag gtg
gcc cct ggc aca cgc ctg 15902 Val Val Glu Glu Leu Arg Asp Leu Gln
Val Ala Pro Gly Thr Arg Leu 5265 5270 5275 gcc aag ttc cag ctc aag
gtg aaa ggc tac cct gct ccc aga tta tac 15950 Ala Lys Phe Gln Leu
Lys Val Lys Gly Tyr Pro Ala Pro Arg Leu Tyr 5280 5285 5290 tgg ttc
aaa gat ggc cag ccc ctg acc gca tct gcc cac atc cgc atg 15998 Trp
Phe Lys Asp Gly Gln Pro Leu Thr Ala Ser Ala His Ile Arg Met 5295
5300 5305 act ggc aag aag atc ctg cac acc ctg gag atc atc tcc gtc
acc cgg 16046 Thr Gly Lys Lys Ile Leu His Thr Leu Glu Ile Ile Ser
Val Thr Arg 5310 5315 5320 5325 gag gac tct ggc cag tat gca gcc tat
atc agc aat gcc atg ggt gct 16094 Glu Asp Ser Gly Gln Tyr Ala Ala
Tyr Ile Ser Asn Ala Met Gly Ala 5330 5335 5340 gcc tac tcg tct gcc
cgg ctg ctg gtt cga ggc cct gat gag cca gaa 16142 Ala Tyr Ser Ser
Ala Arg Leu Leu Val Arg Gly Pro Asp Glu Pro Glu 5345 5350 5355 gag
aag cct gca tca gat gtg cat gag cag ctg gtg ccg ccc cga atg 16190
Glu Lys Pro Ala Ser Asp Val His Glu Gln Leu Val Pro Pro Arg Met
5360 5365 5370 ctg gag agg ttc acc ccc aag aaa gtg aag aaa ggc tcc
agc atc acc 16238 Leu Glu Arg Phe Thr Pro Lys Lys Val Lys Lys Gly
Ser Ser Ile Thr 5375 5380 5385 ttc tct gtg aag gta gaa gga cgc ccg
gtg ccc acc gtg cac tgg ctc 16286 Phe Ser Val Lys Val Glu Gly Arg
Pro Val Pro Thr Val His Trp Leu 5390 5395 5400 5405 agg gag gag gct
gag aga ggc gtg ctg tgg att ggc cct gac aca ccg 16334 Arg Glu Glu
Ala Glu Arg Gly Val Leu Trp Ile Gly Pro Asp Thr Pro 5410 5415 5420
ggc tac acc gtg gcc agc tct gcg cag cag cac agc ctg gtc ctg ctg
16382 Gly Tyr Thr Val Ala Ser Ser Ala Gln Gln His Ser Leu Val Leu
Leu 5425 5430 5435 gac gtg ggc cgg cag cac cag ggc acc tac aca tgc
att gcc agc aac 16430 Asp Val Gly Arg Gln His Gln Gly Thr Tyr
Thr
Cys Ile Ala Ser Asn 5440 5445 5450 gct gcc ggc cag gcc ctc tgc tcc
gcc agc ctg cac gtc tcg ggc ctg 16478 Ala Ala Gly Gln Ala Leu Cys
Ser Ala Ser Leu His Val Ser Gly Leu 5455 5460 5465 cct aag gtg gag
gag cag gag aaa gtg aag gaa gcg ctg att tcc act 16526 Pro Lys Val
Glu Glu Gln Glu Lys Val Lys Glu Ala Leu Ile Ser Thr 5470 5475 5480
5485 ttc ctg cag ggg acc aca caa gcc atc tca gca cag ggg ttg gaa
act 16574 Phe Leu Gln Gly Thr Thr Gln Ala Ile Ser Ala Gln Gly Leu
Glu Thr 5490 5495 5500 gcg agt ttt gct gac ctt ggt ggg cag agg aaa
gaa gag cct ctg gct 16622 Ala Ser Phe Ala Asp Leu Gly Gly Gln Arg
Lys Glu Glu Pro Leu Ala 5505 5510 5515 gcc aag gag gcc ctc ggc cac
ctg tcc ctc gct gag gtg ggc aca gag 16670 Ala Lys Glu Ala Leu Gly
His Leu Ser Leu Ala Glu Val Gly Thr Glu 5520 5525 5530 gag ttc ctg
cag aaa ctg acc tcc cag atc act gag atg gta tcg gcc 16718 Glu Phe
Leu Gln Lys Leu Thr Ser Gln Ile Thr Glu Met Val Ser Ala 5535 5540
5545 aag atc acg cag gcc aag ctg cag gtg ccc gga ggt gac agt gat
gag 16766 Lys Ile Thr Gln Ala Lys Leu Gln Val Pro Gly Gly Asp Ser
Asp Glu 5550 5555 5560 5565 gac tcc aag aca cca tct gca tcc ccc cgc
cat ggc cga tca cgg cca 16814 Asp Ser Lys Thr Pro Ser Ala Ser Pro
Arg His Gly Arg Ser Arg Pro 5570 5575 5580 tcc tcc agc atc cag gag
tct tcc tca gag tca gag gac ggc gat gcc 16862 Ser Ser Ser Ile Gln
Glu Ser Ser Ser Glu Ser Glu Asp Gly Asp Ala 5585 5590 5595 cga ggc
gag atc ttt gac atc tac gtg gtc acc gct gac tac ctg ccc 16910 Arg
Gly Glu Ile Phe Asp Ile Tyr Val Val Thr Ala Asp Tyr Leu Pro 5600
5605 5610 cta ggg gct gag cag gat gcc atc acg ctg cgg gaa ggc cag
tat gtg 16958 Leu Gly Ala Glu Gln Asp Ala Ile Thr Leu Arg Glu Gly
Gln Tyr Val 5615 5620 5625 gag gtc ctg gat gca gcc cac cca ctg cgc
tgg ctt gtc cgc acc aag 17006 Glu Val Leu Asp Ala Ala His Pro Leu
Arg Trp Leu Val Arg Thr Lys 5630 5635 5640 5645 ccc acc aag tcc agc
ccc tca cgg cag ggc tgg gtg tca cca gcc tac 17054 Pro Thr Lys Ser
Ser Pro Ser Arg Gln Gly Trp Val Ser Pro Ala Tyr 5650 5655 5660 ctg
gac agg agg ctc aag ctg tca cct gag tgg ggg gcc gct gag gcc 17102
Leu Asp Arg Arg Leu Lys Leu Ser Pro Glu Trp Gly Ala Ala Glu Ala
5665 5670 5675 cct gag ttc cct ggg gag gct gtg tct gaa gac gaa tac
aag gca agg 17150 Pro Glu Phe Pro Gly Glu Ala Val Ser Glu Asp Glu
Tyr Lys Ala Arg 5680 5685 5690 ctg agc tct gtg atc cag gag ctg ctg
agt tct gag cag gcc ttc gtg 17198 Leu Ser Ser Val Ile Gln Glu Leu
Leu Ser Ser Glu Gln Ala Phe Val 5695 5700 5705 gag gag ctg cag ttc
ctg cag agc cac cac ctg cag cac ctg gag cgc 17246 Glu Glu Leu Gln
Phe Leu Gln Ser His His Leu Gln His Leu Glu Arg 5710 5715 5720 5725
tgc ccc cac gtg ccc ata gcc gtg gcc ggc cag aag gca gtc atc ttc
17294 Cys Pro His Val Pro Ile Ala Val Ala Gly Gln Lys Ala Val Ile
Phe 5730 5735 5740 cgc aat gtg cgg gac atc ggc cgc ttc cac agc agc
ttc ctg cag gag 17342 Arg Asn Val Arg Asp Ile Gly Arg Phe His Ser
Ser Phe Leu Gln Glu 5745 5750 5755 ttg cag cag tgc gac acg gac gac
gac gtg gcc atg tgc ttc atc aag 17390 Leu Gln Gln Cys Asp Thr Asp
Asp Asp Val Ala Met Cys Phe Ile Lys 5760 5765 5770 aac cag gcg gcc
ttt gag cag tac ctg gag ttc ctg gtg ggg cgt gtg 17438 Asn Gln Ala
Ala Phe Glu Gln Tyr Leu Glu Phe Leu Val Gly Arg Val 5775 5780 5785
cag gct gag tcg gtg gtc gtc agc acg gcc atc cag gag ttc tac aag
17486 Gln Ala Glu Ser Val Val Val Ser Thr Ala Ile Gln Glu Phe Tyr
Lys 5790 5795 5800 5805 aaa tac gcg gag gag gcc ctg ttg gca ggg gac
ccc tct cag ccc ccg 17534 Lys Tyr Ala Glu Glu Ala Leu Leu Ala Gly
Asp Pro Ser Gln Pro Pro 5810 5815 5820 cca cca cct ctg cag cac tac
ctg gag cag cca gtg gag cgg gtg cag 17582 Pro Pro Pro Leu Gln His
Tyr Leu Glu Gln Pro Val Glu Arg Val Gln 5825 5830 5835 cgc tac cag
gcc ttg ctg aag gag ttg atc cgc aac aag gcg cgg aac 17630 Arg Tyr
Gln Ala Leu Leu Lys Glu Leu Ile Arg Asn Lys Ala Arg Asn 5840 5845
5850 aga cag aac tgc gcg ctg ctg gag cag gcc tat gcc gtg gtg tct
gcc 17678 Arg Gln Asn Cys Ala Leu Leu Glu Gln Ala Tyr Ala Val Val
Ser Ala 5855 5860 5865 ctg cca cag cgc gct gag aac aag ctg cac gtg
tcc ctc atg gag aac 17726 Leu Pro Gln Arg Ala Glu Asn Lys Leu His
Val Ser Leu Met Glu Asn 5870 5875 5880 5885 tac cca ggc acc ctg gag
gcc ctg ggc gag ccc atc cgc cag ggc cac 17774 Tyr Pro Gly Thr Leu
Glu Ala Leu Gly Glu Pro Ile Arg Gln Gly His 5890 5895 5900 ttc atc
gtg tgg gag ggt gca ccg ggg gcc cgc atg ccc tgg aag ggc 17822 Phe
Ile Val Trp Glu Gly Ala Pro Gly Ala Arg Met Pro Trp Lys Gly 5905
5910 5915 cac aac cgt cac gtg ttc ctc ttc cgc aac cac ctg gta atc
tgc aag 17870 His Asn Arg His Val Phe Leu Phe Arg Asn His Leu Val
Ile Cys Lys 5920 5925 5930 ccc cgg cga gac tcc cgc acc gat acc gtc
agc tac gtg ttc cgg aac 17918 Pro Arg Arg Asp Ser Arg Thr Asp Thr
Val Ser Tyr Val Phe Arg Asn 5935 5940 5945 atg atg aag ctg agc agc
atc gac ctg aac gac cag gtg gag ggg gat 17966 Met Met Lys Leu Ser
Ser Ile Asp Leu Asn Asp Gln Val Glu Gly Asp 5950 5955 5960 5965 gac
cgc gcc ttc gag gtg tgg cag gag cgg gag gac tcg gtg cgc aag 18014
Asp Arg Ala Phe Glu Val Trp Gln Glu Arg Glu Asp Ser Val Arg Lys
5970 5975 5980 tac ctg ctg cag gca cgg aca gcc att atc aag agc tcg
tgg gtg aag 18062 Tyr Leu Leu Gln Ala Arg Thr Ala Ile Ile Lys Ser
Ser Trp Val Lys 5985 5990 5995 gag atc tgt ggc atc cag cag cgt ctg
gcc ctg cct gtg tgg cgg ccc 18110 Glu Ile Cys Gly Ile Gln Gln Arg
Leu Ala Leu Pro Val Trp Arg Pro 6000 6005 6010 ccg gac ttt gaa gag
gag ctg gcc gac tgc aca gcc gag ctg ggt gag 18158 Pro Asp Phe Glu
Glu Glu Leu Ala Asp Cys Thr Ala Glu Leu Gly Glu 6015 6020 6025 aca
gtc aag ctg gcc tgc cgc gtg acg ggc aca ccc aag cct gtc atc 18206
Thr Val Lys Leu Ala Cys Arg Val Thr Gly Thr Pro Lys Pro Val Ile
6030 6035 6040 6045 agc tgg tac aaa gat ggg aaa gca gtg cag gtg gac
ccc cac cac atc 18254 Ser Trp Tyr Lys Asp Gly Lys Ala Val Gln Val
Asp Pro His His Ile 6050 6055 6060 ctc att gaa gac cct gat ggc tcg
tgt gca ctc atc ctg gac agc ctg 18302 Leu Ile Glu Asp Pro Asp Gly
Ser Cys Ala Leu Ile Leu Asp Ser Leu 6065 6070 6075 acc ggt gtg gac
tct ggc cag tac atg tgc ttc gcg gcc agc gcc gct 18350 Thr Gly Val
Asp Ser Gly Gln Tyr Met Cys Phe Ala Ala Ser Ala Ala 6080 6085 6090
ggc aac tgc agt acc ctg ggc aag atc ctg gtg caa gtc cca cca cgg
18398 Gly Asn Cys Ser Thr Leu Gly Lys Ile Leu Val Gln Val Pro Pro
Arg 6095 6100 6105 ttc gtg aac aag gtc cgg gcc tca ccc ttt gtg gag
gga gag gac gcc 18446 Phe Val Asn Lys Val Arg Ala Ser Pro Phe Val
Glu Gly Glu Asp Ala 6110 6115 6120 6125 cag ttc acc tgc acc atc gaa
ggc gcc ccg tac ccg cag atc agg tgg 18494 Gln Phe Thr Cys Thr Ile
Glu Gly Ala Pro Tyr Pro Gln Ile Arg Trp 6130 6135 6140 tac aag gac
ggg gcc ctg ctg acc act ggc aac aag ttc cag aca ctg 18542 Tyr Lys
Asp Gly Ala Leu Leu Thr Thr Gly Asn Lys Phe Gln Thr Leu 6145 6150
6155 agt gag cct cgc agc ggc ctg cta gtg ctg gtg atc cgg gcg gcc
agc 18590 Ser Glu Pro Arg Ser Gly Leu Leu Val Leu Val Ile Arg Ala
Ala Ser 6160 6165 6170 aag gag gac ctg ggg ctc tac gag tgt gag ctg
gtg aac cgg ctg ggc 18638 Lys Glu Asp Leu Gly Leu Tyr Glu Cys Glu
Leu Val Asn Arg Leu Gly 6175 6180 6185 tcc gcg cgg gct agt gcg gag
ctg cgc att cag agc ccc atg ctg cag 18686 Ser Ala Arg Ala Ser Ala
Glu Leu Arg Ile Gln Ser Pro Met Leu Gln 6190 6195 6200 6205 gcc cag
gag cag tgt cac agg gag cag ctc gtg gct gca gtg gaa gac 18734 Ala
Gln Glu Gln Cys His Arg Glu Gln Leu Val Ala Ala Val Glu Asp 6210
6215 6220 acc acc ctg gag cga gcg gac cag gag gtc aca tct gtc ctg
aag aga 18782 Thr Thr Leu Glu Arg Ala Asp Gln Glu Val Thr Ser Val
Leu Lys Arg 6225 6230 6235 ctg ctg ggc ccc aag gcg cca ggc ccc tcc
aca ggg gac ctc act ggc 18830 Leu Leu Gly Pro Lys Ala Pro Gly Pro
Ser Thr Gly Asp Leu Thr Gly 6240 6245 6250 cct ggc ccc tgc ccc agg
ggg gca ccc gca ctc cag gaa acc ggc tcc 18878 Pro Gly Pro Cys Pro
Arg Gly Ala Pro Ala Leu Gln Glu Thr Gly Ser 6255 6260 6265 cag ccc
cca gtc acc gga act tcg gag gca cct gcc gtg ccc ccg agg 18926 Gln
Pro Pro Val Thr Gly Thr Ser Glu Ala Pro Ala Val Pro Pro Arg 6270
6275 6280 6285 gtg cca cag ccc ctc ctc cac gaa ggc cca gag cag gag
ccg gag gcc 18974 Val Pro Gln Pro Leu Leu His Glu Gly Pro Glu Gln
Glu Pro Glu Ala 6290 6295 6300 att gcc aga gcc cag gaa tgg act gtg
ccc att cgg atg gag ggt gca 19022 Ile Ala Arg Ala Gln Glu Trp Thr
Val Pro Ile Arg Met Glu Gly Ala 6305 6310 6315 gcc tgg ccc ggg gca
ggc aca ggg gag ctg ctc tgg gac gtc cac agc 19070 Ala Trp Pro Gly
Ala Gly Thr Gly Glu Leu Leu Trp Asp Val His Ser 6320 6325 6330 cac
gtg gtc aga gag acc aca cag agg acc tac aca tac cag gcc atc 19118
His Val Val Arg Glu Thr Thr Gln Arg Thr Tyr Thr Tyr Gln Ala Ile
6335 6340 6345 gac acg cac acc gca cgg ccc cca tcc atg cag gta acc
atc gag gat 19166 Asp Thr His Thr Ala Arg Pro Pro Ser Met Gln Val
Thr Ile Glu Asp 6350 6355 6360 6365 gtg cag gca cag aca ggc gga acg
gcc caa ttc gag gct atc att gag 19214 Val Gln Ala Gln Thr Gly Gly
Thr Ala Gln Phe Glu Ala Ile Ile Glu 6370 6375 6380 ggc gac cca cag
ccc tcg gtg acc tgg tac aag gac agc gtc cag ctg 19262 Gly Asp Pro
Gln Pro Ser Val Thr Trp Tyr Lys Asp Ser Val Gln Leu 6385 6390 6395
gtg gac agc acc cgg ctt agc cag cag caa gaa ggc acc aca tac tcc
19310 Val Asp Ser Thr Arg Leu Ser Gln Gln Gln Glu Gly Thr Thr Tyr
Ser 6400 6405 6410 ctg gtg ctg agg cat gtg gcc tcg aag gat gcc ggc
gtt tac acc tgc 19358 Leu Val Leu Arg His Val Ala Ser Lys Asp Ala
Gly Val Tyr Thr Cys 6415 6420 6425 ctg gcc caa aac act ggt ggc cag
gtg ctc tgc aag gca gag ctg ctg 19406 Leu Ala Gln Asn Thr Gly Gly
Gln Val Leu Cys Lys Ala Glu Leu Leu 6430 6435 6440 6445 gtg ctt ggg
ggg gac aat gag ccg gac tca gag aag caa agc cac cgg 19454 Val Leu
Gly Gly Asp Asn Glu Pro Asp Ser Glu Lys Gln Ser His Arg 6450 6455
6460 agg aag ctg cac tcc ttc tat gag gtc aag gag gag att gga agg
ggc 19502 Arg Lys Leu His Ser Phe Tyr Glu Val Lys Glu Glu Ile Gly
Arg Gly 6465 6470 6475 gtg ttt ggc ttc gta aaa aga gtg cag cac aaa
gga aac aag atc ttg 19550 Val Phe Gly Phe Val Lys Arg Val Gln His
Lys Gly Asn Lys Ile Leu 6480 6485 6490 tgc gct gcc aag ttc atc ccc
cta cgg agc aga act cgg gcc cag gca 19598 Cys Ala Ala Lys Phe Ile
Pro Leu Arg Ser Arg Thr Arg Ala Gln Ala 6495 6500 6505 tac agg gag
cga gac atc ctg gcc gcg ctg agc cac ccg ctg gtc acg 19646 Tyr Arg
Glu Arg Asp Ile Leu Ala Ala Leu Ser His Pro Leu Val Thr 6510 6515
6520 6525 ggg ctg ctg gac cag ttt gag acc cgc aag acc ctc atc ctc
atc ctg 19694 Gly Leu Leu Asp Gln Phe Glu Thr Arg Lys Thr Leu Ile
Leu Ile Leu 6530 6535 6540 gag ctg tgc tca tcc gag gag ctg ctg gac
cgc ctg tac agg aag ggc 19742 Glu Leu Cys Ser Ser Glu Glu Leu Leu
Asp Arg Leu Tyr Arg Lys Gly 6545 6550 6555 gtg gtg acg gag gcc gag
gtc aag gtc tac atc cag cag ctg gtg gag 19790 Val Val Thr Glu Ala
Glu Val Lys Val Tyr Ile Gln Gln Leu Val Glu 6560 6565 6570 ggg ctg
cac tac ctg cac agc cat ggc gtt ctc cac ctg gac ata aag 19838 Gly
Leu His Tyr Leu His Ser His Gly Val Leu His Leu Asp Ile Lys 6575
6580 6585 ccc tct aac atc ctg atg gtg cat cct gcc cgg gaa gac att
aaa atc 19886 Pro Ser Asn Ile Leu Met Val His Pro Ala Arg Glu Asp
Ile Lys Ile 6590 6595 6600 6605 tgc gac ttt ggc ttt gcc cag aac atc
acc cca gca gag ctg cag ttc 19934 Cys Asp Phe Gly Phe Ala Gln Asn
Ile Thr Pro Ala Glu Leu Gln Phe 6610 6615 6620 agc cag tac ggc tcc
cct gag ttc gtc tcc ccc gag atc atc cag cag 19982 Ser Gln Tyr Gly
Ser Pro Glu Phe Val Ser Pro Glu Ile Ile Gln Gln 6625 6630 6635 aac
cct gtg agc gaa gcc tcc gac att tgg gcc atg ggt gtc atc tcc 20030
Asn Pro Val Ser Glu Ala Ser Asp Ile Trp Ala Met Gly Val Ile Ser
6640 6645 6650 tac ctc agc ctg acc tgc tca tcc cca ttt gcc ggc gag
agt gac cgt 20078 Tyr Leu Ser Leu Thr Cys Ser Ser Pro Phe Ala Gly
Glu Ser Asp Arg 6655 6660 6665 gcc acc ctc ctg aac gtc ctg gag ggg
cgc gtg tca tgg agc agc ccc 20126 Ala Thr Leu Leu Asn Val Leu Glu
Gly Arg Val Ser Trp Ser Ser Pro 6670 6675 6680 6685 atg gct gcc cac
ctc agc gaa gac gcc aaa gac ttc atc aag gct acg 20174 Met Ala Ala
His Leu Ser Glu Asp Ala Lys Asp Phe Ile Lys Ala Thr 6690 6695 6700
ctg cag aga gcc cct cag gcc cgg cct agt gcg gcc cag tgc ctc tcc
20222 Leu Gln Arg Ala Pro Gln Ala Arg Pro Ser Ala Ala Gln Cys Leu
Ser 6705 6710 6715 cac ccc tgg ttc ctg aaa tcc atg cct gcg gag gag
gcc cac ttc atc 20270 His Pro Trp Phe Leu Lys Ser Met Pro Ala Glu
Glu Ala His Phe Ile 6720 6725 6730 aac acc aag cag ctc aag ttc ctc
ctg gcc cga agt cgc tgg cag cgt 20318 Asn Thr Lys Gln Leu Lys Phe
Leu Leu Ala Arg Ser Arg Trp Gln Arg 6735 6740 6745 tcc ctg atg agc
tac aag tcc atc ctg gtg atg cgc tcc atc cct gag 20366 Ser Leu Met
Ser Tyr Lys Ser Ile Leu Val Met Arg Ser Ile Pro Glu 6750 6755 6760
6765 ctg ctg cgg ggc cca ccc gac agc ccc tcc ctc ggc gta gcc cgg
cac 20414 Leu Leu Arg Gly Pro Pro Asp Ser Pro Ser Leu Gly Val Ala
Arg His 6770 6775 6780 ctc tgc agg gac act ggt ggc tcc tcc agt tcc
tcc tcc tcc tct gac 20462 Leu Cys Arg Asp Thr Gly Gly Ser Ser Ser
Ser Ser Ser Ser Ser Asp 6785 6790 6795 aac gag ctc gcc cca ttt gcc
cgg gct aag tca ctg cca ccc tcc ccg 20510 Asn Glu Leu Ala Pro Phe
Ala Arg Ala Lys Ser Leu Pro Pro Ser Pro 6800 6805 6810 gtg aca cac
tca cca ctg ctg cac ccc cgg ggc ttc ctg cgg ccc tcg 20558 Val Thr
His Ser Pro Leu Leu His Pro Arg Gly Phe Leu Arg Pro Ser 6815 6820
6825 gcc agc ctg cct gag gaa gcc gag gcc agt gag cgc tcc acc gag
gcc 20606 Ala Ser Leu Pro Glu Glu Ala Glu Ala Ser Glu Arg Ser Thr
Glu Ala 6830 6835 6840 6845 cca gct ccg cct gca tct ccc gag ggt gcc
ggg cca ccg gcc gcc cag 20654 Pro Ala Pro Pro Ala Ser Pro Glu Gly
Ala Gly Pro Pro Ala Ala Gln 6850 6855 6860 ggc tgc gtg ccc cgg cac
agc gtc atc cgc agc ctg ttc tac cac cag 20702 Gly Cys Val Pro Arg
His Ser Val Ile Arg Ser Leu Phe Tyr His Gln 6865 6870 6875 gcg ggt
gag agc cct gag cac ggg gcc ctg gcc ccg ggg agc agg cgg 20750 Ala
Gly Glu Ser Pro Glu His Gly Ala Leu Ala Pro Gly Ser Arg Arg 6880
6885 6890 cac ccg gcc cgg cgg cgg cac ctg ctg aag ggc ggg tac att
gcg ggg 20798 His Pro Ala Arg Arg Arg His Leu Leu Lys Gly Gly Tyr
Ile Ala Gly 6895 6900 6905 gcg ctg cca ggc ctg cgc gag cca ctg atg
gag cac cgc gtg ctg gag 20846 Ala Leu Pro Gly Leu Arg Glu Pro Leu
Met Glu His Arg Val Leu Glu 6910 6915 6920 6925 gag gag gcc gcc agg
gag gag cag gcc acc ctc ctg gcc aaa gcc ccc 20894 Glu Glu Ala Ala
Arg Glu Glu Gln Ala Thr Leu Leu Ala Lys Ala Pro 6930 6935 6940 tca
ttc gag act gcc ctc cgg ctg cct gcc tct ggc acc cac ttg gcc 20942
Ser Phe Glu Thr Ala Leu Arg Leu Pro Ala Ser Gly Thr His Leu Ala
6945 6950 6955 cct ggc cac agc cac tcc ctg gaa cat gac tct ccg agc
acc ccc cgc 20990 Pro Gly His Ser His Ser Leu Glu His Asp Ser Pro
Ser Thr Pro Arg 6960 6965 6970 ccc tcc tcg gag gcc tgc ggt gag gca
cag cga ctg cct tca gcc ccc 21038 Pro Ser Ser Glu Ala Cys Gly Glu
Ala Gln Arg Leu Pro Ser Ala Pro 6975 6980 6985 tcc ggg ggg gcc cct
atc agg gac atg ggg cac cct cag ggc tcc aag 21086 Ser Gly Gly Ala
Pro Ile Arg Asp Met Gly His Pro Gln Gly Ser Lys 6990 6995 7000 7005
cag ctt cca tcc act ggt ggc cac cca ggc act gct cag cca gag agg
21134 Gln Leu Pro Ser Thr Gly Gly His Pro Gly Thr Ala Gln Pro Glu
Arg 7010 7015 7020 cca tcc ccg gac agc cct tgg ggg cag cca gcc cct
ttc tgc cac ccc 21182 Pro Ser Pro Asp Ser Pro Trp Gly Gln Pro Ala
Pro Phe Cys His Pro 7025 7030 7035 aag cag ggt tct gcc ccc cag gag
ggc tgc agc ccc cac cca gca gtt 21230 Lys Gln Gly Ser Ala Pro Gln
Glu Gly Cys Ser Pro His Pro Ala Val 7040 7045 7050 gcc cca tgc cct
cct ggc tcc ttc cct cca gga tct tgc aaa gag gcc 21278 Ala Pro Cys
Pro Pro Gly Ser Phe Pro Pro Gly Ser Cys Lys Glu Ala 7055 7060 7065
ccc tta gta ccc tca agc ccc ttc ttg gga cag ccc cag gca ccc cct
21326 Pro Leu Val Pro Ser Ser Pro Phe Leu Gly Gln Pro Gln Ala Pro
Pro 7070 7075 7080 7085 gcc cct gcc aaa gca agc ccc cca ttg gac tct
aag atg ggg cct gga 21374 Ala Pro Ala Lys Ala Ser Pro Pro Leu Asp
Ser Lys Met Gly Pro Gly 7090 7095 7100 gac atc tct ctt cct ggg agg
cca aaa ccc ggc ccc tgc agt tcc cca 21422 Asp Ile Ser Leu Pro Gly
Arg Pro Lys Pro Gly Pro Cys Ser Ser Pro 7105 7110 7115 ggg tca gcc
tcc cag gcg agc tct tcc caa gtg agc tcc ctc agg gtg 21470 Gly Ser
Ala Ser Gln Ala Ser Ser Ser Gln Val Ser Ser Leu Arg Val 7120 7125
7130 ggc tcc tcc cag gtg ggc aca gag cct ggc ccc tcc ctg gat gcg
gag 21518 Gly Ser Ser Gln Val Gly Thr Glu Pro Gly Pro Ser Leu Asp
Ala Glu 7135 7140 7145 ggc tgg acc cag gag gct gag gat ctg tcc gac
tcc aca ccc acc ttg 21566 Gly Trp Thr Gln Glu Ala Glu Asp Leu Ser
Asp Ser Thr Pro Thr Leu 7150 7155 7160 7165 cag cgg cct cag gaa cag
gcg acc atg cgc aag ttc tcc ctg ggt ggt 21614 Gln Arg Pro Gln Glu
Gln Ala Thr Met Arg Lys Phe Ser Leu Gly Gly 7170 7175 7180 cgc ggg
ggc tac gca ggc gtg gct ggc tat ggc acc ttt gcc ttt ggt 21662 Arg
Gly Gly Tyr Ala Gly Val Ala Gly Tyr Gly Thr Phe Ala Phe Gly 7185
7190 7195 gga gat gca ggg ggc atg ctg ggg cag ggg ccc atg tgg gcc
agg ata 21710 Gly Asp Ala Gly Gly Met Leu Gly Gln Gly Pro Met Trp
Ala Arg Ile 7200 7205 7210 gcc tgg gct gtg tcc cag tcg gag gag gag
gag cag gag gag gcc agg 21758 Ala Trp Ala Val Ser Gln Ser Glu Glu
Glu Glu Gln Glu Glu Ala Arg 7215 7220 7225 gct gag tcc cag tcg gag
gag cag cag gag gcc agg gct gag agc cca 21806 Ala Glu Ser Gln Ser
Glu Glu Gln Gln Glu Ala Arg Ala Glu Ser Pro 7230 7235 7240 7245 ctg
ccc cag gtc agt gca agg cct gtg cct gag gtc ggc agg gct ccc 21854
Leu Pro Gln Val Ser Ala Arg Pro Val Pro Glu Val Gly Arg Ala Pro
7250 7255 7260 acc agg agc tct cca gag ccc acc cca tgg gag gac atc
ggg cag gtc 21902 Thr Arg Ser Ser Pro Glu Pro Thr Pro Trp Glu Asp
Ile Gly Gln Val 7265 7270 7275 tcc ctg gtg cag atc cgg gac ctg tca
ggt gat gcg gag gcg gcc gac 21950 Ser Leu Val Gln Ile Arg Asp Leu
Ser Gly Asp Ala Glu Ala Ala Asp 7280 7285 7290 aca ata tcc ctg gac
att tcc gag gtg gac ccc gcc tac ctc aac ctc 21998 Thr Ile Ser Leu
Asp Ile Ser Glu Val Asp Pro Ala Tyr Leu Asn Leu 7295 7300 7305 tca
gac ctg tac gat atc aag tac ctc cca ttc gag ttt atg atc ttc 22046
Ser Asp Leu Tyr Asp Ile Lys Tyr Leu Pro Phe Glu Phe Met Ile Phe
7310 7315 7320 7325 agg aaa gtc ccc aag tcc gct cag cca gag ccg ccc
tcc ccc atg gct 22094 Arg Lys Val Pro Lys Ser Ala Gln Pro Glu Pro
Pro Ser Pro Met Ala 7330 7335 7340 gag gag gag ctg gcc gag ttc ccg
gag ccc acg tgg ccc tgg cca ggt 22142 Glu Glu Glu Leu Ala Glu Phe
Pro Glu Pro Thr Trp Pro Trp Pro Gly 7345 7350 7355 gaa ctg ggc ccc
cac gca ggc ctg gag atc aca gag gag tca gag gat 22190 Glu Leu Gly
Pro His Ala Gly Leu Glu Ile Thr Glu Glu Ser Glu Asp 7360 7365 7370
gtg gac gcg ctg ctg gca gag gct gcc gtg ggc agg aag cgc aag tgg
22238 Val Asp Ala Leu Leu Ala Glu Ala Ala Val Gly Arg Lys Arg Lys
Trp 7375 7380 7385 tcc tcg ccg tca cgc agc ctc ttc cac ttc cct ggg
agg cac ctg ccg 22286 Ser Ser Pro Ser Arg Ser Leu Phe His Phe Pro
Gly Arg His Leu Pro 7390 7395 7400 7405 ctg gat gag cct gca gag ctg
ggg ctg cgt gag aga gtg aag gcc tcc 22334 Leu Asp Glu Pro Ala Glu
Leu Gly Leu Arg Glu Arg Val Lys Ala Ser 7410 7415 7420 gtg gag cac
atc tcc cgg atc ctg aag ggc agg ccg gaa ggt ctg gag 22382 Val Glu
His Ile Ser Arg Ile Leu Lys Gly Arg Pro Glu Gly Leu Glu 7425 7430
7435 aag gag ggg ccc ccc agg aag aag cca ggc ctt gct tcc ttc cgg
ctc 22430 Lys Glu Gly Pro Pro Arg Lys Lys Pro Gly Leu Ala Ser Phe
Arg Leu 7440 7445 7450 tca ggt ctg aag agc tgg gac cga gcg ccg aca
ttc cta agg gag ctc 22478 Ser Gly Leu Lys Ser Trp Asp Arg Ala Pro
Thr Phe Leu Arg Glu Leu 7455 7460 7465 tca gat gag act gtg gtc ctg
ggc cag tca gtg aca ctg gcc tgc cag 22526 Ser Asp Glu Thr Val Val
Leu Gly Gln Ser Val Thr Leu Ala Cys Gln 7470 7475 7480 7485 gtg tca
gcc cag cca gct gcc cag gcc acc tgg agc aaa gac gga gcc 22574 Val
Ser Ala Gln Pro Ala Ala Gln Ala Thr Trp Ser Lys Asp Gly Ala 7490
7495 7500 ccc ctg gag agc agc agc cgt gtc ctc atc tct gcc acc ctc
aag aac 22622 Pro Leu Glu Ser Ser Ser Arg Val Leu Ile Ser Ala Thr
Leu Lys Asn 7505 7510 7515 ttc cag ctt ctg acc atc ctg gtg gtg gtg
gct gag gac ctg ggt gtg 22670 Phe Gln Leu Leu Thr Ile Leu Val Val
Val Ala Glu Asp Leu Gly Val 7520 7525 7530 tac acc tgc agc gtg agc
aat gcg ctg ggg aca gtg acc acc acg ggc 22718 Tyr Thr Cys Ser Val
Ser Asn Ala Leu Gly Thr Val Thr Thr Thr Gly 7535 7540 7545 gtc ctc
cgg aag gca gag cgc ccc tca tct tcg cca tgc ccg gat atc 22766 Val
Leu Arg Lys Ala Glu Arg Pro Ser Ser Ser Pro Cys Pro Asp Ile 7550
7555 7560 7565 ggg gag gtg tac gcg gat ggg gtg ctg ctg gtc tgg aag
ccc gtg gaa 22814 Gly Glu Val Tyr Ala Asp Gly Val Leu Leu Val Trp
Lys Pro Val Glu 7570 7575 7580 tcc tac ggc cct gtg acc tac att gtg
cag tgc agc cta gaa ggc ggc 22862 Ser Tyr Gly Pro Val Thr Tyr Ile
Val Gln Cys Ser Leu Glu Gly Gly 7585 7590 7595 agc tgg acc aca ctg
gcc tcc gac atc ttt gac tgc tgc tac ctg acc 22910 Ser Trp Thr Thr
Leu Ala Ser Asp Ile Phe Asp Cys Cys Tyr Leu Thr 7600 7605 7610 agc
aag ctc tcc cgg ggt ggc acc tac acc ttc cgc acg gca tgt gtc 22958
Ser Lys Leu Ser Arg Gly Gly Thr Tyr Thr Phe Arg Thr Ala Cys Val
7615 7620 7625 agc aag gca gga atg ggt ccc tac agc agc ccc tcg gag
caa gtc ctc 23006 Ser Lys Ala Gly Met Gly Pro Tyr Ser Ser Pro Ser
Glu Gln Val Leu 7630 7635 7640 7645 ctg gga ggg ccc agc cac ctg gcc
tct gag gag gag agc cag ggg cgg 23054 Leu Gly Gly Pro Ser His Leu
Ala Ser Glu Glu Glu Ser Gln Gly Arg 7650 7655 7660 tca gcc caa ccc
ctg ccc agc aca aag acc ttc gca ttc cag aca cag 23102 Ser Ala Gln
Pro Leu Pro Ser Thr Lys Thr Phe Ala Phe Gln Thr Gln 7665 7670 7675
atc cag agg ggc cgc ttc agc gtg gtg cgg caa tgc tgg gag aag gcc
23150 Ile Gln Arg Gly Arg Phe Ser Val Val Arg Gln Cys Trp Glu Lys
Ala 7680 7685 7690 agc ggg cgg gcg ctg gcc gcc aag atc atc ccc tac
cac ccc aag gac 23198 Ser Gly Arg Ala Leu Ala Ala Lys Ile Ile Pro
Tyr His Pro Lys Asp 7695 7700 7705 aag aca gca gtg ctg cgc gaa tac
gag gcc ctc aag ggc ctg cgc cac 23246 Lys Thr Ala Val Leu Arg Glu
Tyr Glu Ala Leu Lys Gly Leu Arg His 7710 7715 7720 7725 ccg cac ctg
gcc cag ctg cac gca gcc tac ctc agc ccc cgg cac ctg 23294 Pro His
Leu Ala Gln Leu His Ala Ala Tyr Leu Ser Pro Arg His Leu 7730 7735
7740 gtg ctc atc ttg gag ctg tgc tct ggg ccc gag ctg ctc ccc tgc
ctg 23342 Val Leu Ile Leu Glu Leu Cys Ser Gly Pro Glu Leu Leu Pro
Cys Leu 7745 7750 7755 gcc gag agg gcc tcc tac tca gaa tcc gag gtg
aag gac tac ctg tgg 23390 Ala Glu Arg Ala Ser Tyr Ser Glu Ser Glu
Val Lys Asp Tyr Leu Trp 7760 7765 7770 cag atg ttg agt gcc acc cag
tac ctg cac aac cag cac atc ctg cac 23438 Gln Met Leu Ser Ala Thr
Gln Tyr Leu His Asn Gln His Ile Leu His 7775 7780 7785 ctg gac ctg
agg tcc gag aac atg atc atc acc gaa tac aac ctg ctc 23486 Leu Asp
Leu Arg Ser Glu Asn Met Ile Ile Thr Glu Tyr Asn Leu Leu 7790 7795
7800 7805 aag gtc gtg gac ctg ggc aat gca cag agc ctc agc cag gag
aag gtg 23534 Lys Val Val Asp Leu Gly Asn Ala Gln Ser Leu Ser Gln
Glu Lys Val 7810 7815 7820 ctg ccc tca gac aag ttc aag gac tac cta
gag acc atg gct cca gag 23582 Leu Pro Ser Asp Lys Phe Lys Asp Tyr
Leu Glu Thr Met Ala Pro Glu 7825 7830 7835 ctc ctg gag ggc cag ggg
gct gtt cca cag aca gac atc tgg gcc atc 23630 Leu Leu Glu Gly Gln
Gly Ala Val Pro Gln Thr Asp Ile Trp Ala Ile 7840 7845 7850 ggt gtg
aca gcc ttc atc atg ctg agc gcc gag tac ccg gtg agc agc 23678 Gly
Val Thr Ala Phe Ile Met Leu Ser Ala Glu Tyr Pro Val Ser Ser 7855
7860 7865 gag ggt gca cgc gac ctg cag aga gga ctg cgc aag ggg ctg
gtc cgg 23726 Glu Gly Ala Arg Asp Leu Gln Arg Gly Leu Arg Lys Gly
Leu Val Arg 7870 7875 7880 7885 ctg agc cgc tgc tac gcg ggg ctg tcc
ggg ggc gcc gtg gcc ttc ctg 23774 Leu Ser Arg Cys Tyr Ala Gly Leu
Ser Gly Gly Ala Val Ala Phe Leu 7890 7895 7900 cgc agc act ctg tgc
gcc cag ccc tgg ggc cgg ccc tgc gcg tcc agc 23822 Arg Ser Thr Leu
Cys Ala Gln Pro Trp Gly Arg Pro Cys Ala Ser Ser 7905 7910 7915 tgc
ctg cag tgc ccg tgg cta aca gag gag ggc ccg gcc tgt tcg cgg 23870
Cys Leu Gln Cys Pro Trp Leu Thr Glu Glu Gly Pro Ala Cys Ser Arg
7920 7925 7930 ccc gcg ccc gtg acc ttc cct acc gcg cgg ctg cgc gtc
ttc gtg cgc 23918 Pro Ala Pro Val Thr Phe Pro Thr Ala Arg Leu Arg
Val Phe Val Arg 7935 7940 7945 aat cgc gag aag aga cgc gcg ctg ctg
tac aag agg cac aac ctg gcc 23966 Asn Arg Glu Lys Arg Arg Ala Leu
Leu Tyr Lys Arg His Asn Leu Ala 7950 7955 7960 7965 cag gtg cgc tga
gggtcgcccc ggccacaccc ttggtctccc cgctgggggt 24018 Gln Val Arg *
cgctgcagac gcgccaataa aaacgcccag ccgggcgaga aaaaaaaaaa aaaaaaaaaa
24078 aaaaaaaaaa aaaaaaaaag gcggccgcta aaaaagtcta ga 24120 5 7968
PRT Homo sapiens 5 Met Asp Gln Pro Gln Phe Ser Gly Ala Pro Arg Phe
Leu Thr Arg Pro 1 5 10 15 Lys Ala Phe Val Val Ser Val Gly Lys Asp
Ala Thr Leu Ser Cys Gln 20 25 30 Ile Val Gly Asn Pro Thr Pro Gln
Val Ser Trp Glu Lys Asp Gln Gln 35 40 45 Pro Val Thr Ala Gly Ala
Arg Phe Arg Leu Ala Gln Asp Gly Asp Leu 50 55 60 Tyr Arg Leu Thr
Ile Leu Asp Leu Ala Leu Gly Asp Ser Gly Gln Tyr 65 70 75 80 Val Cys
Arg Ala Arg Asn Ala Ile Gly Glu Ala Phe Ala Ala Val Gly 85 90 95
Leu Gln Val Asp Ala Glu Ala Ala Cys Ala Glu Gln Ala Pro His Phe 100
105 110 Leu Leu Arg Pro Thr Ser Ile Arg Val Arg Glu Gly Ser Glu Ala
Thr 115 120 125 Phe Arg Cys Arg Val Gly Gly Ser Pro Arg Pro Ala Val
Ser Trp Ser 130 135 140 Lys Asp Gly Arg Arg Leu Gly Glu Pro Asp Gly
Pro Arg Val Arg Val 145 150 155 160 Glu Glu Leu Gly Glu Ala Ser Ala
Leu Arg Ile Arg Ala Ala Arg Pro 165 170 175 Arg Asp Gly Gly Thr Tyr
Glu Val Arg Ala Glu Asn Pro Leu Gly Ala 180 185 190 Ala Ser Ala Ala
Ala Ala Leu Val Val Asp Ser Asp Ala Ala Asp Thr 195 200 205 Ala Ser
Arg Pro Gly Thr Ser Thr Ala Ala Leu Leu Ala His Leu Gln 210 215 220
Arg Arg Arg Glu Ala Met Arg Ala Glu Gly Ala Pro Ala Ser Pro Pro 225
230 235 240 Ser Thr Gly Thr Arg Thr Cys Thr Val Thr Glu Gly Lys His
Ala Arg 245 250 255 Leu Ser Cys Tyr Val Thr Gly Glu Pro Lys Pro Glu
Thr Val Trp Lys 260 265 270 Lys Asp Gly Gln Leu Val Thr Glu Gly Arg
Arg His Val Val Tyr Glu 275 280 285 Asp Ala Gln Glu Asn Phe Val Leu
Lys Ile Leu Phe Cys Lys Gln Ser 290 295 300 Asp Arg Gly Leu Tyr Thr
Cys Thr Ala Ser Asn Leu Val Gly Gln Thr 305 310 315 320 Tyr Ser Ser
Val Leu Val Val Val Arg Glu Pro Ala Val Pro Phe Lys 325 330 335 Lys
Arg Leu Gln Asp Leu Glu Val Arg Glu Lys Glu Ser Ala Thr Phe 340 345
350 Leu Cys Glu Val Pro Gln Pro Ser Thr Glu Ala Ala Trp Phe Lys Glu
355 360 365 Glu Thr Arg Leu Trp Ala Ser Ala Lys Tyr Gly Ile Glu Glu
Glu Gly 370 375 380 Thr Glu Arg Arg Leu Thr Val Arg Asn Val Ser Ala
Asp Asp Asp Ala 385 390 395 400 Val Tyr Ile Cys Glu Thr Pro Glu Gly
Ser Arg Thr Val Ala Glu Leu 405 410 415 Ala Val Gln Gly Asn Leu Leu
Arg Lys Leu Pro Arg Lys Thr Ala Val 420 425 430 Arg Val Gly Asp Thr
Ala Met Phe Cys Val Glu Leu Ala Val Pro Val 435 440 445 Gly Pro Val
His Trp Leu Arg Asn Gln Glu Glu Val Val Ala Gly Gly 450 455 460 Arg
Val Ala Ile Ser Ala Glu Gly Thr Arg His Thr Leu Thr Ile Ser 465 470
475 480 Gln Cys Cys Leu Glu Asp Val Gly Gln Val Ala Phe Met Ala Gly
Asp 485 490 495 Cys Gln Thr Ser Thr Arg Phe Cys Val Ser Ala Pro Arg
Lys Pro Pro 500 505 510 Leu Gln Pro Pro Val Asp Pro Val Val Lys Ala
Arg Met Glu Ser Ser 515 520 525 Val Ile Leu Ser Trp Ser Pro Pro Pro
His Gly Glu Arg Pro Val Thr 530 535 540 Ile Asp Gly Tyr Leu Val Glu
Lys Lys Lys Leu Gly Thr Tyr Thr Trp 545 550 555 560 Ile Arg Cys His
Glu Ala Glu Trp Val Ala Thr Pro Glu Leu Thr Val 565 570 575 Ala Asp
Val Ala Glu Glu Gly Asn Phe Gln Phe Arg Val Ser Ala Leu 580 585 590
Asn Ser Phe Gly Gln Ser Pro Tyr Leu Glu Phe Pro Gly Thr Val His 595
600 605 Leu Ala Pro Lys Leu Ala Val Arg Thr Pro Leu Lys Ala Val Gln
Ala 610 615 620 Val Glu Gly Gly Glu Val Thr Phe Ser Val Asp Leu Thr
Val Ala Ser 625 630 635 640 Ala Gly Glu Trp Phe Leu Asp Gly Gln Ala
Leu Lys Ala Ser Ser Val 645 650 655 Tyr Glu Ile His Cys Asp Arg Thr
Arg His Thr Leu Thr Ile Arg Glu 660 665 670 Val Pro Ala Ser Leu His
Gly Ala Gln Leu Lys Phe Val Ala Asn Gly 675 680 685 Ile Glu Ser Ser
Ile Arg Met Glu Val Arg Ala Ala Pro Gly Leu Thr 690 695 700 Ala Asn
Lys Pro Pro Ala Ala Ala Ala Arg Glu Val Leu Ala Arg Leu 705 710 715
720 His Glu Glu Ala Gln Leu Leu Ala Glu Leu Ser Asp Gln Ala Ala Ala
725 730 735 Val Thr Trp Leu Lys Asp Gly Arg Thr Leu Ser Pro Gly Pro
Lys Tyr 740 745 750 Glu Val Gln Ala Ser Ala Gly Arg Arg Val Leu Leu
Val Arg Asp Val 755 760 765
Ala Arg Asp Asp Ala Gly Leu Tyr Glu Cys Val Ser Arg Gly Gly Arg 770
775 780 Ile Ala Tyr Gln Leu Ser Val Gln Gly Leu Ala Arg Phe Leu His
Lys 785 790 795 800 Asp Met Ala Gly Ser Cys Val Asp Ala Val Ala Gly
Gly Pro Ala Gln 805 810 815 Phe Glu Cys Glu Thr Ser Glu Ala His Val
His Val His Trp Tyr Lys 820 825 830 Asp Gly Met Glu Leu Gly His Ser
Gly Glu Arg Phe Leu Gln Glu Asp 835 840 845 Val Gly Thr Arg His Arg
Leu Val Ala Ala Thr Val Thr Arg Gln Asp 850 855 860 Glu Gly Thr Tyr
Ser Cys Arg Val Gly Glu Asp Ser Val Asp Phe Arg 865 870 875 880 Leu
Arg Val Ser Glu Pro Lys Val Val Phe Ala Lys Glu Gln Leu Ala 885 890
895 Arg Arg Lys Leu Gln Ala Glu Ala Gly Ala Ser Ala Thr Leu Ser Cys
900 905 910 Glu Val Ala Gln Ala Gln Thr Glu Val Thr Trp Tyr Lys Asp
Gly Lys 915 920 925 Lys Leu Ser Ser Ser Ser Lys Val Cys Met Glu Ala
Thr Gly Cys Thr 930 935 940 Arg Arg Leu Val Val Gln Gln Ala Gly Gln
Ala Asp Ala Gly Glu Tyr 945 950 955 960 Ser Cys Glu Ala Gly Gly Gln
Arg Leu Ser Phe His Leu Asp Val Lys 965 970 975 Glu Pro Lys Val Val
Phe Ala Lys Asp Gln Val Ala His Ser Glu Val 980 985 990 Gln Ala Glu
Ala Gly Ala Asn Ala Thr Leu Ser Cys Glu Val Ala Gln 995 1000 1005
Ala Gln Ala Glu Val Met Trp Tyr Lys Asp Gly Lys Lys Leu Ser Ser
1010 1015 1020 Ser Leu Lys Val His Val Glu Ala Lys Gly Cys Arg Arg
Arg Leu Val 1025 1030 1035 1040 Val Gln Gln Ala Gly Lys Thr Asp Ala
Gly Asp Tyr Ser Cys Glu Ala 1045 1050 1055 Arg Gly Gln Arg Val Ser
Phe Arg Leu His Ile Thr Glu Pro Lys Met 1060 1065 1070 Met Phe Ala
Lys Glu Gln Ser Val His Asn Glu Val Gln Ala Glu Ala 1075 1080 1085
Gly Ala Ser Ala Met Leu Ser Cys Glu Val Ala Gln Ala Gln Thr Glu
1090 1095 1100 Val Thr Trp Tyr Lys Asp Gly Lys Lys Leu Ser Ser Ser
Ser Lys Val 1105 1110 1115 1120 Gly Met Glu Val Lys Gly Cys Thr Arg
Arg Leu Val Leu Pro Gln Ala 1125 1130 1135 Gly Lys Ala Asp Ala Gly
Glu Tyr Ser Cys Glu Ala Gly Gly Gln Arg 1140 1145 1150 Val Ser Phe
His Leu His Ile Thr Glu Pro Lys Gly Val Phe Ala Lys 1155 1160 1165
Glu Gln Ser Val His Asn Glu Val Gln Ala Glu Ala Gly Thr Thr Ala
1170 1175 1180 Met Leu Ser Cys Glu Val Ala Gln Pro Gln Thr Glu Val
Thr Trp Tyr 1185 1190 1195 1200 Lys Asp Gly Lys Lys Leu Ser Ser Ser
Ser Lys Val Arg Met Glu Val 1205 1210 1215 Lys Gly Cys Thr Arg Arg
Leu Val Val Gln Gln Val Gly Lys Ala Asp 1220 1225 1230 Ala Gly Glu
Tyr Ser Cys Glu Ala Gly Gly Gln Arg Val Ser Phe Gln 1235 1240 1245
Leu His Ile Thr Glu Pro Lys Ala Val Phe Ala Lys Glu Gln Leu Val
1250 1255 1260 His Asn Glu Val Arg Thr Glu Ala Gly Ala Ser Ala Thr
Leu Ser Cys 1265 1270 1275 1280 Glu Val Ala Gln Ala Gln Thr Glu Val
Thr Trp Tyr Lys Asp Gly Lys 1285 1290 1295 Lys Leu Ser Ser Ser Ser
Lys Val Arg Ile Glu Ala Ala Gly Cys Met 1300 1305 1310 Arg Gln Leu
Val Val Gln Gln Ala Gly Gln Ala Asp Ala Gly Glu Tyr 1315 1320 1325
Thr Cys Glu Ala Gly Gly Gln Arg Leu Ser Phe His Leu Asp Val Ser
1330 1335 1340 Glu Pro Lys Ala Val Phe Ala Lys Glu Gln Leu Ala His
Arg Lys Val 1345 1350 1355 1360 Gln Ala Glu Ala Gly Ala Ile Ala Thr
Leu Ser Cys Glu Val Ala Gln 1365 1370 1375 Ala Gln Thr Glu Val Thr
Trp Tyr Lys Asp Gly Lys Lys Leu Ser Ser 1380 1385 1390 Ser Ser Lys
Val Arg Met Glu Ala Val Gly Cys Thr Arg Arg Leu Val 1395 1400 1405
Val Gln Gln Ala Cys Gln Ala Asp Thr Gly Glu Tyr Ser Cys Glu Ala
1410 1415 1420 Gly Gly Gln Arg Leu Ser Phe Ser Leu Asp Val Ala Glu
Pro Lys Val 1425 1430 1435 1440 Val Phe Ala Lys Glu Gln Pro Val His
Arg Glu Val Gln Ala Gln Ala 1445 1450 1455 Gly Ala Ser Thr Thr Leu
Ser Cys Glu Val Ala Gln Ala Gln Thr Glu 1460 1465 1470 Val Met Trp
Tyr Lys Asp Gly Lys Lys Leu Ser Phe Ser Ser Lys Val 1475 1480 1485
Arg Met Glu Ala Val Gly Cys Thr Arg Arg Leu Val Val Gln Gln Ala
1490 1495 1500 Gly Gln Ala Asp Ala Gly Glu Tyr Ser Cys Glu Ala Gly
Ser Gln Arg 1505 1510 1515 1520 Leu Ser Phe His Leu His Val Ala Glu
Pro Lys Ala Val Phe Ala Lys 1525 1530 1535 Glu Gln Pro Ala Ser Arg
Glu Val Gln Ala Glu Ala Gly Thr Ser Ala 1540 1545 1550 Thr Leu Ser
Cys Glu Val Ala Gln Ala Gln Thr Glu Val Thr Trp Tyr 1555 1560 1565
Lys Asp Gly Lys Lys Leu Ser Ser Ser Ser Lys Val Arg Met Glu Ala
1570 1575 1580 Val Gly Cys Thr Arg Arg Leu Val Val Gln Glu Ala Gly
Gln Ala Asp 1585 1590 1595 1600 Ala Gly Glu Tyr Ser Cys Lys Ala Gly
Asp Gln Arg Leu Ser Phe His 1605 1610 1615 Leu His Val Ala Glu Pro
Lys Val Val Phe Ala Lys Glu Gln Pro Ala 1620 1625 1630 His Arg Glu
Val Gln Ala Glu Ala Gly Ala Ser Ala Thr Leu Ser Cys 1635 1640 1645
Glu Val Ala Gln Ala Gln Thr Glu Val Thr Trp Tyr Lys Asp Gly Lys
1650 1655 1660 Lys Leu Ser Ser Ser Ser Lys Val Arg Val Glu Ala Val
Gly Cys Thr 1665 1670 1675 1680 Arg Arg Leu Val Val Gln Gln Ala Gly
Gln Ala Asp Ala Gly Glu Tyr 1685 1690 1695 Ser Cys Glu Ala Gly Gly
Gln Arg Leu Ser Phe Arg Leu His Val Ala 1700 1705 1710 Glu Leu Glu
Pro Gln Ile Ser Glu Arg Pro Cys Arg Arg Glu Pro Leu 1715 1720 1725
Val Val Lys Glu His Glu Asp Ile Ile Leu Thr Ala Thr Leu Ala Thr
1730 1735 1740 Pro Ser Ala Ala Thr Val Thr Trp Leu Lys Asp Gly Val
Glu Ile Arg 1745 1750 1755 1760 Arg Ser Lys Arg His Glu Thr Ala Ser
Gln Gly Asp Thr His Thr Leu 1765 1770 1775 Thr Val His Gly Ala Gln
Val Leu Asp Ser Ala Ile Tyr Ser Cys Arg 1780 1785 1790 Val Gly Ala
Glu Gly Gln Asp Phe Pro Val Gln Val Glu Glu Val Ala 1795 1800 1805
Ala Lys Phe Cys Arg Leu Leu Glu Pro Val Cys Gly Glu Leu Gly Gly
1810 1815 1820 Thr Val Thr Leu Ala Cys Glu Leu Ser Pro Ala Cys Ala
Glu Val Val 1825 1830 1835 1840 Trp Arg Cys Gly Asn Thr Gln Pro Arg
Val Gly Lys Arg Phe Gln Met 1845 1850 1855 Val Ala Glu Gly Pro Val
Arg Ser Leu Thr Val Leu Gly Leu Arg Ala 1860 1865 1870 Glu Asp Ala
Gly Glu Tyr Val Cys Glu Ser Arg Asp Asp His Thr Ser 1875 1880 1885
Ala Gln Leu Thr Val Ser Val Pro Arg Val Val Lys Phe Met Ser Gly
1890 1895 1900 Leu Ser Thr Val Val Ala Glu Glu Gly Gly Glu Ala Thr
Phe Gln Cys 1905 1910 1915 1920 Val Val Ser Pro Ser Asp Val Ala Val
Val Trp Phe Arg Asp Gly Ala 1925 1930 1935 Leu Leu Gln Pro Ser Glu
Lys Phe Ala Ile Ser Gln Ser Gly Ala Ser 1940 1945 1950 His Ser Leu
Thr Ile Ser Asp Leu Val Leu Glu Asp Ala Gly Gln Ile 1955 1960 1965
Thr Val Glu Ala Glu Gly Ala Ser Ser Ser Ala Ala Leu Arg Val Arg
1970 1975 1980 Glu Ala Pro Val Leu Phe Lys Lys Lys Leu Glu Pro Gln
Thr Val Glu 1985 1990 1995 2000 Glu Arg Ser Ser Val Thr Leu Glu Val
Glu Leu Thr Arg Pro Trp Pro 2005 2010 2015 Glu Leu Arg Trp Thr Arg
Asn Ala Thr Ala Leu Ala Pro Gly Lys Asn 2020 2025 2030 Val Glu Ile
His Ala Glu Gly Ala Arg His Arg Leu Val Leu His Asn 2035 2040 2045
Val Gly Phe Ala Asp Arg Gly Phe Phe Gly Cys Glu Thr Pro Asp Asp
2050 2055 2060 Lys Thr Gln Ala Lys Leu Thr Val Glu Met Arg Gln Val
Arg Leu Val 2065 2070 2075 2080 Arg Gly Leu Gln Ala Val Glu Ala Arg
Glu Gln Gly Thr Ala Thr Met 2085 2090 2095 Glu Val Gln Leu Ser His
Ala Asp Val Asp Gly Ser Trp Thr Arg Asp 2100 2105 2110 Gly Leu Arg
Phe Gln Gln Gly Pro Thr Cys His Leu Ala Val Arg Gly 2115 2120 2125
Pro Met His Thr Leu Thr Leu Ser Gly Leu Arg Pro Glu Asp Ser Gly
2130 2135 2140 Leu Met Val Phe Lys Ala Glu Gly Val His Thr Ser Ala
Arg Leu Val 2145 2150 2155 2160 Val Thr Glu Leu Pro Val Ser Phe Ser
Arg Pro Leu Gln Asp Val Val 2165 2170 2175 Thr Thr Glu Lys Glu Lys
Val Thr Leu Glu Cys Glu Leu Ser Arg Pro 2180 2185 2190 Asn Val Asp
Val Arg Trp Leu Lys Asp Gly Val Glu Leu Arg Ala Gly 2195 2200 2205
Lys Thr Met Ala Ile Ala Ala Gln Gly Ala Cys Arg Ser Leu Thr Ile
2210 2215 2220 Tyr Arg Cys Glu Phe Ala Asp Gln Gly Val Tyr Val Cys
Asp Ala His 2225 2230 2235 2240 Asp Ala Gln Ser Ser Ala Ser Val Lys
Val Gln Gly Arg Thr Tyr Thr 2245 2250 2255 Leu Ile Tyr Arg Arg Val
Leu Ala Glu Asp Ala Gly Glu Ile Gln Phe 2260 2265 2270 Val Ala Glu
Asn Ala Glu Ser Arg Ala Gln Leu Arg Val Lys Glu Leu 2275 2280 2285
Pro Val Thr Leu Val Arg Pro Leu Arg Asp Lys Ile Ala Met Glu Lys
2290 2295 2300 His Arg Gly Val Leu Glu Cys Gln Val Ser Arg Ala Ser
Ala Gln Val 2305 2310 2315 2320 Arg Trp Phe Lys Gly Ser Gln Glu Leu
Gln Pro Gly Pro Lys Tyr Glu 2325 2330 2335 Leu Val Ser Asp Gly Leu
Tyr Arg Lys Leu Ile Ile Ser Asp Val His 2340 2345 2350 Ala Glu Asp
Glu Asp Thr Tyr Thr Cys Asp Ala Gly Asp Val Lys Thr 2355 2360 2365
Ser Ala Gln Phe Phe Val Glu Glu Gln Ser Ile Thr Ile Val Arg Gly
2370 2375 2380 Leu Gln Asp Val Thr Val Met Glu Pro Ala Pro Ala Trp
Phe Glu Cys 2385 2390 2395 2400 Glu Thr Ser Ile Pro Ser Val Arg Pro
Pro Lys Trp Leu Leu Gly Lys 2405 2410 2415 Thr Val Leu Gln Ala Gly
Gly Asn Val Gly Leu Glu Gln Glu Gly Thr 2420 2425 2430 Val His Arg
Leu Met Leu Arg Arg Thr Cys Ser Thr Met Thr Gly Pro 2435 2440 2445
Val His Phe Thr Val Gly Lys Ser Arg Ser Ser Ala Arg Leu Val Val
2450 2455 2460 Ser Asp Ile Pro Val Val Leu Thr Arg Pro Leu Glu Pro
Lys Thr Gly 2465 2470 2475 2480 Arg Glu Leu Gln Ser Val Val Leu Ser
Cys Asp Phe Arg Pro Ala Pro 2485 2490 2495 Lys Ala Val Gln Trp Tyr
Lys Asp Asp Thr Pro Leu Ser Pro Ser Glu 2500 2505 2510 Lys Phe Lys
Met Ser Leu Glu Gly Gln Met Ala Glu Leu Arg Ile Leu 2515 2520 2525
Arg Leu Met Pro Ala Asp Ala Gly Val Tyr Arg Cys Gln Ala Gly Ser
2530 2535 2540 Ala His Ser Ser Thr Glu Val Thr Val Glu Ala Arg Glu
Val Thr Val 2545 2550 2555 2560 Thr Gly Pro Leu Gln Asp Ala Glu Ala
Thr Glu Glu Gly Trp Ala Ser 2565 2570 2575 Phe Ser Cys Glu Leu Ser
His Glu Asp Glu Glu Val Glu Trp Ser Leu 2580 2585 2590 Asn Gly Met
Pro Leu Tyr Asn Asp Ser Phe His Glu Ile Ser His Lys 2595 2600 2605
Gly Arg Arg His Thr Leu Val Leu Lys Ser Ile Gln Arg Ala Asp Ala
2610 2615 2620 Gly Ile Val Arg Ala Ser Ser Leu Lys Val Ser Thr Ser
Ala Arg Leu 2625 2630 2635 2640 Glu Val Arg Val Lys Pro Val Val Phe
Leu Lys Ala Leu Asp Asp Leu 2645 2650 2655 Ser Ala Glu Glu Arg Gly
Thr Leu Ala Leu Gln Cys Glu Val Ser Asp 2660 2665 2670 Pro Glu Ala
His Val Val Trp Arg Lys Asp Gly Val Gln Leu Gly Pro 2675 2680 2685
Ser Asp Lys Tyr Asp Phe Leu His Thr Ala Gly Thr Arg Gly Leu Val
2690 2695 2700 Val His Asp Val Ser Pro Glu Asp Ala Gly Leu Tyr Thr
Cys His Val 2705 2710 2715 2720 Gly Ser Glu Glu Thr Arg Ala Arg Val
Arg Val His Asp Leu His Val 2725 2730 2735 Gly Ile Thr Lys Arg Leu
Lys Thr Met Glu Val Leu Glu Gly Glu Ser 2740 2745 2750 Cys Ser Phe
Glu Cys Val Leu Ser His Glu Ser Ala Ser Asp Pro Ala 2755 2760 2765
Met Trp Thr Val Gly Gly Lys Thr Val Gly Ser Ser Ser Arg Phe Gln
2770 2775 2780 Ala Thr Arg Gln Gly Arg Lys Tyr Ile Leu Val Val Arg
Glu Ala Ala 2785 2790 2795 2800 Pro Ser Asp Ala Gly Glu Val Val Phe
Ser Val Arg Gly Leu Thr Ser 2805 2810 2815 Lys Ala Ser Leu Ile Val
Arg Glu Arg Pro Ala Ala Ile Ile Lys Pro 2820 2825 2830 Leu Glu Asp
Gln Trp Val Ala Pro Gly Glu Asp Val Glu Leu Arg Cys 2835 2840 2845
Glu Leu Ser Arg Ala Gly Thr Pro Val His Trp Leu Lys Asp Arg Lys
2850 2855 2860 Ala Ile Arg Lys Ser Gln Lys Tyr Asp Val Val Cys Glu
Gly Thr Met 2865 2870 2875 2880 Ala Met Leu Val Ile Arg Gly Ala Ser
Leu Lys Asp Ala Gly Glu Tyr 2885 2890 2895 Thr Cys Glu Val Glu Ala
Ser Lys Ser Thr Ala Ser Leu His Val Glu 2900 2905 2910 Glu Lys Ala
Asn Cys Phe Thr Glu Glu Leu Thr Asn Leu Gln Val Glu 2915 2920 2925
Glu Lys Gly Thr Ala Val Phe Thr Cys Lys Thr Glu His Pro Ala Ala
2930 2935 2940 Thr Val Thr Trp Arg Lys Gly Leu Leu Glu Leu Arg Ala
Ser Gly Lys 2945 2950 2955 2960 His Gln Pro Ser Gln Glu Gly Leu Thr
Leu Arg Leu Thr Ile Ser Ala 2965 2970 2975 Leu Glu Lys Ala Asp Ser
Asp Thr Tyr Thr Cys Asp Ile Gly Gln Ala 2980 2985 2990 Gln Ser Arg
Ala Gln Leu Leu Val Gln Gly Arg Arg Val His Ile Ile 2995 3000 3005
Glu Asp Leu Glu Asp Val Asp Val Gln Glu Gly Ser Ser Ala Thr Phe
3010 3015 3020 Arg Cys Arg Ile Ser Pro Ala Asn Tyr Glu Pro Val His
Trp Phe Leu 3025 3030 3035 3040 Asp Lys Thr Pro Leu His Ala Asn Glu
Leu Asn Glu Ile Asp Ala Gln 3045 3050 3055 Pro Gly Gly Tyr His Val
Leu Thr Leu Arg Gln Leu Ala Leu Lys Asp 3060 3065 3070 Ser Gly Thr
Ile Tyr Phe Glu Ala Gly Asp Gln Arg Ala Ser Ala Ala 3075 3080 3085
Leu Arg Val Thr Glu Lys Pro Ser Val Phe Ser Arg Glu Leu Thr Asp
3090 3095 3100 Ala Thr Ile Thr Glu Gly Glu Asp Leu Thr Leu Val Cys
Glu Thr Ser 3105 3110 3115 3120 Thr Cys Asp Ile Pro Met Cys Trp Thr
Lys Asp Gly Lys Thr Leu Arg 3125 3130 3135 Gly Ser Ala Arg Cys Gln
Leu Ser His Glu Gly His Arg Ala Gln Leu 3140 3145 3150 Leu Ile Thr
Gly Ala Thr Leu Gln Asp Ser Gly Arg Tyr Lys Cys Glu 3155 3160 3165
Ala Gly Gly Ala Cys Ser Ser Ser Ile Val Arg Val His Ala Arg Pro
3170 3175
3180 Val Arg Phe Gln Glu Ala Leu Lys Asp Leu Glu Val Leu Glu Gly
Gly 3185 3190 3195 3200 Ala Ala Thr Leu Arg Cys Val Leu Ser Ser Val
Ala Ala Pro Val Lys 3205 3210 3215 Trp Cys Tyr Gly Asn Asn Val Leu
Arg Pro Gly Asp Lys Tyr Ser Leu 3220 3225 3230 Arg Gln Glu Gly Ala
Met Leu Glu Leu Val Val Arg Asn Leu Arg Pro 3235 3240 3245 Gln Asp
Ser Gly Arg Tyr Ser Cys Ser Phe Gly Asp Gln Thr Thr Ser 3250 3255
3260 Ala Thr Leu Thr Val Thr Ala Leu Pro Ala Gln Phe Ile Gly Lys
Leu 3265 3270 3275 3280 Arg Asn Lys Glu Ala Thr Glu Gly Ala Thr Ala
Thr Leu Arg Cys Glu 3285 3290 3295 Leu Ser Lys Thr Ala Pro Val Glu
Trp Arg Lys Gly Ser Glu Thr Leu 3300 3305 3310 Arg Asp Gly Asp Arg
Tyr Cys Leu Arg Gln Asp Gly Ala Met Cys Glu 3315 3320 3325 Leu Gln
Ile Arg Gly Leu Ala Met Val Asp Ala Ala Glu Tyr Ser Cys 3330 3335
3340 Val Cys Gly Glu Glu Arg Thr Ser Ala Ser Leu Thr Ile Arg Pro
Met 3345 3350 3355 3360 Pro Ala His Phe Ile Gly Arg Leu Arg His Gln
Glu Ser Ile Glu Gly 3365 3370 3375 Ala Thr Ala Thr Leu Arg Cys Glu
Leu Ser Lys Ala Ala Pro Val Glu 3380 3385 3390 Trp Arg Lys Gly Arg
Glu Ser Leu Arg Asp Gly Asp Arg His Ser Leu 3395 3400 3405 Arg Gln
Asp Gly Ala Val Cys Glu Leu Gln Ile Cys Gly Leu Ala Val 3410 3415
3420 Ala Asp Ala Gly Glu Tyr Ser Cys Val Cys Gly Glu Glu Arg Thr
Ser 3425 3430 3435 3440 Ala Thr Leu Thr Val Lys Ala Leu Pro Ala Lys
Phe Thr Glu Gly Leu 3445 3450 3455 Arg Asn Glu Glu Ala Val Glu Gly
Ala Thr Ala Met Leu Trp Cys Glu 3460 3465 3470 Leu Ser Lys Val Ala
Pro Val Glu Trp Arg Lys Gly Pro Glu Asn Leu 3475 3480 3485 Arg Asp
Gly Asp Arg Tyr Ile Leu Arg Gln Glu Gly Thr Arg Cys Glu 3490 3495
3500 Leu Gln Ile Cys Gly Leu Ala Met Ala Asp Ala Gly Glu Tyr Leu
Cys 3505 3510 3515 3520 Val Cys Gly Gln Glu Arg Thr Ser Ala Thr Leu
Thr Ile Arg Ala Leu 3525 3530 3535 Pro Ala Arg Phe Ile Glu Asp Val
Lys Asn Gln Glu Ala Arg Glu Gly 3540 3545 3550 Ala Thr Ala Val Leu
Gln Cys Glu Leu Asn Ser Ala Ala Pro Val Glu 3555 3560 3565 Trp Arg
Lys Gly Ser Glu Thr Leu Arg Asp Gly Asp Arg Tyr Ser Leu 3570 3575
3580 Arg Gln Asp Gly Thr Lys Cys Glu Leu Gln Ile Arg Gly Leu Ala
Met 3585 3590 3595 3600 Ala Asp Thr Gly Glu Tyr Ser Cys Val Cys Gly
Gln Glu Arg Thr Ser 3605 3610 3615 Ala Met Leu Thr Val Arg Ala Leu
Pro Ile Lys Phe Thr Glu Gly Leu 3620 3625 3630 Arg Asn Glu Glu Ala
Thr Glu Gly Ala Thr Ala Val Leu Arg Cys Glu 3635 3640 3645 Leu Ser
Lys Met Ala Pro Val Glu Trp Trp Lys Gly His Glu Thr Leu 3650 3655
3660 Arg Asp Gly Asp Arg His Ser Leu Arg Gln Asp Gly Ala Arg Cys
Glu 3665 3670 3675 3680 Leu Gln Ile Arg Gly Leu Val Ala Glu Asp Ala
Gly Glu Tyr Leu Cys 3685 3690 3695 Met Cys Gly Lys Glu Arg Thr Ser
Ala Met Leu Thr Val Arg Ala Met 3700 3705 3710 Pro Ser Lys Phe Ile
Glu Gly Leu Arg Asn Glu Glu Ala Thr Glu Gly 3715 3720 3725 Asp Thr
Ala Thr Leu Trp Cys Glu Leu Ser Lys Ala Ala Pro Val Glu 3730 3735
3740 Trp Arg Lys Gly His Glu Thr Leu Arg Asp Gly Asp Arg His Ser
Leu 3745 3750 3755 3760 Arg Gln Asp Gly Ser Arg Cys Glu Leu Gln Ile
Arg Gly Leu Ala Val 3765 3770 3775 Val Asp Ala Gly Glu Tyr Ser Cys
Val Cys Gly Gln Glu Arg Thr Ser 3780 3785 3790 Ala Thr Leu Thr Val
Arg Ala Leu Pro Ala Arg Phe Ile Glu Asp Val 3795 3800 3805 Lys Asn
Gln Glu Ala Arg Glu Gly Ala Thr Ala Val Leu Gln Cys Glu 3810 3815
3820 Leu Ser Lys Ala Ala Pro Val Glu Trp Arg Lys Gly Ser Glu Thr
Leu 3825 3830 3835 3840 Arg Gly Gly Asp Arg Tyr Ser Leu Arg Gln Asp
Gly Thr Arg Cys Glu 3845 3850 3855 Leu Gln Ile His Gly Leu Ser Val
Ala Asp Thr Gly Glu Tyr Ser Cys 3860 3865 3870 Val Cys Gly Gln Glu
Arg Thr Ser Ala Thr Leu Thr Val Arg Ala Pro 3875 3880 3885 Gln Pro
Val Phe Arg Glu Pro Leu Gln Ser Leu Gln Ala Glu Glu Gly 3890 3895
3900 Ser Thr Ala Thr Leu Gln Cys Glu Leu Ser Glu Pro Thr Ala Thr
Val 3905 3910 3915 3920 Val Trp Ser Lys Gly Gly Leu Gln Leu Gln Ala
Asn Gly Arg Arg Glu 3925 3930 3935 Pro Arg Leu Gln Gly Cys Thr Ala
Glu Leu Val Leu Gln Asp Leu Gln 3940 3945 3950 Arg Glu Asp Thr Gly
Glu Tyr Thr Cys Thr Cys Gly Ser Gln Ala Thr 3955 3960 3965 Ser Ala
Thr Leu Thr Val Thr Ala Ala Pro Val Arg Phe Leu Arg Glu 3970 3975
3980 Leu Gln His Gln Glu Val Asp Glu Gly Gly Thr Ala His Leu Cys
Cys 3985 3990 3995 4000 Glu Leu Ser Arg Ala Gly Ala Ser Val Glu Trp
Arg Lys Gly Ser Leu 4005 4010 4015 Gln Leu Phe Pro Cys Ala Lys Tyr
Gln Met Val Gln Asp Gly Ala Ala 4020 4025 4030 Ala Glu Leu Leu Val
Arg Gly Val Glu Gln Glu Asp Ala Gly Asp Tyr 4035 4040 4045 Thr Cys
Asp Thr Gly His Thr Gln Ser Met Ala Ser Leu Ser Val Arg 4050 4055
4060 Val Pro Arg Pro Lys Phe Lys Thr Arg Leu Gln Ser Leu Glu Gln
Glu 4065 4070 4075 4080 Thr Gly Asp Ile Ala Arg Leu Cys Cys Gln Leu
Ser Asp Ala Glu Ser 4085 4090 4095 Gly Ala Val Val Gln Trp Leu Lys
Glu Gly Val Glu Leu His Ala Gly 4100 4105 4110 Pro Lys Tyr Glu Met
Arg Ser Gln Gly Ala Thr Arg Glu Leu Leu Ile 4115 4120 4125 His Gln
Leu Glu Ala Lys Asp Thr Gly Glu Tyr Ala Cys Val Thr Gly 4130 4135
4140 Gly Gln Lys Thr Ala Ala Ser Leu Arg Val Thr Glu Pro Glu Val
Thr 4145 4150 4155 4160 Ile Val Arg Gly Leu Val Asp Ala Glu Val Thr
Ala Asp Glu Asp Val 4165 4170 4175 Glu Phe Ser Cys Glu Val Ser Arg
Ala Gly Ala Thr Gly Val Gln Trp 4180 4185 4190 Cys Leu Gln Gly Leu
Pro Leu Gln Ser Asn Glu Val Thr Glu Val Ala 4195 4200 4205 Val Arg
Asp Gly Arg Ile His Thr Leu Arg Leu Lys Gly Val Thr Pro 4210 4215
4220 Glu Asp Ala Gly Thr Val Ser Phe His Leu Gly Asn His Ala Ser
Ser 4225 4230 4235 4240 Ala Gln Leu Thr Val Arg Ala Pro Glu Val Thr
Ile Leu Glu Pro Leu 4245 4250 4255 Gln Asp Val Gln Leu Ser Glu Gly
Gln Asp Ala Ser Phe Gln Cys Arg 4260 4265 4270 Leu Ser Arg Ala Ser
Gly Gln Glu Ala Arg Trp Ala Leu Gly Gly Val 4275 4280 4285 Pro Leu
Gln Ala Asn Glu Met Asn Asp Ile Thr Val Glu Gln Gly Thr 4290 4295
4300 Leu His Leu Leu Thr Leu His Lys Val Thr Leu Glu Asp Ala Gly
Thr 4305 4310 4315 4320 Val Ser Phe His Val Gly Thr Cys Ser Ser Glu
Ala Gln Leu Lys Val 4325 4330 4335 Thr Ala Lys Asn Thr Val Val Arg
Gly Leu Glu Asn Val Glu Ala Leu 4340 4345 4350 Glu Gly Gly Glu Ala
Leu Phe Glu Cys Gln Leu Ser Gln Pro Glu Val 4355 4360 4365 Ala Ala
His Thr Trp Leu Leu Asp Asp Glu Pro Val Arg Thr Ser Glu 4370 4375
4380 Asn Ala Glu Val Val Phe Phe Glu Asn Gly Leu Arg His Leu Leu
Leu 4385 4390 4395 4400 Leu Lys Asn Leu Arg Pro Gln Asp Ser Cys Arg
Val Thr Phe Leu Ala 4405 4410 4415 Gly Asp Met Val Thr Ser Ala Phe
Leu Thr Val Arg Gly Trp Arg Leu 4420 4425 4430 Glu Ile Leu Glu Pro
Leu Lys Asn Ala Ala Val Arg Ala Gly Ala Gln 4435 4440 4445 Ala Arg
Phe Thr Cys Thr Leu Ser Glu Ala Val Pro Val Gly Glu Ala 4450 4455
4460 Ser Trp Tyr Ile Asn Gly Ala Ala Val Gln Pro Asp Asp Ser Asp
Trp 4465 4470 4475 4480 Thr Val Thr Ala Asp Gly Ser His Gln Ala Leu
Leu Leu Arg Ser Ala 4485 4490 4495 Gln Pro His His Ala Gly Glu Val
Thr Phe Ala Cys Arg Asp Ala Val 4500 4505 4510 Ala Ser Ala Arg Leu
Thr Val Leu Gly Leu Pro Asp Pro Pro Glu Asp 4515 4520 4525 Ala Glu
Val Val Ala His Ser Ser His Thr Val Thr Leu Ser Trp Ala 4530 4535
4540 Ala Pro Met Ser Asp Gly Gly Gly Gly Leu Cys Gly Tyr Arg Val
Glu 4545 4550 4555 4560 Val Lys Glu Gly Ala Thr Gly Gln Trp Arg Leu
Cys His Glu Leu Val 4565 4570 4575 Pro Gly Pro Glu Cys Val Val Asp
Gly Leu Ala Pro Gly Glu Thr Tyr 4580 4585 4590 Arg Phe Arg Val Ala
Ala Val Gly Pro Val Gly Ala Gly Glu Pro Val 4595 4600 4605 His Leu
Pro Gln Thr Val Arg Leu Ala Glu Pro Pro Lys Pro Val Pro 4610 4615
4620 Pro Gln Pro Ser Ala Pro Glu Ser Arg Gln Val Ala Ala Gly Glu
Asp 4625 4630 4635 4640 Val Ser Leu Glu Leu Glu Val Val Ala Glu Ala
Gly Glu Val Ile Trp 4645 4650 4655 His Lys Gly Met Glu Arg Ile Gln
Pro Gly Gly Arg Phe Glu Val Val 4660 4665 4670 Ser Gln Gly Arg Gln
Gln Met Leu Val Ile Lys Gly Phe Thr Ala Glu 4675 4680 4685 Asp Gln
Gly Glu Tyr His Cys Gly Leu Ala Gln Gly Ser Ile Cys Pro 4690 4695
4700 Ala Ala Ala Thr Phe Gln Val Ala Leu Ser Pro Ala Ser Val Asp
Glu 4705 4710 4715 4720 Ala Pro Gln Pro Ser Leu Pro Pro Glu Ala Ala
Gln Glu Gly Asp Leu 4725 4730 4735 His Leu Leu Trp Glu Ala Leu Ala
Arg Lys Arg Arg Met Ser Arg Glu 4740 4745 4750 Pro Thr Leu Asp Ser
Ile Ser Glu Leu Pro Glu Glu Asp Gly Arg Ser 4755 4760 4765 Gln Arg
Leu Pro Gln Glu Ala Glu Glu Val Ala Pro Asp Leu Ser Glu 4770 4775
4780 Gly Tyr Ser Thr Ala Asp Glu Leu Ala Arg Thr Gly Asp Ala Asp
Leu 4785 4790 4795 4800 Ser His Thr Ser Ser Asp Asp Glu Ser Arg Ala
Gly Thr Pro Ser Leu 4805 4810 4815 Val Thr Tyr Leu Lys Lys Ala Gly
Arg Pro Gly Thr Ser Pro Leu Ala 4820 4825 4830 Ser Lys Val Gly Ala
Pro Ala Ala Pro Ser Val Lys Pro Gln Gln Gln 4835 4840 4845 Gln Glu
Pro Leu Ala Ala Val Arg Pro Pro Leu Gly Asp Leu Ser Thr 4850 4855
4860 Lys Asp Leu Gly Asp Pro Ser Met Asp Lys Ala Ala Val Lys Ile
Gln 4865 4870 4875 4880 Ala Ala Phe Lys Gly Tyr Lys Val Arg Lys Glu
Met Lys Gln Gln Glu 4885 4890 4895 Gly Pro Met Phe Ser His Thr Phe
Gly Asp Thr Glu Ala Gln Val Gly 4900 4905 4910 Asp Ala Leu Arg Leu
Glu Cys Val Val Ala Ser Lys Ala Asp Val Arg 4915 4920 4925 Ala Arg
Trp Leu Lys Asp Gly Val Glu Leu Thr Asp Gly Arg His His 4930 4935
4940 His Ile Asp Gln Leu Gly Asp Gly Thr Cys Ser Leu Leu Ile Ala
Gly 4945 4950 4955 4960 Leu Asp Arg Ala Asp Ala Gly Cys Tyr Thr Cys
Gln Val Ser Asn Lys 4965 4970 4975 Phe Gly Gln Val Thr His Ser Ala
Cys Val Val Val Ser Gly Ser Glu 4980 4985 4990 Ser Glu Ala Glu Ser
Ser Ser Gly Gly Glu Leu Asp Asp Ala Phe Arg 4995 5000 5005 Arg Ala
Ala Arg Arg Leu His Arg Leu Phe Arg Thr Lys Ser Pro Ala 5010 5015
5020 Glu Val Ser Asp Glu Glu Leu Phe Leu Ser Ala Asp Glu Gly Pro
Ala 5025 5030 5035 5040 Glu Pro Glu Glu Pro Ala Asp Trp Gln Thr Tyr
Arg Glu Asp Glu His 5045 5050 5055 Phe Ile Cys Ile Arg Phe Glu Ala
Leu Thr Glu Ala Arg Gln Ala Val 5060 5065 5070 Thr Arg Phe Gln Glu
Met Phe Ala Thr Leu Gly Ile Gly Val Glu Ile 5075 5080 5085 Lys Leu
Val Glu Gln Gly Pro Arg Arg Val Glu Met Cys Ile Ser Lys 5090 5095
5100 Glu Thr Pro Ala Pro Val Val Pro Pro Glu Pro Leu Pro Ser Leu
Leu 5105 5110 5115 5120 Thr Ser Asp Ala Ala Pro Val Phe Leu Thr Glu
Leu Gln Asn Gln Glu 5125 5130 5135 Val Gln Asp Gly Tyr Pro Val Ser
Phe Asp Cys Val Val Thr Gly Gln 5140 5145 5150 Pro Met Pro Ser Val
Arg Trp Phe Lys Asp Gly Lys Leu Leu Glu Glu 5155 5160 5165 Asp Asp
His Tyr Met Ile Asn Glu Asp Gln Gln Gly Gly His Gln Leu 5170 5175
5180 Ile Ile Thr Ala Val Val Pro Ala Asp Met Gly Val Tyr Arg Cys
Leu 5185 5190 5195 5200 Ala Glu Asn Ser Met Gly Val Ser Ser Thr Lys
Ala Glu Leu Arg Val 5205 5210 5215 Asp Leu Thr Ser Thr Asp Tyr Asp
Thr Ala Ala Asp Ala Thr Glu Ser 5220 5225 5230 Ser Ser Tyr Phe Ser
Ala Gln Gly Tyr Leu Ser Ser Arg Glu Gln Glu 5235 5240 5245 Gly Thr
Glu Ser Thr Thr Asp Glu Gly Gln Leu Pro Gln Val Val Glu 5250 5255
5260 Glu Leu Arg Asp Leu Gln Val Ala Pro Gly Thr Arg Leu Ala Lys
Phe 5265 5270 5275 5280 Gln Leu Lys Val Lys Gly Tyr Pro Ala Pro Arg
Leu Tyr Trp Phe Lys 5285 5290 5295 Asp Gly Gln Pro Leu Thr Ala Ser
Ala His Ile Arg Met Thr Gly Lys 5300 5305 5310 Lys Ile Leu His Thr
Leu Glu Ile Ile Ser Val Thr Arg Glu Asp Ser 5315 5320 5325 Gly Gln
Tyr Ala Ala Tyr Ile Ser Asn Ala Met Gly Ala Ala Tyr Ser 5330 5335
5340 Ser Ala Arg Leu Leu Val Arg Gly Pro Asp Glu Pro Glu Glu Lys
Pro 5345 5350 5355 5360 Ala Ser Asp Val His Glu Gln Leu Val Pro Pro
Arg Met Leu Glu Arg 5365 5370 5375 Phe Thr Pro Lys Lys Val Lys Lys
Gly Ser Ser Ile Thr Phe Ser Val 5380 5385 5390 Lys Val Glu Gly Arg
Pro Val Pro Thr Val His Trp Leu Arg Glu Glu 5395 5400 5405 Ala Glu
Arg Gly Val Leu Trp Ile Gly Pro Asp Thr Pro Gly Tyr Thr 5410 5415
5420 Val Ala Ser Ser Ala Gln Gln His Ser Leu Val Leu Leu Asp Val
Gly 5425 5430 5435 5440 Arg Gln His Gln Gly Thr Tyr Thr Cys Ile Ala
Ser Asn Ala Ala Gly 5445 5450 5455 Gln Ala Leu Cys Ser Ala Ser Leu
His Val Ser Gly Leu Pro Lys Val 5460 5465 5470 Glu Glu Gln Glu Lys
Val Lys Glu Ala Leu Ile Ser Thr Phe Leu Gln 5475 5480 5485 Gly Thr
Thr Gln Ala Ile Ser Ala Gln Gly Leu Glu Thr Ala Ser Phe 5490 5495
5500 Ala Asp Leu Gly Gly Gln Arg Lys Glu Glu Pro Leu Ala Ala Lys
Glu 5505 5510 5515 5520 Ala Leu Gly His Leu Ser Leu Ala Glu Val Gly
Thr Glu Glu Phe Leu 5525 5530 5535 Gln Lys Leu Thr Ser Gln Ile Thr
Glu Met Val Ser Ala Lys Ile Thr 5540 5545 5550 Gln Ala Lys Leu Gln
Val Pro Gly Gly Asp Ser Asp Glu Asp Ser Lys 5555 5560 5565 Thr Pro
Ser Ala Ser Pro Arg His Gly Arg Ser Arg Pro Ser Ser Ser 5570 5575
5580 Ile Gln Glu Ser Ser Ser Glu Ser Glu Asp Gly Asp Ala Arg
Gly
Glu 5585 5590 5595 5600 Ile Phe Asp Ile Tyr Val Val Thr Ala Asp Tyr
Leu Pro Leu Gly Ala 5605 5610 5615 Glu Gln Asp Ala Ile Thr Leu Arg
Glu Gly Gln Tyr Val Glu Val Leu 5620 5625 5630 Asp Ala Ala His Pro
Leu Arg Trp Leu Val Arg Thr Lys Pro Thr Lys 5635 5640 5645 Ser Ser
Pro Ser Arg Gln Gly Trp Val Ser Pro Ala Tyr Leu Asp Arg 5650 5655
5660 Arg Leu Lys Leu Ser Pro Glu Trp Gly Ala Ala Glu Ala Pro Glu
Phe 5665 5670 5675 5680 Pro Gly Glu Ala Val Ser Glu Asp Glu Tyr Lys
Ala Arg Leu Ser Ser 5685 5690 5695 Val Ile Gln Glu Leu Leu Ser Ser
Glu Gln Ala Phe Val Glu Glu Leu 5700 5705 5710 Gln Phe Leu Gln Ser
His His Leu Gln His Leu Glu Arg Cys Pro His 5715 5720 5725 Val Pro
Ile Ala Val Ala Gly Gln Lys Ala Val Ile Phe Arg Asn Val 5730 5735
5740 Arg Asp Ile Gly Arg Phe His Ser Ser Phe Leu Gln Glu Leu Gln
Gln 5745 5750 5755 5760 Cys Asp Thr Asp Asp Asp Val Ala Met Cys Phe
Ile Lys Asn Gln Ala 5765 5770 5775 Ala Phe Glu Gln Tyr Leu Glu Phe
Leu Val Gly Arg Val Gln Ala Glu 5780 5785 5790 Ser Val Val Val Ser
Thr Ala Ile Gln Glu Phe Tyr Lys Lys Tyr Ala 5795 5800 5805 Glu Glu
Ala Leu Leu Ala Gly Asp Pro Ser Gln Pro Pro Pro Pro Pro 5810 5815
5820 Leu Gln His Tyr Leu Glu Gln Pro Val Glu Arg Val Gln Arg Tyr
Gln 5825 5830 5835 5840 Ala Leu Leu Lys Glu Leu Ile Arg Asn Lys Ala
Arg Asn Arg Gln Asn 5845 5850 5855 Cys Ala Leu Leu Glu Gln Ala Tyr
Ala Val Val Ser Ala Leu Pro Gln 5860 5865 5870 Arg Ala Glu Asn Lys
Leu His Val Ser Leu Met Glu Asn Tyr Pro Gly 5875 5880 5885 Thr Leu
Glu Ala Leu Gly Glu Pro Ile Arg Gln Gly His Phe Ile Val 5890 5895
5900 Trp Glu Gly Ala Pro Gly Ala Arg Met Pro Trp Lys Gly His Asn
Arg 5905 5910 5915 5920 His Val Phe Leu Phe Arg Asn His Leu Val Ile
Cys Lys Pro Arg Arg 5925 5930 5935 Asp Ser Arg Thr Asp Thr Val Ser
Tyr Val Phe Arg Asn Met Met Lys 5940 5945 5950 Leu Ser Ser Ile Asp
Leu Asn Asp Gln Val Glu Gly Asp Asp Arg Ala 5955 5960 5965 Phe Glu
Val Trp Gln Glu Arg Glu Asp Ser Val Arg Lys Tyr Leu Leu 5970 5975
5980 Gln Ala Arg Thr Ala Ile Ile Lys Ser Ser Trp Val Lys Glu Ile
Cys 5985 5990 5995 6000 Gly Ile Gln Gln Arg Leu Ala Leu Pro Val Trp
Arg Pro Pro Asp Phe 6005 6010 6015 Glu Glu Glu Leu Ala Asp Cys Thr
Ala Glu Leu Gly Glu Thr Val Lys 6020 6025 6030 Leu Ala Cys Arg Val
Thr Gly Thr Pro Lys Pro Val Ile Ser Trp Tyr 6035 6040 6045 Lys Asp
Gly Lys Ala Val Gln Val Asp Pro His His Ile Leu Ile Glu 6050 6055
6060 Asp Pro Asp Gly Ser Cys Ala Leu Ile Leu Asp Ser Leu Thr Gly
Val 6065 6070 6075 6080 Asp Ser Gly Gln Tyr Met Cys Phe Ala Ala Ser
Ala Ala Gly Asn Cys 6085 6090 6095 Ser Thr Leu Gly Lys Ile Leu Val
Gln Val Pro Pro Arg Phe Val Asn 6100 6105 6110 Lys Val Arg Ala Ser
Pro Phe Val Glu Gly Glu Asp Ala Gln Phe Thr 6115 6120 6125 Cys Thr
Ile Glu Gly Ala Pro Tyr Pro Gln Ile Arg Trp Tyr Lys Asp 6130 6135
6140 Gly Ala Leu Leu Thr Thr Gly Asn Lys Phe Gln Thr Leu Ser Glu
Pro 6145 6150 6155 6160 Arg Ser Gly Leu Leu Val Leu Val Ile Arg Ala
Ala Ser Lys Glu Asp 6165 6170 6175 Leu Gly Leu Tyr Glu Cys Glu Leu
Val Asn Arg Leu Gly Ser Ala Arg 6180 6185 6190 Ala Ser Ala Glu Leu
Arg Ile Gln Ser Pro Met Leu Gln Ala Gln Glu 6195 6200 6205 Gln Cys
His Arg Glu Gln Leu Val Ala Ala Val Glu Asp Thr Thr Leu 6210 6215
6220 Glu Arg Ala Asp Gln Glu Val Thr Ser Val Leu Lys Arg Leu Leu
Gly 6225 6230 6235 6240 Pro Lys Ala Pro Gly Pro Ser Thr Gly Asp Leu
Thr Gly Pro Gly Pro 6245 6250 6255 Cys Pro Arg Gly Ala Pro Ala Leu
Gln Glu Thr Gly Ser Gln Pro Pro 6260 6265 6270 Val Thr Gly Thr Ser
Glu Ala Pro Ala Val Pro Pro Arg Val Pro Gln 6275 6280 6285 Pro Leu
Leu His Glu Gly Pro Glu Gln Glu Pro Glu Ala Ile Ala Arg 6290 6295
6300 Ala Gln Glu Trp Thr Val Pro Ile Arg Met Glu Gly Ala Ala Trp
Pro 6305 6310 6315 6320 Gly Ala Gly Thr Gly Glu Leu Leu Trp Asp Val
His Ser His Val Val 6325 6330 6335 Arg Glu Thr Thr Gln Arg Thr Tyr
Thr Tyr Gln Ala Ile Asp Thr His 6340 6345 6350 Thr Ala Arg Pro Pro
Ser Met Gln Val Thr Ile Glu Asp Val Gln Ala 6355 6360 6365 Gln Thr
Gly Gly Thr Ala Gln Phe Glu Ala Ile Ile Glu Gly Asp Pro 6370 6375
6380 Gln Pro Ser Val Thr Trp Tyr Lys Asp Ser Val Gln Leu Val Asp
Ser 6385 6390 6395 6400 Thr Arg Leu Ser Gln Gln Gln Glu Gly Thr Thr
Tyr Ser Leu Val Leu 6405 6410 6415 Arg His Val Ala Ser Lys Asp Ala
Gly Val Tyr Thr Cys Leu Ala Gln 6420 6425 6430 Asn Thr Gly Gly Gln
Val Leu Cys Lys Ala Glu Leu Leu Val Leu Gly 6435 6440 6445 Gly Asp
Asn Glu Pro Asp Ser Glu Lys Gln Ser His Arg Arg Lys Leu 6450 6455
6460 His Ser Phe Tyr Glu Val Lys Glu Glu Ile Gly Arg Gly Val Phe
Gly 6465 6470 6475 6480 Phe Val Lys Arg Val Gln His Lys Gly Asn Lys
Ile Leu Cys Ala Ala 6485 6490 6495 Lys Phe Ile Pro Leu Arg Ser Arg
Thr Arg Ala Gln Ala Tyr Arg Glu 6500 6505 6510 Arg Asp Ile Leu Ala
Ala Leu Ser His Pro Leu Val Thr Gly Leu Leu 6515 6520 6525 Asp Gln
Phe Glu Thr Arg Lys Thr Leu Ile Leu Ile Leu Glu Leu Cys 6530 6535
6540 Ser Ser Glu Glu Leu Leu Asp Arg Leu Tyr Arg Lys Gly Val Val
Thr 6545 6550 6555 6560 Glu Ala Glu Val Lys Val Tyr Ile Gln Gln Leu
Val Glu Gly Leu His 6565 6570 6575 Tyr Leu His Ser His Gly Val Leu
His Leu Asp Ile Lys Pro Ser Asn 6580 6585 6590 Ile Leu Met Val His
Pro Ala Arg Glu Asp Ile Lys Ile Cys Asp Phe 6595 6600 6605 Gly Phe
Ala Gln Asn Ile Thr Pro Ala Glu Leu Gln Phe Ser Gln Tyr 6610 6615
6620 Gly Ser Pro Glu Phe Val Ser Pro Glu Ile Ile Gln Gln Asn Pro
Val 6625 6630 6635 6640 Ser Glu Ala Ser Asp Ile Trp Ala Met Gly Val
Ile Ser Tyr Leu Ser 6645 6650 6655 Leu Thr Cys Ser Ser Pro Phe Ala
Gly Glu Ser Asp Arg Ala Thr Leu 6660 6665 6670 Leu Asn Val Leu Glu
Gly Arg Val Ser Trp Ser Ser Pro Met Ala Ala 6675 6680 6685 His Leu
Ser Glu Asp Ala Lys Asp Phe Ile Lys Ala Thr Leu Gln Arg 6690 6695
6700 Ala Pro Gln Ala Arg Pro Ser Ala Ala Gln Cys Leu Ser His Pro
Trp 6705 6710 6715 6720 Phe Leu Lys Ser Met Pro Ala Glu Glu Ala His
Phe Ile Asn Thr Lys 6725 6730 6735 Gln Leu Lys Phe Leu Leu Ala Arg
Ser Arg Trp Gln Arg Ser Leu Met 6740 6745 6750 Ser Tyr Lys Ser Ile
Leu Val Met Arg Ser Ile Pro Glu Leu Leu Arg 6755 6760 6765 Gly Pro
Pro Asp Ser Pro Ser Leu Gly Val Ala Arg His Leu Cys Arg 6770 6775
6780 Asp Thr Gly Gly Ser Ser Ser Ser Ser Ser Ser Ser Asp Asn Glu
Leu 6785 6790 6795 6800 Ala Pro Phe Ala Arg Ala Lys Ser Leu Pro Pro
Ser Pro Val Thr His 6805 6810 6815 Ser Pro Leu Leu His Pro Arg Gly
Phe Leu Arg Pro Ser Ala Ser Leu 6820 6825 6830 Pro Glu Glu Ala Glu
Ala Ser Glu Arg Ser Thr Glu Ala Pro Ala Pro 6835 6840 6845 Pro Ala
Ser Pro Glu Gly Ala Gly Pro Pro Ala Ala Gln Gly Cys Val 6850 6855
6860 Pro Arg His Ser Val Ile Arg Ser Leu Phe Tyr His Gln Ala Gly
Glu 6865 6870 6875 6880 Ser Pro Glu His Gly Ala Leu Ala Pro Gly Ser
Arg Arg His Pro Ala 6885 6890 6895 Arg Arg Arg His Leu Leu Lys Gly
Gly Tyr Ile Ala Gly Ala Leu Pro 6900 6905 6910 Gly Leu Arg Glu Pro
Leu Met Glu His Arg Val Leu Glu Glu Glu Ala 6915 6920 6925 Ala Arg
Glu Glu Gln Ala Thr Leu Leu Ala Lys Ala Pro Ser Phe Glu 6930 6935
6940 Thr Ala Leu Arg Leu Pro Ala Ser Gly Thr His Leu Ala Pro Gly
His 6945 6950 6955 6960 Ser His Ser Leu Glu His Asp Ser Pro Ser Thr
Pro Arg Pro Ser Ser 6965 6970 6975 Glu Ala Cys Gly Glu Ala Gln Arg
Leu Pro Ser Ala Pro Ser Gly Gly 6980 6985 6990 Ala Pro Ile Arg Asp
Met Gly His Pro Gln Gly Ser Lys Gln Leu Pro 6995 7000 7005 Ser Thr
Gly Gly His Pro Gly Thr Ala Gln Pro Glu Arg Pro Ser Pro 7010 7015
7020 Asp Ser Pro Trp Gly Gln Pro Ala Pro Phe Cys His Pro Lys Gln
Gly 7025 7030 7035 7040 Ser Ala Pro Gln Glu Gly Cys Ser Pro His Pro
Ala Val Ala Pro Cys 7045 7050 7055 Pro Pro Gly Ser Phe Pro Pro Gly
Ser Cys Lys Glu Ala Pro Leu Val 7060 7065 7070 Pro Ser Ser Pro Phe
Leu Gly Gln Pro Gln Ala Pro Pro Ala Pro Ala 7075 7080 7085 Lys Ala
Ser Pro Pro Leu Asp Ser Lys Met Gly Pro Gly Asp Ile Ser 7090 7095
7100 Leu Pro Gly Arg Pro Lys Pro Gly Pro Cys Ser Ser Pro Gly Ser
Ala 7105 7110 7115 7120 Ser Gln Ala Ser Ser Ser Gln Val Ser Ser Leu
Arg Val Gly Ser Ser 7125 7130 7135 Gln Val Gly Thr Glu Pro Gly Pro
Ser Leu Asp Ala Glu Gly Trp Thr 7140 7145 7150 Gln Glu Ala Glu Asp
Leu Ser Asp Ser Thr Pro Thr Leu Gln Arg Pro 7155 7160 7165 Gln Glu
Gln Ala Thr Met Arg Lys Phe Ser Leu Gly Gly Arg Gly Gly 7170 7175
7180 Tyr Ala Gly Val Ala Gly Tyr Gly Thr Phe Ala Phe Gly Gly Asp
Ala 7185 7190 7195 7200 Gly Gly Met Leu Gly Gln Gly Pro Met Trp Ala
Arg Ile Ala Trp Ala 7205 7210 7215 Val Ser Gln Ser Glu Glu Glu Glu
Gln Glu Glu Ala Arg Ala Glu Ser 7220 7225 7230 Gln Ser Glu Glu Gln
Gln Glu Ala Arg Ala Glu Ser Pro Leu Pro Gln 7235 7240 7245 Val Ser
Ala Arg Pro Val Pro Glu Val Gly Arg Ala Pro Thr Arg Ser 7250 7255
7260 Ser Pro Glu Pro Thr Pro Trp Glu Asp Ile Gly Gln Val Ser Leu
Val 7265 7270 7275 7280 Gln Ile Arg Asp Leu Ser Gly Asp Ala Glu Ala
Ala Asp Thr Ile Ser 7285 7290 7295 Leu Asp Ile Ser Glu Val Asp Pro
Ala Tyr Leu Asn Leu Ser Asp Leu 7300 7305 7310 Tyr Asp Ile Lys Tyr
Leu Pro Phe Glu Phe Met Ile Phe Arg Lys Val 7315 7320 7325 Pro Lys
Ser Ala Gln Pro Glu Pro Pro Ser Pro Met Ala Glu Glu Glu 7330 7335
7340 Leu Ala Glu Phe Pro Glu Pro Thr Trp Pro Trp Pro Gly Glu Leu
Gly 7345 7350 7355 7360 Pro His Ala Gly Leu Glu Ile Thr Glu Glu Ser
Glu Asp Val Asp Ala 7365 7370 7375 Leu Leu Ala Glu Ala Ala Val Gly
Arg Lys Arg Lys Trp Ser Ser Pro 7380 7385 7390 Ser Arg Ser Leu Phe
His Phe Pro Gly Arg His Leu Pro Leu Asp Glu 7395 7400 7405 Pro Ala
Glu Leu Gly Leu Arg Glu Arg Val Lys Ala Ser Val Glu His 7410 7415
7420 Ile Ser Arg Ile Leu Lys Gly Arg Pro Glu Gly Leu Glu Lys Glu
Gly 7425 7430 7435 7440 Pro Pro Arg Lys Lys Pro Gly Leu Ala Ser Phe
Arg Leu Ser Gly Leu 7445 7450 7455 Lys Ser Trp Asp Arg Ala Pro Thr
Phe Leu Arg Glu Leu Ser Asp Glu 7460 7465 7470 Thr Val Val Leu Gly
Gln Ser Val Thr Leu Ala Cys Gln Val Ser Ala 7475 7480 7485 Gln Pro
Ala Ala Gln Ala Thr Trp Ser Lys Asp Gly Ala Pro Leu Glu 7490 7495
7500 Ser Ser Ser Arg Val Leu Ile Ser Ala Thr Leu Lys Asn Phe Gln
Leu 7505 7510 7515 7520 Leu Thr Ile Leu Val Val Val Ala Glu Asp Leu
Gly Val Tyr Thr Cys 7525 7530 7535 Ser Val Ser Asn Ala Leu Gly Thr
Val Thr Thr Thr Gly Val Leu Arg 7540 7545 7550 Lys Ala Glu Arg Pro
Ser Ser Ser Pro Cys Pro Asp Ile Gly Glu Val 7555 7560 7565 Tyr Ala
Asp Gly Val Leu Leu Val Trp Lys Pro Val Glu Ser Tyr Gly 7570 7575
7580 Pro Val Thr Tyr Ile Val Gln Cys Ser Leu Glu Gly Gly Ser Trp
Thr 7585 7590 7595 7600 Thr Leu Ala Ser Asp Ile Phe Asp Cys Cys Tyr
Leu Thr Ser Lys Leu 7605 7610 7615 Ser Arg Gly Gly Thr Tyr Thr Phe
Arg Thr Ala Cys Val Ser Lys Ala 7620 7625 7630 Gly Met Gly Pro Tyr
Ser Ser Pro Ser Glu Gln Val Leu Leu Gly Gly 7635 7640 7645 Pro Ser
His Leu Ala Ser Glu Glu Glu Ser Gln Gly Arg Ser Ala Gln 7650 7655
7660 Pro Leu Pro Ser Thr Lys Thr Phe Ala Phe Gln Thr Gln Ile Gln
Arg 7665 7670 7675 7680 Gly Arg Phe Ser Val Val Arg Gln Cys Trp Glu
Lys Ala Ser Gly Arg 7685 7690 7695 Ala Leu Ala Ala Lys Ile Ile Pro
Tyr His Pro Lys Asp Lys Thr Ala 7700 7705 7710 Val Leu Arg Glu Tyr
Glu Ala Leu Lys Gly Leu Arg His Pro His Leu 7715 7720 7725 Ala Gln
Leu His Ala Ala Tyr Leu Ser Pro Arg His Leu Val Leu Ile 7730 7735
7740 Leu Glu Leu Cys Ser Gly Pro Glu Leu Leu Pro Cys Leu Ala Glu
Arg 7745 7750 7755 7760 Ala Ser Tyr Ser Glu Ser Glu Val Lys Asp Tyr
Leu Trp Gln Met Leu 7765 7770 7775 Ser Ala Thr Gln Tyr Leu His Asn
Gln His Ile Leu His Leu Asp Leu 7780 7785 7790 Arg Ser Glu Asn Met
Ile Ile Thr Glu Tyr Asn Leu Leu Lys Val Val 7795 7800 7805 Asp Leu
Gly Asn Ala Gln Ser Leu Ser Gln Glu Lys Val Leu Pro Ser 7810 7815
7820 Asp Lys Phe Lys Asp Tyr Leu Glu Thr Met Ala Pro Glu Leu Leu
Glu 7825 7830 7835 7840 Gly Gln Gly Ala Val Pro Gln Thr Asp Ile Trp
Ala Ile Gly Val Thr 7845 7850 7855 Ala Phe Ile Met Leu Ser Ala Glu
Tyr Pro Val Ser Ser Glu Gly Ala 7860 7865 7870 Arg Asp Leu Gln Arg
Gly Leu Arg Lys Gly Leu Val Arg Leu Ser Arg 7875 7880 7885 Cys Tyr
Ala Gly Leu Ser Gly Gly Ala Val Ala Phe Leu Arg Ser Thr 7890 7895
7900 Leu Cys Ala Gln Pro Trp Gly Arg Pro Cys Ala Ser Ser Cys Leu
Gln 7905 7910 7915 7920 Cys Pro Trp Leu Thr Glu Glu Gly Pro Ala Cys
Ser Arg Pro Ala Pro 7925 7930 7935 Val Thr Phe Pro Thr Ala Arg Leu
Arg Val Phe Val Arg Asn Arg Glu 7940 7945 7950 Lys Arg Arg Ala Leu
Leu Tyr Lys Arg His Asn Leu Ala Gln Val Arg 7955 7960 7965 6 23907
DNA Homo sapiens 6 atggatcagc cacagttcag cggggcgccc cgctttctca
cccggcccaa ggccttcgtg 60 gtgtcggtgg gcaaggacgc caccctcagc
tgccagatcg tgggtaatcc cacgccacag 120 gtgagctggg agaaggacca
gcagccggtg acggccggcg cgcgcttccg tctggcccag 180
gacggcgacc tctaccgcct cactatcctg gacctggcgc tgggcgacag tgggcaatac
240 gtgtgccgcg cgcgcaatgc cataggcgag gccttcgctg ccgtgggcct
gcaggtggac 300 gcggaggccg cgtgcgccga gcaggcgccg cacttcctgc
tgcggcccac gtccatccgc 360 gtgcgcgagg gctcagaggc caccttccgc
tgccgcgtgg gtggctcccc gaggccggca 420 gtgagctggt ccaaggacgg
gcggcgcctg ggtgagcccg acggcccccg cgtgcgcgtg 480 gaggagctcg
gcgaggcaag tgcgctgcgc attcgggcgg cgcggccgcg cgacggcggc 540
acttacgagg tccgcgccga gaacccgctg ggcgctgcca gcgccgccgc ggcgctagtg
600 gtggactcgg acgccgcgga cacggccagc cggcccggga cctccacggc
cgcgctcctg 660 gcgcacctgc agcggcggcg cgaggctatg cgcgccgagg
gcgcccccgc ctcaccgccc 720 agcaccggca cgcgcacctg cacggtgact
gaaggcaagc acgcgcgcct cagctgctac 780 gtgaccggcg agcccaagcc
cgagacggtg tggaagaagg acggccagct ggtgaccgag 840 ggccggcgcc
acgtggtgta cgaggacgcg caggagaact tcgtgctcaa gatcctcttc 900
tgcaagcagt cggaccgcgg cctctacacc tgcacggcgt ccaacctcgt gggccagacc
960 tacagctctg tgctggtcgt agtgcgcgag cccgcggttc ccttcaaaaa
gcggctgcaa 1020 gatctggagg tgcgggagaa ggagtcggct acgttcctat
gtgaggtgcc ccagccgtcc 1080 actgaggccg cgtggttcaa ggaggagacg
cggttgtggg cgagcgccaa gtacggcatc 1140 gaggaggagg gcaccgagcg
ccgcctgacc gtgcgcaatg tctcggccga cgacgacgcg 1200 gtgtacatct
gcgagacgcc agagggcagc cgcacggtgg cggagctcgc agtccaagga 1260
aacctcctcc gaaagctccc tcggaagacg gcggtgcgcg tgggcgacac ggctatgttt
1320 tgcgtggagc tggcggtccc ggtgggcccc gtccactggc tgcggaacca
ggaggaagtg 1380 gtggcggggg gccgcgtggc catctccgcg gagggcacgc
gccacacact gaccatctcc 1440 cagtgctgcc tggaggatgt gggccaggtg
gcctttatgg ctggcgactg ccagacgtcc 1500 acccggttct gcgtgtcggc
ccccaggaag cctcccctgc aaccccctgt ggatcctgtg 1560 gtaaaggcca
ggatggagag ttccgtgatt ctcagctggt ccccaccacc ccatggggaa 1620
cgccctgtca ctatcgacgg ctacctggta gagaagaaga agcttggcac ctacacctgg
1680 atcaggtgcc acgaggctga atgggtggct acacctgagc tgaccgtggc
tgatgtggcg 1740 gaggagggga acttccagtt ccgagtgtcc gctctcaaca
gctttggtca gagtccctac 1800 ctcgagttcc cggggactgt ccacctggcc
cccaagctgg ccgtgaggac accgctgaag 1860 gcggtgcagg cggtagaggg
tggcgaggtc actttctccg tggacctcac ggtggcctca 1920 gcgggtgagt
ggttcctgga tgggcaggcc ctgaaggcca gcagtgtgta tgagatccac 1980
tgtgatcgca cccggcacac gctcaccatc cgggaggtgc ccgccagcct gcacggggcg
2040 cagctgaagt tcgtggccaa cggcattgag agcagcatcc ggatggaggt
ccgggcggcc 2100 ccagggctga ctgccaacaa gccgccagcc gcagctgccc
gggaggtgct ggctcggctg 2160 cacgaggagg cgcagctgct ggctgagctg
tcagatcagg ctgcggctgt gacgtggctg 2220 aaggatggtc gcacactgtc
cccaggcccc aagtatgagg tgcaggcatc ggccgggcgg 2280 cgggtgctcc
ttgtgcgaga tgtggcccgg gacgatgcag gcctctacga gtgcgtcagc 2340
cgcgggggcc gcatcgccta ccagctctcc gtgcaaggcc tcgcgcgctt tctgcacaag
2400 gacatggcgg gcagctgtgt ggatgccgtg gctgggggcc cggcgcagtt
tgagtgtgag 2460 acctccgaag cccacgtcca cgtgcactgg tacaaggatg
gcatggagct gggccactcc 2520 ggtgagcgct tcttgcagga ggatgtgggg
acgcggcacc ggctggtggc agccacagtc 2580 accaggcagg atgaaggcac
ctactcctgc cgcgtgggcg aggactctgt ggacttccgg 2640 ctccgcgtct
ctgagcccaa ggtggtgttt gctaaggagc agctggcacg caggaagctg 2700
caggcagagg caggagccag tgccacactg agctgcgagg tggcccaggc ccagacggag
2760 gtgacgtggt acaaggatgg gaagaagctg agctccagct cgaaagtgtg
catggaggcc 2820 acaggctgca cgcgcaggct ggttgtgcag caggcaggcc
aggcggatgc cggggagtat 2880 agctgcgagg ctgggggcca gcggctctcc
ttccatctgg atgtcaaaga gcccaaggtg 2940 gtgtttgcca aggaccaggt
ggcacacagt gaggtgcagg ctgaggcagg ggccaatgcc 3000 acgctgagct
gcgaggtggc ccaggcccag gcggaggtga tgtggtacaa agatgggaag 3060
aagctgagct ccagcttgaa agtgcatgta gaggccaaag gctgcagacg gaggctggtg
3120 gtgcagcagg caggcaagac ggatgccggg gactacagct gcgaggccag
gggccagagg 3180 gtctccttcc gcctgcacat cacagagccc aagatgatgt
ttgcaaagga gcagtcagtg 3240 cataatgagg tgcaggctga ggcgggggcc
agtgccatgc tgagctgtga ggtggcccag 3300 gcccagacgg aggtgacgtg
gtacaaggat gggaagaagc tgagctccag ctcaaaagtg 3360 ggcatggagg
tcaaagggtg cacacggagg ctggtgctgc cacaggcggg caaagcagat 3420
gctggggagt acagctgtga ggctgggggc cagagagtct ccttccacct gcacatcaca
3480 gagcccaagg gggtgtttgc gaaggagcag tcagtgcata atgaggtgca
ggctgaggcg 3540 gggaccactg ccatgctgag ctgtgaggtg gcccagcccc
agacggaggt gacgtggtac 3600 aaggacggga agaagctgag ctccagctca
aaagtacgca tggaggtcaa gggctgcaca 3660 cgaaggctgg tagtgcagca
ggtgggcaaa gcagatgctg gggagtacag ctgcgaggct 3720 gggggccaga
gagtctcctt tcaactgcac atcacagagc ccaaggcagt gtttgccaag 3780
gagcagttgg tgcataatga ggtgcggact gaggcagggg ccagtgccac actgagctgt
3840 gaggtggccc aggcccagac agaggtgacg tggtacaagg atgggaagaa
gctgagctcc 3900 agttcgaaag tgcgcataga ggctgcgggc tgcatgcggc
agctggtggt gcagcaggca 3960 ggccaggcag atgctgggga gtacacctgt
gaggctgggg gccagcggct ctccttccac 4020 ctggatgttt cagagcccaa
ggcggtgttt gcaaaggagc agctggcaca caggaaggtg 4080 caggccgagg
cgggggccat tgccacgctg agctgcgagg tggcccaggc ccagacagag 4140
gtgacgtggt acaaggacgg gaagaagctg agctccagct cgaaagttcg aatggaggct
4200 gtgggctgca cacggaggct ggtggtgcag caggcatgcc aggcggacac
cggggagtat 4260 agctgcgagg ccgggggcca gcggctctcc ttcagcctgg
acgtggcaga gcccaaggtg 4320 gtgtttgcca aggagcagcc agtgcacagg
gaggtgcagg cccaggcggg ggccagcacc 4380 acactcagct gcgaggtggc
tcaggcccag acggaggtga tgtggtacaa ggacgggaag 4440 aagctgagct
tcagctcgaa agtgcgcatg gaggctgtgg gctgcacacg gaggctggtg 4500
gtgcagcagg cgggccaggc ggacgccggg gagtacagct gcgaggcggg gagccagcgg
4560 ctctccttcc acctgcacgt ggcagagccc aaggcggtgt ttgccaagga
gcagccagcg 4620 agcagggagg tgcaggctga ggcggggacc agtgccacgc
tgagctgcga ggtggcccag 4680 gcccagacag aggtgacgtg gtacaaggac
gggaagaaac tgagctccag ctcgaaagtg 4740 cgaatggagg ccgtgggctg
cacacggagg ctggtggtgc aggaggcagg ccaggcggac 4800 gccggggagt
acagctgcaa ggccggggat cagcggctgt ccttccacct gcacgtggca 4860
gagcccaagg tggtgtttgc caaggagcag ccagcacaca gggaggtgca ggctgaggcg
4920 ggggccagtg ccacgctgag ctgcgaggtg gcccaggccc agacagaggt
gacgtggtac 4980 aaggatggga agaagctgag ttccagctcg aaagtgcgcg
tggaggccgt gggctgcaca 5040 cggaggctgg tggtgcagca ggcgggccag
gcggatgctg gggagtacag ctgtgaggcg 5100 gggggccaac ggctgtcctt
ccgcctgcac gtggcagagc tggagcccca aatttcagag 5160 agaccctgcc
gcagggagcc tctggtggtc aaggagcatg aagacatcat cctgaccgcc 5220
acactggcca caccctctgc ggccacggtg acctggctca aggatggtgt ggagattcgc
5280 cgcagcaagc ggcatgagac agccagccag ggggacaccc acaccctgac
cgtgcatggc 5340 gcccaggttc tggacagcgc catctacagc tgccgtgtgg
gcgcagaggg gcaggacttc 5400 ccagtgcagg tggaagaggt ggccgccaag
ttctgccggc tgctggagcc tgtgtgcggc 5460 gagctgggtg gcacggtgac
actggcctgc gagctaagcc cagcgtgtgc agaggtggtg 5520 tggcgctgcg
gcaacacgca gcctcgggtg ggcaagcgct tccagatggt ggccgagggg 5580
cccgtgcgct cactcactgt gttggggctg cgcgcagagg acgcagggga gtacgtgtgt
5640 gagagccgtg atgaccacac cagtgcgcag ctcaccgtca gtgtgccccg
agtggtgaag 5700 tttatgtctg ggctgagcac cgtggtcgca gaggagggcg
gcgaggccac cttccagtgc 5760 gtggtgtccc ccagtgatgt ggcagtcgtg
tggttccggg acggtgccct gcttcagccc 5820 agcgagaagt ttgccatatc
acagagtggc gccagccaca gcctgaccat ctcagacctg 5880 gtgctggagg
acgcgggcca gatcaccgtg gaggctgagg gcgcctcatc ctctgctgcc 5940
ctgagggtcc gagaggcgcc tgtgctgttc aaaaagaagc tggagccgca gacggtggag
6000 gagcggagct cggtgaccct ggaggtggag ctgacgcggc cgtggccgga
gctgaggtgg 6060 acacggaacg cgacggccct ggcgccggga aagaacgtgg
agatccacgc cgagggcgcc 6120 cgccaccgcc tggttctgca caacgtaggt
tttgccgacc gtggcttctt tggctgcgag 6180 acgccggatg acaagacaca
ggccaaactc accgtggaga tgcgccaggt acggctcgta 6240 cggggcctgc
aggcagtgga ggcacgggag cagggcacgg ctaccatgga ggtgcagctg 6300
tcgcatgcgg acgtggatgg cagctggact cgtgacggtc tgcggttcca gcaggggccc
6360 acgtgccacc tggctgtgcg gggccccatg cacaccctca cactctcggg
gctgcggcca 6420 gaggatagtg gccttatggt cttcaaggcc gaaggagtgc
acacgtcggc gcggctcgtg 6480 gtcaccgagc ttcccgtgag cttcagccgc
ccgctgcagg acgtggtgac cactgagaag 6540 gagaaggtta ccctggagtg
cgagctgtcg cgtcctaatg tggatgtgcg ctggctgaag 6600 gacggtgtgg
agctgcgggc aggcaagacg atggccatcg cagcccaggg cgcctgcagg 6660
agcctcacca tttaccggtg cgagttcgcg gatcagggag tgtatgtgtg tgatgcccat
6720 gatgcccaga gctctgcctc cgtgaaggta caaggaagga catacactct
catctaccgg 6780 agagtcctgg cggaagatgc aggagagatc caatttgtag
ccgaaaatgc agaatcgcga 6840 gcccagctcc gagtgaagga gctgccagtg
accctcgtgc gcccgctgcg ggacaagatt 6900 gccatggaga agcaccgcgg
tgtgctggag tgtcaggtgt cccgggccag cgcccaggtg 6960 cggtggttca
agggcagtca ggagctgcag cccgggccca agtacgagct ggtcagtgat 7020
ggcctctacc gcaagctgat catcagtgat gtccacgcag aggacgagga cacctacacc
7080 tgtgacgccg gtgatgtcaa gaccagtgca cagttcttcg tggaagagca
atccatcacc 7140 attgtgcggg gtctgcagga cgtgacagtg atggagcccg
ctcctgcctg gtttgagtgt 7200 gagacctcca tcccctcagt gcggccacct
aagtggctcc tggggaagac ggtgttgcag 7260 gctgggggga acgtgggcct
ggagcaggag ggcacggtgc accggctgat gctgcggcgg 7320 acctgctcca
ccatgaccgg gcccgtgcac ttcaccgttg gcaagtcgcg ctcctctgcc 7380
cgcctggtgg tctcagacat ccccgtagtc ctcacacggc cgttggagcc caagacaggg
7440 cgtgagctgc agtcagtggt cctgtcctgc gacttccggc cagcccccaa
ggctgtgcag 7500 tggtacaagg atgacacgcc cctgtctccc tctgagaagt
ttaagatgag cctggagggt 7560 cagatggctg agctgcgcat cctccggctc
atgcctgctg atgctggtgt ctaccggtgc 7620 caggcgggca gtgcccacag
cagcactgag gtcactgtgg aagcgcggga ggtgacagtg 7680 acagggccgc
tacaggatgc agaggccacg gaggagggct gggccagctt ctcctgtgag 7740
ctgtcccacg aggatgagga ggtcgagtgg tcgctcaacg ggatgcccct gtacaacgac
7800 agcttccatg agatctcaca caagggccgg cgccacacgc tggtactgaa
gagcatccag 7860 cgggctgatg cgggcatagt acgcgcctcc tccctgaagg
tgtcgacctc tgcccgcctg 7920 gaggtccgag tgaagccggt ggtgttcctg
aaggcgctgg atgacctgtc cgcagaggag 7980 cgcggcaccc tggccctgca
gtgtgaagtc tctgaccccg aggcccatgt ggtgtggcgc 8040 aaagatggcg
tgcagctggg ccccagtgac aagtatgact tcctgcacac ggcgggcacg 8100
cgggggctcg tggtgcatga cgtgagccct gaagacgccg gcctgtacac ctgccacgtg
8160 ggctccgagg agacccgggc ccgggtccgc gtgcacgatc tgcacgtggg
catcaccaag 8220 aggctgaaga caatggaggt gctggaaggg gaaagctgca
gctttgagtg cgtcctgtcc 8280 cacgagagtg ccagcgaccc ggccatgtgg
acagtcggtg ggaagacagt gggcagctcc 8340 agccgcttcc aggccacacg
tcagggccga aaatacatcc tggtggtccg ggaggctgca 8400 ccaagtgatg
ccggggaggt ggtcttctct gtgcggggcc tcacctccaa ggcctcactc 8460
attgtcagag agaggccggc cgccatcatc aagcccctgg aagaccagtg ggtggcgcca
8520 ggggaggacg tggagctgcg ctgtgagctg tcacgggcgg gaacgcccgt
gcactggctg 8580 aaggacagga aggccatccg caagagccag aagtatgatg
tggtctgcga gggcacgatg 8640 gccatgctgg tcatccgcgg ggcctcgctc
aaggacgcgg gcgagtacac gtgtgaggtg 8700 gaggcttcca agagcacagc
cagcctccat gtggaagaaa aagcaaactg cttcacagag 8760 gagctgacca
atctgcaggt ggaggagaaa ggcacagctg tgttcacgtg caagacggag 8820
caccccgcgg ccacagtgac ctggcgcaag ggcctcttgg agctacgggc ctcagggaag
8880 caccagccca gccaggaggg cctgaccctg cggctcacca tcagtgccct
ggagaaggca 8940 gacagcgaca cctatacctg cgacattggc caggcccagt
cccgggccca gctcctagtg 9000 caaggccgga gagtgcacat catcgaggac
ctggaggatg tggatgtgca ggagggctcc 9060 tcggccacct tccgttgccg
gatctccccg gccaactacg agcctgtgca ctggttcctg 9120 gacaagacac
ccctgcatgc caacgagctc aatgagatcg atgcccagcc cgggggctac 9180
cacgtgctga ccctgcggca gctggcgctc aaggactcgg gcaccatcta ctttgaggcg
9240 ggtgaccagc gggcctcggc cgccctgcgg gtcactgaga agccaagcgt
cttctcccgg 9300 gagctcacag atgccaccat cacagagggt gaggacttga
ccctggtgtg cgagaccagc 9360 acctgcgaca ttcctatgtg ctggaccaag
gatgggaaga ccctgcgggg gtctgcccgg 9420 tgccagctga gccatgaggg
ccaccgggcc cagctgctca tcactggggc caccctgcag 9480 gacagtggac
gctacaagtg tgaggctggg ggcgcctgca gcagctccat tgtcagggtg 9540
catgcgcggc cagtgcggtt ccaggaggcc ctgaaggacc tggaggtgct ggagggtggt
9600 gctgccacac tgcgctgtgt gctgtcatct gtggctgcgc ccgtgaagtg
gtgctatgga 9660 aacaacgtcc tgaggccagg tgacaaatac agcctacgcc
aggagggtgc catgctggag 9720 ctggtggtcc ggaacctccg gccgcaggac
agcgggcggt actcatgctc cttcggggac 9780 cagactactt ctgccaccct
cacagtgact gccctgcctg cccagttcat cgggaaactg 9840 agaaacaagg
aggccacaga aggggccacg gccacgctgc ggtgtgagct gagcaagaca 9900
gcccctgtgg agtggagaaa ggggtccgag accctcagag atggggacag atactgtctg
9960 aggcaggacg gggccatgtg tgagctgcag atccgtggcc tggccatggt
ggatgccgcg 10020 gagtactcgt gtgtgtgtgg agaggagagg acctcagcct
cactcaccat caggcccatg 10080 cctgcccact tcataggaag actgagacac
caagagagca tagaaggggc cacagccacg 10140 ctgcggtgtg agctgagcaa
ggcggccccc gtggagtgga ggaaggggcg tgagagcctc 10200 agagatgggg
acagacatag cctgaggcag gacggggctg tgtgcgagct gcagatctgt 10260
ggcctggctg tggcagatgc tggggagtac tcctgtgtgt gtggggagga gaggacctct
10320 gccactctca ccgtgaaggc cctgccagcc aagttcacag agggtctgag
gaatgaagag 10380 gccgtggaag gggccacagc catgttgtgg tgtgaactga
gcaaggtggc ccctgtggag 10440 tggaggaagg ggcccgagaa cctcagagat
ggggacagat acatcctgag gcaggagggg 10500 accaggtgtg agctgcagat
ctgtggcctg gccatggcgg acgccgggga gtacttgtgt 10560 gtgtgcgggc
aggagaggac ctcagccacg ctcaccatca gggctctgcc tgccaggttc 10620
atagaagatg tgaaaaacca ggaggccaga gaaggggcca cggctgtgct gcagtgtgag
10680 ctgaacagtg cagcccctgt ggagtggaga aaggggtctg agaccctcag
agatggggac 10740 agatacagcc tgaggcagga cgggactaaa tgtgagctgc
agattcgtgg cctggccatg 10800 gcagacactg gggagtactc gtgcgtgtgc
gggcaggaga ggacctcggc tatgctcacc 10860 gtcagggctc tacccatcaa
gttcacagag ggtctgagga acgaagaggc cacagaaggg 10920 gcaacagccg
tgctgcggtg tgagctgagc aagatggccc ccgtggagtg gtggaagggg 10980
catgagaccc tcagagatgg agacagacac agcctgaggc aggacggggc caggtgtgag
11040 ctgcagatcc gcggcctcgt ggcagaggac gctggggagt acctgtgcat
gtgcgggaag 11100 gagaggacct cagccatgct caccgtcagg gccatgcctt
ccaagttcat agagggtctg 11160 aggaatgaag aggccacaga aggggacacg
gccacgctgt ggtgtgagct gagcaaggcg 11220 gcaccggtgg agtggaggaa
ggggcatgag accctcagag atggggacag acacagcctg 11280 aggcaggacg
ggtccaggtg tgagctgcag atccgtggcc tggctgtggt ggatgccggg 11340
gagtactcgt gtgtgtgcgg gcaggagagg acctcagcca cactcactgt cagggccctg
11400 cctgccagat tcatagaaga tgtgaaaaac caggaggcca gagaaggggc
cacggccgtg 11460 ctgcaatgtg agctgagcaa ggcggccccc gtggagtgga
ggaaggggtc tgagaccctc 11520 agaggtgggg acagatacag cctgaggcag
gatgggacca gatgtgagct gcagattcat 11580 ggcctgtctg tggcagacac
tggggagtac tcgtgtgtgt gcgggcagga gaggacctcg 11640 gccacactca
ccgtcagggc cccacagcca gtgttccggg agccgctgca gagtctgcag 11700
gcggaggagg gctccacggc caccctgcag tgtgagctgt ctgagcccac tgctacagtg
11760 gtctggagca agggtggcct gcagctgcag gccaatgggc gccgggagcc
acggcttcag 11820 ggctgcaccg cggagctggt gttacaggac ctacaacgtg
aagacactgg cgaatacact 11880 tgcacctgtg gctcccaggc caccagtgcc
accctcactg tcacagctgc gcctgtgcgg 11940 ttcctccgag agctgcagca
ccaggaggtg gatgagggag gcaccgcaca cttatgctgc 12000 gagctgagcc
gggcgggtgc gagcgtggag tggcgcaagg gctccctaca gctcttccct 12060
tgtgccaagt accagatggt gcaggatggt gcagctgcag agctgctggt acgcggagtg
12120 gagcaggagg atgcgggtga ctacacgtgt gacacgggcc acacgcagag
catggccagc 12180 ctctctgtcc gtgtccccag gcccaagttc aagacccggc
ttcagagtct ggagcaggag 12240 acaggtgaca tagcccggct gtgctgtcag
ctgagtgatg cagagtcggg ggccgtggtg 12300 caatggctca aggagggcgt
ggagctgcat gcgggcccca agtacgagat gcggagccag 12360 ggggccacgc
gggagctgct gatccaccaa ctggaggcca aggacacggg cgagtatgcc 12420
tgtgtgacag gcggccagaa aaccgctgcc tccctcaggg tcacagagcc tgaggtgacc
12480 attgtacggg ggctggttga tgcggaggtg acggccgatg aggatgttga
gttcagctgt 12540 gaggtgtcca gggctggagc cacaggcgtg cagtggtgcc
tacagggcct gccactgcaa 12600 agcaatgagg tgacagaggt ggctgtgcgg
gatggccgca tccacaccct gcggctgaag 12660 ggcgtgacgc ccgaggacgc
tggcactgtc tccttccatt tgggaaacca tgcttcctct 12720 gcccagctca
ccgtcagagc tcctgaggtg accatcctgg agcccctgca ggacgtgcag 12780
ctcagtgagg gccaggatgc cagcttccag tgccggctat ccagagcttc aggccaggag
12840 gcccgctggg ctttaggagg ggtgcccctg caggccaacg agatgaatga
catcactgtg 12900 gagcagggca cactccacct gctcaccctg cacaaggtga
cccttgagga tgctggaact 12960 gtcagtttcc acgtgggcac gtgtagctct
gaggcccagc tgaaagtcac agccaagaac 13020 acggtggtgc gggggctgga
gaatgtggag gcgctggagg gcggcgaggc gctgttcgag 13080 tgccagctgt
cccagcccga ggtggccgcc cacacctggc tgctggacga cgaacccgtg 13140
cgcacctcgg agaacgccga ggtggtcttc ttcgagaacg gcctgcgcca cctgctgctg
13200 ctcaaaaact tgcggccaca agacagctgc cgggtgacct tcctggctgg
ggatatggtg 13260 acgtccgcat tcctcacggt ccgaggctgg cgcctggaga
tcctggagcc tctgaaaaac 13320 gcggcggtcc gggccggcgc acaggcacgc
ttcacctgca cgctcagcga ggcggtgccc 13380 gtgggagagg cgtcctggta
catcaatggc gcggcagtgc agccggatga cagcgactgg 13440 actgtcaccg
ccgacggcag tcaccaagcc ctactgctgc gcagcgccca gccccaccac 13500
gccggggagg tcaccttcgc ttgccgcgac gccgtggcct ctgcacggct caccgtgctg
13560 ggcctccctg atcccccaga ggatgctgag gtggtggctc acagcagcca
cactgtgaca 13620 ctgtcttggg cagctcccat gagtgatgga ggcggtggtc
tctgtggcta ccgcgtggag 13680 gtgaaggagg gggccacagg ccagtggcgg
ctgtgccacg agctggtgcc tggacccgag 13740 tgtgtggtgg atggcctggc
ccccggggag acctaccgct tccgtgtggc agctgtgggc 13800 cctgtgggtg
ctggggaacc ggttcacctg ccccagacag tgcggcttgc agagccaccg 13860
aagcctgtgc ctccccagcc ctcagcccct gagagccggc aggtggcagc tggtgaagat
13920 gtctctctgg agcttgaggt ggtggctgag gctggtgagg tcatctggca
caagggaatg 13980 gagcgcatcc agcccggtgg gcggttcgag gtggtctccc
agggtcggca acagatgctg 14040 gtgatcaagg gcttcacggc agaagaccag
ggcgagtacc actgtggcct ggctcagggc 14100 tccatctgcc ctgcggctgc
caccttccag gtggcactga gcccagcctc tgtggatgag 14160 gcccctcagc
ccagcttgcc ccccgaggca gcccaggagg gtgacctgca cctactgtgg 14220
gaggccctgg ctcggaaacg tcgcatgagc cgtgagccca cgctggactc cattagcgag
14280 ctgccagagg aggacggccg ctcgcagcgc ctgccacagg aggcagagga
ggtggcacct 14340 gatctctctg aaggctactc cacggccgat gagctggccc
gcactggaga tgctgacctc 14400 tcacacacca gctctgatga tgagtcccgg
gcaggcaccc cttccctggt cacctacctc 14460 aagaaggctg ggaggccagg
cacctcacca ctggccagca aggttggggc cccagcagcc 14520 ccctctgtga
agccacagca gcagcaggag ccactggctg ctgtgcgccc accactggga 14580
gacctgagca ccaaagacct gggtgatccc tcaatggaca aggcagctgt gaagatccag
14640 gctgccttta agggctacaa ggtccggaag gagatgaagc agcaggaagg
gcccatgttc 14700 tcccacacat ttggggacac cgaggcacag gtgggggatg
ccctgcggct ggagtgtgtc 14760 gtggccagca aggcagatgt gcgagcccgc
tggctgaagg atggtgtgga gctgaccgat 14820 gggcggcacc atcacatcga
ccagcttggg gatggcacct gctctctgct gatcgctggc 14880 ctggaccgtg
ctgatgctgg ctgctacacc tgtcaggtga gcaacaagtt tggccaggtg 14940
acccacagtg cctgtgtggt ggtcagtggg tcagagagtg aagccgagag ctcctctggg
15000 ggtgagctgg acgatgcctt ccgccgggct gcccgtcggc tgcaccggct
cttccgcacc 15060 aaaagtccgg ctgaagtttc agatgaggag ctcttcctga
gtgcagacga gggccctgca 15120 gagccagagg agcccgcgga ctggcagaca
taccgcgaag atgagcattt catctgcatc 15180 cgttttgagg cgctcactga
ggcccgccag gcggtaactc gcttccagga gatgtttgcc 15240
acactgggca ttggggtgga gatcaagctg gtggaacagg ggcctcggag ggtagagatg
15300 tgcatcagca aagagactcc tgcccctgtg gtgcctccag agccattgcc
cagcctactg 15360 acttctgacg ctgccccagt gttcctgact gagttgcaga
accaagaagt gcaggatggg 15420 tatcctgtga gctttgactg cgtggtgaca
ggtcagccca tgcccagtgt gcgctggttc 15480 aaggatggga agttgttgga
ggaggatgat cactacatga ttaatgaaga ccaacagggt 15540 ggccatcagc
tcatcatcac agccgtggtg ccagcagaca tgggcgtcta ccgctgcctg 15600
gccgagaaca gcatgggtgt ctcctccacc aaggctgagc tccgtgtgga cttgacaagc
15660 acagactatg acactgcagc agatgccacg gagtcctcat cctacttcag
tgcccaaggc 15720 tacctgtcca gccgggagca ggagggaaca gagtccacca
ctgatgaggg ccagctgccc 15780 caggtggtgg aggagctgag agacctccag
gtggcccctg gcacacgcct ggccaagttc 15840 cagctcaagg tgaaaggcta
ccctgctccc agattatact ggttcaaaga tggccagccc 15900 ctgaccgcat
ctgcccacat ccgcatgact ggcaagaaga tcctgcacac cctggagatc 15960
atctccgtca cccgggagga ctctggccag tatgcagcct atatcagcaa tgccatgggt
16020 gctgcctact cgtctgcccg gctgctggtt cgaggccctg atgagccaga
agagaagcct 16080 gcatcagatg tgcatgagca gctggtgccg ccccgaatgc
tggagaggtt cacccccaag 16140 aaagtgaaga aaggctccag catcaccttc
tctgtgaagg tagaaggacg cccggtgccc 16200 accgtgcact ggctcaggga
ggaggctgag agaggcgtgc tgtggattgg ccctgacaca 16260 ccgggctaca
ccgtggccag ctctgcgcag cagcacagcc tggtcctgct ggacgtgggc 16320
cggcagcacc agggcaccta cacatgcatt gccagcaacg ctgccggcca ggccctctgc
16380 tccgccagcc tgcacgtctc gggcctgcct aaggtggagg agcaggagaa
agtgaaggaa 16440 gcgctgattt ccactttcct gcaggggacc acacaagcca
tctcagcaca ggggttggaa 16500 actgcgagtt ttgctgacct tggtgggcag
aggaaagaag agcctctggc tgccaaggag 16560 gccctcggcc acctgtccct
cgctgaggtg ggcacagagg agttcctgca gaaactgacc 16620 tcccagatca
ctgagatggt atcggccaag atcacgcagg ccaagctgca ggtgcccgga 16680
ggtgacagtg atgaggactc caagacacca tctgcatccc cccgccatgg ccgatcacgg
16740 ccatcctcca gcatccagga gtcttcctca gagtcagagg acggcgatgc
ccgaggcgag 16800 atctttgaca tctacgtggt caccgctgac tacctgcccc
taggggctga gcaggatgcc 16860 atcacgctgc gggaaggcca gtatgtggag
gtcctggatg cagcccaccc actgcgctgg 16920 cttgtccgca ccaagcccac
caagtccagc ccctcacggc agggctgggt gtcaccagcc 16980 tacctggaca
ggaggctcaa gctgtcacct gagtgggggg ccgctgaggc ccctgagttc 17040
cctggggagg ctgtgtctga agacgaatac aaggcaaggc tgagctctgt gatccaggag
17100 ctgctgagtt ctgagcaggc cttcgtggag gagctgcagt tcctgcagag
ccaccacctg 17160 cagcacctgg agcgctgccc ccacgtgccc atagccgtgg
ccggccagaa ggcagtcatc 17220 ttccgcaatg tgcgggacat cggccgcttc
cacagcagct tcctgcagga gttgcagcag 17280 tgcgacacgg acgacgacgt
ggccatgtgc ttcatcaaga accaggcggc ctttgagcag 17340 tacctggagt
tcctggtggg gcgtgtgcag gctgagtcgg tggtcgtcag cacggccatc 17400
caggagttct acaagaaata cgcggaggag gccctgttgg caggggaccc ctctcagccc
17460 ccgccaccac ctctgcagca ctacctggag cagccagtgg agcgggtgca
gcgctaccag 17520 gccttgctga aggagttgat ccgcaacaag gcgcggaaca
gacagaactg cgcgctgctg 17580 gagcaggcct atgccgtggt gtctgccctg
ccacagcgcg ctgagaacaa gctgcacgtg 17640 tccctcatgg agaactaccc
aggcaccctg gaggccctgg gcgagcccat ccgccagggc 17700 cacttcatcg
tgtgggaggg tgcaccgggg gcccgcatgc cctggaaggg ccacaaccgt 17760
cacgtgttcc tcttccgcaa ccacctggta atctgcaagc cccggcgaga ctcccgcacc
17820 gataccgtca gctacgtgtt ccggaacatg atgaagctga gcagcatcga
cctgaacgac 17880 caggtggagg gggatgaccg cgccttcgag gtgtggcagg
agcgggagga ctcggtgcgc 17940 aagtacctgc tgcaggcacg gacagccatt
atcaagagct cgtgggtgaa ggagatctgt 18000 ggcatccagc agcgtctggc
cctgcctgtg tggcggcccc cggactttga agaggagctg 18060 gccgactgca
cagccgagct gggtgagaca gtcaagctgg cctgccgcgt gacgggcaca 18120
cccaagcctg tcatcagctg gtacaaagat gggaaagcag tgcaggtgga cccccaccac
18180 atcctcattg aagaccctga tggctcgtgt gcactcatcc tggacagcct
gaccggtgtg 18240 gactctggcc agtacatgtg cttcgcggcc agcgccgctg
gcaactgcag taccctgggc 18300 aagatcctgg tgcaagtccc accacggttc
gtgaacaagg tccgggcctc accctttgtg 18360 gagggagagg acgcccagtt
cacctgcacc atcgaaggcg ccccgtaccc gcagatcagg 18420 tggtacaagg
acggggccct gctgaccact ggcaacaagt tccagacact gagtgagcct 18480
cgcagcggcc tgctagtgct ggtgatccgg gcggccagca aggaggacct ggggctctac
18540 gagtgtgagc tggtgaaccg gctgggctcc gcgcgggcta gtgcggagct
gcgcattcag 18600 agccccatgc tgcaggccca ggagcagtgt cacagggagc
agctcgtggc tgcagtggaa 18660 gacaccaccc tggagcgagc ggaccaggag
gtcacatctg tcctgaagag actgctgggc 18720 cccaaggcgc caggcccctc
cacaggggac ctcactggcc ctggcccctg ccccaggggg 18780 gcacccgcac
tccaggaaac cggctcccag cccccagtca ccggaacttc ggaggcacct 18840
gccgtgcccc cgagggtgcc acagcccctc ctccacgaag gcccagagca ggagccggag
18900 gccattgcca gagcccagga atggactgtg cccattcgga tggagggtgc
agcctggccc 18960 ggggcaggca caggggagct gctctgggac gtccacagcc
acgtggtcag agagaccaca 19020 cagaggacct acacatacca ggccatcgac
acgcacaccg cacggccccc atccatgcag 19080 gtaaccatcg aggatgtgca
ggcacagaca ggcggaacgg cccaattcga ggctatcatt 19140 gagggcgacc
cacagccctc ggtgacctgg tacaaggaca gcgtccagct ggtggacagc 19200
acccggctta gccagcagca agaaggcacc acatactccc tggtgctgag gcatgtggcc
19260 tcgaaggatg ccggcgttta cacctgcctg gcccaaaaca ctggtggcca
ggtgctctgc 19320 aaggcagagc tgctggtgct tgggggggac aatgagccgg
actcagagaa gcaaagccac 19380 cggaggaagc tgcactcctt ctatgaggtc
aaggaggaga ttggaagggg cgtgtttggc 19440 ttcgtaaaaa gagtgcagca
caaaggaaac aagatcttgt gcgctgccaa gttcatcccc 19500 ctacggagca
gaactcgggc ccaggcatac agggagcgag acatcctggc cgcgctgagc 19560
cacccgctgg tcacggggct gctggaccag tttgagaccc gcaagaccct catcctcatc
19620 ctggagctgt gctcatccga ggagctgctg gaccgcctgt acaggaaggg
cgtggtgacg 19680 gaggccgagg tcaaggtcta catccagcag ctggtggagg
ggctgcacta cctgcacagc 19740 catggcgttc tccacctgga cataaagccc
tctaacatcc tgatggtgca tcctgcccgg 19800 gaagacatta aaatctgcga
ctttggcttt gcccagaaca tcaccccagc agagctgcag 19860 ttcagccagt
acggctcccc tgagttcgtc tcccccgaga tcatccagca gaaccctgtg 19920
agcgaagcct ccgacatttg ggccatgggt gtcatctcct acctcagcct gacctgctca
19980 tccccatttg ccggcgagag tgaccgtgcc accctcctga acgtcctgga
ggggcgcgtg 20040 tcatggagca gccccatggc tgcccacctc agcgaagacg
ccaaagactt catcaaggct 20100 acgctgcaga gagcccctca ggcccggcct
agtgcggccc agtgcctctc ccacccctgg 20160 ttcctgaaat ccatgcctgc
ggaggaggcc cacttcatca acaccaagca gctcaagttc 20220 ctcctggccc
gaagtcgctg gcagcgttcc ctgatgagct acaagtccat cctggtgatg 20280
cgctccatcc ctgagctgct gcggggccca cccgacagcc cctccctcgg cgtagcccgg
20340 cacctctgca gggacactgg tggctcctcc agttcctcct cctcctctga
caacgagctc 20400 gccccatttg cccgggctaa gtcactgcca ccctccccgg
tgacacactc accactgctg 20460 cacccccggg gcttcctgcg gccctcggcc
agcctgcctg aggaagccga ggccagtgag 20520 cgctccaccg aggccccagc
tccgcctgca tctcccgagg gtgccgggcc accggccgcc 20580 cagggctgcg
tgccccggca cagcgtcatc cgcagcctgt tctaccacca ggcgggtgag 20640
agccctgagc acggggccct ggccccgggg agcaggcggc acccggcccg gcggcggcac
20700 ctgctgaagg gcgggtacat tgcgggggcg ctgccaggcc tgcgcgagcc
actgatggag 20760 caccgcgtgc tggaggagga ggccgccagg gaggagcagg
ccaccctcct ggccaaagcc 20820 ccctcattcg agactgccct ccggctgcct
gcctctggca cccacttggc ccctggccac 20880 agccactccc tggaacatga
ctctccgagc accccccgcc cctcctcgga ggcctgcggt 20940 gaggcacagc
gactgccttc agccccctcc gggggggccc ctatcaggga catggggcac 21000
cctcagggct ccaagcagct tccatccact ggtggccacc caggcactgc tcagccagag
21060 aggccatccc cggacagccc ttgggggcag ccagcccctt tctgccaccc
caagcagggt 21120 tctgcccccc aggagggctg cagcccccac ccagcagttg
ccccatgccc tcctggctcc 21180 ttccctccag gatcttgcaa agaggccccc
ttagtaccct caagcccctt cttgggacag 21240 ccccaggcac cccctgcccc
tgccaaagca agccccccat tggactctaa gatggggcct 21300 ggagacatct
ctcttcctgg gaggccaaaa cccggcccct gcagttcccc agggtcagcc 21360
tcccaggcga gctcttccca agtgagctcc ctcagggtgg gctcctccca ggtgggcaca
21420 gagcctggcc cctccctgga tgcggagggc tggacccagg aggctgagga
tctgtccgac 21480 tccacaccca ccttgcagcg gcctcaggaa caggcgacca
tgcgcaagtt ctccctgggt 21540 ggtcgcgggg gctacgcagg cgtggctggc
tatggcacct ttgcctttgg tggagatgca 21600 gggggcatgc tggggcaggg
gcccatgtgg gccaggatag cctgggctgt gtcccagtcg 21660 gaggaggagg
agcaggagga ggccagggct gagtcccagt cggaggagca gcaggaggcc 21720
agggctgaga gcccactgcc ccaggtcagt gcaaggcctg tgcctgaggt cggcagggct
21780 cccaccagga gctctccaga gcccacccca tgggaggaca tcgggcaggt
ctccctggtg 21840 cagatccggg acctgtcagg tgatgcggag gcggccgaca
caatatccct ggacatttcc 21900 gaggtggacc ccgcctacct caacctctca
gacctgtacg atatcaagta cctcccattc 21960 gagtttatga tcttcaggaa
agtccccaag tccgctcagc cagagccgcc ctcccccatg 22020 gctgaggagg
agctggccga gttcccggag cccacgtggc cctggccagg tgaactgggc 22080
ccccacgcag gcctggagat cacagaggag tcagaggatg tggacgcgct gctggcagag
22140 gctgccgtgg gcaggaagcg caagtggtcc tcgccgtcac gcagcctctt
ccacttccct 22200 gggaggcacc tgccgctgga tgagcctgca gagctggggc
tgcgtgagag agtgaaggcc 22260 tccgtggagc acatctcccg gatcctgaag
ggcaggccgg aaggtctgga gaaggagggg 22320 ccccccagga agaagccagg
ccttgcttcc ttccggctct caggtctgaa gagctgggac 22380 cgagcgccga
cattcctaag ggagctctca gatgagactg tggtcctggg ccagtcagtg 22440
acactggcct gccaggtgtc agcccagcca gctgcccagg ccacctggag caaagacgga
22500 gcccccctgg agagcagcag ccgtgtcctc atctctgcca ccctcaagaa
cttccagctt 22560 ctgaccatcc tggtggtggt ggctgaggac ctgggtgtgt
acacctgcag cgtgagcaat 22620 gcgctgggga cagtgaccac cacgggcgtc
ctccggaagg cagagcgccc ctcatcttcg 22680 ccatgcccgg atatcgggga
ggtgtacgcg gatggggtgc tgctggtctg gaagcccgtg 22740 gaatcctacg
gccctgtgac ctacattgtg cagtgcagcc tagaaggcgg cagctggacc 22800
acactggcct ccgacatctt tgactgctgc tacctgacca gcaagctctc ccggggtggc
22860 acctacacct tccgcacggc atgtgtcagc aaggcaggaa tgggtcccta
cagcagcccc 22920 tcggagcaag tcctcctggg agggcccagc cacctggcct
ctgaggagga gagccagggg 22980 cggtcagccc aacccctgcc cagcacaaag
accttcgcat tccagacaca gatccagagg 23040 ggccgcttca gcgtggtgcg
gcaatgctgg gagaaggcca gcgggcgggc gctggccgcc 23100 aagatcatcc
cctaccaccc caaggacaag acagcagtgc tgcgcgaata cgaggccctc 23160
aagggcctgc gccacccgca cctggcccag ctgcacgcag cctacctcag cccccggcac
23220 ctggtgctca tcttggagct gtgctctggg cccgagctgc tcccctgcct
ggccgagagg 23280 gcctcctact cagaatccga ggtgaaggac tacctgtggc
agatgttgag tgccacccag 23340 tacctgcaca accagcacat cctgcacctg
gacctgaggt ccgagaacat gatcatcacc 23400 gaatacaacc tgctcaaggt
cgtggacctg ggcaatgcac agagcctcag ccaggagaag 23460 gtgctgccct
cagacaagtt caaggactac ctagagacca tggctccaga gctcctggag 23520
ggccaggggg ctgttccaca gacagacatc tgggccatcg gtgtgacagc cttcatcatg
23580 ctgagcgccg agtacccggt gagcagcgag ggtgcacgcg acctgcagag
aggactgcgc 23640 aaggggctgg tccggctgag ccgctgctac gcggggctgt
ccgggggcgc cgtggccttc 23700 ctgcgcagca ctctgtgcgc ccagccctgg
ggccggccct gcgcgtccag ctgcctgcag 23760 tgcccgtggc taacagagga
gggcccggcc tgttcgcggc ccgcgcccgt gaccttccct 23820 accgcgcggc
tgcgcgtctt cgtgcgcaat cgcgagaaga gacgcgcgct gctgtacaag 23880
aggcacaacc tggcccaggt gcgctga 23907 7 17 PRT Artificial Sequence
VARIANT 1 The L at position 1 can be I or V. 7 Leu Gly Xaa Gly Xaa
Phe Ser Xaa Leu Xaa Xaa Gly Xaa Leu Ala Leu 1 5 10 15 Lys 8 12 PRT
Artificial Sequence VARIANT 1 The L at position 1 can be I, V, M,
F, Y, or C. 8 Leu Xaa His Xaa Asp Leu Lys Xaa Asn Xaa Xaa Xaa 1 5
10 9 13 PRT Artificial Sequence VARIANT 1 The L at position 1 can
be I, V, M, F, Y, or C. 9 Leu Xaa His Xaa Asp Leu Arg Xaa Xaa Asn
Xaa Xaa Xaa 1 5 10
* * * * *
References